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Abstract  
Background: People with substance use disorders (SUDs) often have co-existing 
physical and/or mental health conditions and are prescribed a large number of 
medications which may or may not be justified. Among this population, psychiatric 
medications and opioids are often involved in adverse events. There is, however, a lack 
of research on the quality of prescribing of these medications. In this thesis, the 
appropriateness of these medications is explored, as well as the response of prescribers 
in a specialist addiction service (SAS) to their inappropriate prescribing. 
 
Methods: A mixed methods design was utilised. A descriptive quantitative study using 
routinely available data was conducted to describe the scale of prescribing for service 
users. A second quantitative component involving questionnaires was carried out to 
assess the appropriateness of psychiatric medications and opioids in a sample of service 
users by SAS prescribers. Qualitative interviews were conducted with service users to 
explore their perspectives on the appropriateness of these medications while prescriber 
interviews explored how they responded to inappropriate prescribing. 
 
Results: The descriptive study showed that 27% of service users were prescribed four or 
more medications with almost half of them receiving antidepressants. The second study 
showed that nearly half of service users had at least one inappropriate psychiatric 
medication or opioid. Interviews with service users revealed that most of them benefited 
from these medications but that their use often involved making a compromise between 
risks and benefits. Benefits/risks of medications, prescriber expertise, nature of addiction 
and communication with service users and prescribers were considered by SAS 
prescribers before responding to inappropriate prescribing. It appears the need to 
maintain service users’ stability and well-being may lead to a greater focus on these 
issues when assessing the appropriateness of prescribing decisions. 
 
Conclusion: The quality of prescribing of opioids and psychiatric medications to service 
users referred to this SAS appeared to present room for improvement. Further research is 
required with the availability of a more mixed economy of service providers in the 
alcohol and drug treatment sector to establish if these findings are applicable. 
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Chapter 1: Introduction 
The use of substances such as alcohol and illegal drugs has been linked with diverse 
problems among people who use them, their families and the wider society. In particular, 
mental and physical health problems are common in people with substance use disorders 
(hereafter SUDs) and medications are often required in their management. Given the 
extent of prescribing for this patient group, it is important to consider whether prescribed 
medications are appropriate for safety reasons, optimal benefit and also for cost-effective 
prescribing. This thesis therefore considers the appropriateness of opioids and 
psychiatric medications among people with SUDs (except nicotine use disorders) while 
also exploring how prescribers in a specialist addiction service (hereafter SAS) respond 
to inappropriate prescribing. Appropriateness in this thesis encompasses consideration of 
effectiveness, safety, cost, patients’ preferences and outcomes as well as prescribers’ 
perspectives. This introduction section will focus on the rationale for this thesis, 
definition and prevalence of SUDs, the concept of appropriateness, comorbidities 
associated with SUDs and their pharmacotherapeutic management, medication 
adherence as well as UK prescribing models.  
 
1.1. Thesis rationale 
People with SUDs often have co-existing physical and/or mental health problems 
(McLellan, 2009). In particular, high levels of mental health problems (Delgadillo et al., 
2012; Grant et al., 2004; Mortlock, Deane and Crowe, 2011; Regier et al., 1990) and 
pain (Jamison, Kauffman and Katz, 2000; Peles et al., 2005; Rosenblum et al., 2003) are 
prevalent in this population, with life expectancy being shorter than that of the general 
population (Chang et al., 2011; Hannerz, Borga and Borritz, 2001; Oppenheimer et al., 
1994). Potential reasons for these high levels of morbidity and mortality include the 
toxicity of substances (Lieber, 1995; Stein, 1999), the adverse effects of some 
medications such as antipsychotics, benzodiazepines and opioids (Leslie and Rosenheck, 
2004; Roose, 2000) used in treating these comorbid conditions as well as poor quality of 
medical care (Bjorkenstam et al., 2012). These reasons underscore the need for careful 
monitoring of the effect of substances and medications prescribed for people with SUDs, 
especially those with co-occurring mental disorders and pain.  
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People with comorbid mental disorders and SUDs usually have complex needs 
comprising health, social and economic needs (Hughes, 2006), require more resources 
and are challenging to manage (Department of Health, 2004). Similarly, people with 
comorbid pain and SUDs are more likely to have health problems, mental health 
symptoms and less social support when compared to those without pain (Jamison et al., 
2000; Rosenblum et al., 2003). The management of comorbid pain in people with SUDs 
also presents a clinical challenge as there is the risk of compounding an existing SUD or 
even fatality through overdose if opioid analgesics are prescribed for pain relief (Action 
on Addiction, 2013). Furthermore, these patients are often stigmatised by healthcare 
professionals due to their substance use and difficult behaviour (Link et al., 1997; Lloyd, 
2010) and may therefore receive suboptimal healthcare (Henderson, Stacey and Dohan, 
2008), including prescribing.  
 
Given the high levels of comorbid conditions (Arora and Kaur, 2012; Caldeiro et al., 
2008; Delgadillo et al., 2012; Kidorf et al., 2004; Peles et al., 2005; Rosenblum et al., 
2003; Weaver et al., 2003) and prescribing (McManus et al., 2009; Oluyase et al., 2013) 
among substance users who access treatment, there is the need for scrutiny of 
prescribing practice in this group, especially, as the quality of healthcare has been 
identified as a priority by the UK Government (Department of Health, 2013a). 
Consequently, this research explores two important aspects concerning the care for this 
population: the appropriateness of psychiatric medications and opioids prescribed for 
people with SUDs and SAS prescribers’ responses to inappropriate prescribing.  
 
Medications used in the treatment of mental disorders (for example, benzodiazepines 
and antidepressants) and pain (for example, opioids) have been implicated in the 
occurrence of adverse events including overdose and mortality in patients with SUDs 
(Darke, Duflou and Torok, 2011; Darke and Hall, 2003; Darke and Ross, 2000). 
Benzodiazepines and alcohol have often been found to be used in combination with 
opioids such as dihydrocodeine and oxycodone in opioid-related overdose and fatalities 
(Darke, Duflou and Torok, 2011; Zamparutti et al., 2011). Zamparutti et al. (2011) found 
that in 96% of accidental deaths involving dihydrocodeine among opiate misusers, 
dihydrocodeine was used in combination with other substances such as 
hypnotics/sedatives and other opiates (methadone, heroin and morphine). Almost half 
(45%) of victims who accidentally overdosed on dihydrocodeine had been prescribed it. 
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Antidepressant prescriptions, especially tricyclic antidepressants (hereafter TCAs), have 
also been linked to heroin overdose (Darke and Hall, 2003; Darke and Ross, 2000). 
When used in combination with heroin, TCAs significantly increase the risk of 
respiratory depression, coma and cardiac arrest (Darke and Ross, 2000).  
 
In the UK, 1.5 million people are believed to be dependent on prescription drugs, 
surpassing the number of people in treatment for illicit drug use (Home Affairs 
Committee, 2013). In particular, the rise in opioid prescriptions for pain has been 
accompanied by an increase in its non-medical use and additional risk of morbidity and 
mortality (Bohnert et al., 2011; Dasgupta, 2006; Dunn et al., 2010), with a history of 
SUDs being a risk factor for such use (Chou, 2009; Sehgal, Manchikanti and Smith, 
2012; Solanki et al., 2011). Fatal overdose involving prescription opioids more than 
tripled in USA between 1999 and 2002 (Paulozzi, Budnitz and Xi, 2006). These studies 
imply that the risk of overdose may be affected by prescribed medications taken by 
people with SUDs and underscore the need to assess the appropriateness of medications 
prescribed for this group. 
 
There has been limited research on the appropriateness of opioids and psychiatric 
medications among people with SUDs. A comprehensive search of the literature 
conducted as part of this thesis found only eight studies (Baca-Garcia et al., 2009; Clark, 
Xie and Brunette, 2004; Leslie and Rosenheck, 2001; Morasco, Duckart and Dobscha, 
2011; Morrison et al., 1994; Thirion et al., 2002; Walkup et al., 2000; Weinmann, 
Janssen and Gaebel, 2005) that assessed the appropriateness of psychiatric medications 
and opioids prescribed for people with co-existing mental disorders or chronic pain and 
SUDs. While some of these studies found that doses and duration of opioids and 
psychiatric medications sometimes exceeded guideline recommendations, two studies 
(Baca-Garcia et al., 2009; Leslie and Rosenheck, 2001) found that there was sometimes 
underdosing.  
  
Britten et al. (2003) have advocated a holistic view of appropriateness encompassing 
patient and prescriber perspectives. The perspectives of patients and prescribers may 
well differ concerning prescribing appropriateness. Attempts to measure appropriateness 
that incorporates both perspectives will lead to a deeper understanding of the complex 
process of prescribing (Britten et al., 2003). Patients’ perspectives could assist in 
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understanding their views on prescribing appropriateness, how they influence 
prescribing, their beliefs and concerns about medications and the possible influence of 
these on medication adherence. Prescribers’ perspectives could assist in determining the 
necessity of medications and the reasons prescribing may sometimes not follow 
recommended standards while also providing insight into the process of clinical 
decision-making that prescribers go through in order to assess the appropriateness of 
prescribed medications. The above perspectives are however not the only criteria for 
evaluating prescribing. There is a need to further consider the interest of those around 
the patient, including the wider society, as prescribing may lead to benefit or harm for 
others (Cribb and Barber, 1997). For instance, there is the need to consider the impact 
prescribing could make on social issues associated with substance use such as crime and 
violence. Judgment on the appropriateness of prescribing is therefore complex and 
would entail consideration of these different aspects for optimal decision-making.  
 
This thesis adds to knowledge on the clinical management of people with SUDs by 
assessing the appropriateness of medications prescribed for them from two perspectives 
(patient and prescriber
1
) with a particular focus on psychiatric medications and opioids 
while also assessing how prescribers addressed inappropriate prescribing. This study 
used a mixed method design and is the first to the best of my knowledge that has 
explored the appropriateness of prescribing of psychiatric medications and opioids from 
the above perspectives. 
1.2. Thesis aims and structure 
1.2.1. Aims  
The aims of this thesis were: 
 
 To investigate the level and nature of appropriateness of current medications for 
service users in a specialist addiction service (SAS); 
 To explore prescribers’ responses to inappropriate prescribing in a SAS. 
 
The fact that prescribing appropriateness is a complex and under-researched area, and 
the need to understand the scale and nature of prescribing for people with SUDs 
                                                 
1 Prescriber perspectives include their ratings of medication appropriateness on the study questionnaires as well as the 
perspectives they expressed in their interviews. 
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necessitated the adoption of multiple methods. In addition, mixing quantitative and 
qualitative methods allowed for a more holistic picture on prescribing appropriateness. 
Quantitative methods were used to provide an overview of the different classes of 
medications taken by service users during their first assessment at the SAS and to enable 
the estimation of the magnitude of inappropriate prescribing (including medication 
omissions or failure to prescribe needed medications) using questionnaires. The 
questionnaires used include an adapted version of the Medication Appropriateness Index 
(hereafter MAI) and a questionnaire designed for assessing medication omissions 
(hereafter medication omissions questionnaire). Qualitative methods were used to 
provide an in-depth understanding of the appropriateness of prescribing from the service 
users’ perspectives in addition to allowing exploration of prescribers’ responses to 
inappropriate prescribing. It was also intended that the evidence obtained from this 
research would assist in making recommendations for the development of better practice 
in relation to prescribing of psychiatric medications and opioids for this group of people. 
1.2.2. Thesis structure  
The rest of chapter one provides the backdrop to the study in terms of the definition and 
prevalence of SUDs, the concept of appropriateness, comorbidities associated with 
SUDs and their pharmacotherapeutic management, medication adherence and UK 
prescribing models. Chapter two reviews published research exploring the 
appropriateness of prescribing of psychiatric medications and opioids among people 
with SUDs. Chapter three provides an overview of the methodology adopted for this 
thesis and the rationale for the mixed methods design. Chapter four presents the first 
study carried out. It is a descriptive study detailing the different classes of medications 
taken by service users who were newly referred to the SAS. This study involved analysis 
of routinely collected data obtained from the SAS electronic database. Chapter five 
comprises the second study. It is a cohort study involving assessment of the 
appropriateness of service users’ prescribed psychiatric medications and opioids by 
prescribers working at the SAS. Chapters six and seven present the methodology, result 
and discussion of the qualitative interview studies carried out with SAS service users 
and SAS prescribers respectively. Chapter eight offers an integration and discussion of 
the findings of this thesis with a focus on its practice implications, directions for future 
research and conclusions. 
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1.3. Substance use disorders (SUDs) 
This thesis focuses on the medications prescribed for people with SUDs and as a result, 
it is pertinent to understand how SUDs have been classified by the diagnostic manual 
used in the UK (including the SAS) for mental disorders: the International Classification 
of Diseases, tenth edition (ICD-10) published by the World Health Organisation (World 
Health Organisation, 1992). The ICD-10 classifies SUDs into harmful use and 
dependence. Harmful use is defined as “a pattern of psychoactive substance use that is 
causing damage to health” (World Health Organisation, 1992). 
 
Dependence is defined as:  
 
A cluster of behavioural, cognitive, and physiological phenomena that develop 
after repeated substance use and that typically include a strong desire to take the 
substance, difficulties in controlling its use, persisting in its use despite harmful 
consequences, a higher priority given to drug use than to other activities and 
obligations, increased tolerance, and sometimes a physical withdrawal state 
(World Health Organisation, 1992). 
 
In order to diagnose dependence, at least three criteria occurring at any time in the same 
12-month period are required among those stated above (Hasin et al., 2006). Diagnosis 
of dependence is further specified by the following: 
 
 Currently abstinent; 
 Currently abstinent, but in a protected environment (e.g. in hospital);  
 Currently on a clinically supervised maintenance or replacement regime (e.g. 
with methadone);  
 Currently abstinent, but receiving treatment with aversive or blocking drugs (e.g. 
naltrexone);  
 Currently using the substance;  
 Continuous use;  
 Episodic use.  
  
The American Psychiatric Association’s (hereafter APA) Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV) is another manual that was 
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commonly used in clinical practice during the period this research was carried out. It 
classified SUDs into abuse
2
 and dependence unlike the ICD-10 which classified SUDs 
into harmful use and dependence. The diagnostic criteria for dependence are however 
similar between DSM-IV and ICD-10 (Hasin et al., 2006). The DSM-IV criteria for 
abuse and dependence have recently been updated in the DSM-5 with abuse and 
dependence combined into one disorder (American Psychiatric Association, 2013). 
1.3.1. Prevalence of SUDs 
Accurate measurement of the prevalence of SUDs is challenging because people may 
underestimate or deny usage to avoid being stigmatised because of their illicit status or 
due to the surreptitious nature of activities used in obtaining them (Hay et al., 2006; 
Somers et al., 2004), and are likely to be absent from many of the survey methods used 
to measure prevalence. People with severe SUDs are often not captured in surveys 
because they may be homeless or transient (Somers et al., 2004). Furthermore, studies 
use different definitions for SUDs which may range from frequent use to the use of 
formal diagnostic criteria such as ICD-10 as discussed in the previous section.  
 
The most recent adult Psychiatric Morbidity Survey (hereafter PMS) (McManus et al., 
2009) carried out in 2007, assessed the prevalence of alcohol use disorders (hereafter 
AUDs) in people aged 16 and above in private households in the UK. Three categories 
were specified for AUDs: hazardous drinking, harmful drinking and alcohol dependence. 
Hazardous drinking was defined as a pattern of drinking that could lead to harmful 
consequences whereas harmful drinking represents a type of drinking that has already 
resulted in harm (McManus et al., 2009). Harm may be physical or psychological. 
Alcohol dependence was defined as a cluster of behavioural, cognitive, and 
physiological phenomena that typically include a strong desire to consume alcohol, and 
difficulties in controlling drinking. Hazardous and harmful drinking were identified 
using the Alcohol Use Disorders Identification Test (AUDIT) (Saunders et al., 1993), 
and alcohol dependence was assessed using the Severity of Alcohol Dependence 
Questionnaire, Community Version (SADQ-C) (Stockwell et al., 1994). The prevalence 
of hazardous/harmful drinking was 24.2% (33.2% of men, 15.7% of women) with 
harmful drinking involving 3.8% of adults (5.8% of men, 1.9% of women). The 
                                                 
2 Abuse is diagnosed by the presence of one of the following four criteria which must cause clinically significant 
impairment or distress: hazardous use, legal problems, neglect of major roles due to substance use and 
social/interpersonal problems related to use. 
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prevalence of alcohol dependence was found to be 5.9% (8.7% of men, 3.3% of 
women). This survey showed a slight decrease in the prevalence of alcohol dependence 
compared to the previous PMS carried out in year 2000 (Singleton et al., 2001).   
 
The prevalence of drug misuse and dependence was also reported in the adult PMS in 
2007. Drug misuse was defined according to the WHO criteria as the use of a substance 
for purposes not consistent with legal or medical guidelines, for example the non-
medical use of prescription medications or the recreational use of illegal drugs (World 
Health Organisation, 1994). Although drug misuse is not necessarily problematic, it 
could escalate to problematic levels (Advisory Council on the Misuse of Drugs, 2008). 
The prevalence of illicit drug use in the past year was 9.2% (12.0% of men, 6.7% of 
women) with lifetime illicit use being 25.8% (29.9% of men and 21.8% of women). 
Dependence was defined as the presence of one of five symptoms of dependence stated 
in ICD-10 in the past year and its prevalence was estimated to be 3.4% (4.5% of men, 
2.3% of women). This survey found a similar prevalence of drug dependence when 
compared to the previous PMS (Singleton et al., 2001). Similar prevalence (8.8%) for 
illicit drug use was reported in the 2013/14 Crime Survey for England and Wales among 
people aged 16 to 59 years while that for lifetime use was higher (35.6%) (Home Office, 
2014).  
 
Other methods such as the capture-recapture method and the multiple indicator method 
have been used to estimate the prevalence of problematic drug use in the UK. Both are 
indirect methods of assessment of the prevalence of drug use (Hay et al., 2010). 
Accurate assessment of the numbers of people involved in covert activities such as 
opioid or cocaine use is difficult and surveys tend to underestimate their prevalence 
(Hay, Rael dos Santos and Worsley, 2013). Capture-recapture method uses information 
on the overlap between data sources that are available at the local level to provide 
estimates of the size of the hidden population: that is, problem drug users not identified 
from any data source (Hay et al., 2006). The capture-recapture method uses multiple 
data sources such as drug treatment data, probation, police and prison data for 
calculating prevalence estimates of substances (Hay et al., 2010). Overlap between data 
sources are determined by comparison of initials, date of birth and gender. Statistical 
modelling techniques are used to examine this overlap and to produce prevalence 
estimates (Hay et al., 2010). The multiple indicator method models the relationship 
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between the capture-recapture estimates and readily available indicator data such as 
aggregate number of drug users in treatment or committing drug-related crimes in an 
area (Hay et al., 2006). It uses this relationship to provide prevalence estimates in areas 
where capture-recapture estimates are not available (Hay et al., 2006).  
 
These two methods were used to estimate the prevalence of problem drug use, defined as 
opiate (heroin, methadone, other opiate drugs) and/or crack cocaine use, in England. The 
estimated prevalence of problem drug use among people between 15 and 64 years was 
found to be 8.4 (95% CI: 8.3 to 8.6) per 1000 population between 2011 and 2012 (Hay, 
Rael dos Santos and Worsley, 2013). This was similar to the reported prevalence in the 
survey carried out between 2010 and 2011 (Hay, Rael dos Santos and Millar, 2012). 
Overall, the reported prevalence of SUDs is likely to be underestimated. The next 
section provides a brief description of service users in structured treatment in the UK. 
1.3.2. Service users with SUDs in structured treatment 
Despite the problems associated with dependence, only a minority of UK adults who are 
alcohol dependent and two-thirds of those dependent on drugs receive treatment 
annually (National Institute for Health and Clinical Excellence, 2011a; The Centre for 
Social Justice, 2013). Possible explanations for this include inadequate numbers of 
specialist treatment services, long intervals between dependence and seeking help, and 
the under-recognition of dependence by healthcare professionals (National Institute for 
Health and Clinical Excellence, 2011a).  
 
Recent statistics concerning those in structured treatment in England show that 114,920 
service users aged 18 to 75 years cited alcohol as their primary problematic substance 
between 2013 and 2014 while 193,198 clients were in treatment for drug dependence 
(Public Health England, 2014a; Public Health England, 2014b). A further 34,237 service 
users cited problematic alcohol use as being concurrent with other primary substances. 
The numbers in treatment for alcohol have increased over the last three years with a 5% 
increase occurring between 2012/13 and 2013/14 (Public Health England, 2013a). 
However, the numbers in treatment for drug dependence were similar to that of the 
previous year (Public Health England, 2013b). Almost 80% of those in treatment for 
drug dependence between 2013 and 2014 were opiate users. These data probably 
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represent an underestimation of the numbers in treatment due to data quality issues such 
as incomplete reporting (Department of Health, 2012b).  
 
Service users in structured treatment may receive different types of interventions ranging 
from prescribing to psychosocial interventions in different settings. Data obtained 
between 2013 and 2014 shows that among those in treatment for alcohol, psychosocial 
interventions were more common in the community, primary care, residential and 
recovery houses
3
 (Public Health England, 2014a) compared to prescribing. Prescribing 
was however more prevalent in in-patient units. Figure 1.1 shows the interventions 
received by service users in structured treatment for alcohol in different settings between 
2013 and 2014.  
 
Figure 1.1: Interventions received by service users in alcohol treatment in 2013/14 
 
Note: Interventions received in recovery houses were not shown due to small numbers: 170 service users received 
psychosocial interventions while <5 service users received prescribing interventions.   
                   Adapted from Public Health England (2014a) 
                                                 
3A recovery house is a residential living environment that provides integrated peer support and/or integrated recovery 
support. It usually requires less staffing and the care provided is less intensive than a residential rehabilitation service. 
Care Quality Commission. (2014). A fresh start for the regulation and inspection of substance misuse services: 
working together to change how we regulate, inspect and monitor specialist substance misuse services. [Online]. 
Available at: 
http://www.cqc.org.uk/sites/default/files/20140919_cqc_a_fresh_start_substance_misuse_final_low_res.pdf 
[Accessed 7 March 2015]. 
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Among those in treatment for drug dependence, prescribing was more common in in-
patient units and primary care (Public Health England, 2014b). Figure 1.2 shows the 
interventions received by those in structured treatment for drug dependence between 
2013 and 2014. 
 
Figure 1.2: Interventions received by service users in drug treatment in 2013/14 
 
Note: Interventions received in recovery houses were not shown due to small numbers: 237 service users received 
psychosocial interventions while 61 service users received prescribing interventions.   
          Adapted from Public Health England (2014b) 
               
The median age of those who reported alcohol and drugs as their primary problematic 
substances were 43 and 36 years, respectively. A total of 64% of those with alcohol as 
their primary problematic substance were males while almost three-quarters (74%) of 
those in treatment for drug dependence were also males. Over 80% of service users in 
treatment for alcohol and drug dependence were white British. A total of 14% of people 
in treatment for alcohol reported housing problems. Almost one quarter of those in 
treatment for drugs had housing problems. Among those in treatment for alcohol, over 
40% were self-referrals. Similar proportions were reported for those in treatment for 
drugs. Almost half of those exiting treatment for drug dependence and 60% of those 
exiting treatment for alcohol in 2013/14 were no longer dependent.  
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1.4. The appropriateness concept in prescribing 
A central aim of this thesis is to explore the appropriateness of prescribing of psychiatric 
medications and opioids for people with SUDs. This section therefore explores the 
concept of appropriateness in wider healthcare and how it relates to prescribing with a 
particular focus on SUDs. 
1.4.1. Definition of appropriateness in healthcare 
Appropriateness in healthcare is a complex concept with no generally accepted 
definition (Bowling, 2002). The Oxford Dictionary defines appropriateness as the 
quality of being suitable or proper in the circumstances (Oxford Dictionaries, 2016a).  
Donald Berwick in the USA further refers to appropriateness as the provision and use of 
“what works” (Berwick, 1989). This definition however makes no attempt to define 
“what works” (Buetow et al., 1997). A definition of appropriate care that originated from 
Australia by Roy Harvey considers it as:  
 
that strategy of action which maximises the potential health benefits valued by 
informed individuals or populations after considering the likely outcomes, their 
probabilities and their costs, for each of the separate components of the strategy, 
and that healthcare professionals are willing to provide (Harvey, 1991, p.79). 
 
This definition considers appropriate care to involve making a decision from different 
available options about alternative use of resources. The Health Services Utilisation 
Study (HSUS) of the USA RAND Corporation, by comparison, includes judgments on 
the benefit and risk of care. It states that appropriate care means that “the expected 
health benefit exceeds the negative consequences by a sufficiently wide margin that the 
procedure is worth doing” (Kahn et al., 1988, p.418). 
 
This definition was developed after much research and takes a medical perspective by 
weighing risk against benefit. However, it has been criticised because it ignores the 
individuality of patients and does not take their needs and preferences into consideration 
(Buetow et al., 1997). It also does not specify the nature and size of the expected risk 
and benefit (Hicks, 1994) or clarify when the benefit of the procedure becomes 
sufficiently large that it is therefore worth doing. Further, there is no consideration of the 
financial implications of care (Buetow et al., 1997). In the UK, appropriate care has been 
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defined alternatively as the selection “of the intervention that is most likely to produce 
the outcomes desired by the individual patient” (Working group for the Director of 
Research and Development of the NHS Management Executive, 1993, p.117).  
 
This definition clearly includes the patient’s perspective but again, does not encompass 
the cost-effectiveness implications (Buetow et al., 1997). In general, definitions of 
appropriateness in healthcare tend to include one or more of the following: provision of 
care that is effective, evidence-based, cost-effective, and consistent with the ethical 
principles and preferences of the individual or society (World Health Organisation, 
2000). Appropriateness in healthcare is a judgment across these different dimensions. 
These dimensions are also relevant when considering appropriate prescribing. For 
instance, Lexchin (1998) has described appropriate prescribing as ‘trying to maximise 
effectiveness, minimise risks and costs, and respecting patients’ choice. An earlier 
publication by Barber (1995) stated that prescribers should try to achieve the above aims 
highlighted by Lexchin (1998) in order to ensure good prescribing.  
 
Whether a medication is seen as effective, safe (including risks) and sometimes cost-
effective has been referred to as pharmacological appropriateness (Spinewine et al., 
2007). Effectiveness, risks, costs and patient choice are discussed in sections 1.4.2 to 
1.4.5, followed by a discussion of another definition of appropriate prescribing 
(outcome-focused prescribing) by Buetow et al. (1997) in section 1.4.6.  
1.4.2. Effectiveness 
The definition of effect is usually based on the biomedical model of disease (Barber, 
1995). It involves the use of objective measurements to assess effect: for example, blood 
pressure lowering below a certain point. The effectiveness of treatments including 
medications, is usually established in clinical trials, especially, randomised controlled 
trials (hereafter RCTs) which are considered as the gold standard in clinical research 
(Dale, 2005; Lomas and Haynes, 1988; Tucker and Roth, 2006). RCTs from multiple 
studies are synthesized in systematic reviews and meta-analyses in order to provide a 
quantitative estimate of net benefit aggregated over all the included studies (Crombie, 
2009; Naylor, 1995). Where available, these reviews are usually the foundation for 
guidelines that establish the standards for best practices in healthcare (Tucker and Roth, 
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2006). Guidelines may also be based on expert opinions where there is no evidence from 
clinical trials or observational studies (Geleris and Boudoulas, 2011).  
 
Most of the evidence from clinical trials concerning psychiatric medications and opioids 
for chronic pain do not include people with SUDs (Furlan et al., 2006; Ostacher, 2011; 
Samet and Walley, 2008). Intervention studies targeted at individuals with both SUDs 
and chronic pain or mental health problems are rare. People with SUDs are particularly 
difficult to recruit into studies due to issues of trust between people with SUDs and 
recruiters since substance use is a sensitive topic and may sometimes be illegal (Ompad 
et al., 2008; Oransky et al., 2009). Perceived risk of research participation including 
concerns about personal risk, discomfort and inconvenience have also been identified as 
barriers to research participation among this group (Barratt, Norman and Fry, 2007).  
 
Where people with SUDs are included in research, it usually involves the use of 
restricted samples that do not mirror the heterogeneous and often complex group of 
people with SUDs who are likely to be encountered in real-life settings (Blanco et al., 
2008; Tucker and Roth, 2006). In RCTs involving people with SUDs, it is common for 
investigators to exclude those with complicating comorbidities and circumstances 
(Hoertel et al., 2014; Humphreys et al., 2005). The complex problems of this client 
group include co-existing physical and mental health problems (Hoertel et al., 2014; 
McLellan, 2009), use of multiple medications (Oluyase et al., 2013), cognitive 
impairments, family disruptions, social as well as economic deprivation (Lloyd, 1998). 
Consequently, they present with problems that lie outside the remit of guidelines which 
are usually focused on ‘normal’ populations. Guidelines based on studies excluding 
people with SUDs or those focused on homogeneous populations with SUDs may 
therefore not be appropriate for this patient population as their findings cannot be 
directly extrapolated to the heterogeneous population of people with SUDs. Prescribing 
in such situations may need to be outside guideline recommendations or regulatory 
approval (off-label prescribing) (Ali and Ajmal, 2012).  
 
The psychopathology of addiction also adds to the complexity of managing people with 
SUDs. Chronic exposure to substances usually leads to changes in the neurochemistry of 
reward pathways in the brain (The British Pain Society, 2007). This leads to the 
development of tolerance and eventually withdrawal symptoms if the substance is 
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stopped (Action on Addiction, 2013). Tolerance occurs when identical doses of a drug 
induce decreasing levels of effect or higher doses are needed to produce the same level 
of effect (The British Pain Society, 2007). Tolerance may have implications for some 
aspects of medication use such as dosing. For instance, tolerance to opioids makes the 
usual opioid doses inadequate (Gershwin and Hamilton, 1998), and higher doses that 
exceed that used in the general population will be needed. Similarly, tolerance to the 
effects of psychiatric medications such as benzodiazepines may lead to the need for 
higher doses to achieve the same effect (Willems et al., 2013). Furthermore, opioid 
tolerance in people with SUDs may be complicated by the need for further dose 
escalation during opioid therapy as a result of opioid-induced abnormal pain sensitivity 
(opioid-induced hyperalgesia) which manifests as increased pain (Ballantyne and Mao, 
2003).    
 
Overall, the definition of effectiveness applicable to populations with mental disorders 
and chronic pain is not directly applicable to people with SUDs who have these 
comorbidities because most of the evidence on which effectiveness is based does not 
include them. Where they include SUDs patients, they focus on a restricted sample that 
does not adequately represent this heterogeneous population who often have complex 
needs. This implies that effectiveness is limited when considering the appropriateness of 
prescribing for people with SUDs. Changes in the brain following chronic substance use 
further imply that prescribing for SUD patients may sometimes need to exceed that of 
the general population.  
1.4.3. Minimising risk  
Risk has been defined as the probability of an untoward happening resulting from drug 
treatment (Barber, 1995). All medications including prescribed ones carry the potential 
for harm in addition to their benefits (Barber et al., 2005). Further, individual 
medications for specific diseases may be less beneficial or even harmful when used 
along with other medications (Tinetti, Bogardus and Agostini, 2004) or substances in 
people with SUDs. People with SUDs are highly susceptible to medication-related risks 
due to their use of multiple substances with medications. Medications such as 
benzodiazepines, antidepressants and opioids have been implicated in adverse events 
including overdose and mortality in patients with SUDs (Darke, Duflou and Torok, 
2011; Darke and Hall, 2003; Darke and Ross, 2000). The need to sometimes treat people 
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with SUDs outside the confines of guidelines also carries its own risks. Before 
prescribing off-label, the General Medical Council’s Good Practice guidelines (General 
Medical Council, 2013) recommend that the prescriber should either be satisfied that 
sufficient evidence exists or they should have sufficient experience of using the 
medication to ensure safety and effectiveness. However, most off-label prescribing have 
not been evaluated for their safety and effectiveness (Chen et al., 2006). Prescribing off-
label therefore places greater professional responsibility and liability on prescribers 
(General Medical Council, 2013).  
 
Substance use may further contribute to the intensity of adverse effects experienced by 
people with SUDs. For example, SUD patients may have higher levels of side effects 
and toxicity with limited clinical benefits when compared to those without SUDs. 
Among schizophrenic patients treated with antipsychotics, higher levels of 
extrapyramidal symptoms have been reported among patients with comorbid SUDs than 
those without SUDs (Potvin et al., 2006). Treating persistent pain with higher opioid 
doses in people with SUDs may be counterproductive due to opioid-induced 
hyperalgesia as analgesia may never be achieved and the potential for opioid toxicity is 
greatly increased (Ballantyne and Mao, 2003).  
 
Although prescribers try to achieve clinical benefit with minimal risk of harm, there is 
sometimes conflict between balancing effectiveness and risk (Barber, 1995). Besides the 
possibility of toxicity, the need for high doses of psychiatric medications or opioids may 
also expose the patient to the risk of dependence on those with dependence potential 
such as benzodiazepines and opioids. In addition, people with SUDs may exceed the 
recommended doses of these medications with the potential for overdosing (Action on 
Addiction, 2013; Edlund and Harris, 2006). A key feature of dependence is loss of 
ability to regulate and control behaviour (Griffiths, 2013). There will therefore be need 
to set boundaries, behavioural rules as well as monitoring and follow-up (Action on 
Addiction, 2013; Gershwin and Hamilton, 1998). Patients on repeat prescriptions of 
these medications will also need to be monitored regularly to ensure that their 
medications are still needed and to resolve any drug-therapy problem.  
 
There is need for caution when prescribing medications with dependence potential such 
as benzodiazepines and opioids for abstinent people with a history of SUDs because they 
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may be prone to relapse. Prolonged abstinence from protracted substance use is usually 
accompanied by craving, high stress responsiveness and negative emotional state, all of 
which makes the patient prone to relapse when exposed to the same substance or another 
substance (including medication) with dependence potential (Action on Addiction, 
2013). In people with a history of SUDs, any reinforcing drug including those from 
another class can lead to craving and relapse (Savage, 2002). The neuroplastic changes 
caused by substances are not fully reversible and may explain the risk of relapse in 
people who have a history of SUDs (Action on Addiction, 2013). The potential for 
medication-related risk may be higher in people with SUDs. Appropriate prescribing 
would therefore involve minimising risk as much as possible while ensuring optimal 
benefit from medications.  
1.4.4. Minimising costs  
Relevant costs include medication costs, costs associated with the need for medication 
monitoring, administration (for example by a nurse) and dispensing costs (Barber, 1995). 
In particular, prescription items cost the National Health Service (hereafter NHS) £13.3 
billion in 2012 with 62.2% and 36.5% of this cost attributable to primary care and 
hospital use respectively (Health and Social Care Information Centre, 2013). The cost of 
medications is of particular relevance because it can be managed by prescribers through 
cost-effective prescribing. In the UK, there is a strong push for prescribing of generic 
medications wherever possible because they are cheaper than branded products, with no 
difference in their efficacy for most medications (Meadows, 2005). It is an NHS 
directive for prescribers to prescribe generic drugs unless there is clinical justification 
for branded prescribing (Williamson et al., 2010). The NHS is publicly funded and 
reducing medication cost allows for the availability of more funds for other areas of 
healthcare (Barber, 1995). 
 
As described in section 1.4.2, people with SUDs present a myriad of health and life 
problems and they may require more medications than that used in the general 
population in order to maintain their stability and functioning. Consequently, a 
dimension of cost that needs to be considered among people with SUDs is the cost of 
relapse to substances for them and the society if there are not prescribed medications that 
meet their needs. This sort of prescribing may well include prescribing that is outside 
guideline recommendations. Although prescribing outwith guidelines carries its own risk 
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(Sugarman et al., 2013), dosage or duration that exceeds guideline recommendations 
may be clinically justifiable if it promotes the patient’s stability and prevents relapse to a 
substance-using lifestyle. For instance, illicit drug use is associated with great societal 
cost. This includes cost to the individual in terms of premature death and drug-related 
illnesses (BMA Board of Science, 2013). Other societal costs include the costs of drug-
related crime or violence as well as damage to marital/family relationships (BMA Board 
of Science, 2013). The economic and social costs of drug use including heroin, crack, 
cocaine, ecstasy, methadone, LSD and psilocybin (magic mushrooms), in 2003-2004 in 
England and Wales were estimated by a Home Office report to be £15.4 billion 
(Singleton, Murray and Tinsley, 2006).  
 
Appropriate prescribing in this population therefore involves cost-effective prescribing 
among equally potent alternatives as well as consideration of the consequences that may 
result from not prescribing medications or prescribing inadequate medications. It could 
be argued that it is cheaper to prescribe more medications (than that used in the general 
population) if this will contribute to the service user’s stability and optimal functioning 
and therefore prevent relapse.   
1.4.5. Patient choice 
Patient involvement in their own care has gained momentum over the past decades and 
now represents a core value in the medical profession (General Medical Council., 2009). 
Ethical and practical reasons have also been advanced on the need for the inclusion of 
patient’s choice, particularly informed choice in prescribing (Barber, 1995). It is the 
patient who bears the immediate burden of illness and prescribing should assist the 
patient in alleviating this burden (Cribb and Barber, 1997). Furthermore, as discussed in 
section 1.4.3, prescribing often carries its own risk. It is therefore pertinent that clinical 
decisions integrate patient’s preferences and the trade-off patients are willing to make in 
terms of the risk of various health outcomes (Tinetti, Bogardus and Agostini, 2004). This 
may include a choice of not having medications prescribed (Barber et al., 2005). 
 
The generalisability of results from studies that exclude people with SUDs or that 
includes only homogeneous SUDs populations is unknown. The lack of a solid evidence 
base often leads to uncertainty about prescribing and the best approach for clinical 
management. Patients in particular have an important role to play in determining the best 
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course of action when such uncertainties exist (Evans et al., 2011). It could be argued 
people with SUDs should be more involved with prescribing decisions than the general 
population due to these uncertainties. They should therefore be provided adequate 
information (including treatment risks and benefits) that will allow them make an 
informed choice concerning their management (Towle et al., 2006). They should be able 
to express their expectations and preferences; there should be effective communication 
between the prescriber and patient as well as partnership for the best decision to be 
arrived at (Little et al., 2001). There is a need to tailor therapy to meet the needs of 
individual patients according to their unique attributes as patients may differ in their 
illness presentation, their understanding and acceptance of treatment, preferences as well 
as their responses (Dale, 2005; Sullivan and MacNaughton, 1996).  
 
Patients have been found to influence prescribers in primary care (Britten and 
Ukoumunne, 1997; Cockburn and Pit, 1997), and secondary care settings (Lewis and 
Tully, 2011; Merrill et al., 2002). Previous studies have described patient pressure or 
request for medications as one of the reasons for prescribing. A study carried out in 
general practice settings in England reported that doctors described being very pressured 
by patients to prescribe in 3% of consultations (Britten et al., 2003). Cockburn and Pit 
(1997) explored patients’ expectations and GP’s perception of patients’ expectations on 
prescribing in general practice settings in Australia and found that patients who expect 
medications were three times more likely to receive them and when general practitioners 
(hereafter GPs) thought that the patient expected medications, such patients were ten 
times more likely to receive them.  
 
The tendency for doctors to prescribe due to patient pressure has been described as a 
means of avoiding spending time with patients (Harris, Heywood and Clayden, 1990). 
Prescribing could be used as a means of terminating difficult consultations (Britten, 
1995). This may be more common among patient groups such as those with SUDs. 
There is evidence that consultations with SUD patients may be difficult because they 
may withhold information (Action on Addiction, 2013) or may be manipulative 
(Conway, 2000; McGillion et al., 2000; McKeown, Matheson and Bond, 2003). This 
may lead to some of these patients receiving inappropriate medications or those with 
little or no pharmacological benefits but with the potential for side effects (Ashworth, 
Clement and Wright, 2002; Lewis and Tully, 2011). Some prescriptions are thought to 
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be unnecessary by those who prescribed them (Britten et al., 2003; Macfarlane et al., 
1997). Patient involvement may therefore present a problem when considering 
prescribing appropriateness (Schwartz, Soumerai and Avorn, 1989; Young and Ward, 
2001). Complying with a patient’s choice could be problematic and unethical as they 
may request medications that are not clinically justifiable (Barber, 1995). This may take 
the form of request for a drug of abuse or request for a medication for its euphoric 
effects. People with SUDs may be more likely to demand medications they do not need 
because of their impaired control over drug use (Action on Addiction, 2013). This could 
lead to conflicts between the prescriber’s assessment of the patient’s needs and the 
patient’s preferences and there is no simple means of resolving the question of how far 
the goals of therapy should be determined by patient’s wants rather than professionally-
assessed need (Cribb and Barber, 1997).  
 
Furthermore, during periods of active dependence, clinicians may lose access to one of 
the most fundamental tools in medicine: the patient’s self-report (Bailey, Hurley and 
Gold, 2010). Patients with SUDs may not be open about the substances and medications 
they use. Some have been described as difficult, aggressive, manipulative and rude 
(Conway, 2000; McGillion et al., 2000; McKeown, Matheson and Bond, 2003) and 
consequently challenging to treat. The weight therefore accorded to patient’s choice 
would need to be carefully considered to minimise medication-related risk. In addiction 
medicine, these issues are sometimes faced by clinicians and have led to the introduction 
of ‘safeguards’ such as limit setting, regular urine testing, supervision of drug 
administration and regular review of health and functioning (Action on Addiction, 
2013). 
 
People with SUDs can also experience stigma and discrimination in healthcare settings 
which can hinder care-seeking and also result in poor quality of care by healthcare 
professionals (Ahern, Stuber and Galea, 2007; Link et al., 1997). For example, a study 
where doctors and problem drug users who had been admitted to a hospital in the USA 
were interviewed found that doctors described concerns about being deceived by 
patients with opioid use disorders (hereafter OUDs) particularly where opiate pain relief 
was needed or requested (Merrill et al., 2002). The patients in this study also expressed 
concerns about receiving poor medical care as they described being intentionally 
mistreated due to their addiction. The doctors further expressed fear of being 
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manipulated into inappropriately prescribing opiates. These concerns by doctors may 
ultimately result in denying patients needed medications. Henderson et al. (2008) in a 
study that examined care delivery to substance users in a hospital emergency department 
in USA also expressed concerns around drug-seeking behaviour by substance users. This 
study concluded that care had a different tone or quality when patients had alcohol or 
drug problems and clinical decisions were sometimes influenced by providers’ adverse 
social judgments.  
 
This thesis provides a means to further explore the complexities around the quality of 
medical care, in particular, medications provided to this underserved and often 
stigmatised population in a SAS in the UK. This thesis goes a step further than previous 
studies by considering psychiatric medications as well as opioids while also including 
the patient and prescriber perspectives on prescribing. The patient’s perspective explored 
their views on the appropriateness of prescribing of psychiatric medications and opioids. 
The prescriber perspective involved assessment of the appropriateness of psychiatric 
medications and opioids using questionnaires and also exploring how they responded to 
inappropriate prescribing in a SAS.   
1.4.6. Outcome-focused prescribing 
Another definition by Buetow et al. (1997, p.261) considers appropriate prescribing to 
be “the outcome of a process of decision-making that maximizes net individual health 
gains within society's available resources”.  
 
This definition is focused on the outcome of prescribing. It is particularly important 
because prescribing for people with co-existing mental disorders or chronic pain and 
SUDs may need to be outside guideline recommendations because of their often 
complex presentation and circumstances. As described in section 1.4.2, people with 
SUDs are often excluded from the evidence on which guidelines are based and they 
present with issues that are not addressed in guidelines. There is generally lack of a solid 
evidence base for the management of individuals with these comorbidities. The 
outcomes of these patients therefore play a pivotal role in assessing the appropriateness 
of prescribing.  
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Buetow et al. (1997) have argued that it is possible for prescribing to follow the right or 
‘rational’ decision-making process that involves considering effectiveness, risk and cost 
and still result in poor outcomes. This may happen when correct reasoning is not applied 
to the patient’s individual circumstance. The definition by Buetow et al. (1997) suggests 
that appropriate prescribing takes into consideration the needs of individual patients 
within population-centred constraints. Poor outcomes may result if patients’ preferences 
are not elicited or if the patient is treated as a condition rather than a person (Barber et 
al., 2005). Buetow’s definition therefore extends beyond mere pharmacological 
appropriateness to include the outcome of the prescribing process. If the outcome of 
prescribing is good for an individual, then this definition suggests that is appropriate 
prescribing.  
 
Furthermore, it is pertinent to state that the targeted outcome of prescribing may be non-
medical. Reduced social functioning of people who are dependent on substances may 
lead to harm for both the user and people around them (Strategy Unit Drugs Report, 
2003). Substance use reduces capacity for work, may lead to breakdown of family 
relationships, violence and crime (Choi and Pope, 1994; Miller, Maguin and Downs, 
1997; Sinha and Easton, 1999; Strategy Unit Drugs Report, 2003). The need for crime 
reduction has been identified as one of the reasons for substitute prescribing among 
people who are dependent on opiates (Coid et al., 2000). For instance, the increase in 
methadone prescribing in the UK was not only aimed at reducing opiate use but also 
crime (Coid et al., 2000). 
 
Generally, a strong association between SUDs and crime has been reported in the 
literature (Hammersley, Forsyth and Lavelle, 1990; Reuter and Stevens, 2008; Sinha and 
Easton, 1999). There is however continued debate concerning the causal pathway 
between substance use and crime with suggestions that the use of substances causes 
crime because users may need to commit crime in order to finance their drug habits 
while others have argued that crime often precedes substance use (Coid et al., 2000). 
The former suggestion implies that a supply of substances on prescription such as opioid 
substitute prescribing may well reduce the need to commit crime in order to finance drug 
use (Coid et al., 2000). 
 
39 
 
Patients have reported that psychiatric medications such as antidepressants have assisted 
them in returning to normal functioning including fulfilling their social roles and 
regaining control (Malpass et al., 2009). Benzodiazepines have also been reported to 
assist patients in dealing with daily stress (Cook et al., 2007) and patients have often 
described their reliance on them (Iliffe et al., 2004; Cook et al., 2007). These findings 
suggest that prescribing of psychiatric medications have profound effects on patients as 
they assist them in living normal lives, with the potential for benefits for those around 
the patient. It could be argued that benefits accruing from these medications contribute 
to maintaining equilibrium in the lives of these patients, many of whom have complex 
life problems, while also assisting in preventing relapse to a substance-using lifestyle 
and its associated consequences such as crime described above.    
 
There is the need to consider the impact of prescribing on those around the patient since 
prescribing may lead to benefit or harm for others (Cribb and Barber, 1997). For 
instance, concerns have been raised that the prescription of opioids for chronic non-
cancer pain may lead to an increase in their non-medical use in the community (Collett, 
2001). A decision to prescribe should therefore include consideration of the impact of 
prescribing within society as well. 
 
In this thesis, the term appropriate prescribing encompasses both the process of decision-
making as well as the outcome of this process.  
1.4.7. Measures for assessing prescribing appropriateness  
In this thesis, identification of the measures used in assessing prescribing 
appropriateness involved a systematic approach. The review published by Spinewine et 
al. (2007) on different instruments that are available to measure prescribing 
appropriateness in the elderly was the starting point. This was followed by a systematic 
search of Medline database for other measures.  
 
Two of the most important set of values in judging appropriateness are what the patient 
wants or prefers and the scientific rationalisation (pharmacological appropriateness) 
(Cribb and Barber, 1997). Most of the published research on this topic have focused on 
assessment of pharmacological appropriateness (Barber et al., 2005). However, Barber et 
al. (2005) found that judgments on appropriateness that included patient’s preferences 
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and contextual factors sometimes led to better conclusions when compared with those 
based solely on pharmacological criteria. Two studies were found that assessed patients’ 
wants or preferences and these were incorporated into decision-making when judging 
prescribing appropriateness (Barber et al., 2005; Britten et al., 2003). In the study by 
Barber et al. (2005) patient perspectives were obtained through in-depth interviews 
while Britten et al. (2003) used questionnaire surveys. By contrast, pharmacological 
appropriateness has been assessed using different measures. This section will discuss the 
measures that have been used in assessing pharmacological appropriateness due to its 
predominance in the literature. They include explicit (criterion-based) or implicit 
(judgment-based) measures.  
1.4.7.1. Explicit or criterion-based measures 
Explicit measures are usually developed from expert opinions, published reviews and 
consensus methods (Spinewine et al., 2007). Generally, explicit measures focus on 
narrow categories of medications or are disease-oriented and require little or no clinical 
judgment to be applied (Buetow et al., 1997). They do not tend to take into consideration 
factors such as comorbidities and patients’ choices (Boyd et al., 2005; Tinetti, Bogardus 
and Agostini, 2004). Moreover, in prescribing research, evidence of validity and 
reliability of consensus methods are usually lacking (Buetow et al., 1997). Despite these 
shortcomings, explicit measures are time-saving when compared with other methods for 
assessing prescribing appropriateness as they can be applied to large databases. 
Examples of explicit measures are the Beers criteria (Beers et al., 1991) and its 
derivatives
4
 (Dimitrow et al., 2011), Assessing Care of the Vulnerable Elder (hereafter 
ACOVE) criteria (Wenger and Shekelle, 2001), START (Screening Tool to Alert to 
Right Treatment) criteria (Barry et al., 2007) and STOPP (Screening Tool of Older 
Persons’ Prescriptions) criteria (Gallagher et al., 2008).  
 
Beers criteria consist of a list of drugs to avoid as well as doses that should not be 
exceeded in the elderly whereas ACOVE criteria include indicators for appropriate 
treatment, prevention, monitoring, education and documentation for the elderly (Wenger 
and Shekelle, 2001; Beers et al., 1991). START consist of criteria for the detection of 
prescribing omissions in the elderly whereas STOPP was developed to identify 
potentially inappropriate drugs in the elderly population. Other examples of explicit 
                                                 
4 Derivatives of the Beers criteria include the Norwegian General Practice Criteria (NORGEP) criteria, Improving 
Prescribing in the Elderly tool, McLeod’s criteria, Zhan’s criteria and the French criteria. 
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measures include manufacturers’ recommendations, defined daily dose (hereafter DDD)5 
such as diazepam milligram equivalents for benzodiazepines and treatment guidelines. 
Explicit measures have been used to detect overprescribing (prescribing more 
medications than clinically needed) and underprescribing (defined as failure to prescribe 
needed medications or medication omission) (Briesacher et al., 2005; Oborne et al., 
2002; Strothers et al., 2005; Unutzer et al., 2004). They are however limited because 
they do not consider patients’ perspective of prescribing (Hanlon and Schmader, 2013).  
1.4.7.2. Implicit or judgment-based measures  
Implicit measures are judgment-based measures which usually utilise information 
collected from patients and published evidence to arrive at a clinical decision (Spinewine 
et al., 2007). Although implicit measures are sensitive and usually consider patients’ 
preferences, they depend on clinicians’ knowledge, are time-consuming and have low 
reliability (ibid). They are usually neither reproducible nor generalisable and can be 
highly subjective (Spinewine et al., 2007).  
 
These shortcomings can be addressed by developing a standardised data collection tool 
that will improve reliability and validity such as the Medication Appropriateness Index 
(hereafter MAI) (Hanlon et al., 1992; Samsa et al., 1994), Prescribing Appropriateness 
Index (hereafter PAI) (Cantrill, Sibbald and Buetow, 1998) and the Assessment of 
Underutilisation of Medication index (hereafter AOU) (Jeffery et al., 1999). The PAI 
was developed to assess long–term prescribing in general practice in the UK and is 
restricted to the British National Formulary (hereafter BNF) while the MAI was 
developed to address multiple elements of drug prescribing and is applicable to various 
medications and conditions. The AOU is used to assess underprescribing of medications 
(Spinewine et al., 2007). It requires that a health professional matches a list of medical 
disorders to prescribed medications in order to establish if there is an omission of a 
needed medication. The MAI will be further discussed below because it was adapted for 
use in this thesis. 
 
The Medication Appropriateness Index (MAI) 
The MAI has been used in diverse types of studies to assess prescribing appropriateness 
by different healthcare professionals (Crotty et al., 2004; Hanlon et al., 1992; Schmader 
et al., 1994; Schmader et al., 2004). It was developed by American healthcare 
                                                 
5 The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. 
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professionals and measures 10 dimensions of prescribing, namely: indication, 
effectiveness, dosage, correct directions, drug-drug interactions, drug-disease 
interactions, practical directions, expense, duplication and duration (Hanlon et al., 1992). 
The dimensions on the index are based on a review of the literature and the clinical 
experience of the developers. Despite the fact that clinical judgment is needed in rating 
some MAI dimensions, it has operational definitions and instructions that assist in 
standardising the process (Hanlon et al., 1992; Spinewine et al., 2007). The different 
MAI dimensions are rated as appropriate, marginally appropriate and inappropriate for 
each medication that is being used by the patient. If additional information is needed to 
answer a question on the MAI, a rating of ‘don’t know’ may be given. The MAI has a 
section for comments after each question.  
 
Weights ranging from 0 to 3 are assigned to each dimension which can be summated to 
give a total score ranging from 0 to 18 (Samsa et al., 1994). Indication and effectiveness 
have the highest weight of 3 as they are considered to be the most important dimensions. 
Dosage, correct directions, drug-drug- interactions and drug-disease interactions are 
given equal weights of 2 whilst practical directions, expense, duplication and duration 
are each given weights of 1. A score of 0 indicates there are no inappropriate dimensions 
while a score of 18 indicates that all dimensions for the medication are inappropriate. If 
the patient is taking multiple medications, the score for each medication could be 
summed up to obtain a score for the patient. Thus, either the patient or the medication 
could be used as the unit of analysis.  
 
In this thesis, the MAI was adapted for use by prescribers in the assessment of the 
appropriateness of psychiatric medications and opioids because it allows for clinical 
judgment and also focuses on the patient (O’Connor, Gallagher and O’Mahony, 2012). It 
allows the patient’s perspective to be considered and is applicable to any medication or 
clinical condition in any setting (O’Connor, Gallagher and O’Mahony, 2012). An 
alternative measure such as the PAI is restricted to medications in the BNF and also has 
a focus on hypertension. Although both the MAI and PAI have a standardised format, 
the MAI has the advantage of having instructions for its use, specific definitions of each 
dimension, instructions on how to answer each of the 10 questions and examples of 
appropriate, marginally appropriate and inappropriate ratings (Hanlon and Schmader, 
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2013). The MAI is also the commonly used implicit measure for assessing prescribing 
appropriateness (O’Connor, Gallagher and O’Mahony, 2012).     
 
For the MAI to be used, the minimal requirements are the patient’s current medical 
history problem list and the medication list. The validity and reliability of the MAI have 
been widely tested and good inter-rater and intra-rater reliability has been found. Hanlon 
et al. (1992) evaluated the reliability of MAI ratings between a clinical pharmacist and a 
geriatrician using ambulatory elderly male patients. Independent assessments of the 
appropriateness of chronic medications taken by these patients were made by the clinical 
pharmacist and geriatrician and agreement was assessed using kappa statistic, a 
statistical measure that indicates the proportion of agreement beyond that expected by 
chance (Cohen, 1960; Cohen, 1968). The kappa statistic was found to be 0.83 for inter-
rater agreement and 0.92 for intra-rater agreement. Inter-rater reliability assesses the 
agreement between ratings made by two or more clinicians whereas intra-rater reliability 
measures agreement between ratings made by the same clinician on at least two 
occasions (Sim and Wright, 2005). A kappa statistic of 0 means that agreement is not 
better than that expected by chance.  
 
Landis and Koch (1977) have suggested that kappa coefficients of 0.41 to 0.60 represent 
moderate strength of agreement, 0.61 to 0.80 represent substantial agreement whereas > 
0.81 represent very good agreement (Landis and Koch, 1977). The values of kappa 
ranges from -1 to 1, with -1 indicating agreement is worse than that expected by chance 
and 1 indicating perfect agreement (Sim and Wright, 2005). Additionally, inter-rater 
agreement was also assessed between two clinical pharmacists and the kappa statistic 
found to be 0.59.  
 
Content validity, in particular item suitability and weighting have also been assessed in a 
previous study which found that healthcare professionals (geriatricians, internists, 
clinical pharmacists) considered MAI dimensions to be ‘definitely’ important or 
‘moderately’ important measures of prescribing appropriateness (Samsa et al., 1994). 
Moreover, the healthcare professionals surveyed were able to distinguish the relative 
importance of the different MAI dimensions with the development of a weighting 
scheme which can be combined to get a single summated score as described above. In 
the study by Samsa et al. (1994), the summated MAI also demonstrated descriptive 
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validity as the heterogeneity in prescribing appropriateness among patients was reflected 
in the distribution of the MAI scores. For instance, one quarter (25.5%) of medications 
had a score of 0 which implies that there were no ‘inappropriate’ MAI dimensions; 
38.5% had scores of 1 to 2 and 36% had scores of > 3. The validity and reliability of the 
MAI has however not been assessed among people with SUDs. Despite the utility of the 
MAI, it does not address the issue of adherence, adverse drug reactions and drug allergy 
(Spinewine et al., 2006). It has the potential to be time-consuming and does not assess 
underprescribing (Bergkvist et al., 2009).  
1.4.8. Summary: Appropriateness concept in prescribing  
Appropriate prescribing is a complex concept involving a judgment across a number of 
factors such as effectiveness, risk, cost, patients’ choices, patients’ outcomes as well as 
the societal impact of prescribing. It often entails making a complex trade-off between 
conflicting aims (Barber, 1995). Effectiveness will need to be balanced against risk. 
Patient preferences will also need to be weighed against effectiveness, safety and the 
general good of the society. The applicability of effectiveness is however somewhat 
limited when considering people with comorbid mental disorders or chronic pain and 
SUDs because SUDs is usually an exclusionary criterion in studies assessing 
medications for these comorbidities. Furthermore, studies that include SUD patients do 
not include those with complex comorbidities and circumstances. In practice, the 
consultation between a patient with a SUD and her prescriber is an active process in 
which the prescriber deals with the individual and her complex needs (Sullivan and 
MacNaughton, 1996). Decision-making on the appropriateness of prescribing for a SUD 
patient will inevitably involve consideration of the evidence-base, clinical judgment, the 
patient’s perspective and outcomes, unique circumstances of the patient (Straus et al., 
2011; Sullivan and MacNaughton, 1996) and the societal impact of prescribing.  
 
Most of the measures that have been used in assessing prescribing appropriateness have 
focused solely on pharmacological appropriateness (effectiveness, safety and cost) using 
explicit or implicit measures while neglecting patients’ wants or preferences. However, 
the few studies that have included patients’ preferences have come to a more robust 
conclusion when compared with those based solely on pharmacological criteria. The 
consideration of patients’ views in this thesis provides a way to explore appropriateness 
from their perspective. Prescribers assessed pharmacological appropriateness using an 
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adapted version of the MAI and a questionnaire designed in this research for medication 
omissions (medication omissions questionnaires). Interviews were carried out with them 
to explore how they responded to inappropriate prescribing. These different perspectives 
provided a more holistic picture on this complex subject. 
 
1.5. Comorbidities in people with SUDs 
More than half of people with SUDs have been found to have co-existing physical 
and/or mental health problems (McLellan, 2009), making their healthcare needs 
complex. The presence of these comorbidities and the medications used in treating them 
may lead to poor outcomes such as serious drug interactions and overdose (Darke and 
Ross, 2000; Zamparutti et al., 2011). Some of these health conditions may be 
consequences of SUDs or may be exacerbated by SUDs (Crome et al., 2009). A causal 
relationship has been found between alcohol and over sixty diseases with the presence of 
most comorbidities having a relationship with the volume and pattern of alcohol 
consumption (Rehm et al., 2003). Drug use disorders (hereafter DUDs) have also been 
associated with adverse health outcomes. For instance, intravenous drug users (hereafter 
IDUs) are vulnerable to thrombosis, abscesses and blood borne diseases particularly 
HIV, hepatitis B and C (Mehta et al., 2011; National Institute for Health and Clinical 
Excellence, 2007; Stein, 1990).  
 
Many people with SUDs also have poor mental health and vice versa (McManus et al., 
2009). Comorbidity in these patients have been associated with reduced life expectancy 
(Chang et al., 2011; Cosci and Fava, 2011), lower quality of life (Donovan et al., 2005; 
Smith and Larson, 2003), medication non-adherence (Drake and Mueser, 2000; Owen et 
al., 1996), more physical health problems (Batki et al., 2009; Phillips and Labrow, 2000) 
and increased length of hospitalisation (Lyketsos et al., 2002). In addition, the cost of 
caring for comorbid patients is much higher than for those with single conditions due to 
the need for greater service utilisation including emergency service (Hoff and 
Rosenheck, 1998; Hoff and Rosenheck, 1999; Teesson, Slade and Mills, 2009).  
 
Another prevalent comorbid condition with SUDs is chronic pain. Chronic pain is 
usually defined as pain of more than three months duration (Martell et al., 2007; 
Rosenblum et al., 2003). Opioids are one of the groups of medications commonly used 
in chronic pain management (Fishbain et al., 2008). However, some patients being 
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treated with opioids may develop OUDs including dependence (Fishbain et al., 2008; 
Portenoy, 1996). A strong predictor of OUDs is a history of SUDs. The next section 
further examines comorbid chronic pain and mental health conditions in people with 
SUDs. 
1.5.1. Co-existing chronic pain and SUDs 
Chronic pain (pain of more than three months duration) has been reported to be a 
prevalent comorbidity in people with SUDs and vice versa (Caldeiro et al., 2008; 
Jamison et al., 2000; Kouyanou, Pither and Wessely, 1997; Martell et al., 2007; Peles et 
al., 2005; Rosenblum et al., 2003). Studies relevant to this thesis have focused on the 
prevalence of chronic pain in people with SUDs who are in treatment. Three studies 
(Jamison et al., 2000; Peles et al., 2005; Rosenblum et al., 2003) were found that 
assessed the prevalence of chronic pain among opioid dependent patients in methadone 
maintenance treatment programmes (hereafter MMTPs). These studies all reported 
higher prevalence of chronic pain when compared to other studies that assessed chronic 
pain in people using other substances besides opioids (Caldeiro et al., 2008) or a mixed 
population that included both those using opioids and other substances (Larson et al., 
2007).  
 
Rosenblum et al. (2003) also reported on the prevalence of chronic pain among opioid 
dependent patients in inpatient residential treatment programmes (hereafter RTPs) for 
alcohol or cocaine dependence. Caldeiro et al. (2008) assessed chronic pain among SUD 
patients in an outpatient addiction centre who are dependent on other substances besides 
opioids while Larson et al. (2007) assessed chronic pain among SUD patients in a 
residential detoxification programme. Patients were included in the study by Larson et 
al. (2007) if heroin, cocaine or alcohol were their first or second drug of choice. These 
studies have all been non-UK studies and have reported the prevalence of chronic pain to 
be between 16% and 61%. No UK study was found that has reported on the prevalence 
of chronic pain among people with SUDs in treatment. Table 1.1 provides a description 
of the percentage of people with SUDs in treatment who have chronic pain. 
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Table 1.1: Percentage of chronic pain among people with SUDs in treatment 
Author and 
country 
Population studied How pain was 
measured  
% with chronic 
pain 
Jamison et al. 
2000 (USA) 
Opioid dependent patients 
in MMTPs 
Questionnaire 
developed for study 
61.3% with pain of > 
4 months 
Rosenblum et 
al. 2003 
(USA) 
Opioid dependent patients 
in MMTPs and alcohol or 
cocaine dependent patients 
in RTPs 
Numeric scale 
adapted from the 
Brief Pain Inventory 
61% and 48% with 
pain of > 6 months 
in MMTPs and 
inpatient RTPs 
respectively  
Peles et al. 
2005 (Israel) 
Opioid dependent patients 
in MMTPs 
Ordinal scale  55.3% with pain of > 
6 months 
Larson et al. 
2007 (USA) 
Patients receiving 
residential substance abuse 
detoxification from heroin, 
alcohol or cocaine 
Pain section of the 
36-item Short-Form 
Health Survey (SF-
36) 
16% with pain over 
a two-year period 
Caldeiro et 
al. 2008 
(USA) 
Veterans attending 
outpatient addiction centres 
who are dependent on other 
drugs besides opioids 
Pain section of the 
36-item Short-Form 
Health Survey (SF-
36) 
33.2% with pain 
over a year period 
Where MMTPs = methadone maintenance treatment programmes and RTPs = residential treatment programmes 
 
In USA, Rosenblum et al. (2003) found that 61% of opioid dependent patients in MMTP 
and 48% of people in inpatient RTPs for alcohol or cocaine dependence had pain of at 
least six months duration. The prevalence of chronic severe pain defined as pain of more 
than six months duration and of moderate to severe intensity (intensity assessed on a 
numeric scale adapted from the Brief Pain Inventory) or that interfered with daily 
activities was found to be 37% in MMTPs and 24% in inpatient RTPs. A similar 
prevalence for chronic pain (61.3%) among opioid dependent patients in MMTPs was 
reported by another USA study (Jamison et al., 2000) which assessed pain of at least 
four months duration. Another study carried out by Peles et al. (2005) found the 
prevalence of chronic pain of any intensity defined as current pain lasting at least six 
months to be 55.3% among patients in MMTPs in Israel. The prevalence of chronic 
moderate to very severe pain assessed on an ordinal scale between 1 (mild) and 4 (very 
severe) was found to be 48.2%. Most patients reported having pain for over ten years 
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and that pain significantly interfered with their level of activity. Caldeiro et al. (2008) in 
another USA study found the prevalence of chronic pain of over one year duration 
among veterans attending outpatient addiction centres who were dependent on other 
substances besides opioids to be 33.2%. Chronic pain was considered to be pain of 
moderate to very severe intensity at all times. Larson et al. (2007) found the prevalence 
of chronic pain defined as moderate or a higher level of pain over a two-year period to 
be 16% among patients in a residential detoxification programme for heroin, alcohol or 
cocaine (Larson et al., 2007).  
 
Besides the studies by Rosenblum et al. (2003) and Jamison et al. (2000) which reported 
similar prevalence for chronic pain, the prevalence reported by other studies differed. 
The difference in the prevalence rates reported may have resulted from the diverse 
definitions of chronic pain used and the populations assessed. Some studies assessed 
pain of at least six months duration while others assessed pain of one or two-year 
duration in different populations. Furthermore, most used different scales for assessing 
chronic pain. 
 
Increased pain sensitivity (opioid-induced hyperalgesia) due to long-term use of opioids 
may be a possible explanation for the higher prevalence of pain among opioid dependent 
patients in MMTPs (Alford, Compton and Samet, 2006; Scimeca et al., 2000). Available 
evidence suggests long-term opioid use may intensify rather than ameliorate chronic 
pain (Carroll, Angst and Clark, 2004; Rapp, Ready and Nessly, 1995), leaving clinicians 
with very limited options for its treatment.  
  
Possible explanations for the frequent co-occurrence between chronic pain and SUDs 
include a shared common pathway between chronic pain and SUDs since both disorders 
have many shared neurophysiological patterns such as abnormal neural processing in the 
central nervous system (Centre for Substance Abuse Treatment, 2012), the use of 
substances to self-medicate or decrease the physical experience of pain (Rosenblum et 
al., 2003), or the development of pain as a result of injuries secondary to the risky 
lifestyle associated with prolonged SUDs (Compton, Darakjian and Miotto, 1998; 
Karasz et al., 2004). Furthermore, chronic pain (Bair et al., 2003; Manchikanti et al., 
2007) and SUDs (Boden and Fergusson, 2011; Strathdee et al., 2002) have been 
associated with mental disorders such as depression and anxiety. The comorbidity 
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between mental disorders and SUDs is further considered in the next section. The risk of 
mental disorders such as depression have been found to increase with worsening pain 
(Bair et al., 2003). Unrecognised and untreated mental disorders may exacerbate pain 
intensity and disability (Manchikanti et al., 2007).   
1.5.2. Co-existing mental disorders and SUDs 
Mental disorders commonly co-exist with SUDs (Boden and Fergusson, 2011; Grant et 
al., 2004; Mortlock et al., 2011; Regier et al., 1990; Weaver et al., 2003). This co-
existence is often referred to as dual diagnosis (Carter, Fisher and Isaac, 2013; Crome et 
al., 2009; Gafoor and Rassool, 1998). Other terms that have been used interchangeably 
with dual diagnosis include dual disorders and SUD comorbidity (Drake and Mueser, 
2000; Gilder et al., 2007). The term dual diagnosis is however preferred in the UK 
(Department of Health, 2002; Department of Health, 2006a). The definition of dual 
diagnosis remains controversial (Carter et al., 2013), as it may also refer to a 
heterogeneous group of individuals with more than just two illnesses (Cosci and Fava, 
2011; Drake et al., 2001).  
 
Different models or hypotheses have been proposed to explain the frequent co-
occurrence between mental disorders and SUDs. These models have proposed a shared, 
causal or bidirectional pathway (Merikangas et al., 1998; Mueser, Drake and Wallach, 
1998). The common factor model posits that one or more factors independently increase 
the risk of both mental disorders and SUDs (Bierut et al., 1998; Boden and Fergusson, 
2011; Kendler, Gruenberg and Kinney, 1994; McLaughlin et al., 2012; Mueser et al., 
1998). The bidirectional model proposes that interactional effects between mental 
disorders and SUDs are responsible for increased co-occurrence of these disorders 
(Mueser et al., 1998). The secondary psychiatric disorder model proposes that SUDs 
lead to or trigger mental disorders that otherwise would not have developed (Mueser et 
al., 1998; Torrens, Martin-Santos and Samet, 2006) while the secondary substance use 
disorder posits that mental disorders lead to SUDs (Mueser et al., 1998). 
 
In the UK, the prevalence of co-existing mental disorders and SUDs was found to be 
almost 30% across a range of treatment services (Strathdee et al., 2002). The highest 
rates were in substance misuse services (83%), followed by a forensic service with 56%. 
A rate of 43% was reported in an inpatient mental health service, with 20% in a 
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community mental health teams. The lowest rate (8%) was reported in a primary care 
sample. Generally, the prevalence reported in clinical populations is higher than that 
reported in general population samples (Grant et al., 2004; Kenneson, Funderburk and 
Maisto, 2013; Merikangas et al., 1998; Regier et al., 1990). This may be because people 
with multiple disorders are more likely to seek treatment resulting in the detection of 
higher rates of comorbid conditions in clinical populations (Bennett, Peer and Gjonbalaj-
Marovic, 2011; Grant, 1997). This greater treatment-seeking behaviour among people 
with comorbidity is usually referred to as Berkson’s bias (Berkson, 1946).  
 
Due to the wide variety of different combinations of mental disorders and SUDs that can 
co-occur (Compton et al., 2007; Crawford, Crome and Clancy, 2003; Lenzenweger et 
al., 2007), as well as the focus of this thesis on prescribing in a SAS, this section will 
concentrate only on the overlap between SUDs and the more prevalent mental disorders 
namely mood, anxiety and psychotic disorders in clinical populations. There have been 
many studies carried out on these comorbidities in the UK and they will be the focus of 
the subsequent sections.   
1.5.2.1. Mood and anxiety disorders 
Studies carried out in clinical populations in the UK have reported a high prevalence of 
mood and anxiety disorders (Delgadillo et al., 2012; Marsden et al., 2000; Strathdee et 
al., 2002; Virgo et al., 2001; Walsh and Copello, 2014; Weaver et al., 2003) among 
people with SUDs. The prevalence of depression among this population have been 
reported to be between 22.3% and 66% while that of anxiety disorders have been 
between 29% and 55%. Comorbid mood and/or anxiety disorders have been reported to 
be between 68% and 81% among this population. Table 1.2 below provides a description 
of the prevalence of comorbid mood and anxiety disorders among UK clinical 
populations with SUDs. 
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Table 1.2: Prevalence of comorbid mood and anxiety disorders among UK clinical 
populations with SUDs 
Author Population studied How mood and anxiety 
disorders were assessed  
% with comorbidity 
Marsden et 
al. 2000  
Dependent drug users in 
treatment
a
 
Mental disorders were 
assessed using the Brief 
Symptom Inventory   
22.3% had depression 
and 24.9% had anxiety 
disorders 
Virgo et al. 
2001  
Patients attending addiction 
services comprising 
community drug and alcohol 
teams, a rehabilitation ward 
and a day treatment unit
 
  
Mental disorders assessed 
using the Department of 
Health’s Building Bridges 
report criteria
b
 
66% had depression,  
29% had anxiety and 
5% had bipolar disorder 
Strathdee 
et al. 2002  
Clients in different services 
comprising substance misuse 
services, forensic service, 
inpatient mental health 
service, community mental 
health teams and primary 
care. 
45-60 mins dual diagnosis 
assessment  
55% had generalised 
anxiety disorder, 43% 
had agoraphobia and 
41% had depression 
Weaver et 
al. 2003
c
 
Clients in substance misuse 
settings
d
 
The Comprehensive 
Psychopathological 
Rating Scale and its sub-
scales for rating 
depression and anxiety 
disorders  
68% of drug service 
patients had a comorbid 
mood and/or anxiety 
disorder. 81% of alcohol 
service patients had a 
comorbid mood and/or 
anxiety disorder 
Delgadillo 
et al. 2012
e
 
Patients accessing a 
community drug treatment 
service 
Mental health diagnosis 
was established using the 
Revised Clinical 
Interview Schedule 
70% of patients had 
current depressive 
and/or anxiety disorders 
Walsh and 
Copello, 
2014 
Patients within statutory and 
non-statutory teams of a UK 
substance misuse treatment 
partnership 
Diagnosis recorded by 
keyworker
f
 
31.9% had major 
depression and 11.6% 
had bipolar disorder 
aIncludes those from inpatient units, rehabilitation units, methadone maintenance clinics and methadone reduction 
programs. 
 bThis definition includes any axis I disorder as a severe mental illness depending on the patient’s diagnosis and level 
of disability, vulnerability, risk and need for care.  
cThe mood disorders assessed were mild and severe depression while only severe anxiety was assessed.  
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dThe drug and alcohol services assessed were statutory providers that offered structured appointment-based services 
within nurse-led clinics. 
eIn addition to depression, the other disorders considered in this study include generalised anxiety disorder, panic 
disorder, social phobia, non-specified mild neurotic disorder, agoraphobia, other specific phobias, obsessive 
compulsive disorder, mixed anxiety and depressive disorders. 
f
Diagnosis recorded for a patient was either that documented in the case note by a psychiatrist or that identified by a 
client’s keyworker using a set of standard criteria. 
 
 
The prevalence of comorbid mood and anxiety disorders among UK clinical populations 
varied. The differences in prevalence rates may have resulted from the diverse 
definitions of comorbidity used. For instance, while some studies included mild forms of 
mood and anxiety disorders, others did not. Furthermore, how comorbidity was assessed 
and the type of setting in which the study was carried out may also contribute to 
differences in reported prevalence rates.  
 
High rates of mood and anxiety disorders have also been reported among patients in 
treatment for SUDs in other countries, such as USA (Kidorf et al., 2004) and India 
(Arora and Kaur, 2012). Besides Arora and Kaur (2012), the other studies did not 
attempt to distinguish between substance-induced and independent disorders. Making 
this distinction is important because intoxication and withdrawal symptoms of alcohol 
and other substances often resemble those of anxiety and depressive disorders (Grant et 
al., 2004; Raimo and Schuckit, 1998). These symptoms can sometimes be severe and 
usually resolve within two to four weeks of abstinence. While pharmacotherapy may be 
necessary for the management of an independent mood or anxiety disorder, it may not be 
needed for a substance-induced disorder (Schuckit, 2006). The study by Arora and Kaur 
(2012) found the prevalence of substance-induced depression and anxiety disorders to be 
29% and 28%, respectively, among outpatients with OUDs in India. This study used the 
research version of the Structured Clinical Interview for DSM-IV Axis I Disorders in 
assessing diagnosis.    
1.5.2.2. Psychotic disorders 
The prevalence of psychotic disorders reported among clinical populations with SUDs in 
the UK differs. This is mainly due to differences in how psychotic disorders are defined. 
Prevalence rates between 7% and 56% have been reported in the UK. Table 1.3 provides 
a description of the prevalence of comorbid psychotic disorders among UK clinical 
populations with SUDs. 
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Table 1.3: Prevalence of comorbid psychotic disorders among UK clinical populations 
with SUDs 
Author Population studied How psychotic disorders 
were assessed  
% with comorbidity 
Virgo et al. 
2001  
Patients attending  
addiction services 
comprising community 
drug and alcohol teams, 
a rehabilitation ward and 
a day treatment unit  
Mental disorders assessed 
using the Department of 
Health’s Building Bridges 
report criteria
a
 
13% had psychotic disorders 
(5% had schizophrenia, 5% 
had schizoaffective disorder 
and 3% had psychotic 
episodes). 
Weaver et 
al. 2003
b
 
Clients in substance 
misuse settings
c
 
Psychiatrists assessed 
patients with SUDs for 
psychotic disorders using 
the Operational Checklist 
for Psychiatric Disorders 
7.4% of drug service patients 
had non-substance-induced 
psychotic disorders (hereafter 
NSIPD) and 14.5% of 
alcohol service patients had 
NSIPD. 
Walsh and 
Copello, 
2014
d
 
Patients within statutory 
and non-statutory teams 
of a UK substance 
misuse treatment 
partnership 
Diagnosis recorded by 
keyworker
e
 
56.6% had psychotic 
disorders 
aThis definition includes any axis I disorder as a severe mental illness depending on the patient’s diagnosis and level 
of disability, vulnerability, risk and need for care. 
bPsychotic disorders considered include schizophrenia and non-specific psychosis. 
cThe drug and alcohol services assessed were statutory providers that offered structured appointment-based services 
within nurse-led clinics. 
dPsychotic disorders assessed were schizophrenia, psychosis, schizoaffective and delusional disorders. 
eDiagnosis recorded for a patient was either that documented in the case notes by a psychiatrist or that identified by 
the client’s keyworker using a set of standard criteria. None of the keyworkers were doctors. They were nurses 
(including community psychiatric nurses), social workers, drug workers and alcohol practitioners. 
 
 
Weaver et al. (2003) found the prevalence of non-substance-induced psychotic disorders 
to be 7.4% among drug service patients and 14.5% among alcohol service patients. 
Virgo et al. (2001) reported a prevalence of 13% among patients attending addiction 
services while Walsh and Copello (2014) reported the prevalence of psychotic disorders 
to be 56.6% among patients within statutory and non-statutory teams of a UK substance 
misuse treatment partnership. The difference in prevalence rates reported might be due 
to how these disorders were defined and identified. Walsh and Copello (2014) who 
reported the highest prevalence classified patients as having psychotic disorders using 
either of two ways:  if they have been previously diagnosed by a psychiatrist or for those 
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without formal diagnosis (one-third of patients), psychotic disorders were identified by 
the patient’s keyworker using a set of standard criteria. None of the keyworkers were 
psychiatrists. Identification of psychotic disorders by keyworkers who are not 
psychiatrists may have led to the overestimation of its prevalence. Furthermore, this 
study included more categories of disorders under the broad group of psychotic disorders 
it considered. 
 
A study carried out in Spain by Torrens et al. (2011) explored the prevalence of 
independent and substance-induced psychotic disorders among illicit drug users 
recruited from treatment and non-treatment settings. The treatment settings were an 
inpatient detoxification unit of a hospital and outpatient methadone maintenance 
programs. Nineteen (6.3%) of the 304 illicit drug users recruited from treatment settings 
had psychotic disorders, of which 10 (3.3%) were substance-induced. The psychotic 
disorders examined include schizophrenia, schizoaffective disorders and psychotic 
disorder not otherwise specified (NOS). The Spanish version of the Psychiatric Research 
Interview for Substance and Mental Disorders (PRISM) (Torrens et al., 2004) was used 
in assessing DSM-IV psychiatric diagnoses. 
1.5.3. Summary: Comorbidities in people with SUDs 
The evidence from the literature indicates that mental disorders and chronic pain 
commonly co-exist with SUDs among treatment populations. Consequently, clinicians 
will often encounter service users with this comorbidity. In the SAS where the research 
presented in this thesis was carried out, the presence of comorbid chronic pain and 
mental disorders among substance users is likely to be the norm rather than the 
exception. Some mental disorders could be substance-induced and may not respond 
adequately to pharmacotherapy (Schuckit, 2006). It may therefore be appropriate for 
such patients not to be prescribed medications.  
 
1.6. Pharmacotherapies for comorbidities 
While pharmacotherapy for mental disorders such as depression (National Institute for 
Clinical Excellence, 2009), anxiety disorders (National Institute for Health and Clinical 
Excellence, 2011b), bipolar disorder (National Institute for Health and Clinical 
Excellence, 2006) and pain (The British Pain Society, 2010) have been described and 
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their benefits demonstrated in the general population, the literature concerning 
management in people with SUDs have been less extensive. The only guideline 
published by the National Institute for Health and Clinical Excellence (hereafter NICE) 
that is specific to this population is that relating to the management of psychosis co-
existing with SUDs (National Institute for Health and Clinical Excellence, 2011c). NICE 
has no published guidelines on the management of pain in people with SUDs.  
 
Besides the NICE guideline on the management of psychosis co-existing with SUDs, 
other published guidelines on the management of mental disorders in people with SUDs 
include those published by the British Association for Psychopharmacology (hereafter 
BAP) (Lingford-Hughes et al., 2012). The British Pain Society has published a guideline 
on pain management in people with SUDs (The British Pain Society, 2007). There is 
also a publication on this issue commissioned by Action on Addiction (Action on 
Addiction, 2013). This section briefly highlights the medications recommended in these 
guidelines for the management of comorbid mental disorders and pain among people 
with SUDs. 
1.6.1. Pharmacotherapies for co-existing mental disorders and SUDs 
There is generally a paucity of evidence to effectively guide the pharmacological 
management of co-existing mental disorders and SUDs (Edlund and Harris, 2006; 
Kranzler and Rosenthal, 2003; Ostacher, 2011). A systematic review on the 
pharmacological and psychological treatment of comorbid mental disorders and SUDs 
reported limited numbers of RCTs, and did not find treatments that were equally 
efficacious for both SUDs and mental disorders (Tiet and Mausbach, 2007). The review 
suggested that existing efficacious treatment for mental disorders and SUDs also tend to 
work in patients with this comorbidity. A more recent review by Kelly, Daley and 
Douaihy (2012) suggests that the most effective treatments for comorbid patients may be 
multi-faceted, involving combinations of different therapeutic approaches such as 
pharmacotherapy, psychotherapy and behavioural treatments.  
 
Psychotherapeutic approaches that have been found to be most effective include a 
combination of motivational interviewing, cognitive behavioural therapy and 12-Step 
therapy (Kelly, Daley and Douaihy, 2012). This section will focus on 
pharmacotherapeutic approaches recommended in guidelines for the management of 
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comorbid mental disorders and SUDs in the UK during the period this research was 
carried out because they were the recommendations for best practice at the time of this 
research.  
 
There are two types of guidelines addressing this comorbidity: 
 Guidelines that were specifically written for this comorbidity; 
 Guidelines written for individual mental health problems that address 
comorbidity as a complicating factor. 
NICE has only one guideline addressing this comorbidity: Psychosis with co-existing 
SUDs (National Institute for Health and Clinical Excellence, 2011c). The BAP has 
published a number of guidelines on different comorbid mental disorders and SUDs. 
Recommendations from these guidelines and guidelines for individual mental disorders 
are highlighted below if they address management of comorbid mental disorders and 
SUDs.   
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Table 1.4: Pharmacotherapeutic approaches recommended for the management of 
comorbid mental disorders and SUDs 
Guidelines Guideline recommendations 
NICE, 2011c  Recommendations for the management of psychosis with co-existing SUDs  
Due to limited evidence from RCTs for the relative effectiveness of 
pharmacological treatments for people with psychosis and co-existing SUDs, 
NICE recommends that people with psychosis (including bipolar disorder) and co-
existing SUDs be offered the same range of interventions recommended by NICE 
or BAP for people with a single diagnosis
6
.  
BAP 
guidelines 
(Goodwin, 
2009)  
BAP recommendations for the management of bipolar disorder 
Established addictive problems should be independently assessed and treated, and 
consideration given to involving the specialist drug and alcohol team or dual 
diagnosis team if available. 
BAP 
guidelines 
(Barnes and 
Schizophrenia 
Consensus 
Group of the 
British 
Association 
for 
Psychopharma
cology, 2011) 
BAP recommendations for schizophrenia 
Recommendations for patients with schizophrenia and comorbid substance use: 
 
- Antipsychotic medication should be optimized and clozapine considered in 
patients with persisting substance misuse.  
- Treatment focused on substance misuse should be offered. While psychosocial 
approaches will be the mainstay, pharmacotherapy should be considered and 
offered where possible, e.g. alcohol detoxification and relapse prevention. 
BAP 
(Lingford-
Hughes et al., 
2012) 
BAP recommendations for comorbid bipolar disorder and SUDs 
- Treat different phases of bipolar disorder as recommended in guidelines, for 
example NICE, BAP; however, assess contribution of substance use to hypomania 
or mania and consider if medically assisted withdrawal is required.  
- Review pharmacotherapy for bipolar disorder particularly if only on lithium, and 
consider adding sodium valproate. 
- Offer naltrexone to help patients reduce their alcohol consumption.  
- Offer acamprosate if naltrexone has not been effective to help patients remain 
abstinent.  
- Consider disulfiram if patient wants abstinence and acamprosate and naltrexone 
have failed. 
BAP 
(Lingford-
Hughes et al., 
2012) 
BAP recommendations for comorbid schizophrenia and SUDs 
- The negative impact of harmful substance use, abuse or dependence on patients 
with schizophrenia requires that their substance use is assessed and treatment is 
also focused on any harmful substance use, abuse or dependence.  
- Antipsychotic medication should be optimised following existing guidance, for 
example NICE, BAP. 
 - Clozapine should be considered in patients with persisting harmful substance 
use, abuse or dependence, since it has been reported to reduce substance use and 
improve psychosis, but these data are still preliminary.  
- Medication for patients’ substance misuse should be considered, such as 
optimising opioid substitution, use of alcohol relapse prevention such as 
naltrexone or acamprosate. 
BAP 
(Lingford-
Hughes et al., 
2012) 
BAP recommendations for comorbid depression and SUDs 
- Antidepressants may improve mood but not necessarily substance use in those 
who are depressed with harmful or dependent substance use. Generally mood will 
only improve in those with a significant depressive disorder, and use of 
antidepressants should be restricted to this population and then monitored.  
                                                 
6
 Medications commonly used in the management of psychosis (including bipolar disorder) are antipsychotics, 
antidepressants and anticonvulsants.  
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- A comprehensive assessment should be carried out to determine how substance 
use and depression are linked.  
- Tricyclic antidepressants (TCAs) are not recommended due to potentially serious 
interactions between TCAs and substances, including cardiotoxicity and death in 
overdose. Consider using an antidepressant with mixed serotonergic/ 
noradrenergic pharmacology since they may be better in improving mood in 
contrast to SSRIs, which have not shown consistent benefits in improving mood.  
- Medication for harmful substance use, abuse or dependence should be 
considered such as optimising opioid substitution, use of alcohol relapse 
prevention such as naltrexone or acamprosate. 
BAP 
(Lingford-
Hughes et al., 
2012) 
BAP recommendations for comorbid anxiety disorders and SUDs 
- Ideally patients should first undergo alcohol detoxification. 
- If detoxification is not possible, treatment of the anxiety disorder should still be 
attempted: follow guidelines to select most appropriate pharmacotherapy for 
management of their anxiety disorder.  
- Assessment by a specialist addiction service is recommended prior to using a 
benzodiazepine to treat their anxiety.  
- Medication for the patient’s harmful substance use, abuse or dependence should 
be considered, such as optimising opioid substitution, use of alcohol relapse 
prevention such as naltrexone or acamprosate.  
 
Overall, the recommendations from these guidelines are sometimes non-specific and 
where they recommend medications for management of comorbidity, those for 
individual disorders (SUDs or mental disorders) are suggested.       
1.6.2. Pharmacotherapies for co-existing chronic pain and SUDs 
The management of chronic pain in people with a history of SUDs has received limited 
attention in the literature (Action on Addiction, 2013). A literature review carried out in 
the USA found no research studies relating to the management of chronic pain in people 
with a history of SUDs (Chou et al., 2009). Intervention studies targeted at individuals 
with both SUDs and chronic pain are rare (Samet and Walley, 2008). Most of the 
guidelines including UK guidelines are based on expert consensus due to lack of strong 
evidence.  
 
A number of guidelines have been published in the UK concerning pain management 
with varying degrees of recommendations concerning the management of chronic pain 
in people with SUDs (The British Pain Society, 2010; The British Pain Society, 2007; 
Action on Addiction, 2013). This section will focus on recommendations concerning use 
of opioids in chronic pain management because opioids are the most effective 
medications for the treatment of pain (McQuay, 1999; Rosenblum et al., 2008). In 
addition, opioid prescribing is the greatest challenge when considering pain management 
in people with SUDs (Action on Addiction, 2013). Table 1.5 provides the 
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pharmacotherapeutic approaches recommended for the management of chronic pain in 
people with SUDs with a particular focus on the use of opioids. 
 
Table 1.5: Pharmacotherapeutic approaches recommended for the management of 
comorbid chronic pain and SUDs 
Guidelines  Recommendations 
Pain and 
substance 
misuse: 
improving the 
patient 
experience 
(The British 
Pain Society, 
2007) 
 
Pain control in patients with SUDs 
General principles that may be applied for management of patients who have chronic pain 
requiring opioid therapy, and who currently exhibit aberrant behaviour which may indicate 
misuse or addiction, or have a history of SUDs: 
- The therapeutic regimen should be selected with the risk of aberrant drug-related 
behaviours in mind. For example, short-acting opioids (e.g. pethidine) are known to have 
greater abuse potential than long-acting or sustained release preparations. Also, non-
sustained release tablets can be more easily crushed and injected.  
- The prescriber must communicate clearly with the patient about setting reasonable 
expectations or goals for therapy and about the necessity to frequently assess progress 
toward these goals. This must include a regular review of the prescription. 
- The process of building trust between clinician and the patient should include a candid 
discussion of acceptable and unacceptable behaviour. The results of such a discussion 
should be written down and given to the patient.  
- Be aware of the various potential presentations of drug-seeking behaviour. Refer patient to, 
or seek advice from, a pain specialist or substance misuse specialist at an early stage where 
appropriate. 
- Response to treatment including degree of pain control and progress towards agreed goals 
needs to be assessed frequently. 
 
Specific considerations for patients receiving methadone, buprenorphine or naltrexone 
Methadone 
If an opioid analgesic is appropriate, a non-methadone opioid may be co-prescribed. It is not 
necessary to rationalise the patient’s entire opioid requirements to one drug. 
 
Buprenorphine 
The partial agonist action of this drug means that it should not be prescribed as an analgesic 
to patients receiving full agonists (e.g. methadone) as withdrawal may be precipitated.  
 
Naltrexone  
Naltrexone is a long-acting opioid antagonist and patients receiving it as therapy for 
addiction are likely to be refractory to opioid analgesia. When opioid therapy is introduced 
after cessation of naltrexone, careful monitoring will be required.  
 
It is particularly important that the substance misuse team and the patient’s primary care 
team are kept informed of progress with pain management.  
Opioids for 
persistent pain 
(The British 
Pain Society, 
2010) 
 
Prescribing for patients with a history of SUDs 
- Individuals with a history of SUDs are at risk of developing problems when prescribed 
opioids for pain relief. If opioids are the most appropriate therapy, they may be prescribed 
for patients as part of a multidisciplinary treatment plan. Comprehensive assessment of both 
pain and addiction is mandatory, and therapy should be closely monitored by professionals 
in both pain management and addiction medicine. 
Managing 
persistent pain 
in secure 
settings 
(Public Health 
England, 
2013c) 
The role of opioids in managing persistent pain 
Methadone is suitable for managing persistent pain. Patients with long-term pain also 
receiving methadone for SUDs may experience pain as the dose reduces. Pain can be treated 
in this circumstance by maintaining an effective methadone dose. The pharmacokinetics of 
methadone mean that once-daily dosing is unsuitable for managing pain and it should 
instead be given as a twice-daily divided dose. 
Action on 
addiction 
This guideline was based on key guidelines published in English language. The 
recommendations and the guidelines from which they were derived are presented below: 
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(Action on 
Addiction, 
2013) 
 
Chronic pain management in recovering, abstinent addicts (Centre for Substance 
Abuse Treatment, 2012) 
Goals for treating chronic non-cancer pain (hereafter CNCP) in patients who are in long-
term recovery are: 
• Initiate opioid therapy only if the potential benefits outweigh risk and only for as long as it 
is unequivocally beneficial to the patient. For relapse in patients for whom opioid addiction 
is a serious problem, referral to an opioid treatment programme (hereafter OTP) may be the 
best choice. 
 
Chronic pain management in patients on Opioid Substitution Treatment (Centre for 
Substance Abuse Treatment, 2012) 
Pain clinicians should work closely with the patient’s SUD treatment provider. Patients with 
chronic pain likely will not obtain adequate pain control through a single daily dose of 
methadone. Prescription of additional opioids for pain management through a medical 
provider may be required. Such arrangements require close communication between the 
OTP and the prescribing clinician. The buprenorphine dose-response curve declines as the 
dose is increased. To optimise analgesic efficacy, the drug should be given three times a day 
when pain reduction is a goal. 
 
Chronic pain management in patients currently or recently addicted (Centre for 
Substance Abuse Treatment, 2012) 
- Most patients addicted to prescription opioids have a prior SUD. Clinicians should adopt 
universal precautions in considering opioid therapy for patients who have CNCP. The 
presence of active addiction makes successful treatment of chronic pain improbable.  
- Identification of an active SUD indicates that the patient should be referred for formal 
addiction treatment. In patients who relapse to opioid addiction, referral to an OTP may be 
the best choice.  
- Patients who have chronic pain likely will not obtain adequate pain control through the 
single daily dose of methadone that can be provided through an OTP. Such programmes 
may be willing to collaborate in the management of patients, allowing the prescription of 
additional opioids for pain management through a medical provider. Such arrangements 
require close communication between the OTP and the prescribing clinician. 
 
Chronic pain management in patients currently or recently addicted (Macintyre et al., 
2010) 
Long-term opioids may not provide continuing effective pain relief and there is an uncertain 
risk of abuse of the drugs. Inadequate pain relief because of pharmacological tolerance may 
improve with opioid dose escalation, while improvements in analgesia in the presence of 
opioid-induced hyperalgesia may follow a reduction in opioid dose.  
 
In summary, opioids are not contra-indicated for chronic pain management in 
individuals with SUDs or a history of SUDs. However, people with a past or current 
history of SUDs may be at risk of developing OUDs. Therefore, chronic pain 
management in this group of people may need to involve professionals working in pain 
medicine and addiction medicine for optimal management. Professionals working in 
pain medicine are more oriented towards support and are therefore trained to respond to 
the patient’s pain while those in addiction medicine have an orientation that is focused 
on structure (Action on Addiction, 2013). Structure often involves the need to set 
boundaries, behavioural rules, monitoring and independent corroboration of patients’ 
self-report (Action on Addiction, 2013).   
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1.6.3. Summary: Pharmacotherapies for comorbidities 
In general, there is a paucity of evidence for the management of comorbid mental 
disorders and SUDs as well as comorbid chronic pain and SUDs. Evidence for the 
management of comorbid mental disorders and SUDs are generally not detailed. They 
however recommend medications for individual disorders in the management of this 
comorbidity. Guidelines for chronic pain management do not oppose the use of opioids 
in people with a current or past history of SUDs. If the benefit of prescribing opioids 
outweighs the risk in this group, prescribing should involve a close-working relationship 
between the pain team and the addiction team. While there is need for more research to 
guide the pharmacological management of these comorbidities, this thesis will in the 
interim assess the appropriateness of medications prescribed for the management of 
these frequently co-occurring disorders. 
 
1.7. Medication adherence 
Adherence has been defined as the extent to which a patient’s behaviour coincides with 
medical or health advice (Mackay, Taylor and Patel, 2011). Non-adherence to prescribed 
medications prevents people from experiencing full benefit from them (Chapman and 
Horne, 2013). It represents a lost opportunity for health gains for the patient with the 
potential for increased morbidity and mortality if health deteriorates (Simpson et al., 
2006). It also leads to waste of healthcare resources (Horne et al., 2005).  
 
Symptoms of mental disorders such as disorganisation and lack of insight in psychotic 
disorders and low mood in depression may limit a patient’s ability to adhere to 
prescribed medications (Beck et al., 2011; Mackay, Taylor and Patel, 2011). Substances 
use may also contribute to such behaviours. Intoxication as a result of substances and 
alcohol-related brain damage may have negative effects on cognitive function, thereby 
contributing to non-adherence (Berry et al., 1993; Horner, 1997; Schilt et al., 2008; 
Sullivan and Pfefferbaum, 2005). Non-adherence may be further influenced by the 
patient’s beliefs or perceptions about the need for medications (Mackay, Taylor and 
Patel, 2011). Patients often have beliefs about their illness and treatment (Horne and 
Weinman, 1999; Weinman et al., 1996). These beliefs have been found to influence their 
views of their prescriptions and adherence (Brown et al., 2005; Horne and Weinman, 
1999). Consequently, exploring patients’ beliefs is fundamental to understanding 
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adherence (National Institute for Health and Clinical Excellence, 2009). Consideration 
of patients’ beliefs could lead to improved quality of prescribing as clinicians would be 
able to engage patients in decision-making concerning therapy (Horne et al., 2013). 
 
Prescribers may contribute to non-adherence by failing to explain the benefits and side 
effects of treatment, having a poor therapeutic relationship with patients and prescribing 
multiple regimens (Duerden, Avery and Payne, 2013; Gellad, Grenard and Marcum, 
2011; Mackay et al., 2011). Prescribing multiple regimens (polypharmacy) increases the 
number of unnecessary or inappropriate medications (Goh, 2002; Nobili, Garattini and 
Mannucci, 2011; Rambhade et al., 2012), drug interactions and adverse events 
(Bourgeois et al., 2010; Duerden, Avery and Payne, 2013; Guthrie et al., 2011). Britten 
et al. (2003) found that patients receiving unnecessary prescriptions in general practices 
in England were more likely to be non-adherent.  
 
Different methods have been used for measuring adherence. This includes direct and 
indirect methods (Patel and David, 2007). Direct methods include measurement of the 
blood levels of the drug or its metabolite while indirect methods include pill count, use 
of self-report, clinician report (Kemp et al., 1996), rates of prescription refill and 
electronic medication monitors (Patel and David, 2007). Self-report of adherence has 
however been identified by NICE to be appropriate for use in clinical settings generally 
since it is cheap, quick and easy to use when compared to other methods (Nunes et al., 
2009). 
 
Rates of non-adherence in mental health vary depending on the diagnosis, setting, type 
of adherence difficulty and measure used for assessing level of adherence (Mackay, 
Taylor and Patel, 2011). The prevalence of non-adherence has been reported to be 
between 40–60% for antipsychotics (Zygmunt et al., 2002), 30–97% (median 63%) for 
antidepressants (Pampallona et al., 2002) and 18–52% for mood stabilizers (Scott and 
Pope, 2002) with the presence of a SUD being a strong predictor of non-adherence 
(Patel and David, 2007). When compared to those without SUDs, some previous studies 
(Manwani et al., 2007; Owen et al., 1996; Sajatovic et al., 2006; Weiss, 2004) have 
found higher levels of non-adherence among those with co-occurring SUDs and mental 
disorders. Owen et al. (1996) found that schizophrenic patients with SUDs were 
significantly more likely to report non-adherence when compared to those without co-
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occurring SUDs. Similarly, bipolar patients with SUDs have reported higher levels of 
non-adherence (Manwani et al., 2007; Sajatovic et al., 2006).  
 
Various studies have explored the relationship between adherence and the beliefs of 
patients with mental health problems such as depression, schizophrenia and bipolar 
disorder (Brown et al., 2005; Clatworthy et al., 2009; Jonsdottir et al., 2009) and chronic 
pain (Nicklas, Dunbar and Wild, 2010). Generally, across these studies higher levels of 
adherence were associated with stronger beliefs or perceptions about the need for 
treatment and lower concerns about treatment. However, no study was found that 
examined this relationship among people with SUD comorbidity. Due to evidence of the 
high levels of non-adherence among people with SUDs and the fact that patients’ beliefs 
or perceptions have been found to have an influence on adherence, this thesis assessed 
patients’ level of adherence to their medications using a self-report questionnaire 
developed for this purpose (adherence questionnaire) as well as the influence of their 
beliefs or perceptions on their reported level of adherence.  
 
1.8. Prescribing models in the UK   
This section extends the discussion of prescribing by considering the prescribing models 
available in the UK. In the SAS where this research was carried out, both medical and 
non-medical prescribers (in particular, nurses) are able to prescribe substitute and relapse 
prevention medications for people with SUDs. Prescribing has traditionally been a 
medically dominated activity but is now extended to other healthcare professionals (also 
known as non-medical prescribers), such as nurses, pharmacists, physiotherapists, 
radiographers, optometrists, chiropodists and podiatrists, in the UK as part of the NHS 
modernisation agenda (Hacking and Taylor, 2010).  
 
The origin of non-medical prescribing in the UK can be traced to the Cumberlege Report 
which suggested that:  
 
The Department of Health and Social Security (hereafter DHSS) should agree a 
list of items and simple agents which may be prescribed by nurses as part of a 
nursing care programme, and issue guidelines to enable nurses to control drug 
dosage in well-defined circumstances (DHSS, 1986).  
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Further, the Report of the Advisory Group on Nurse Prescribing, also called the Crown 
Report, recommended that health visitors and district nurses be empowered to prescribe 
from a limited formulary within set protocols (Department of Health, 1989). Following 
these recommendations, a pilot scheme for nurse prescribing that included sites in 
different regions of England was set up (Luker et al., 1998). Nurse prescribing 
subsequently became part of government policy following the success of the pilot 
programmes and became a national initiative in 1998 (Department of Health, 1999). 
Pharmacists were also subsequently given prescribing rights (Department of Health, 
2006b; Department of Health, 2003). Over the years, other healthcare professionals such 
as physiotherapists and podiatrists have been given rights to prescribe medicines within 
their clinical competence and legislative frameworks (Hacking and Taylor, 2010).  
 
Reasons for the extension of prescribing rights to other healthcare professionals include 
the need to provide quicker and more efficient access to medicines for patients without 
safety being compromised, more efficient utilisation of the skills of these healthcare 
professionals and less fragmentation of care (Emmerton et al., 2005; Hacking and 
Taylor, 2010). Non-medical prescribing for nurses and pharmacists in the UK now 
involves a single postgraduate independent and supplementary prescribing qualification 
(Cooper et al., 2008; Courtenay, Gerada and Haywood, 2011).  
 
The non-medical prescribing course is generic and prepares practitioners to prescribe 
(Public Health England, 2014c). While there are no legal restrictions on the clinical 
conditions that may be treated, clinical areas of practice are usually defined and agreed 
with the employing organisation (National Prescribing Centre, 2012; Nursing and 
Midwifery Council., 2006). In particular, the selection of nurses and pharmacists to train 
as independent prescribers is usually a matter for the employing organisation. The 
potential prescriber should be deemed competent by their employer to undertake the 
prescribing training (Nursing and Midwifery Council., 2006). The clinical areas in which 
they will prescribe is usually that in which they have considerable expertise and this 
should have been defined before they begin training (Department of Health, 2006b). The 
two main models for non-medical prescribing in the UK are supplementary prescribing 
and independent prescribing (Department of Health, 1999). Each of these models is 
considered in sections 1.8.1 and 1.8.2. 
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1.8.1. Supplementary prescribing  
Supplementary prescribing has been defined as a “voluntary partnership between a 
doctor or dentist (independent prescriber) and a supplementary prescriber to implement 
an agreed patient-specific clinical management plan (hereafter CMP) with the patient’s 
agreement” (Department of Health, 2005a). This prescribing model was introduced in 
the UK in 2003. It allows trained healthcare professionals to take prescribing 
responsibility within their clinical competence for patients according to a specific CMP 
(Department of Health, 2005a). A supplementary prescriber may be a specially trained 
nurse, pharmacist, optometrist, physiotherapist, podiatrist or radiographer (Fittock, 
2010). Supplementary prescribing can be from a full medicines formulary, including 
controlled drugs. In the past, non-medical prescribers could only use supplementary 
prescribing to treat drug dependence (Public Health England, 2014c). Legislative 
changes have now made it possible for them to independently treat drug dependence 
(Public Health England, 2014c).  
1.8.2. Independent prescribing 
Independent prescribing has been defined as “prescribing by a practitioner, responsible 
and accountable for the assessment of patients with diagnosed or undiagnosed 
conditions, and for decisions about the clinical management including prescribing” 
(Department of Health, 2006c). It requires an initial patient assessment, interpretation of 
that assessment, a decision on safe and appropriate therapy, and a process for ongoing 
monitoring (Joint Allied Health Professions, 2013). Independent prescribing was 
introduced in 2006 (Hacking and Taylor, 2010). There are two forms of independent 
prescribers (Fittock, 2010):  
 
 An independent prescriber, such as a specially trained nurse, pharmacist and 
optometrist, who can prescribe any licensed medicine within their clinical 
competence.  
 A community practitioner nurse prescriber, such as district nurses and health 
visitors who can independently prescribe from a limited formulary, the Nurse 
Prescribers’ Formulary for Community Practitioners in the BNF. 
 
For SUD management, non-medical prescribing is only provided by nurses, pharmacists 
or midwives (Public Health England, 2014c). In 2012, legislation amendment allowed 
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nurses and pharmacists to assess, diagnose and independently prescribe controlled drugs 
for the treatment of drug dependence except diamorphine, cocaine and dipipanone which 
are restricted to medical practitioners licensed by the Home Office (in England and 
Wales) (Department of Health, 2012a; Public Health England, 2014c). Furthermore, 
besides medical prescribers, only nurse and pharmacist prescribers can prescribe 
unlicensed medicines. 
 
The management of SUDs presents special issues because the majority of prescribing 
involves controlled drugs. Furthermore, the often complex needs of people with SUDs 
present challenges in terms of risk management (Public Health England, 2014c). Many 
people attending drug and alcohol services have severe comorbid mental and physical 
health problems. Consequently, Public Health England (2014c) has concluded that 
meeting these complex needs will require suitable qualified medical practitioners to 
work alongside non-medical prescribers in a multidisciplinary team. Options available to 
assist non-medical prescribers make informed and clinically appropriate decisions 
include clinical supervision from a medical prescriber or non-medical prescriber, 
managerial supervision and discussion with peer support networks (ibid).       
    
1.9. Chapter summary 
This chapter has described different definitions of SUDs and health conditions that are 
frequently comorbid with SUDs, with a particular focus on mental disorders and chronic 
pain. High rates of mental disorders and chronic pain have been found in clinical 
populations with SUDs and there is generally a paucity of evidence on the 
pharmacological management of co-occurring mental disorders and chronic pain, and 
SUDs. This introduction chapter further showed that appropriateness is a complex 
concept. In relation to prescribing, it involves a judgment across a number of areas that 
include effectiveness, risk, cost, patients’ choices, patients’ outcomes as well as the 
societal impact of prescribing. Outcome-focused prescribing is particularly relevant 
among people with comorbid mental disorders or chronic pain and SUDs due to the 
limited nature of the evidence base for medication management. Furthermore, the 
benefit of prescribing among people with SUDs may not always be medical as there are 
important social outcomes that need to be considered among this population. 
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Appropriate prescribing in this population would ultimately involve consideration of a 
holistic assessment of the patient (including their choices, outcomes, circumstances, 
symptoms and comorbidities), the social impact of prescribing, the evidence base 
concerning the clinical pharmacology of the medication as well as clinical expertise 
represented by the skill and experience of the prescriber. 
 
The different prescribing models in the UK were also presented. In the SAS where this 
research was carried out, both medical and non-medical prescribing (in particular, 
independent nurse prescribing) are utilised. The next chapter presents a scoping review 
that ascertains what can be learnt from the literature about the appropriateness of 
medications commonly used in the treatment of chronic pain and mental disorders 
among people with SUDs. 
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Chapter 2: Appropriateness of opioids 
and psychiatric medications prescribed 
for people with SUDs: A scoping review 
2.1. Introduction 
As described in chapter one, mental disorders and chronic pain are often comorbid with 
SUDs and this raises fundamental questions about prescribing practice in this group. 
Prescribing appropriateness involves the consideration of multiple dimensions such as 
effectiveness, risk, cost, preferences of individuals, their outcomes and the societal 
impact of prescribing. Pharmacological appropriateness encompasses medication 
effectiveness, safety (including risks) and cost (Spinewine et al., 2007), and has been 
assessed using implicit or explicit measures. Since different medications are used in 
treating the diverse forms of co-existing mental disorders and chronic pain, a detailed 
review was carried out in order to ascertain what could be learnt from the literature 
about the appropriateness of prescribing of medications commonly used in the treatment 
of these conditions: namely antidepressants, antipsychotics, anxiolytics/hypnotics, 
antimanic agents, anticonvulsants and opioids (excluding substitute opioids) among 
people with SUDs. This review includes only quantitative studies on this topic due to 
time constraints in this thesis. Before presenting the methods and findings of this review, 
the justification for the use of a scoping review rather than a systematic review is 
presented below.  
2.1.1. Justification for scoping review 
This review was carried out in order to provide an overview of relevant literature 
concerning the appropriateness of medicines commonly prescribed for mental disorders 
and chronic pain. A scoping review was chosen over a systematic review for a number 
of reasons. Systematic reviews involve a systematic process for defining research 
questions, searching for studies, assessing their quality and synthesizing findings  
(Arksey and O'Malley, 2005; Armstrong et al., 2011). They usually focus on well-
defined questions where appropriate study designs can be identified in advance. This 
often requires a prior understanding of the existing literature (Armstrong et al., 2011). 
On the contrary, a scoping study tends to address broader topics, where different study 
designs might be applicable (Arksey and O'Malley, 2005). A scoping review aims to 
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‘map’ the literature pertaining to an area of research, the sources and types of evidence 
available especially when the area is complex or under-researched (Mays, Roberts and 
Popay, 2001). This is pertinent in this thesis because the topic explored is both complex 
and under-researched, and there has been no previous review. Scoping reviews may also 
be useful for identifying gaps in the evidence base (Arksey and O'Malley, 2005), that 
can inform research questions and methodology. Although systematic reviews are not 
limited to any kind of study, most are on the effectiveness of interventions and therefore 
usually focus on RCTs (Levac, Colquhoun and O'Brien, 2009). Studies in this area are 
unlikely to be RCTs. Consequently, a scoping review methodology was employed to 
develop a picture of the evidence base (Armstrong et al., 2011) through the inclusion of 
a range of relevant study designs that address the review topic.  
 
2.2. Objectives 
The purpose of this scoping review was to address the following question: What is 
known from the existing literature about the appropriateness of prescribing of 
antidepressants, antipsychotics, anxiolytics/hypnotics, antimanic agents, anticonvulsants 
and opioids
7
 (excluding substitute opioids) for people with SUDs? 
 
2.3. Methods 
This review utilised a rigorous and comprehensive approach in order to be transparent 
and thorough (Mays et al., 2001). It involved the documentation of each stage of the 
review process to enable it to be replicated by others (Arksey and O'Malley, 2005), thus 
ensuring methodological rigour (Mays et al., 2001). This section considers the following 
areas: 
1. Types of study designs 
2. Types of participants 
3. Measures of appropriateness 
4. Exclusion criteria 
5. Outcome 
6. Search strategy 
7. Data collection 
                                                 
7 Medications grouped into any of these classes by the BNF were examined.   
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2.3.1. Types of study designs 
All available designs were included in this review with the exception of case reports. 
Case reports were excluded because they are usually limited to individual patients and as 
a result, are not generalizable (Isaacs, 2007). 
2.3.2. Types of participants 
Studies recruiting adults aged 18 years and above with SUDs, who were also receiving 
opioids for chronic pain or medications for mental disorders were included in this 
review. Studies recruiting adults were the focus of this review because the therapeutic 
doses of the medications to be assessed differ between adults and children (Cella et al., 
2010; Findling et al., 1998; Findling et al., 2000; Joint Formulary Committee, 2010), and 
the focus of this thesis is on adults. Studies including people younger than 18 years as 
well as adults with SUDs were considered if they separately reported prescribing 
appropriateness in adults. Where the age of study participants were not reported, such 
studies were included provided they did not explicitly refer to non-adults. This review 
relied on investigators’ definitions of SUDs rather than providing a pre-specified 
definition because it was a scoping review which aimed at providing an overview of the 
range and extent of available evidence. This was done in order to reduce the possibility 
of missing relevant studies. This wide approach has been suggested for use in scoping 
reviews in order to increase the breadth of evidence covered (Arksey and O'Malley, 
2005). Consequently, investigators’ definitions of SUDs might be based on a range of 
measures: 
 
1. Medical records (for example, documentation of SUDs from medical records); 
2. Screening for illicit substances;  
3. Self-report;  
4. Responses to structured interviews such as the Diagnostic Interview Schedule 
(Malgady, Rogler and Tryon, 1992). 
 
This review also relied on investigators’ definitions of chronic pain and mental disorders 
such as mood, anxiety and psychotic disorders. There was no restriction on the setting 
where people with SUDs were identified. 
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2.3.3. Measures of appropriateness 
Papers were included in this review if they involved some form of assessment or 
measurement of appropriateness. This could include guideline adherence; 
manufacturers’ recommendations; DDD8; validated measures such as the MAI and the 
PAI or any other measure specified in the study.  
2.3.4. Exclusion criteria 
The following were the exclusion criteria for this review: 
1. Studies that do not include some form of assessment or measurement of 
appropriateness; 
2. Studies that assessed appropriateness only in people less than 18 years of age; 
3. Studies that assessed the appropriateness of opioid substitute prescribing; 
4. Studies in languages other than English; 
5. Unpublished studies. 
2.3.5. Outcome 
Appropriateness of prescribing defined using some form of assessment or measurement 
of appropriateness. 
2.3.6. Search strategy 
Electronic databases were searched for relevant published literature. Prior to conducting 
a search of the databases, a researcher with experience in the systematic review 
methodology at the University of York was consulted in order to ensure the search 
strings were comprehensive. In addition to the searching of electronic databases listed 
below, hand-searching of the references of relevant studies was carried out. Hand-
searching was necessary because electronic databases may be incomplete or vary in 
coverage (Arksey and O'Malley, 2005). All the six journals from which relevant studies 
were retrieved were also hand-searched in order to obtain any study that has been missed 
in database and reference list searches. The journals were hand-searched from June 1994 
to November 2015 because the oldest relevant study was published in June 1994.  
 
                                                 
8 The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. 
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Electronic databases 
Three databases were searched through the Ovid SP platform on the 5
th
 of March 2012. 
The following databases were searched: 
 
1. PsycINFO (1806 to February Week 4 2012); 
2. Medline (1946 to February Week 4 2012);  
3. EMBASE (1974 to 2012 March 05). 
 
The search strings used in Medline are shown in appendix 2.1. These search strings were 
adapted for use in psycINFO and Embase (appendices 2.2 and 2.3 respectively). An 
update of the electronic databases was carried out on the 12
th
 of November 2015.  
2.3.7. Data collection  
Study selection 
All the references identified by searching were imported into Endnote X4 and duplicates 
were removed. After removal of duplicates, the titles and abstracts of the remaining 
references were screened to identify potentially relevant studies. Copies of the full 
article of studies that appeared to be relevant were assessed for eligibility based on the 
stated inclusion/exclusion criteria. Ideally, the screening process should have been 
carried out by two independent reviewers in order to reduce the risk of missing out 
relevant studies (Edwards et al., 2002). However, the resources available prevented the 
inclusion of a second reviewer.  
   
Data extraction 
Data on study characteristics such as study type, setting, year of publication, country of 
study, participants, diagnosis assessment, sample size, measure of appropriateness and 
result were extracted on a standard form. Information retrieved from these studies are 
presented in section 2.6.2.  
2.4. Quality assessment 
Study quality was assessed in order to reduce the possibility of bias since the quality of 
studies in a review can affect its overall conclusion. Studies of low quality may give 
misleading results (Detsky et al., 1992). Quality assessment of non-randomised studies 
poses some challenges due to the different types of methods that could be used. 
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Although there are quality assessment tools that assess the quality of these studies 
(Deeks et al., 2003), it is rare to find a tool that is tailored to specific topics. Deeks et al. 
(2003) assessed 193 tools that could be used in evaluating the quality of non-randomised 
studies and six of them were thought to be suitable for use in systematic reviews. 
Although this was not a systematic review, one of these tools was chosen for this 
scoping review because it allows for the assessment of individual studies in a systematic 
way. This ensured that the quality of relevant studies could be compared.  
 
Of these six tools, the Quality Assessment Tool for Quantitative Studies (Thomas et al., 
2004), was chosen because it covers key areas of quality and has a comprehensive guide 
for its completion. Furthermore, the content and construct validity of the checklist has 
been found to be acceptable and its test-retest reliability has been demonstrated to be 
good (Thomas et al., 2004). The Quality Assessment Tool for Quantitative Studies 
(hereafter QATQS) is designed for assessing randomised and non-randomised studies. It 
includes 21 items separated into eight components: selection bias, study design, 
confounders, blinding, data collection methods, withdrawals and dropouts, intervention 
integrity and analysis. After completion of the tool, ratings of ‘strong’, ‘moderate’ or 
‘weak’ are given for each of the first six components in order to provide a global rating 
of quality. This tool was adapted for use in this study. Appendix 2.4 shows the adapted 
QATQS. The following items that are not relevant to the types of studies included in this 
review were removed (they were not taken into consideration in the global rating of 
study quality): 
 
1. The ‘blinding’ questions were removed because they are not relevant to the 
studies in this review. 
2. The ‘intervention integrity’ questions were removed because there were no 
interventions in the studies included in this review. 
3. The ‘analysis’ questions were also removed because they were not relevant to the 
studies in this review. 
 
Although the authors of the QATQS recommend that it should be used by two 
reviewers, quality assessment was conducted by one reviewer (A.O.) due to resource 
limitations. The quality assessment process was however overseen by the supervisors of 
this thesis. 
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2.5. Data synthesis  
The data were synthesized based on the different measures of appropriateness used in 
the included studies. These include guidelines, summary of product characteristics and 
antidepressant treatment history form. Due to the diverse nature of the medications 
studied, the different populations, settings and measures utilised in assessing prescribing 
appropriateness, a meta-analysis of the studies was not possible. In addition, the Centre 
for Reviews and Dissemination (CRD) Guidance for Undertaking Reviews in Health 
Care does not recommend the pooling of results from diverse non-randomised studies 
(Centre for Review and Dissemination, 2009). Consequently, a narrative synthesis of the 
diverse measures of prescribing appropriateness was carried out. 
 
2.6. Results  
This section presents the results for the study selection and data extraction process. It 
further provides a brief description of relevant studies, quality assessment and a 
narrative synthesis of the measures of prescribing appropriateness.  
2.6.1. Study selection 
There were 6,544 and 27 references identified through database searching and hand-
searching, respectively. After removal of duplicates, 3,185 were screened from which 91 
appeared to be potentially relevant from their retrieved abstracts. The full-text versions 
for the 91 studies were examined and eight were found to be relevant. Figure 2.1 shows 
the study selection process. Eighty three full-text versions of studies were excluded 
because they either did not assess prescribing appropriateness (n = 65) or state whether 
participants had SUDs (n=16). Other reasons for study exclusion are as follows: study 
did not include patients with SUDs (n = 1) and study included patients who were less 
than 18 years (n = 1). Appendix 2.5 displays the excluded references.  
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     Figure 2.1: Study selection process  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6.2. Description of studies 
Eight articles meeting the inclusion criteria were included in this review. One study 
focused on antidepressants, two on benzodiazepines, three on antipsychotics and two 
assessed opioids. There were no studies that focused on antimanic agents and 
anticonvulsants. Morrison et al. (1994) assessed opioid prescribing for different types of 
pain. However, this study did not state how long a patient had to have pain for it to be 
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considered as acute or otherwise
9
. The majority of studies (six studies) in this review 
were carried out in the USA. There was one study each from France (Thirion et al., 
2002) and Germany (Weinmann et al., 2005). Four studies (Clark, Xie and Brunette, 
2004; Leslie and Rosenheck, 2001; Morasco, Duckart and Dobscha, 2011; Morrison et 
al., 1994) involved assessment of prescribing for outpatients. Weinmann et al. (2005) 
assessed prescribing for patients recruited in psychiatric hospitals while Baca-Garcia et 
al. (2009) assessed those in a university hospital. Walkup et al. (2000) assessed 
prescribing for inpatients recruited from general hospitals while Thirion et al. (2002) 
assessed prescribing from diverse settings namely GPs (accounting for 85% of 
prescriptions), care centres and specialists. There was no study that assessed prescribing 
for people in substance misuse settings. Studies utilised different measures for assessing 
prescribing appropriateness of which majority were guidelines. Others are the 
Antidepressant Treatment History Form (ATHF) and Summary of Product 
Characteristics (SPC). Table 2.1 shows the information retrieved from included studies. 
 
 
                                                 
9 A decision was taken to include it in this scoping review despite the absence of information concerning pain 
duration. 
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Table 2.1: Information retrieved from included studies 
 
Study Participants Type of 
setting 
Diagnosis assessment Sample size Measures used for 
appropriateness  
Results 
 
Baca-Garcia et al. 2009. USA. 
Cross-sectional study 
Depressed bipolar patients 
with a lifetime history of 
AUDs and those without 
AUDs 
University 
hospital 
Diagnoses of AUDs (alcohol 
abuse or dependence) and 
current bipolar major 
depressive episode were 
made using SCID for DSM-
III-R or DSM-IV 
39 patients in 
the AUD group 
and 58 in the 
group without 
AUDs 
Antidepressant 
treatment history 
form (ATHF) 
Those with AUDs had higher proportion 
of inadequate treatment (74.3%) compared 
to those without AUDs (67.3%), p = 0.03. 
Proportion of intensive antidepressant 
treatment is higher (ATHF rating of 4 and 
5) in those without AUDs (15.5% vs 
2.6%). 
Leslie and Rosenheck. 2001. 
USA. 
Cross-sectional study 
Department of Veterans 
Affair (VA) outpatients 
diagnosed with 
schizophrenia. Some had 
comorbid SUDs 
Outpatient Diagnoses of SUDs (in 
particular, substance abuse) 
and schizophrenia were based 
on ICD-9.  
34,925 patients. 
21% had a 
comorbid SUD 
The Schizophrenia 
Patient Outcomes 
Research Team 
(PORT) 
recommendations 
Patients with SUDs were significantly less 
likely to be dosed above PORT guidelines 
compared to those without SUD (OR = 
0.85, 95% CI: 0.78 – 0.93). There was no 
significant difference in likelihood of 
dosing below guidelines (OR = 1.01, 95% 
CI: 0.93 – 1.10). 
Weinmann, Janssen and 
Gaebel. 2005. Germany. 
Cohort study 
 
Patients diagnosed with a 
primary psychotic 
disorder at the time of 
hospital admission. Some 
had comorbid SUDs  
Psychiatric 
hospital 
Diagnoses of psychotic 
disorders were based on ICD-
10. How SUDs (substance 
abuse and dependence) were 
diagnosed was not stated  
508 patients. 
17% had a 
comorbid SUD 
Based on the PORT, 
APA guidelines and 
guidelines of the 
German Society of 
Psychiatry, 
Psychotherapy and 
Nervous Disease 
There was no significant difference in the 
likelihood of receiving medication care 
outside guideline recommendations 
between those with and without SUD (OR 
= 0.80, 95% CI = 0.40 - 1.79). 
Clark, Xie and Brunette. 2004. 
USA. Cross-sectional study 
Medicaid beneficiaries 
with a range of 
psychiatric disorders. 
Some had comorbid 
SUDs 
Outpatient Diagnoses of psychiatric 
disorders and SUDs (abuse or 
dependence) were based on 
ICD-9.  
9,589 patients. 
36.8% had a 
comorbid SUD 
The APA 
recommendations 
Those with comorbid SUDs were more 
likely to use benzodiazepines for > 4 
months (p < 0.0001) except those with 
schizophrenia. Those with major 
depression (p < 0.0001) or other 
psychiatric disorders (p = 0.05) comorbid 
with SUDs were significantly more likely 
to use fast-acting benzodiazepines.  
Thirion et al. 2002. France. 
Cross-sectional study 
Opiate dependent patients 
prescribed buprenorphine 
maintenance therapy 
Outpatient 
mostly GPs 
(85%). Others 
include care 
centres (11%) 
and specialists 
(4%) 
Not stated  2,078 patients Summary of product 
characteristics (SPC) 
for benzodiazepines 
Daily doses of prescribed benzodiazepines 
often above that specified in the SPC but 
proportion of patients in which this 
occurred was not stated 
Morrison et al. 1994. USA.  
Cohort study 
Ambulatory HIV-infected 
patients. This included 
intravenous drug users 
(IDUs) 
HIV clinic  Not stated  190 patients. 
11% were IDUs 
Published guidelines 
for the use of opioids 
in the treatment of 
cancer patients 
IDUs were more likely to be prescribed 
opioids inappropriately than were men 
who were homosexuals (p < 0.001) or 
heterosexual people (p = 0.01) 
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Morasco, Duckart and 
Dobscha. 2011. USA. Cohort 
study 
Veterans with chronic 
non-cancer pain (CNCP) 
prescribed chronic opioid 
therapy. Some had 
comorbid SUDs  
Outpatient  Patients classified as having 
CNCP based on electronic 
medical record pain numeric 
rating scores. SUDs (AUDs, 
illicit SUDs, prescription 
DUDs) diagnoses were based 
on ICD-9-CM 
5,814 patients. 
19.5% had a 
SUD diagnosis 
Guidelines for the 
use of chronic opioid 
therapy published by 
Chou and colleagues, 
2009.  
Those with SUDs did not differ from those 
without SUDs in receipt of long acting 
opioids (OR = 0.94, 95% CI: 0.81 - 1.09) 
Walkup et al. 2000. USA. 
Cohort study 
Inpatients with 
schizophrenia or 
schizoaffective disorder. 
Some had comorbid 
SUDs  
General 
hospital 
Diagnoses of SUDs (in 
particular, substance abuse) 
was based on the MINI while 
diagnoses of schizophrenia or 
schizoaffective disorder was 
confirmed using SCID for 
DSM-III-R or DSM-IV 
293 patients. 
36.9% had a 
comorbid SUD 
The Schizophrenia 
Patient Outcomes 
Research Team 
(PORT) 
recommendations 
There was no significant difference in 
likelihood of excess discharge doses 
between patients with and without 
comorbid SUDs (17.6% vs 22.7%; p = 
0.17). 
Note: ICD-9 classifies SUDs into abuse and dependence unlike ICD-10 which classifies SUDs into harmful use and dependence 
 
Where,  
APA = American Psychiatric Association 
AUD = Alcohol use disorder 
DUD = Drug use disorder 
SCID = Structured Clinical Interview for DSM Disorders 
ICD-9 = International Classification of Diseases, 9th Revision 
ICD-9-CM = International Classification of Diseases, Clinical Modification-9th Revision 
ICD-10 = International Classification of Diseases, 10th Revision 
MINI = Mini-International Neuropsychiatric Interview 
OR = Odds ratio 
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2.6.3. Quality assessment 
Most of the studies had either ‘moderate’ or ‘strong’ global ratings using the adapted 
QATQS (see table 2.2). Studies were given a global rating of ‘strong’ if they had three or 
more strong ratings in each of the assessment components and no weak ratings. A global 
rating of ‘moderate’ was given if less than four strong ratings and one weak rating whereas 
a global rating of ‘weak’ denoted the presence of two or more weak ratings. One of the 
criteria ‘withdrawals and drop-outs’ was not applicable to six studies because all eligible 
patients were included and there were no withdrawals/drop-outs. This criterion was 
excluded when assessing the global rating for these six studies. While the adapted QATQS 
was useful in assessing the quality of studies in a systematic way, some of its components 
were difficult to rate due to their subjective nature. For instance, it was difficult to decide 
the percentage of relevant confounders controlled for. The adapted QATQS does not also 
state explicitly the number of confounders that will need to be taken into consideration for 
at least 80% of confounders to be controlled for. In this review, where studies controlled 
for factors known to influence prescribing such as age and comorbidites, they were given 
strong ratings in the ‘confounder’ component of the assessment tool.          
 
A number of studies did not control for these confounders and may lead to flawed 
conclusions about the quality of prescribing for people with SUDs, especially those with 
co-existing mental disorders. This is particularly apposite given that people with SUDs co-
existing with mental disorders may have more severe and persistent symptoms and they 
may be more resistant to treatment compared to those with single conditions (Volkow, 
2010; Green, 2005). Consequently, they may require higher doses or need to be treated for 
a long duration. Further information about each quality rating category is described below.  
 
Selection bias 
Six studies were considered to be ‘strong’ in this component. Five of these studies included 
all the eligible patients during the period examined and analysed existing administrative 
databases while in one study (Weinmann et al., 2005) over 80% of those screened provided 
consent. In the study by Baca-Garcia et al. (2009), a ‘weak’ rating was given because 
participants (bipolar patients with and without SUDs) were recruited through advertising 
and referrals. There was no information on where adverts were placed and who referred 
patients. Advertising and referrals may result in self-selection as those recruited may be 
different from those who were not (Levin, 2006). As a self-selecting group, there may be 
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less ill. Hence, their willingness to take part in this study. A ‘weak’ rating was also given 
to the study by Walkup et al. (2000) because there was insufficient detail provided on the 
number and characteristics of eligible patients who agreed to participate.     
 
Study design 
All the studies were considered to be ‘strong’ in their designs as the designs used were 
appropriate in addressing their objectives. The types of studies that are most likely to 
address the research question posed in this review are observational studies such as cross-
sectional or cohort studies. Four studies (Morasco et al., 2011; Morrison et al., 1994;  
Walkup et al., 2000; Weinmann et al., 2005) included in this review were cohort studies 
while the remaining were cross-sectional studies.  
 
Confounders 
Three of the included studies were considered ‘weak’ in this component because those 
with mental disorders or pain co-existing with SUDs were not compared with those 
without SUDs in order to determine whether there are any differences that could explain 
the tendency for more or less inappropriate prescribing. For instance, comorbidities such as 
hepatic impairment may lead to a reduction of antipsychotic doses (Kane et al., 1998). 
Furthermore, none of these three studies controlled for potential confounders such as age 
and number of comorbidities between people with and without SUDs in their analysis. This 
suggests that they may be biased towards overestimating the percentage of inappropriate 
medications.  
 
Age and number of comorbidities may influence medication dosing (Rochon, Schmader 
and Sokol, 2014). People with comorbidities may need higher or lower doses depending on 
the type and severity of comorbidities. On the other hand, four other studies were 
considered to be ‘strong’ in this component because they controlled for variables such as 
age and comorbidities (Leslie and Rosenheck, 2001; Morasco et al., 2011; Walkup et al., 
2000; Weinmann et al., 2005). One study (Thirion et al., 2002) that assessed 
benzodiazepine prescribing among opiate dependent patients was considered ‘weak’ as 
there was no comparison of those prescribed benzodiazepines with those who were not 
prescribed in order to determine if there are differences that could explain the reasons for 
doses above the SPC of benzodiazepines. 
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Data collection methods 
Six studies were rated as ‘moderate’ in this component because the data assessed were 
from existing medical records. Medical records may be subject to error due to failure to 
consistently document relevant information, errors in medical record abstraction, under-
reporting or over-reporting of care (Chen et al., 2006). The remaining two studies (Baca-
Garcia et al., 2009; Weinmann et al., 2005) were considered to be ‘strong’ because they 
described their data collection tools and the validity and reliability of these tools have been 
tested. 
 
Withdrawals and drop-outs 
This component was not applicable to most studies because of their retrospective or cross-
sectional design. Six studies assessed past medications of people. One study (Weinmann et 
al., 2005) was rated as ‘moderate’ because the number of patients excluded was stated and 
60 to 79% of patients completed the study as recommended in the adapted quality 
assessment tool. Walkup et al. (2000) was given a ‘weak’ rating because it does not 
provide information on withdrawals/drop-outs from the study.  
 
Global rating of studies 
Overall, the quality of the studies included in this review varied (see table 2.2). Six studies 
had either strong or moderate global ratings: three studies were strong and three were 
moderate. Two studies had weak global ratings. Table 2.2 describes the global quality 
rating of studies included in this review. 
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Table 2.2: Global quality rating of studies  
 
Author and 
year 
Selection 
bias 
Study 
design 
Confounders Data 
collection 
methods 
Withdrawals 
and drop-
outs 
Global 
rating 
Morrison et 
al. 1994 
Strong Strong  Weak Moderate  Not 
applicable 
Moderate  
Walkup et al. 
2000 
Weak Strong Strong Moderate Weak Weak 
Leslie and 
Rosenheck 
2001 
Strong Strong  Strong Moderate  Not 
applicable 
Strong  
Thirion et al. 
2002 
Strong Strong Weak  Moderate Not 
applicable 
Moderate 
Clark, Xie 
and Brunette 
2004 
Strong Strong Weak Moderate  Not 
applicable 
Moderate  
Weinmann, 
Janssen and 
Gaebel 2005 
Strong Strong Strong  Strong Moderate Strong  
Baca-Garcia 
et al. 2009 
Weak Strong  Weak Strong Not 
applicable 
Weak 
Morasco, 
Duckart and 
Dobscha 
2011 
Strong Strong Strong Moderate  Not 
applicable 
Strong  
2.6.4. Narrative synthesis of prescribing appropriateness 
This section presents a narrative synthesis of the studies according to the measure of 
prescribing appropriateness used. Six studies assessed adherence to guideline 
recommendations while one study assessed whether recommendations in the summary of 
product characteristics for benzodiazepines was followed. Another study used a computer 
algorithm that is based on the antidepressant treatment history form to assess the 
appropriateness of antidepressant medications prescribed by psychiatrists. Seven studies 
compared prescribing appropriateness between those with and without SUDs. Thirion et al. 
(2002) however assessed the appropriateness of benzodiazepine dosage only in people with 
SUDs (opiate dependent patients on buprenorphine-maintenance treatment). The narrative 
syntheses of these studies are presented below. 
2.6.4.1. Use of guidelines as a measure of appropriateness 
The narrative syntheses of studies assessing guideline adherence for prescribing of opioids 
and psychiatric medications are presented separately because they are different classes of 
medications. 
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Guideline adherence as a measure of appropriateness of psychiatric medications 
Four studies (Clark et al., 2004; Leslie and Rosenheck, 2001; Walkup et al., 2000; 
Weinmann et al., 2005) assessed guideline adherence in prescribing of psychiatric 
medications. Leslie and Rosenheck (2001) and Walkup et al. (2000) assessed adherence to 
the Schizophrenia Patient Outcomes Research Team (hereafter PORT) recommendations 
for antipsychotic prescribing while Weinmann, Janssen and Gaebel (2005) assessed 
adherence to recommendations for antipsychotic prescribing developed from three 
guidelines namely the PORT recommendations, the American Psychiatric Association 
(APA) guidelines and guidelines of the German Society of Psychiatry, Psychotherapy and 
Nervous Disease. Clark, Xie and Brunette (2004) assessed adherence to the APA 
guidelines for benzodiazepine prescribing. 
 
The study by Leslie and Rosenheck (2001) was conducted in the USA and assessed 
whether the dose of oral antipsychotics prescribed for outpatients with schizophrenia in the 
Department of Veterans Affairs (hereafter VA) conformed to the PORT recommendations. 
Dose was defined as the total amount of medicine prescribed for the patient. In particular, 
administrative database comprising antipsychotic prescription drug records written 
between June 1999 and September 1999 for 34,925 patients was assessed (21% had a 
comorbid SUD). Diagnoses of schizophrenia and SUDs (in particular substance abuse) 
were based on the ICD-9 diagnostic codes. Schizophrenia was determined by the presence 
of a primary or secondary diagnosis of schizophrenia in at least two outpatient encounters 
in a specialty mental health outpatient clinic.  
 
The PORT guideline recommends that the total daily chlorpromazine equivalents for all 
typical antipsychotics should be between 300 mg and 1000 mg while different doses are 
recommended for different atypical antipsychotics. Patients with substance abuse diagnosis 
were significantly less likely to be dosed above PORT guidelines compared to those 
without substance abuse diagnosis (OR = 0.85, 95% CI: 0.78 – 0.93). There was no 
significant difference in the likelihood of dosing below guidelines between those with and 
without co-existing substance abuse diagnosis (OR = 1.01, 95% CI: 0.93 – 1.10). This 
suggests that in people with and without co-existing substance abuse diagnosis, there was 
also underdosing of medications. Overall, for this group of schizophrenic patients, there 
was significantly less inappropriate prescribing of antipsychotics for those with a SUD.  
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This study adjusted for patient characteristics such as age, patient ethnicity (black or 
Hispanic), distance of patients’ residence from the hospital, presence of primary or 
secondary diagnosis of mental illness in addition to schizophrenia, hospital/facility 
characteristics as well as days of psychiatric hospitalisation during the period considered 
using multivariate regression analysis. This study had a ‘strong’ global rating on the 
adapted QATQS because it was considered to be devoid of selection bias since it included 
all the eligible patients during the study period. Its study design was appropriate in 
addressing its research question and it controlled for confounders. It therefore had no weak 
rating in any of the components on the adapted QATQS. 
  
The study by Walkup et al. (2000) was also conducted in the USA and assessed whether 
the dose of antipsychotics (oral and depot preparations) prescribed for inpatients with 
schizophrenia or schizoaffective disorder recruited from four general hospitals conformed 
to the PORT recommendations. In particular, this study assessed the antipsychotic dose 
prescribed for 293 patients at discharge. Over a third of these patients had a comorbid 
SUDs (in particular, substance abuse). Diagnoses of schizophrenia and schizoaffective 
disorder were confirmed using the Structured Clinical Interview for DSM-III-R or DSM-
IV. Diagnosis of substance abuse was based on the Mini-International Neuropsychiatric 
Interview (MINI). In addition, this study required that there should be at least one 
indication that staff were aware of patient’s substance abuse either through report of this by 
the primary therapist or documentation in the patient’s record. This study assessed whether 
antipsychotic prescriptions were excessive at discharge. Excessive antipsychotic dosage 
was defined as dosing that exceeded the 1000mg/day recommended in the PORT 
guidelines. There was no significant difference in likelihood of excess discharge doses 
between patients with and without comorbid SUDs (17.6% vs 22.7%; p = 0.17). 
 
This study adjusted for patient characteristics such as age, length of stay in hospital, 
voluntary admission and comorbidities using logistic regression analysis. This study had a 
‘weak’ global rating for selection bias on the adapted QATQS because the number and 
characteristics of eligible patients were not clearly stated. It also had a weak rating on the 
withdrawal/drop out component on the adapted QATQS because it did not state the 
number of patients that completed the study. 
 
The study by Weinmann, Janssen and Gaebel (2005) assessed adherence to an expert panel 
recommendation concerning antipsychotics among inpatients with psychotic disorders 
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recruited from three different hospitals in Germany. The study assessed 508 patients aged 
between 18 and 65 years with a primary psychotic disorder according to ICD-10 between 
October 2000 and May 2002 at the time of hospital admission. Seventy eight percent (78%, 
394) had a diagnosis of schizophrenia while 17% had a comorbid substance abuse or 
dependence diagnosis. How substance abuse and dependence were diagnosed was not 
stated. Illness severity, psychopathology symptoms, social functioning and side effects 
were assessed using validated instruments. After reviewing the literature for available 
guidelines and considering three prominent guidelines (the PORT recommendations, the 
APA guidelines and the guidelines of the German Society of Psychiatry, Psychotherapy 
and Nervous Disease), an expert panel decided on quality criteria against which patients’ 
medications were assessed. Five measures of quality were chosen by the panel: 
 
1. For a first psychotic episode, second generation antipsychotic (hereafter SGA) 
monotherapy should be prescribed at discharge 
2. Antipsychotic dosage at discharge should not exceed 1000 chlorpromazine 
equivalents 
3. Patients with severe persistent psychotic symptoms which are unchanged for more 
than three weeks should have a significant change of antipsychotic dosage or a 
switch to a different antipsychotic within three weeks 
4. Patients with severe depressive symptoms for at least two weeks should receive an 
antidepressant medication or a change of antipsychotic medication (switch to SGA) 
5. Dosage of antipsychotic should be reduced if there is severe akathisia, parkinsonian 
side effects, tardive dyskinesia or a different antipsychotic monotherapy should be 
used within 3 weeks, or medication prescribed for the side effect should be changed 
or clozapine or another SGA should be prescribed. 
 
The main outcome was defined as guideline adherence without patient factors contributing. 
Patient factors that were considered include poor compliance which was assessed using a 
compliance scale consisting of 7-items, drop-out from study or escape from hospital. There 
was no significant difference in the likelihood of receiving medication care outside 
guideline recommendation between those with and without co-existing SUDs (OR = 0.80, 
95% CI: 0.40 - 1.79).  
 
This study controlled for factors such as gender, episode of treatment, number of previous 
hospital stays, social functioning, severity of psychotic and depressive symptoms using 
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logistic regression. This study had a ‘strong’ global rating on the adapted QATQS because 
it had no ‘weak’ rating in any of its components. Selection bias was considered to be 
absent because over 80% of those screened provided consent. Its study design was 
appropriate in addressing its research questions as it controlled for confounders and also 
described its data collection methods. It was given a moderate rating in one of the 
components on the adapted QATQS (withdrawals and drop-outs) because some patients 
did not complete the study.  
 
The study by Clark et al. (2004) was conducted in the USA and assessed adherence to the 
APA guideline on benzodiazepine prescribing among New Hampshire Medicaid 
beneficiaries with psychiatric disorders between January 1995 and December 1999. The 
APA panel on benzodiazepine recommends the following: 
 
1. Persons with SUDs should receive lower-risk benzodiazepines rather than those 
with high abuse potential such as alprazolam, estazolam and triazolam.  
2. Persons with SUDs should be prescribed benzodiazepines for short duration (less 
than four months) due to the risk of dependence. 
 
All Medicaid
10
 claims for people aged 18 to 64 years were examined and those with 
psychiatric disorders among these patients were identified retrospectively. For people who 
had both Medicaid and Medicare
11
 eligibility, psychiatric disorders and comorbid SUDs 
were also identified from their Medicare data. The following primary psychiatric diagnoses 
using ICD-9 were examined: schizophrenia, bipolar disorder and major depression. Other 
psychiatric disorders were grouped into a single category. People with a diagnosis of 
substance abuse or dependence (except tobacco) or who were treated for SUDs were 
defined as those with SUDs.  
 
There were 9,589 patients who were participants in this study. Of 1552 schizophrenic 
patients, 614 (39.6%) had a SUD while 228 (46.4%) of 491 bipolar patients, 1195 (31.8%) 
of 3757 patients with major depression and 1496 (39.5%) of 3789 patients with other 
psychiatric disorders had SUDs as defined by the study criteria. Those with SUDs 
                                                 
10 Medicaid is a health services program for people and families with low incomes in America. Centers for Medicare & 
Medicaid Services. (2013). Medicaid [Online]. http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-
Topics/Eligibility/Eligibility.html.  [Accessed 10 January 2014]. 
11 Medicare is a Federal health insurance program that pays for medical care for the elderly and certain disabled 
Americans. Centres for Medicare and Medicaid Services. (2013). Medicare program - General information [Online]. 
http://www.cms.gov/Medicare/Medicare-General-Information/MedicareGenInfo/index.html.  [Accessed 10 January 
2014].. 
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comorbid with bipolar disorder, major depression or other psychiatric disorders were 
significantly more likely to be prescribed benzodiazepines for four or more months (p < 
0.0001). However, patients with co-occurring schizophrenia and SUDs were significantly 
less likely to be prescribed benzodiazepines (P < 0.0001). Furthermore, those with major 
depression co-existing with SUDs or other psychiatric disorders co-existing with SUDs 
were significantly more likely to be prescribed fast acting/high potency benzodiazepines 
than those without SUDs (25.2% vs 14.6%, p < 0.0001 and 18.2% vs 13.5%, p = 0.05 
respectively). There was no significant difference between patients with bipolar disorder 
co-existing with and without SUDs and schizophrenia co-existing with and without SUDs 
on the prescribing of fast acting/high potency benzodiazepines (18.5% vs 13.5%, p = 0.22 
and 5.3% vs 4.3%, p = 0.49, respectively). This study had a ‘moderate’ global rating 
because it had one ‘weak’ rating. It did not take other factors (such as comorbidities and 
severity of illness) that could account for longer duration of prescribing into consideration. 
 
In summary, all the studies that used guidelines as a measure of prescribing of psychiatric 
medicines assessed the appropriateness of only one class of psychiatric medications. An 
American study of good quality by Leslie and Rosenheck (2001) found that oral 
antipsychotics prescribed in outpatient settings for people with co-existing schizophrenia 
and SUDs in the VA tended to comply with guideline recommendations though there were 
also instances of dosing of people with SUDs below guideline recommendations. This 
study recommended that there should be further research to explore the reasons for 
prescribing by physicians.  
 
Another American study of poor quality by Walkup et al. (2000) found that among 
inpatients with schizophrenia or schizoaffective disorders from four general hospitals those 
with SUD comorbidity were unlikely to be prescribed antipsychotics outside guideline 
recommendations when compared to those without SUD comorbidity. A study of good 
quality carried out among inpatients with psychotic disorders recruited from three different 
psychiatric hospitals in Germany found that patients with SUD comorbidity were unlikely 
to receive medication care outside of current guideline recommendation compared to those 
without comorbidity. These two studies suggest that the appropriateness of antipsychotic 
prescribing in these settings is comparable between psychotic patients with and without 
SUD comorbidity.   
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Another American study of moderate quality found that adherence to the APA guidelines 
on benzodiazepine prescribing varied depending on patients’ comorbid psychiatric 
disorders. For conditions such as comorbid SUDs and bipolar disorder, major depression or 
other psychiatric disorders, benzodiazepines were prescribed for longer than 
recommended. This may reflect a tendency for people with these comorbid conditions to 
exhibit anxiety, insomnia or other conditions for which benzodiazepines may be used over 
a period of time. It may also imply that patients are not being regularly reviewed since 
benzodiazepines are usually recommended for short-term use due to their dependence 
potential (American Psychiatric Association, 1990; Joint Formulary Committee, 2010). 
The effectiveness of benzodiazepines diminishes with prolonged use (Vinkers and Olivier, 
2012).   
 
Guideline adherence as a measure of opioid prescribing appropriateness 
Two studies (Morasco et al., 2011; Morrison et al., 1994) assessed guideline adherence in 
opioid prescribing. Morrison et al. (1994) assessed adherence to published guidelines for 
opioid prescribing among HIV patients while Morasco, Duckart and Dobscha (2011) 
assessed adherence to guidelines for the use of chronic opioid therapy. 
 
Morrison et al. (1994) conducted their study in USA and assessed the appropriateness of 
prescribing by looking at indication. Indication has been defined by Hanlon et al. (1992) as 
the sign, symptom, disease or condition for which the medication is prescribed. This study 
was a retrospective cohort study that reviewed the appropriateness of opioid prescribing 
(mostly codeine or oxycodone-containing formulations) for patients in an ambulatory HIV 
clinic located in a public teaching hospital. The study sample were patients with HIV of 
which some had a history of intravenous drug use. The records of 220 patients out of 
which 190 were HIV positive were reviewed between 1986 and 1989. The patients’ 
medication lists and physician notes for each visit were used for assessing opioid 
prescribing. This study used the guideline for the management of pain in cancer patients in 
an outpatient setting as the standard against which opioid prescribing was compared 
because of the lack of guidelines for the use of opioids in HIV patients.  
 
Inappropriate opioid prescribing was considered to be prescribing for conditions for which 
the guideline stated that they were not efficacious such as muscle spasm, bone pain and 
vascular headache. Prescribing was also considered inappropriate if a clear indication was 
not documented or a prescription was refilled without it being for an appropriate 
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indication. The following were the percentages of various risk factors for HIV among the 
190 HIV patients: 57% were homosexual/bisexual, 11% were IDUs, 18% were both 
homosexual/bisexual and IDUs, 7% were heterosexual and 8% fell into ‘other’ category. 
IDUs were more likely to be prescribed opioids inappropriately than heterosexual men or 
women (p = 0.013) or homosexual men (p < 0.001). Of 53 opioid prescriptions for IDUs, 
48 (90.6%) of them were considered inappropriate.  
 
The authors suggested that patients who had abused drugs previously such as the IDUs 
may have requested unnecessary opioid medications. It was not known to what extent 
prescribers thought these medications were inappropriate. Further, the guideline used was 
not specific to HIV but cancer and the management of these conditions differ. Thus, it may 
not be best practice to use a guideline for cancer to assess HIV. This study concluded that 
physicians should prescribe opioids appropriately and future studies should incorporate 
patients’ views. This study had a ‘moderate’ global rating because it had one ‘weak’ rating 
in the confounder component of the adapted QATQS. It did not control for potential 
confounders such as a diagnosis of cancer.  
 
Morasco, Duckart and Dobscha (2011) carried out a retrospective cohort study that 
assessed opioid guideline adherence in the management of chronic non-cancer pain 
(hereafter CNCP) in patients with and without SUDs. This study included veterans with 
CNCP receiving opioid treatment within a Veterans Affairs regional healthcare network in 
the Pacific Northwest (Washington, Oregon, Idaho and Alaska) in 2008. Administrative 
data concerning these veterans were collected from the Veterans Integrated Service 
Network (VISN)-20 Data Warehouse which contains data from the main clinical software 
packages of the national VA databases. CNCP was identified from the electronic medical 
record pain Numeric Rating Scores (NRS) that is routinely administered during ambulatory 
visit. Pain intensity was rated on a scale of 0 to 10 with 0 being no pain and 10 being worst 
pain imaginable. CNCP was assessed by the presence of pain scores of > 4 on the NRS in 
three or more different months.  
 
A total of 5,814 patients who had an opioid prescription for 90 or more days were included 
in this study. Some patients such as those with cancer diagnosis were excluded. SUDs 
considered in this study include all AUDs, prescription DUDs and illicit SUDs. This 
includes patients whose SUDs were in remission. All diagnoses were based on the ICD, 
clinical modification-9
th
 revision. Opioid prescriptions were converted to their morphine 
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equivalents. The guideline published by Chou and colleagues (Chou et al., 2009) was used 
as the standard and recommends that long-acting rather than short-acting opioids should be 
prescribed to patients with SUDs due to their lower abuse potential. It also recommends 
that patients with CNCP should be prescribed antidepressants if they have major 
depression or dysthymia because treatment of these conditions is associated with 
improvement in pain.   
 
Almost one-fifth (19.5%) of patients had a SUD diagnosis. Those with SUDs had a higher 
pain score than those without SUDs (6.7 (SD = 1.3) vs 6.6 (SD = 1.3), p < 0.001). Those 
with SUDs did not differ from those without SUDs in receipt of short-acting (85.7% vs 
87.8%) or long acting opioids (26.9% vs 26.0%). Patients with SUDs were more likely to 
receive concurrent antidepressant prescriptions (73% vs 61.7%). However, on controlling 
for age, VA facility, gender, major depression diagnosis and pain intensity using 
generalized estimating equations, no difference was observed between patients with SUDs 
and those without SUDs in the likelihood of receiving antidepressants or long-acting 
opioids. This study therefore found that among veterans with CNCP receiving opioid 
treatment within a Veterans Affairs regional healthcare network in the Pacific Northwest, 
there was no difference in opioid guideline adherence between those with and without 
SUDs. This study had a ‘strong’ global rating on the adapted quality assessment tool 
because it included all eligible patients and therefore was not biased in patient selection. 
Moreover, it controlled for potential confounders and had no ‘weak’ rating in any of the 
components on the adapted quality assessment tool.  
2.6.4.2. SPC as a measure of benzodiazepine prescribing appropriateness 
Only one study by Thirion et al. (2002) used the SPC as a measure of prescribing 
appropriateness. Thirion et al. (2002) assessed whether the doses of benzodiazepines 
prescribed for buprenorphine-maintained opiate-dependent patients in France were within 
the standards specified in the summary of product characteristics
12
 (SPC) of 
benzodiazepines. Benzodiazepines and buprenorphine were issued in a variety of 
outpatient settings: GPs, care centres and specialists. The benzodiazepines assessed in this 
study were alprazolam, bromazepam, clorazepate, diazepam and flunitrazepam. This study 
did not however state the reasons for benzodiazepine prescribing. Forty-three percent 
(43%) of patients (total = 2078) were prescribed benzodiazepines with the most frequently 
prescribed being flunitrazepam (584, 28.1%) followed by bromazepam (373, 17.9%) and 
                                                 
12 A Summary of Product Characteristics (SPC) contains information on how to use a particular medication safely and 
effectively. 
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clorazepate (166, 8%). The daily doses of prescribed benzodiazepines were reported to be 
often above that specified in the SPC for benzodiazepines. However, the percentage of 
prescriptions in which this occurred was not stated. This study had a ‘moderate’ global 
rating because it had one ‘weak’ rating in the confounder component of the adapted 
QATQS. There was no comparison of those prescribed excessive benzodiazepine doses 
with those who were not prescribed to determine if there were any obvious differences that 
may account for this prescribing. 
 
In summary, the study that examined benzodiazepines found that in a variety of outpatient 
settings in France, benzodiazepine doses among buprenorphine-maintained opiate-
dependent patients were higher than recommended by guidelines. This result may reflect 
excessive benzodiazepine prescribing and a tendency for its abuse in this population. A 
previous study has reported benzodiazepine abuse among buprenorphine-maintained 
opiate-dependent patients (Lavie et al., 2009). 
2.6.4.3. ATHF as a measure of antidepressant prescribing appropriateness 
The study by Baca-Garcia et al. (2009) was conducted in the USA and compared the 
appropriateness of antidepressants prescribed for 39 depressed bipolar patients with a 
history of AUDs with those of 58 depressed bipolar patients without AUD history. A 
computer algorithm that is based on the Antidepressant Treatment History Form (hereafter 
ATHF) was used to assess antidepressant medications issued by the patients’ psychiatrist 
in the three months before patients were recruited into the study. The ATHF rates 
antidepressant treatment based on indication, dose, treatment duration and patient 
adherence (Oquendo et al., 2003). The ATHF assigns a score of 0 to 5. A rating of 0 
indicates that no psychopharmacologic treatment was prescribed while 1 or 2 indicates 
inadequate treatment. Treatment receives a rating of 1 if the medication dose is less than 
50% of an adequate dose. A rating of 3 or greater indicates adequacy of treatment. Scores 
of 1 or 2 were considered inadequate treatment whereas 3 and above were adequate 
treatment.  
 
Participants were recruited via advertising/referrals and participated in mood disorders 
research in a hospital setting. No information was provided concerning where adverts were 
placed and how referrals were carried out. Diagnoses of current bipolar major depressive 
episode and AUDs were assessed using the Structured Clinical Interview (SCID) for DSM-
III-R or DSM-IV. Symptoms of depression, mania, aggression, hostility as well as suicide 
history were assessed using validated instruments. Of 39 participants with a history of 
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AUDs, 27 patients were diagnosed with alcohol dependence (with 4 patients having 
current alcohol dependence, 6 patients in partial remission, 17 patients in full remission) 
whilst 12 (30.8%) patients had alcohol abuse (4 with current alcohol abuse and 8 in full 
remission).  
 
The results showed that bipolar patients with AUDs had a higher proportion of inadequate 
antidepressant treatment (ATHF ratings of 1 and 2) than those without AUDs (74.3% vs 
67.3%, p = 0.03). The proportion of intensive treatment with antidepressants determined 
via ATHF ratings of 4 and 5 was higher in those without AUDs compared with patients 
with AUDs (15.5 vs 2.6%). The statistical significance was however not stated. This study 
had a ‘weak’ global rating on the adapted QATQS because it had weak ratings in each of 
the following: selection bias and confounders. Recruitment through advertising and 
referrals may result in self-selection. Consequently, those recruited may differ in notable 
ways from those who were not recruited (Levin, 2006). Furthermore, the study did not 
control for confounders such as comorbidities.  
 
A study of poor quality found that among depressed bipolar patients prescribed 
antidepressants by psychiatrists in a hospital setting in America, those with AUDs were 
more likely to have inadequate antidepressant treatment. Given the high proportion of 
inadequate treatment in both groups of patients, the authors proposed that inadequate 
prescribing may be more related to physician factors than patient characteristics, as some 
psychiatrists may be reluctant to prescribe antidepressants due to the potential for 
antidepressant-induced mania. They also proposed that alcohol use may be a contributing 
factor to inadequate antidepressant treatment due to the fact that stigma associated with 
alcohol could lead to differential treatment of those with and without AUDs. Stigmatising 
attitudes towards people with SUD have been found to be common among health 
professionals (Lloyd, 2010).  
 
2.7. Strengths and weaknesses 
This scoping review explored the range and extent of available evidence on the 
appropriateness of prescribing of opioids for chronic pain relief and psychiatric 
medications for people with SUDs. It is the first review in this area and found a paucity of 
evidence. Furthermore, none of the studies were carried out in a substance misuse setting. 
There is therefore a paucity of information on the appropriateness of prescribing of opioids 
for chronic pain relief and psychiatric medications for people with SUDs in a substance 
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misuse setting. The studies in this review were of mixed quality, with over half of them 
assessing adherence to a range of different guidelines. Studies that assess guideline 
adherence have been criticised because guidelines are usually specific to particular 
diseases or drugs (Cantrill et al., 1998; Tinetti, Bogardus and Agostini, 2004). Clinical 
guidelines do not usually take all co-existing conditions/diseases of the patient into 
consideration (Cantrill et al., 1998; Duerden, Avery and Payne, 2013). They assess disease 
management and not patient management (Shaneyfelt and Centor, 2009). This limitation 
was obvious in most of the studies included in this review because they could only assess 
the appropriateness of particular medications for specific conditions without taking into 
consideration the patients’ comorbidities and medications for them as well as their 
preferences.  
 
Comorbidities and co-prescribed medications may affect the effectiveness, dose and 
duration of other prescribed medications (Joint Formulary Committee, 2010). Interactions 
between substances and medications or between medications may further affect prescribing 
decisions. In addition, patient preferences play a role in decision-making when prescribing 
medications and should be considered when assessing appropriateness (Barber et al., 
2005). As discussed in section 1.4.2, the development of tolerance to medications such as 
opioids and benzodiazepines may necessitate prescribing of higher doses of these 
medications (Gershwin and Hamilton, 1998; Willems et al., 2013). Consequently, sound 
judgment on the appropriateness of prescribing cannot be disconnected from the overall 
context of prescribing. If the context is not taken into consideration, medications may be 
erroneously identified to be inappropriate. This is particularly apposite among people with 
co-existing mental disorders or chronic pain and SUDs because their often complex health 
situation may necessitate deviation from guidelines in order for the best possible care to be 
provided (Hughes, 2011).  
 
Studies in this review were based on individual hospitals or included outpatients in 
particular settings. The diverse nature of the study settings and population may also 
account for variation in prescribing. For instance, patients who are more complex in terms 
of the severity of their illness and comorbidities may more likely be treated in hospitals 
(Verdoux et al., 1996). This may necessitate the adjustment of medications above or below 
those recommended in guidelines. Such prescribing may be appropriate for these patients. 
However, the studies included in this review did not assess whether deviation from 
guidelines were appropriate for patients. On the other hand, it is possible that some 
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situations in which guidelines were adhered to may have been clinically inappropriate for 
patients based on their complex health situations. Strict adherence to guidelines may 
inadvertently promote inappropriate prescribing. There is therefore the need for the use of 
measures that allow for clinical judgment (including eliciting patient’s preferences) when 
assessing prescribing appropriateness. An example of such measure is the MAI which 
allows for the use of clinical judgment with explicit instructions in rating prescribing 
appropriateness.     
 
A number of studies in this review assessed single guideline areas such as dose or 
indication while those that assessed more than one area considered a limited number of 
areas. Therefore, the results of the studies in this review do not provide a holistic picture 
concerning all areas of prescribing appropriateness that are considered important by 
healthcare professionals such as indication, effectiveness, dose, drug-interactions, duration, 
duplication and cost (Samsa et al., 1994). More research is therefore needed to investigate 
multiple areas relating to prescribing appropriateness among people with SUDs in a 
substance misuse setting. In addition, most of the studies were conducted in the US where 
provision of healthcare is largely dependent on the patients’ ability to pay or insurance 
coverage. The findings of this review cannot therefore be generalised to the UK where the 
healthcare system is free at the point of delivery.  
 
It is possible that this review may have missed out relevant papers due to its focus on 
studies published in English and the limited number of databases searched. Some of the 
review studies were also limited because they did not control for confounding factors that 
could have influenced their outcomes. In addition, it was not possible to assess reasons for 
non-adherence to guidelines from prescribers’ perspective due to the retrospective design 
of most of the studies. The perspectives of patients on the appropriateness of their 
medications were also not included in any of the studies despite the influence of these 
perspectives on the actual use of medications (adherence). Focusing only on quantitative 
studies further made it impossible to explore appropriateness from the perspectives of 
patients and prescribers. Qualitative studies are useful for exploring and describing 
participant’s understanding and interpretation of phenomenona (Ritchie, 2003). Patient and 
prescriber perspectives are important areas to further explore in order to provide a holistic 
view of appropriateness.  
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Chapter 5 of this thesis describes a research study which seeks to address these gaps by 
assessing multiple areas of prescribing appropriateness among patients with SUDs 
attending an outpatient addiction service. Chapters 6 and 7 also describe research studies 
that assess the perspectives of patients and prescribers concerning prescribing 
appropriateness respectively, using qualitative interview methods. 
 
2.8. Summary 
Overall, these studies together suggest that there are frequently variations in prescribing of 
opioids for chronic pain relief and psychiatric medications across people with and without 
SUDs in particular contexts and settings. None of them incorporated the views of 
prescribers or patients concerning the appropriateness of these medications though these 
were suggested as areas to further explore. All the studies were undertaken outside the UK 
and their findings are therefore not generalizable to the UK setting. The studies were of 
mixed quality and over half assessed guideline adherence. Furthermore, while some of the 
studies assessed single areas relating to appropriateness others assessed a limited number 
of areas. None of the studies assessed appropriateness in a substance misuse setting. There 
is therefore a gap in the literature on the appropriateness of prescribing of opioids for 
chronic pain and psychiatric medications for substance users attending a substance misuse 
setting. In particular, this review highlights the need for studies assessing multiple areas of 
appropriateness of opioids and psychiatric medications among people with SUDs in this 
setting. 
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Chapter 3: An overview of aims, 
methodology and methods 
Following on from the scoping review, the aims of this thesis were two-fold. These aims 
and the research questions addressing them are described below. For the purposes of this 
thesis, patients attending the SAS will be termed ‘service users’. 
 
3.1. Thesis aims 
Aim 1:  
To investigate the level and nature of appropriateness of current prescribed medications for 
service users in a SAS. 
 
Research questions addressing Aim 1: 
1. What types and quantities of prescribed medications are taken by service users? 
2. What is the level and nature of inappropriate prescribing? 
3. How do service users with inappropriate medications differ from those who do not 
have such medications? 
4. Does the appropriateness of prescribed medications change over the course of 
service users’ treatment? 
5. How do service users perceive the appropriateness of their prescribed medications, 
changes to them and its impact on their quality of life? 
6. To what extent do service users adhere to their medications and is this influenced 
by their perceptions on appropriateness? 
7. What are the potential cost savings that could result from stopping or reducing the 
use of inappropriate medications?     
 
Aim 2:  
To explore prescribers’ responses to inappropriate prescribing in a SAS.  
 
Research questions addressing Aim 2: 
1. How do prescribers at the SAS assess the appropriateness of prescribed 
medications and how are changes made? 
2. What factors are considered before initiating changes to service users’ medications? 
3. How has the MAI impacted prescribers’ practices? 
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The SAS prescribers were interviewed rather than the original prescribers of service users’ 
medications. It would have been difficult to trace the original prescribers and this was 
thought to be beyond the resources of this thesis. Moreover, this thesis is firmly focused on 
the assessment of prescribing appropriateness in a SAS, in which the evidence (Delgadillo 
et al., 2012; Marsden et al., 2000; Weaver et al., 2003) suggests there will be large 
proportions of service users with comorbid conditions. They therefore represent a 
particularly apposite group for exploring questions of prescribing appropriateness. The 
medications whose appropriateness were assessed include psychiatric medications and 
opioids
13
. The absence of these medications without justification (medication omission) 
was also considered to be inappropriate. 
 
3.2. Specialist Addiction Service (SAS) setting  
The setting where this research was carried out is a statutory NHS specialist service that 
provides tier 3 level interventions to adults who misuse alcohol and/or drugs. However, 
almost 80% of service users attending the SAS are people who misuse alcohol (Oluyase et 
al., 2013). The SAS is located in Leeds, a city of West Yorkshire, with a population of 
751,500 of whom 81% are white British (as of 27 March 2011) (Office of National 
Statistics, 2012). The SAS is part of the Leeds and York Partnership NHS Foundation 
Trust, a Trust that provides specialist mental health and learning disability services to 
people in Yorkshire. At present, the SAS no longer exists in its original form. The clinical 
service of the SAS has now been joined with four other services in Leeds under the banner 
of Forward Leeds. 
 
Tier 3 interventions generally involve the provision of care-planned interventions 
following a comprehensive assessment (National Treatment Agency for Substance Misuse, 
2006b). It involves community-based assessment, care planning and review, provision of 
evidence-based interventions (detoxification, maintenance and psychosocial interventions) 
including addressing of co-existing conditions such as depression and anxiety as well as 
liaison services for acute medical (including pregnancy), psychiatric and social care 
(National Treatment Agency for Substance Misuse, 2006a).  
 
Service users coming to the SAS may self-refer or they could be referred from other 
sources such as general practitioners (GPs), psychiatrists, hospital, social services, drug 
                                                 
13Although this thesis is concerned with opioids for chronic pain relief, SAS consultants suggested that opioids prescribed 
as substitutes for those with opioid use disorders should be included among medications assessed. Consequently, the 
appropriateness of opioids prescribed for chronic pain and substitute opioids were assessed. 
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services as well as the criminal justice system. Some information is usually collected about 
newly referred service users (such as their demographic information, health problems and 
medications) and included on the referral form. All newly referred service users are usually 
required to book an appointment before their first assessment. They are then sent a self-
completion booklet to complete before their first or baseline assessment. Those who come 
to the clinic without their booklets are given a new copy to complete before they are 
assessed.  
 
Evidence obtained from a senior SAS staff suggested that new referrals to the SAS are all 
screened by a nurse on the basis of their referral information in order to get more 
information if needed or reject the referral. If the referral is accepted, the nurse further 
determines which of the three teams the person should be allocated to and whether the 
person should be seen by a doctor. Allocation to a doctor was said to be based on 
complexity and in particular any prescribing issues while allocation to nurse prescribers 
and other therapists was decided by the SAS team organising the clinic. Evidence from this 
study (section 5.9.6) and that obtained by the researcher suggests the allocation system was 
not often implemented in practice. The researcher observed that receptionists tended to 
allocate service users to doctors, nurse prescribers and other therapists in all the three SAS 
teams on their clinic days.  
 
The three teams are the pregnancy and parenting team, the hospital team and the dual 
diagnosis team. Whilst the pregnancy and parenting team manages service users who are 
pregnant or those with child care issues, the hospital team manages those identified and 
referred by hospital in-reach workers and the dual diagnosis team manages those with co-
existing mental disorders and SUDs. Each team has its own clinic day in which newly 
referred service users are assessed. The keyworker (nurse prescriber, doctor or other 
therapists) carries out the baseline assessment which involves a 45- to 60- minute 
comprehensive assessment of the service user. Keyworkers, including prescribers, are 
expected to complete booklets relating to their assessment of the service user after the 
consultation and also fill in a care plan. They are expected to provide a summary of their 
assessment to the secretaries of the different teams to be typed for documentation in the 
service user’s folder. Keyworkers may also need to attend to existing service users with 
whom they have scheduled appointments. Consequently, the clinic is usually busy for 
keyworkers. The same keyworker is often responsible for the follow-up of service users 
throughout their treatment at the SAS.  
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3.3. Consultation process with psychiatrists 
This consultation was carried out to determine the views of the SAS consultant 
psychiatrists (there were three psychiatrists at the SAS) on the classes of medications that 
are likely to be inappropriately prescribed for people with SUDs. Information obtained 
from this consultation was intended to guide the selection of medications whose 
appropriateness will be assessed by SAS prescribers in the medication appropriateness 
study. Only consultant psychiatrists were involved in this process because they were the 
only group of doctors working at the SAS during this period. Although, there were nurse 
prescribers at the SAS, they were not involved because of the narrower area in which they 
prescribe.  
 
All the different classes of prescribed medications which were being taken by service users 
in the secondary data analysis (study 1) were included in a questionnaire which was sent 
via email to the three consultant psychiatrists. The questionnaire asked “how often do you 
think these medications are inappropriately prescribed for service users with SUDs?” and 
provided four potential responses: frequently, sometimes, rarely and never. The 
questionnaire is shown in appendix 3.1. They were asked to complete the questionnaire 
and a meeting was organised to discuss their responses.  
 
At the meeting, the consultants brought the questionnaire along and discussed the reasons 
for their responses to each class of medication. By the end of the meeting, there was 
agreement on seven classes of medications that they thought may be inappropriately 
prescribed for service users with SUDs, namely: opioids (including those prescribed as 
opioid substitution therapy), antidepressants, antipsychotics, anticonvulsants, drugs used in 
substance dependence (disulfiram, acamprosate, bupropion, varenicline, lofexidine and 
baclofen), antimanic agents and anxiolytics/hypnotics. Although this thesis is concerned 
with opioids for pain relief, the consultants suggested that opioids prescribed as 
substitution therapy for those with OUDs should be included. Consequently, the 
appropriateness of opioids prescribed for chronic pain and substitute opioids
14
 were 
assessed in the medication appropriateness study. There were three classes of medications 
on which there was no agreement among the consultants, namely, antihypertensives (beta-
blockers prescribed for anxiety disorders or during alcohol detoxification were included 
under anxiolytics), proton pump inhibitors and drugs used in asthma and COPD 
management. The consultants agreed on the exclusion of all the other classes of 
                                                 
14 Only two service users were on opioids prescribed as substitution therapy in the medication appropriateness study. 
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medications. Another meeting was subsequently scheduled where a final decision was 
taken on the medications on which there was no agreement. 
 
Before the second meeting I sent a list including the medications on which there was 
agreement and those on which there was lack of agreement to the consultants for their 
consideration. Only two of the consultant psychiatrists were present at this second meeting. 
Antihypertensives (except beta-blockers prescribed for anxiety disorders or during alcohol 
detoxification), proton pump inhibitors and drugs used in asthma and COPD management 
were excluded at this meeting on the basis of lack of expertise to assess their 
appropriateness as they are not routinely prescribed in mental health/addiction settings. 
The consultant psychiatrists agreed on the seven classes of medications listed above and 
suggested that these medications should be considered for inclusion among those to be 
assessed in the medication appropriateness study. 
 
3.4. Methodology 
The research methodology is important because it sets out the theoretical assumptions of 
the researcher and the work plan for research. Methodology has been defined as the 
“science of studying how research is to be carried out” (Rajasekar, Philominathan and 
Chinnathambi, 2013) and delineates the research design. According to Creswell (2009), 
there are three components of a research design: the philosophical worldview, strategies of 
inquiry and the research methods. The philosophical worldview encompasses the 
philosophical assumptions guiding research and it usually informs the strategies of inquiry 
that will be adopted. The methods refer to the techniques or procedures used for data 
collection and analysis and results from the strategies of inquiry chosen for research. The 
elements utilised in this thesis are shown in figure 3.1. 
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                       Figure 3.1: Thesis components  
 
                                                                       Adapted from Creswell (2009) 
3.4.1. Philosophical worldview 
The philosophical worldview for this thesis was pragmatism. Pragmatism became the 
logical worldview because it is typically associated with mixed methods research (Feilzer, 
2010; Morgan, 2007; Tashakkori and Teddlie, 2003) due to its pluralistic nature (Creswell, 
2009; Creswell and Plano Clark, 2011) and focus on “what works” (Patton, 1990). A 
pragmatic approach employs ‘what works’ in particular circumstances, with the research 
questions given prominence (Creswell et al., 2011; Morgan, 2007). Unlike other 
worldviews such as the positivist/empiricist or interpretivist/constructivist worldviews that 
have been associated with quantitative and qualitative methods respectively, pragmatism 
allows for the adoption of multiple methods. It allows for the use of pluralistic approaches 
to derive knowledge about the research problem (Creswell, 2009). This is pertinent in this 
thesis because it addresses a complex issue that demands exploration through multiple 
perspectives.  
 
Pragmatism has been criticized because it does not provide a solution to philosophical 
disputes (Johnson and Onwuegbuzie, 2004). There have been arguments for and against 
mixing qualitative and quantitative methods due to their different philosophical 
foundations (Johnson and Onwuegbuzie, 2004; Morgan, 2007). Some authors have argued 
Strategy of inquiry  
Mixed 
 
Methods 
Secondary data analysis, 
survey and interviews 
Philosophical worldview 
Pragmatism  
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that the philosophical foundations of quantitative (positivism/empiricism) and qualitative 
(interpretivism/constructivism) research are incompatible because of their different 
assumptions about the world and reality (Howe, 1988). Johnson and Onwuegbuzie (2004) 
have however argued that the aim of pragmatism is not to provide a solution to ancient 
disputes about different philosophical assumptions. Rather, pragmatism provides a means 
for the mixing of methods to address the research questions.  
 
The pluralistic nature of pragmatism implies that multiple philosophical perspectives can 
be adopted for research. In particular, postpositivism and phenomenology were adopted in 
this thesis. The ontological and epistemological position of each method is considered 
below, ontology being concerned with the nature of the ‘knowable’ or the nature of reality 
(Guba, 1990), thus reflecting the researcher’s ‘beliefs about the nature of the social world 
and what can be known about it’ (Bisman, 2010; Snape and Spencer, 2003). Epistemology 
is concerned with ‘the nature of the relationship between the knower (the inquirer) and the 
known (or knowable)’ (Guba, 1990).  
3.4.1.1. Postpositivism  
Postpositivism is a philosophical approach that attempts to address some of the limitations 
of positivism (Clark, 1998). The following are the premises upon which postpositivism is 
based. 
 
Ontological position 
Similar to positivism, reality is deemed to exist in postpostivism (Clark, 1998; Guba, 
1990). However, unlike positivism, postpositivism holds that reality is only imperfectly 
apprehendable because it is impossible for reality to be perceived by imperfect human 
sensory and intellectual mechanisms (Guba, 1990). Consequently, postpositivism 
represents a shift from the ‘naïve’ realism position adopted in positivism to one of ‘critical’ 
realism (Guba, 1990). It is the belief in both positivism and postpositivism that science 
requires precision, logical reasoning and attention to evidence (Clark, 1998; Crossan, 
2003). There is an emphasis on well-defined concepts or variables, controlled conditions or 
as close an approximation to it as possible, precise instrumentation and empirical testing 
(Guba and Lincoln, 1994).  
 
Epistemological position 
Unlike positivism that advocates objectivism such that the inquirer adopts a distant non-
interactive posture with what is being inquired into, postpositivism advances a modified 
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form of objectivism since in reality objectivism cannot be truly attained (Guba, 1990). 
Reality is viewed by a subjective receiver and is therefore always someone’s reality 
(Bisman, 2010; Racher and Robinson, 2003). Every part of research from identifying and 
operationalising the research question to data collection/analysis and report writing is 
influenced by the researcher. Objectivism however represents an ideal that could be 
achieved reasonably closely if the inquirer strives to be neutral as much as possible and 
also provides an account of their own predispositions and influences on that which is being 
inquired into (Guba, 1990). In postpositivism, claims about reality must be subjected to 
critical examination to facilitate apprehending it as closely as possible (Letourneau and 
Allen, 1999).  
 
In this thesis, postpositivism influenced the researcher’s adoption of quantitative methods 
of inquiry as seen in the secondary analysis of routinely collected data and medication 
appropriateness study. It also influenced my views on the role of the researcher and the 
researcher’s beliefs on the research process (Clark, 1998). For instance, my background as 
a pharmacist has influenced aspects of the research process such as choices made in 
research planning and data collection/analysis. The influence of the researcher on the 
research process is described in section 3.5.  
 
3.4.1.2. Phenomenology  
Ontological position 
Phenomenology is based on the assumption that reality is multiple and socially constructed 
through the interaction of individuals with others and the world, with individuals assigning 
meaning to their perceptions and experience (Guba, 1990; Racher and Robinson, 2003). 
Phenomenology adopts a ‘relativist’ ontology because there are many possible 
interpretations of phenomena with no foundational process by which truth or its falsity can 
be determined (Guba, 1990). Social facts are characterised and recognised by their 
meanings to individuals (Bowling, 2002). In phenomenology, the inquirer aims to discover 
these subjective or lived experiences of those being studied (Balls, 2009). It is the belief in 
phenomenology that the most interesting questions are not about the reality of the world 
but about peoples’ interpretations of them (Green and Thorogood, 2004). Phenomenology 
considers how the subject relates to the experience, how he understands and also values the 
phenomenon (Kockelmans, 1987). 
 
 
104 
 
Epistemological position 
The epistemological stance of phenomenology is ‘subjectivity’ since this represents the 
only means of understanding the experiences of individuals (Guba, 1990). Reality is 
deemed to exist only in respondents’ minds and subjective interactions are the only means 
of discovering them. Due to its focus on drawing out individual experiences and 
perceptions, methods often employed in phenomenological research include interviews and 
observations (Lester, 1999). Just like postpositivism, it is the belief in phenomenology that 
the researcher and the inquiry are not detached, rather the researcher shapes the research 
process (Englander, 2012; Racher and Robinson, 2003). 
 
Two approaches have been described in phenomenology namely descriptive 
phenomenology and interpretative phenomenology (Balls, 2009). Descriptive 
phenomenology is attributed to Edmund Husserl (Husserl, 1963) and seeks to describe 
rather than explain. It usually starts with a perspective free from preconceptions by the 
researcher (Lester, 1999). The researcher sheds all prior personal knowledge and 
preconceptions in order to engage with the lived experiences of research participants 
(Balls, 2009). This approach has however been criticised because it is impossible to put 
aside all preconceptions and knowledge, and approach what is being researched in a 
completely blank or neutral way (Koch, 1995; Lopez and Willis, 2004). This criticism led 
to the development of the interpretative phenomenology by Martin Heidegger (Creswell, 
2009).  
 
In interpretative phenomenology, it is believed that the researcher’s experience is utilised 
when developing research questions and shaping other peoples’ interpretations. 
Interpretative phenomenology was adopted in this thesis because of the view that the 
researcher is interpreting something in which she exists (Lopez and Willis, 2004). It is 
therefore impossible to have a blank or neutral standpoint (Koch, 1995). However, making 
preconceptions explicit and explaining how they are being used in the inquiry is part of 
interpretative phenomenology (Lopez and Willis, 2004). In keeping with the tenets of 
interpretative phenomenology, the researcher presented her own experiences, its influence 
on her research topic, questions and interpretation in section 3.5.  
 
Interpretative phenomenology contributed to the exploration of service users and 
prescribers’ views on the appropriateness of prescribing in this thesis using an interview 
method. Service users are likely to construct their views on the appropriateness of 
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prescribing based on their experience of using their medicines. However, prescribers may 
assess prescribing appropriateness based on their medical training and through their 
experience of working with service users. It is therefore possible that how they view the 
appropriateness of prescribing may be different. 
 
3.4.1.3. Use of postpositivism and phenomenology in thesis  
This thesis involved the use of both postpositivism and phenomenological philosophical 
perspectives. The early postpositivist perspectives, focusing on the secondary data analysis 
and medication appropriateness study showed the limitations of these approaches for 
understanding a complex and multidimensional construct like 'appropriateness'. These 
approaches were limited because it was not possible to understand the meaning of 
appropriateness from the perspective of different participants. Taking a phenomenological 
approach in the latter part of the project allowed a better understanding of multiple 
perspectives and complex attributions about appropriateness.  
3.4.2. Strategy of inquiry 
The pragmatic approach embracing both postpositivist and phenomenological perspectives 
allowed a pluralistic mixed methods approach to be adopted. This section introduces mixed 
methods research (hereafter MMR), its use in this thesis, the particular design of MMR 
adopted and the integration of the different methods.  
 
MMR has been defined as:   
 
The type of research in which a researcher or team of researchers combine elements 
of qualitative and quantitative research approaches (e.g., use of qualitative and 
quantitative viewpoints, data collection, analysis, inference techniques) for the 
purposes of breadth and depth of understanding and corroboration (Johnson, 
Onwuegbuzie and Turner, 2007, p.123). 
 
Johnson, Onwuegbuzie and Turner (2007) arrived at this definition after carrying out a 
survey of the views of experts on the definition of MMR. A total of 36 leading 
methodologists in MMR identified from Tashakkori’s “Bridges Website” and from 
contributions in a special journal (Research in the Schools) issue on MMR were contacted 
and asked to respond via email. Tashakkori’s Bridges Website15 is a mixed methods 
                                                 
15Available at http://www.tashakkori.com/bridges.html 
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network for the behavioural, social and health sciences. The above definition of MMR was 
reached after a cross-case analysis of the definitions provided by the experts. Although 
there have been arguments concerning mixing qualitative and quantitative methods as 
described in section 3.4.1, there are similarities that have been acknowledged between 
qualitative and quantitative research such as the commitment of both types of methods to 
the understanding of the world as well as a shared commitment to rigor and critique in the 
research process (Reichardt and Rallis, 1994). Casebeer and Verhoef (1997) have argued 
that qualitative and quantitative research are part of a continuum of research, and 
techniques should be selected based on the research question. MMR thus applies 
quantitative and qualitative research methods depending on the research questions.  
 
MMR can be used for five broad purposes (Greene, Caracelli and Graham, 1989): 
triangulation, complementary, development, initiation and expansion purposes. 
Triangulation involves the comparison of the findings from one method against that of 
another method. In particular, different methods with offsetting or counteracting biases are 
used in investigating the same phenomenon in order to strengthen the validity of findings. 
Complementary purpose involves enhancing or clarifying the results from one method with 
another. Here, qualitative and quantitative methods are used to measure overlapping but 
also different facets of a phenomenon in order to produce an enriched understanding of that 
phenomenon. In development purpose, the result of one method informs the other method. 
Initiation purpose entails revealing contradictions in one method with another. Expansion 
on the other hand involves seeking breadth and depth of one method with another.  
3.4.2.1. Justification for MMR in thesis 
In this thesis, MMR was used for complementary, development and expansion purposes. 
The research aims argued for a mixed method strategy because the appropriateness of 
prescribing is a complex concept that cannot be adequately explored using only one 
method. The first quantitative method (secondary data analysis) provided a picture of the 
different classes of prescribed medications taken by service users. It assisted in 
understanding the scale of prescribing for service users and also informed the second study 
(questionnaire survey) as the medications assessed for appropriateness were selected from 
it.  
 
The questionnaire survey allowed SAS prescribers to assess the level and nature of 
inappropriate prescribing among service users. The questionnaires used (in particular, the 
adapted-Medication Appropriateness Index and the Medication Omissions Questionnaire) 
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allowed both quantitative and qualitative data to be obtained from SAS prescribers about 
medication appropriateness. The qualitative data expanded on the quantitative data as it 
assisted in understanding the reasons for the ratings given by prescribers. Data from the 
questionnaire survey further informed some aspects of sampling in the service user 
interviews as interviewed service users were those found to be on prescribed opioids 
and/or psychiatric medications in the survey.  
 
The interviews with SAS prescribers contributed to an understanding of the process of 
clinical decision-making that prescribers go through in order to assess the appropriateness 
of prescribed medications as well as how they responded to inappropriate prescribing. 
Service user interviews provided a means of understanding how service users perceive 
their prescribed medications and changes made to them. Both prescriber and service user 
interviews were therefore useful in exploring the complexity of decision-making without 
the simplification required for quantitative data collection, thereby providing a more 
complete picture. Finally, findings from the quantitative and qualitative methods were 
integrated for a more complete understanding of the topic.  
3.4.2.2. Design of MMR 
According to Creswell (2009), factors that can influence the design of MMR include 
timing, weighting and mixing. Timing is important because it determines whether the 
qualitative and quantitative methods will be sequential or concurrent. It is also possible to 
have a combination of sequential and concurrent timing (multiphase combination timing) 
over a program of study (Creswell and Plano Clark, 2011). The multiphase combination 
timing was used in this thesis.  
 
Weighting considers whether priority will be given to one method or if both will be given 
equal weighting. The quantitative and qualitative methods were given equal weighting 
except in the questionnaire survey (medication appropriateness study) where the 
quantitative data in the adapted-Medication Appropriateness Index (hereafter A-MAI) and 
Medication Omissions Questionnaire (hereafter MOQ) were given priority because the 
qualitative data assisted in expanding on the reasons for ratings of appropriateness given 
by prescribers.  
 
Mixing deals with when and how mixing of the different methods will take place. It can 
occur during any of the stages of research. Mixing of methods occurred in the medication 
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appropriateness study as well as during the interpretation of the research findings from the 
various methods. Figure 3.2 shows the MMR design for this thesis.  
 
                                                 Figure 3.2: Mixed methods design 
 
 
 
 
 
 
 
 
 
 
                                                                           
                                                                                        Adapted from Creswell (2009) 
Note: 
The consultation process with SAS consultant psychiatrists was used to inform the classes of medications 
whose appropriateness were later explored in study 2. 
              Indicates that data were collected sequentially. 
Capitalisation in figure 3.2 indicates that weight is given to the quantitative data in study 2.  
 
In the early stages of this study, the researcher considered the different methods that could 
be used in addressing the aims and research questions. She decided to use the following 
methods within a multiphase combination timing: 
  
1. Study 1: Secondary data analysis involving investigation of routine clinical data. 
The total number of service users whose data were analysed was 1783;   
 
2. Study 2: Questionnaire survey in the medication appropriateness study (use of the 
A-MAI and MOQ by SAS prescribers to assess the appropriateness of service 
users’ medications and use of the Adherence Questionnaire (hereafter AQ) to 
assess service users’ adherence). Sixty service users consented to participate in this 
study and were all assessed by SAS prescribers for the omission of opioids and/or 
psychiatric medications at their first SAS appointment using the MOQ. A total of 
37 of these 60 service users were on prescribed opioids
16
 and/or psychiatric 
medications and were assessed by SAS prescribers using the A-MAI. The 37 
                                                 
16
 Only two service users were prescribed opioids as substitution therapy, others were prescribed opioids for chronic 
pain. 
Study 2: 
Questionnaire survey 
 (medication 
appropriateness study) 
 
 
 
 
   QUANTITATIVE 
Consultation 
process with  
psychiatrists 
Study 3: 
Interviews 
 
QUALITATIVE 
Study 1: 
Secondary data 
analysis 
 
QUANTITATIVE 
  qualitative 
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service users were also administered the AQ. The total number of prescribed 
opioids and psychiatric medications taken by these 37 service users was 59.  
 
Twenty-three of the 37 service users were available for follow-up data collection 
three months later and had their prescribed opioids and/or psychiatric medications 
assessed again at their three-month follow-up appointment by the same prescriber 
(except three service users) using the A-MAI. The total of prescribed opioids 
and/or psychiatric medications taken by these 23 service users was 33;  
 
Study 3: Semi-structured interviews with service users and SAS prescribers.  
Fourteen service users were interviewed during their three-month follow-up 
appointment or at their next visit if this was not convenient. Interviewed service 
users were a sample of those whose prescribed opioids and psychiatric medications 
were assessed using the A-MAI at their first SAS visit. All but two SAS prescribers 
were interviewed either before they left the SAS if they were on short rotation or at 
the end of the medication appropriateness study if otherwise.  
  
The secondary data analysis was first carried out. This was followed by a consultation 
process with SAS consultant psychiatrists to inform the classes of medications whose 
appropriateness was later explored using the A-MAI and MOQ in the medication 
appropriateness study. The consultation process has been described in section 3.3. The 
medication appropriateness study was the second to be carried out. In this study, the A-
MAI and MOQ were used by prescribers to assess prescribing appropriateness. Both the A-
MAI and MOQ were used to collect quantitative and qualitative data. However, the 
qualitative data in this context only comprised the reasons for the appropriateness ratings 
given by prescribers and consequently lacked sufficient depth (richness). In addition, the 
qualitative data were responses to closed questions and therefore did not allow exploration 
of prescribers’ responses (O'Cathain and Thomas, 2004). Interviews were thus needed as a 
means for obtaining more detailed information and allowed probing of interviewees’ 
responses (Adams et al., 2008). Interviews were the last to be carried out.  
 
Semi-structured interviews rather than structured or unstructured interviews were 
employed for an in-depth understanding of the perspectives of service users on the 
appropriateness of prescribed medications and the responses of prescribers to inappropriate 
prescribing. It also provided the flexibility for issues relevant to respondents to be 
explored. Structured interviews, as the name implies, have a rigid set of questions and this 
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rigidity forecloses the exploration of important issues that may emerge during the 
interview that have not been pre-planned (Alshenqeeti, 2014; Berg, 2007). Unstructured 
interviews allow for the discussion of issues that emerge from the interview with the 
respondent charting the course of the interview through their response (Berg, 2007). This 
type of interview is very time-consuming and difficult to manage due to its lack of 
structure (Gill et al., 2008). Semi-structured interviews are somewhere in the middle 
between structured and unstructured interviews and allow for flexibility in exploration of 
issues not anticipated in the planning stage of research (Alshenqeeti, 2014; Berg, 2007).  
 
It was necessary for the researcher to carry out the studies in this thesis as described in the 
temporal order above because the first study (secondary data analysis) not only provided 
an overview of prescribing in general, it gave the researcher the opportunity to know the 
SAS, understand how it works, how prescribers operate in this setting and subsequently 
plan for the other studies. Prior to this study, the researcher had no experience of working 
in a SAS. She was introduced to the SAS prescribing protocol, the booklets completed by 
service users, the roles of nurse prescribers and doctors, and she also had the opportunity to 
shadow prescribers during their consultations with a number of service users. 
Consequently, the secondary data analysis was an important starting point for subsequent 
studies. Starting with the interviews would have led to a loss of appreciation of the SAS 
setting and would have been challenging without the studies that preceded it.  
3.4.2.3. Integrating qualitative and quantitative results 
The linking of qualitative and quantitative results has been described as one of the most 
important steps in MMR (Teddlie and Tashakkori, 2009). However, many mixed methods 
studies have been criticized because they have failed in this respect (Bryman, 2007). 
Bryman (2007) has argued that the connection between qualitative and quantitative 
findings should always be explored in mixed designs for purposes of clarification or 
breadth and depth of understanding. Consequently, this section describes how the results of 
the quantitative and qualitative methods used in this thesis were linked.  
 
The data obtained from the quantitative and qualitative methods were initially analysed 
separately because they addressed different research questions relating to appropriateness. 
In addition, sequential mixed studies such as the one carried out in this thesis are often 
analysed separately in order to support the follow-up actions (Creswell and Plano Clark, 
2011). For example, the service users interviewed were those found to be taking prescribed 
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opioids and/or psychiatric medications in the A-MAI questionnaire survey. Thus, the A-
MAI questionnaire survey informed some aspects of the service user interviews.  
 
One strategy through which results can be integrated in MMR is the side-by-side 
comparison proposed by Creswell and Plano Clark (2011). Side-by-side comparison 
involves presenting the quantitative results and the qualitative findings together in a 
discussion or in a summary table so that they can be easily compared. This assists in 
highlighting areas where the results from each study agree (converge), are complementary 
or contradictory for a greater level of understanding (O'Cathain, Murphy and Nicholl, 
2010). This approach was adopted in this thesis as the quantitative and qualitative studies 
were examined for the themes that cut across them whilst also highlighting themes that 
were unique to each study for a holistic picture. The results obtained from the secondary 
data analysis, questionnaire survey and the interviews were compared along five themes 
derived from these studies.  
 
3.5. Reflexivity 
Reflexivity refers to sensitivity to the ways in which the researcher, their experience, 
beliefs and characteristics such as professional status may have shaped the research process 
(Mays and Pope, 2000). In qualitative research with a phenomenological perspective, 
reflexivity is important because the researcher is the primary instrument of data elicitation 
(Smith, 2004). This implies that it is important for researchers to evaluate how they have 
influenced research (Demi and Warren, 1995). Below the researcher presents a brief 
account of her characteristics, background and values, and how these might have 
influenced this thesis.  
  
This research was carried out by A. O, a young female pharmacist. Prior to undertaking 
this Ph.D., she had gained a Bachelor’s degree in Pharmacy (Nigeria) and a Master’s 
degree in Clinical Pharmacy, International Practice and Policy (London). She practiced as 
a pharmacist for a year in Nigeria before studying for her Master’s degree. Coming from a 
pharmacy background probably influenced some of the decisions she made while planning 
for this research. For instance, the researcher’s pharmacy background made her initially 
more inclined to view mental disorders (including SUDs) as a brain disease and this 
accounted for her interest in pharmacological management. However, her engagement with 
service users, prescribers and the literature in the course of this research has broadened her 
view as she now considers mental disorders to be complex disorders with multi-level 
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mechanisms comprising social, psychological and behavioural factors as well (Deacon, 
2013). 
 
Furthermore, the researcher’s pharmacy practice prior to starting her PhD programme had 
involved interaction with doctors as prescribers rather than nurses. This probably had some 
influence on her initial approach to nurse prescribers. For example, the consultation that 
informed the selection of medications she focused on in the medication appropriateness 
study comprised only doctors (in particular, consultant psychiatrists). Only consultant 
psychiatrists were involved in the consultation because they were the only group of doctors 
working at the SAS during this period. Although she interacted with some nurse 
prescribers about medications they prescribe prior to carrying out this research, having a 
consultation with them similar to that with doctors would have been helpful in 
understanding their collective perspective. This might have influenced the medications the 
researcher focused on in the medication appropriateness study.  
     
The researcher developed an interest in SUDs during her undergraduate training and 
became particularly interested in prescribing for this group as a result of her own clinical 
experience while working in Nigeria. While writing up her Master’s degree dissertation, 
she applied for the Collaboration for Leadership in Applied Health Research and Care 
(CLAHRC) funded studentship in research on the appropriateness of prescriptions given to 
people with SUDs. The inspiration for this research came from a NHS staff who raised the 
quality of prescribing for service users with SUDs as a potentially important issue which 
required investigation. The researcher subsequently commenced her Ph.D programme. 
Although she is not registered as a pharmacist in the UK, she gained some clinical 
experience through her hospital rotation during her Master’s degree.  
 
The researcher’s professional background may have influenced her views about the 
appropriateness of medications such as its indication, side effects and drug interactions. 
For instance, due to her prior clinical experience, reading relevant literature and talking to 
a range of people, she had developed an assumption that people with SUDs may be more 
likely to be prescribed certain medications (for example, opioids) inappropriately. These 
assumptions may have influenced some aspects of this research such as the way in which 
data was collected and analysed. The researcher was aware of this and tried to remain open 
to the possibility that participants did not share this view. The researcher made effort to 
ensure that the questions she asked during the interviews were not leading. She also 
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ensured that she paid attention to competing explanations during analysis and these were 
reported when presenting results and discussing them. The involvement of her thesis 
advisory panel in the research process was also a means of ensuring an accurate 
representation of findings as much as possible. 
 
In addition, it has been suggested that researchers should consider how they introduce 
themselves to participants since this may influence participant’s views about them and the 
information they chose to disclose (Jack, 2008; Richards and Emslie, 2000; Schutz, 1994). 
For instance, Richard and Emslie (2000) found that disclosure of the professional role of 
the researcher to participants and participants’ perceptions of that role influenced the type 
of information participants chose to share. For prescribing research, if the interviewer is a 
healthcare professional, the interviewee (for example, service users) may choose not to 
disclose actual information concerning their prescribed medications (for example, 
information concerning their adherence) for fear of being judged or having their medicines 
withdrawn. This may lead to the social desirability bias with service users providing the 
answers that they believe the researcher wants to hear (Ganster, Hennessey and Luthans, 
1983). However, this possibility was off-set as service users were informed that any 
information shared with the researcher will not be disclosed to healthcare professionals at 
the SAS.  
 
Further, in this study the researcher did not introduce herself as a pharmacist to service 
users but rather as a research student at the University of York. She only went further to 
disclose her professional identity if asked. Although no service user asked about the 
researcher’s professional background, it is possible that some might have assumed she had 
a health background. This may have affected how they responded. In spite of this 
possibility, some service users disclosed that they were non-adherent to their medications.    
 
Prior to conducting the interviews, the researcher was initially apprehensive about her       
planned interaction with service users. The researcher is a professional from a different 
cultural background to most service users and does not have a history of substance use. 
Furthermore, although she is knowledgeable about the clinical management of the 
comorbidities she focused on in this research, she does not have a history of being 
prescribed psychiatric medications for mental disorders or opioids for chronic pain. She 
was therefore concerned about what service users’ perceptions of her would be, rapport 
building and how this might impact on the data she obtained from them. These 
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considerations made her ensure that she showed respect and empathy to service users. 
During the interviews the researcher ensured she listened carefully, avoided unnecessary 
interruptions except for purposes of clarification, and was sensitive to what participants 
said. It is the researcher’s view that her pharmacy background and experience had given 
her good listening skills and a sense of empathy which she carried over into the 
interviewing process with participants. Contrary to her initial apprehension, she found that 
she was able to engage with most service users. Service users appeared at ease during the 
interviews though there were occasions when some of them said they could not remember 
information (this may be related to some form of cognitive impairment or reluctance to 
disclose information). The rapport she built with participants before the interviews was 
probably advantageous as some service users sometimes wondered aloud how she was able 
to get so much information from them at the end of the interview while others appreciated 
the opportunity to talk to someone. It is the researcher’s opinion that these service users 
valued the opportunity to tell their stories because of the rapport she had built with them, 
as well as the attention and interest she showed. A study of people with a past history of 
SUDs reported that they sometimes described their experience of relating their stories as 
therapeutic (Grant, 2014).  
 
There were however a few interviews that posed challenges for the researcher. In one of 
the challenging interviews, the service user’s partner followed her into the interview room 
though the researcher had initially informed her that she would be conducting a one-on-one 
interview. The researcher found this interview to be difficult because she could not ask her 
partner to leave the interview room and the service user was also not engaging with the 
interview. She provided very short responses to the questions the researcher asked and 
within about 10 minutes the interview was over. The researcher realised that she obtained 
very limited information from this interview. In retrospect, the researcher’s view is that she 
should not have proceeded with this interview since it is possible that the service user was 
reluctant to discuss her medical/medication history and SUD history in the presence of her 
partner. The second challenging interview she had was with a service user who walked out 
during interview because it was boring him. Again, this service user was not engaging with 
the interview and provided short responses. The useful information she obtained from 
these two interviews were very limited.    
    
The professional background of the researcher was probably both an advantage and a 
disadvantage in her interviews with prescribers. It was an advantage in that she is familiar 
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with the medications used in the management of commonly co-existing disorders with 
SUDs. She could understand the technical terms used by the healthcare professionals that 
participated in the interviews. On the other hand, it is possible that her background 
influenced how prescribers responded to the interviews since they were aware of her 
professional background. Prescribers may have exaggerated how they assessed the 
appropriateness of service users’ medications (social desirability effect) due to fear of 
admitting less than optimal practice to her. It is therefore possible that the findings of this 
study may differ if she had been from a different professional group.  
  
3.6. Summary 
This chapter has described the methodological approach and techniques used to investigate 
the appropriateness of prescribing for service users as well as the responses of prescribers 
to inappropriate prescribing. The philosophical worldview the researcher adopted in this 
thesis was pragmatism. The pluralistic nature of pragmatism enabled the use of both 
postpositivist and phenomenological perspectives. This further allowed a mixed methods 
approach to be used. Furthermore, a comprehensive understanding of the appropriateness 
of prescribing and responses to inappropriate prescribing required the adoption of multiple 
methods, thus building a more holistic picture than could be obtainable using a single 
method. Quantitative methods were used to provide an overview of the different classes of 
medications taken by service users during their first assessment at the SAS in addition to 
allowing for the estimation of the magnitude of inappropriate prescribing. Interviews with 
prescribers provided a means for an understanding of their responses to inappropriate 
prescribing while interviews with service users aided an understanding of their 
perspectives on the appropriateness of medicines assessed in this study. The next chapter 
presents the first study carried out in this thesis: a secondary data analysis of routine 
clinical data obtained from the SAS electronic database and its findings.  
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Chapter 4: Secondary data analysis of 
routine clinical data  
4.1. Study rationale 
 
As discussed in chapter 3, the analysis of routinely collected data obtained from the SAS 
electronic database was carried out in order to provide a comprehensive overview of the 
different classes of medications taken by service users who are newly referred to the SAS. 
This was the first quantitative study in this thesis. It represents a first step towards 
understanding prescribing in this client group since there is a lack of research assessing the 
different types of medications prescribed for them. Published studies have only described 
particular psychiatric medications such as antidepressants (Petrakis, Leslie and Rosenheck, 
2003) and benzodiazepines (Brunette et al., 2003; Clark et al., 2004) prescribed for service 
users. Due to the dearth of published research in this area, the types of medications 
prescribed for service users were studied using routinely available data in a single SAS. 
The research questions addressed are described below:  
 
1. What types and quantities of prescribed medications are taken by service users? 
a. What types of medications are service users at the SAS taking at their first 
treatment episode between September 2007 and January 2011? 
b. What is the prevalence of polypharmacy (four or more medications) among 
service users?  
c. What is the prevalence of psychiatric polypharmacy (four or more psychiatric 
medications) among service users? 
d. What are the distinguishing profiles of service users on polypharmacy and 
psychiatric polypharmacy? 
 
Polypharmacy was defined as prescribing four or more medications for the same person 
(Department of Health, 2001) while complex psychiatric polypharmacy was considered to 
be prescribing of four or more psychiatric medications for the same person. The following 
medications were regarded as psychiatric medications: antidepressants, anxiolytics, 
hypnotics, anticonvulsants, antipsychotics and mood stabilisers. Although polypharmacy is 
not synonymous with inappropriate prescribing, the number of unnecessary or 
inappropriately prescribed medications increases with polypharmacy (Goh, 2002; Nobili et 
al., 2011; Rambhade et al., 2012). Only the prevalence of polypharmacy was assessed in 
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this study because other aspects of prescribing appropriateness such as indication, dose and 
duration of therapy were not consistently documented on the SAS database.  
4.2. Methods 
This section describes the method used in this study: a secondary data analysis of routine 
clinical data at the SAS. It also describes the inclusion and exclusion criteria, data 
management and analysis plan, and ethical process for this study.   
4.2.1. Secondary data analysis of routine clinical data 
Information about service users assessed during their first treatment episode between  
September 2007 and January 2011 were extracted from the SAS electronic database by the 
information analyst. This period was selected for study in order to provide a picture of the 
medications prescribed for service users over a considerable period of time. As described 
in section 3.2, prior to visiting the SAS for their first treatment episode, service users are 
sent a self-completion booklet. This booklet enquires about the newly referred service user, 
their prescribed medications and measures considered to be key in addiction such as 
dependence, psychological well-being and social well-being (Raistrick, Heather and 
Godfrey, 2006). Dependence and psychological well-being are assessed at the SAS using 
the Leeds Dependence Questionnaire (hereafter LDQ) (Raistrick et al., 1994), and the 
Clinical Outcomes in Routine Evaluation 10-item measure (hereafter CORE-10) (Barkham 
et al., 2013) respectively. Social well-being is assessed using the Social Satisfaction 
Questionnaire (hereafter SSQ) (Raistrick et al., 2007). In addition to these three measures, 
a fourth measure EQ 5D (Brooks, Rabin and De Charro, 2003) is used in assessing quality 
of life. These measures are further described in section 4.3.1.2. 
 
The completed booklets are collected from service users at their appointment and entered 
into the electronic database by secretaries of the different clinical teams, who have been 
trained in the use of the database. The database has been developed over the last 20 years. 
Data of service users attending for their first treatment episode between September 2007 
and January 2011 were analysed in this study. The prescribed medications of service users 
were grouped into different classes using the British National Formulary (BNF), No 59, 
classification (Joint Formulary Committee, 2010). The BNF classification was used 
because it is the official formulary used by healthcare professionals in the UK. It contains 
information on the medications prescribed, dispensed and administered in the UK. This 
study informed the selection of medications whose appropriateness was subsequently 
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assessed in the medication appropriateness study following a consultation process with 
SAS psychiatrists.  
4.2.2. Inclusion/exclusion criteria for secondary data analysis 
Service users were eligible for inclusion in this study if they attended for their first session 
of a new course of treatment at the SAS between September 2007 and January 2011. 
People classified as newly referred service users therefore include those previously 
discharged but starting a new course of treatment within the specified time period. If 
included service users were discharged and then attended the SAS again within the time 
period, these later courses of treatment were excluded. This approach avoided 
representation of multiple episodes of the same person in this analysis. 
4.2.3. Data management and analysis 
This section presents how data obtained from this study were managed and analysed. Data 
management is first presented followed by the analysis of data. 
 
Data management 
Data used in this study were anonymised and extracted from the SAS electronic database 
by the SAS information analyst. The dataset was sent to the researcher by the information 
analyst through a password protected excel file via the SAS intranet as approved by the 
ethical committee. Data were then transferred via an encrypted memory stick to the 
University of York for analysis on a double password protected computer. The researcher 
converted the excel file to an SPSS file before analysing it. Some inaccuracies were 
observed in the data. For example, some medications were incorrectly spelt. Citalopram, an 
antidepressant, was sometimes spelt as citaolpram or citaloopram. Where the spellings of 
medications could not be reconciled with any known medication, they were not included in 
the analysis.  
 
The researcher grouped all the medications on the database using SPSS syntax into their 
different classes as obtainable in BNF, No 59, including those that were incorrectly spelt. 
For example, different groups of antidepressants such as the tricyclic antidepressants, the 
selective serotonin reuptake inhibitors and monoamine oxidase inhibitors were all grouped 
into the antidepressant class. All medications were assigned only to one class. For instance, 
some antidepressants such as amitriptyline are also used for the treatment of neuropathic 
pain (Joint Formulary Committee, 2010). However, they were only classified as 
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antidepressants in this study. This was through necessity as the indications for medications 
were often not recorded on the database. Data were retained for five years to allow for 
completion of the PhD and dissemination of the results.   
 
Data analysis 
Data analysis was performed using SPSS (v 18) at the Department of Health Sciences, 
University of York. Descriptive statistics for continuous variables were expressed as means 
(SD) and those for categorical variables as frequencies and proportions. Median and 
interquartile range (Q1, Q3) were presented for variables that are not normally distributed. 
The independent samples t-test was used in the analysis of data comprising two 
independent groups that are normally distributed. The independent samples t-test is used to 
compare the means between two independent or unrelated groups on the same continuous, 
dependent variable (Peacock, 2010). Data that are not normally distributed were 
transformed to the logarithmic form for improvement in their distribution. However, if the 
logarithmic transformation did not improve the distribution, then analysis of two 
independent groups was carried out using a non-parametric test (Wilcoxon Rank Sum test). 
Wilcoxon Rank Sum test is a non-parametric test that is used to compare two independent 
groups when the assumption of normality is not met (Bland, 2000). Chi-squared test was 
used in the analysis of two or more categorical variables. Where the assumptions for it 
were not met, Fisher’s exact test was used. For chi-squared to be used in testing for 
association between variables, 80% of the expected frequencies must be greater than five 
and all expected frequencies must be greater than one (Bland, 2000).  
 
Binary logistic regression was used to determine whether there are any significant 
differences between those service users who were on polypharmacy and those who were 
not on them, on any of the predictor variables (age, sex, level of dependence, referral 
pathway, referral substance, quality of life), while simultaneously controlling for each of 
the other variables. Binary logistic regression is used to assess the association between 
predictors of a variable and the variable itself while controlling for potential confounders 
(Antonogeorgos et al., 2009). It is used when the dependent variable is dichotomous (in 
this case, presence or absence of polypharmacy).  
 
Predictor variables were included in the model based upon theoretical justification as well 
as evidence from published studies for an association with the dependent variable. For 
instance, age has been reported to be associated with polypharmacy in previous studies (Al 
Ameri et al., 2014; Moen et al., 2009) while the type of referral substance and level of 
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dependence may be important because some substances such as alcohol have been 
associated with more illnesses (Gutjahr, Gmel and Rehm, 2001). This may result in the 
need for more medications among people who are dependent on alcohol. There may also 
be a tendency for the severity of illness and by extension, number of prescribed 
medications, to be related to levels of dependence. Some studies have reported use of more 
medications among women compared to men (Bjerrum et al., 1998; Venturini et al., 2011). 
Referral pathway may also be important because people referred from hospital may be on 
more medications since they may be more ill compared to those who self-referred or those 
referred from their GPs. Those with lower quality of life may be more ill and therefore 
more likely to be on more medications when compared to those with a higher quality of 
life.  
 
Binary logistic regression was also used to assess if there are any significant differences 
between service users who were on psychiatric polypharmacy and those who were not on 
them on the above-mentioned predictor variables. Information relevant to statistical 
modelling such as the value of R-squared and goodness of fit test are not presented because 
the purpose of this analysis is not model building. P-values, odds ratios and 95% 
confidence intervals for the odds ratios are reported. An alternative method of analysis to 
logistic regression is discriminant analysis. However, logistic regression was preferred 
because it produces more accurate results when the independent variables are a 
combination of continuous and categorical variables (Pohar, Blas and Turk, 2004) as it is 
in this study. Statistical significance was at the 5% level and all reported p-values were 
two-sided. Where multiple testing occurred, Bonferroni adjustment (Bland and Altman, 
1995) was carried out. 
4.2.4. Ethical considerations 
The ethical application for the secondary data analysis was first submitted for 
consideration by the Health Sciences Research Governance Committee (hereafter HSRGC) 
at the University of York before being sent via email to the NRES Committee South West 
Exeter on the 19
th
 of October 2011 for proportionate review. Proportionate review is used 
when a study carries minimal risk to the study participants due to the absence of patient 
identifiable information. This study involved analysis of anonymised data extracted from 
the SAS electronic database and therefore carried minimal risk of identification of study 
participants. The NRES Committee requested the inclusion of evidence of valid insurance, 
confirmation of support from the University of York, clarification of research site, 
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confirmation of scientific critique and statistical review in their opinion letter on the 26
th
 of 
October 2011 before a favourable ethical opinion would be given. A favourable ethical 
opinion (shown in appendix 4.1) was subsequently obtained from the NRES Committee. 
This was followed by approval from the Research and Development (R & D) Department 
of the Leeds Partnership NHS Foundation Trust (now Leeds and York Partnership NHS 
Foundation Trust). 
 
4.3. Results  
4.3.1. Characteristics of newly referred service users 
This section presents a description of the sociodemographic characteristics of newly 
referred service users attending the SAS as well as comparison of key addiction measures 
obtained for service users with their normative ranges.    
4.3.1.1. Sociodemographic characteristics 
There were a total of 1783 newly referred service users during the period examined. 
Majority were males (58.3%) with a mean age of 40.5 (SD = 11.2). Most service users 
were of white ethnicity (86.1%) and cited alcohol (78.2%) as their primary problematic 
substance. Self-referral accounted for the highest number of referrals making up about one-
third (31.5%), followed by referral from general practitioners (21.6%). Drug services were 
responsible for 13.6% of referrals, general hospital (including accident and emergency) 
11.5%, psychiatrists 7.9% and others such as social services and criminal justice 13.9%. 
Over half (53.1%) of service users were unemployed and most of them (about 60%) lived 
in rented accommodation. Table 4.1 presents service users’ sociodemographic 
characteristics.  
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Table 4.1: Sociodemographic characteristics of service users in the secondary data analysis 
study (n and % presented for all characteristics except age) 
 
Sociodemographic characteristics 
 
Total sample (n) 
 
Age (mean, SD) 1783 40.5 + 11.2 
Gender 
Male 
Female 
 
 
1783 
 
1040 (58.3%) 
743 (41.7%) 
Ethnicity
a
 
White 
Other 
Not stated 
 
 
 
1783 
 
1536 (86.1%) 
92 (5.2%) 
155 (8.7%) 
Housing status
b
 
Rented 
Home owner 
Homeless 
Other 
 
 
 
 
1690 
 
1011 (59.8%) 
349 (20.7%) 
225 (13.3%) 
105 (6.2%) 
Referral substance
c
 
Alcohol 
Opioids 
Other 
 
 
 
1783 
 
1395 (78.2%) 
263 (14.8%) 
125 (7%) 
Referral source
d
 
Self 
General hospital and A&E 
General practitioner 
Psychiatrist 
Drug services 
Other 
 
 
 
 
 
 
1783 
 
560 (31.5%) 
205 (11.5%) 
385 (21.6%) 
141 (7.9%) 
243 (13.6%) 
248 (13.9%) 
Employment status
e
 
Employed 
Unemployed 
Other 
 
 
 
1684 
 
333 (19.8%) 
894 (53.1%) 
457 (27.1%) 
Number of previous SAS episodes
f
 1783 1 (1, 2) 
Number of prescribed medicines
f
 1761 2 (1, 4) 
aOther ethnicity includes mixed (3.2%), Asian or Asian British (1.2%), Black or Black British (0.3%)  and other ethnic 
groups (0.4%), bother housing status includes those living in supported housing (6%) and travellers (0.2%), cother referral 
substances include those referred because of sedatives (0.8%), cannabis (2.4%), stimulants (2.7%), hallucinogens (0.3%), 
polyuse (0.7%) and solvents (0.1%), donly 0.1% of service users were referred from hospital A & E, drug services 
include statutory (7%) and non-statutory drug services (6.7%) whereas other includes social services (2.4%), criminal 
justice (0.7%) and other referral sources (10.8%), eother employment status includes inactive people (16.9%), those who 
preferred not to state their status (0.8%) and others (9.4%). fdata not normally distributed, therefore median and 
interquartile range presented. Where A & E = Accident & Emergency and SD = standard deviation. 
 
Due to the fact that almost 8 out of every 10 service users had alcohol as their primary 
referral substance, their demographics were compared to the population of service users in 
contact with structured treatment for alcohol (primary problematic substance) in England 
(Public Health England, 2014a), and they were found to be similar in their age. There were 
however more males, more service users of white ethnicity and more self-referrals among 
those in structured treatment. No data were presented on employment status by Public 
Health England (2014a) and data on housing status were not directly comparable due to 
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differences in categories of housing situation used. Service users attending for their first 
new treatment episode had a median of one treatment episode in the past. 
4.3.1.2. Key measures of addiction used in the SAS  
As already described in section 4.2.1, dependence, psychological well-being and social 
well-being are considered to be key outcome measures in addiction (Raistrick, Heather and 
Godfrey, 2006). Dependence and psychological well-being are assessed at the SAS using 
the Leeds Dependence Questionnaire (hereafter LDQ) (Raistrick et al., 1994), and the 
Clinical Outcomes in Routine Evaluation 10-item measure (hereafter CORE-10) (Barkham 
et al., 2013) respectively. Social well-being is assessed using the Social Satisfaction 
Questionnaire (hereafter SSQ) (Raistrick et al., 2007). In addition to these measures, the 
EQ 5D (Brooks et al., 2003) is used in assessing quality of life.  
 
The LDQ is a 10-item self-completion questionnaire for the assessment of the level of 
dependence on substances such as alcohol, illicit drugs as well as prescribed medications 
(Heather et al., 2001; Raistrick et al., 1994). It measures similar areas of dependence to the 
ICD-10 (World Health Organisation, 1993). The areas measured include pre-occupation 
with substance, salience of substance-related activity, compulsion to start using, planning 
procurement and use of substance, maximising the drug effect, narrowing of the repertoire 
of drug-taking behaviour, compulsion to continue use, primacy of drug effect over other 
aspects of substance use, constancy of drug-induced state and a cognitive set of needing to 
use in order to cope with everyday life. The LDQ has a score ranging from 0 to 30 with 
higher scores representing higher levels of dependence. The LDQ has extensive and 
independent validation (Heather et al., 2001; Kelly et al., 2010; Paton-Simpson and 
MacKinnon, 1999). 
 
Heather et al. (2001) proposed the following normative ranges for alcohol dependence 
using the LDQ: mild (0 to 15), moderate (16 to 23) and severe dependence (24 to 30). Cut-
offs were also proposed for mild opioid dependence (0 to 20), moderate opioid dependence 
(21 to 25) and severe opioid dependence (26 to 30). When compared to these normative 
ranges, SAS service users referred for their alcohol problems were moderately dependent 
(18.1 + 8.4) whereas those referred for opioids were mildly dependent (8.2 + 8.9). The 
value obtained for alcohol is similar to that previously reported by Raistrick et al. (1994) 
for service users who were dependent on alcohol at the SAS. However, the value for 
opioids is lower compared to the study by Raistrick et al. (1994). 
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The CORE-10 (Barkham et al., 2013) is a short version of the 34-item Clinical Outcomes 
in Routine Evaluation – Outcome Measure (CORE-OM) (Barkham et al., 2001; Evans et 
al., 2002). It is a self-reported 10-item questionnaire for assessing different domains of 
psychological well-being, namely, depression, anxiety, physical, trauma, general 
functioning, social functioning, close functioning, subjective well-being, risk to self as well 
as risk to others.  
 
Each item on the CORE-10 is scored on a five point scale ranging from 0 to 4 with the 
lowest possible score being 0 and the highest being 40. Higher scores indicate a higher 
level of psychological distress. Its psychometric properties have been investigated and 
reported (Connell and Barkham, 2007). The clinical cut-off for psychological distress 
using CORE-10 is 11 (Barkham et al., 2013). Within this clinical range, a score of 11 is the 
lower boundary of the ‘mild’ level, 15 for the ‘moderate’ level, and 20 for the ‘moderate-
to-severe’ level (Connell and Barkham, 2007). A score of 25 or more marks the ‘severe’ 
level. The CORE-10 score obtained for SAS service users was 21.8 (SD = 9.1), indicating 
the presence of ‘moderate to severe’ levels of psychological distress among this 
population. There has been no previous study that used the CORE-10 among substance 
users. However, the score obtained in this study is similar to that obtained from a clinical 
population (20.2 + 7.9) recruited from a GP practice in the UK (Connell and Barkham, 
2007).  
 
The SSQ was developed to assess social satisfaction in people with SUDs (Raistrick et al., 
2007). It is an 8-item scale adapted from a pre-existing scale, Social Problems 
Questionnaire (Corney and Clare, 1985). The areas assessed by the SSQ include 
accommodation, living arrangements, employment, financial position, amount of time you 
are able to go out, amount of time you see your friends, closest relationship and 
relationship with your family. The SSQ has a score ranging from 0 to 24 with higher scores 
indicating higher levels of social satisfaction. The psychometric properties of the SSQ has 
been investigated and reported (Raistrick et al., 2007). A score of 16 or more indicates a 
well-functioning population (Raistrick et al., 2014). The mean level of social satisfaction 
among SAS service users using the SSQ was 13.9 (SD = 5.6), and is similar to that 
reported in a recent study among the SAS population (Raistrick et al., 2014).  
 
The EQ 5D assesses five domains which comprise mobility, self-care, social, pain, and 
psychological with three levels (no problems, some problems, extreme problems) within 
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each domain (Sanz et al., 2011). A person’s health state can therefore be classified into one 
of 243 (3
5
) theoretically possible health states, each of which has been assigned a utility. 
These health states have been ranged as EQ 5D index scores in a large UK population 
sample from 0 (worst possible health state) to 1 (best possible health state) (Dolan, 1999). 
Some states are considered to be worse than death and given negative values. Higher 
values indicate better health-related quality of life. Quality of life was assessed using the 
EQ 5D among SAS service users and found to be 0.5 (SD = 0.4). The EQ 5D score was 
similar to that previously reported (0.4 + 0.4) in an alcohol dependent population in an 
outpatient setting in the UK (Foster, Peters and Kind, 2002). The EQ 5D has been 
validated in clinical and non-clinical populations (Brazier, Jones and Kind, 1993; Johnson 
and Pickard, 2000; Schrag et al., 2000). It has also been shown to be a valid measure of 
quality of life among people with alcohol and heroin dependence (Gunther et al., 2007; van 
der Zanden et al., 2006). Table 4.2 provides a description of these measures. 
 
Table 4.2: Key measures of addiction for service users in the SAS 
 
Measures of addiction 
 
Total sample (n) 
 
LDQ
a
 1745 17 (9, 24) 
CORE-10 1749 21.8 + 9.1 
SSQ 1708 13.9 + 5.6 
EQ5D
a
 1748 0.6 (0.2, 0.8) 
aData not normally distributed, therefore median and interquartile range presented. 
4.3.2. Types of medications taken at first treatment episode  
Service users were prescribed a variety of medications. The three most commonly 
prescribed medications were antidepressants (48.7%), analgesics (29.1%) - mostly opioids- 
and vitamins/minerals (28.1%). Thus, nearly half of service users arriving for treatment 
had a prescription for antidepressants. Of the analgesics prescribed, 84.4% were opioids, 
with methadone, buprenorphine and suboxone
17
 making up 60% of them. Figure 4.1 
provides a description of the seven most commonly prescribed medications for SAS 
service users between September 2007 and January 2011. The percentage of other 
prescribed medications ranged from 0.2% to 6.6%. Appendix 4.2 provides a full 
description of the prescribed medications.  
 
 
 
 
                                                 
17 It is unclear if these medications were prescribed as substitution therapy for opioid dependence or not due to lack of 
consistent documentation of indication on the SAS electronic database.  
126 
 
Figure 4.1: The seven most commonly prescribed medications for service users 
 
4.3.3. Prevalence of polypharmacy and psychiatric polypharmacy  
Over one-quarter (27%) of service users were on polypharmacy whereas only 1.7%  were 
on psychiatric polypharmacy.  
4.3.4. Profiles of service users on polypharmacy and psychiatric 
polypharmacy 
This section presents the following results: 
 Comparison of the sociodemographic characteristics of service users with and 
without polypharmacy and psychiatric polypharmacy 
 Comparison of key measures of addiction among service users with and without 
polypharmacy and psychiatric polypharmacy 
 Variables associated with polypharmacy and psychiatric polypharmacy using 
logistic regression. 
4.3.4.1. Sociodemographic characteristics of service users with and without 
polypharmacy 
Service users on polypharmacy were significantly older (p < 0.0005), differed in their 
referral source (p < 0.0005), referral substance (p < 0.0005) and employment status (p < 
0.0005). Service users with polypharmacy were more likely to be referred from general 
hospital, general practitioners (GPs) and psychiatrists while those without polypharmacy 
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had more self-referrals, referrals from drug services and others. Those on polypharmacy 
were more likely to have alcohol as their referral substance whereas in those without 
polypharmacy, opioids and ‘other’ substances were more common as referral substances. 
They were also more likely to be in ‘other’ employment category comprising inactive 
people (retirees, students, home-makers, long-term sick), those who preferred not to state 
their status, and any categories besides those considered to be employed or unemployed. 
Table 4.3 presents the significant sociodemographic differences between service users with 
and without polypharmacy (appendix 4.3 provides a full description of sociodemographic 
characteristics). The level of significance was set at 0.4% due to Bonferroni adjustment for 
multiple testing (Bland and Altman, 1995). 
 
Table 4.3: Sociodemographic characteristics of service users with and without 
polypharmacy (n and % presented for all characteristics except age) 
Sociodemographic 
characteristics 
Service users 
without 
polypharmacy 
Service users with 
polypharmacy 
P-values  
Age
a
  38.4 + 10.43 46.15 + 11.11 P < 0.0005
#
 
Referral source
b
 
Self 
General hospital 
General practitioner 
Psychiatrist 
Drug services 
Other  
Total 
 
415 (32.3%) 
124 (9.6%) 
270 (21%) 
93 (7.2%) 
196 (15.3%) 
187 (14.6%) 
1285 
 
138 (29%) 
78 (16.4%) 
110 (23.1%) 
48 (10.1%) 
44 (9.2%) 
58 (12.2%) 
476 
 
 
 
 
 
 
 
P < 0.0005
+
 
Referral substance
c
    
Alcohol 948 (73.8%) 427 (89.7%)  
Opioids 238 (18.5%) 25 (5.3%)  
Other 99 (7.7%) 24 (5%)  
Total  1285 476 P < 0.0005
+
 
Employment status
d
    
Employed 266 (21.9%) 63 (14%)  
Unemployed 670 (55.2%) 215 (47.8%)  
Other 
Total  
277 (22.8%) 
1213 
172 (38.2%) 
450 
 
P < 0.0005
+
 
aMean and standard deviation presented for age, bother referral sources include social services, criminal justice and 
others, cother referral substances include sedatives, cannabis, stimulants, hallucinogens, solvents and polyuse, dother 
employment status includes inactive, not stated and others, #calculated using independent sample t-test, +calculated using 
chi-squared test. 
4.3.4.2. Key measures of addiction in service users with and without polypharmacy 
Service users on polypharmacy had higher levels of psychological distress and lower 
quality of life measured using the CORE-10 and EQ 5D respectively (p < 0.0005). Table 
4.4 shows only the CORE-10 and EQ 5D scores because there were statistically significant 
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differences between service users with and without polypharmacy (appendix 4.4 provides a 
full description of these key measures of addiction).  
 
Table 4.4: Key measures of addiction in service users with and without polypharmacy 
Measures of 
addiction 
Service users 
without 
polypharmacy 
Service users with 
polypharmacy 
P-values 
CORE-10 21.41 + 9.27 23.07 + 8.46 P < 0.0005 
EQ 5D 0.69 (0.27, 0.85) 0.29 (0.08, 0.69) P < 0.0005 
 
4.3.4.3. Sociodemographic characteristics of service users with and without 
psychiatric polypharmacy 
Service users on psychiatric polypharmacy differed significantly only in their referral 
source from those who were not on psychiatric polypharmacy (p < 0.0005). Those on 
psychiatric polypharmacy were more likely to be referred from psychiatrists while those 
without psychiatric polypharmacy had more self-referrals and referrals from general 
hospital, GPs and drug services. Appendix 4.5 provides a full description of these 
sociodemographic characteristics.  
4.3.4.4. Key measures of addiction in service users with and without psychiatric 
polypharmacy 
There were no significant differences in the SAS key measures of addiction between those 
with and without psychiatric polypharmacy. Appendix 4.6 presents a description of the key 
measures. 
4.3.4.5. Variables associated with polypharmacy using logistic regression 
This section presents the independent variables that are associated with polypharmacy in 
the logistic regression analysis (see table 4.5). The dependent variable in this analysis was 
dichotomous, that is the presence or absence of polypharmacy. Polypharmacy was defined 
as prescribing of four or more medications for the same person (Department of Health, 
2001). The independent variables that were significantly associated with polypharmacy 
were age, level of dependence measured using the LDQ, quality of life measured using the 
EQ 5D, referral source, referral substance and employment status. Controlling for all other 
variables, the odds of polypharmacy increased as age increased (p < 0.0005). Level of 
dependence and quality of life had an inverse relationship with polypharmacy and were 
both statistically significant. The odds of polypharmacy decreased as LDQ and EQ 5D 
both increased, adjusting for other variables. This means that as level of dependence 
increased, the odds of polypharmacy decreased. Similarly, as quality of life improved the 
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odds of polypharmacy decreased. The association between referral sources and 
polypharmacy was significant (p = 0.04) with referrals from drug services (p = 0.04) and 
self-referral (0.002) in particular being significant. Compared to those referred from 
general hospital, service users referred from drug services and self-referrals were 
significantly less likely to be on polypharmacy. The relationship of the referral substances 
with polypharmacy was also statistically significant (p < 0.0005) with opioids in particular 
being inversely associated with polypharmacy, while ‘other’ substances were not. 
Controlling for other variables, the odds of polypharmacy among service users referred for 
opioid use was 0.3 times that among those referred for alcohol use (95% CI: 0.16 to 0.54). 
Employment status was significantly associated with polypharmacy (p = 0.004). The odds 
of polypharmacy among inactive people were two times that among the employed 
population (95% CI: 1.33 to 3.10). The odds of polypharmacy among unemployed people 
were 1.4 times that among those who were employed (95% CI: 0.97 to 1.99). However, 
this was not statistically significant. Table 4.5 shows the variables associated with 
polypharmacy. 
 
Table 4.5: Variables associated with polypharmacy 
Predictor variables B-coefficient P-value Odds ratio and 95% CI 
Age  0.05 P < 0.0005 1.05 (1.04 to 1.06) 
Gender -0.08 P = 0.59 0.93 (0.70 to 1.22) 
LDQ -0.03 P = 0.006 0.97 (0.96 to 0.99) 
CORE-10 -0.02 P = 0.07 0.98 (0.96 to 1.0) 
EQ 5D -2.20 P < 0.0005 0.11 (0.07 to 0.18) 
Referral source  P = 0.04  
GP -0.45 P = 0.05 0.64 (0.41 to 1.00) 
Psychiatrist -0.16  P = 0.59 0.85 (0.47 to 1.53) 
Drug services -0.57 P = 0.04 0.57 (0.33 to 0.98) 
Self  -0.68 P = 0.002 0.51 (0.33 to 0.78) 
Other -0.50 P = 0.05 0.61 (0.37 to 1.01) 
Referral substance  P < 0.0005  
Opioids -1.21 P < 0.0005 0.30 (0.16 to 0.54) 
Other -0.40 P = 0.19 0.67 (0.37 to 1.22) 
Employment status
a
  P = 0.004  
Unemployed 0.33 P = 0.08 1.39 (0.97 to 1.99) 
Inactive 0.71 P = 0.001 2.03 (1.33 to 3.10) 
Constant -0.89 P = 0.08 0.41
b
 
Where CI = confidence intervals 
aOnly ‘inactive’ comprising long-term sick, retirees, students and home makers was used among ‘other’ employment 
status, bonly odds ratio is presented.   
 
4.3.4.6. Variables associated with psychiatric polypharmacy using logistic regression 
The independent variables associated with psychiatric polypharmacy were analysed using 
logistic regression. Psychiatric polypharmacy was defined as prescribing of four or more 
psychiatric medications for the same person. The dependent variable was dichotomous, 
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that is the presence or absence of psychiatric polypharmacy. The large number of 
independent variables for the dependent variable (presence or absence of psychiatric 
polypharmacy) prevented the calculation of the odds ratio and 95% CI for some of the 
variables. The minimum number of independent variables recommended for the dependent 
variable when using logistic regression is 10 (that is, 10 service users with psychiatric 
polypharmacy and 10 service users without psychiatric polypharmacy (Hosmer and 
Lemeshow, 2000), otherwise the estimation of the coefficients becomes unstable resulting 
in misleading results. The number of service users with psychiatric polypharmacy was only 
30 which was small compared to the required minimum of 10 variables per independent 
variable. For all the eight independent variables of psychiatric polypharmacy to be used, 
there should be at least 80 service users with psychiatric polypharmacy and 80 without 
psychiatric polypharmacy. Consequently, the independent variables associated with 
psychiatric polypharmacy are not presented. 
4.4. Discussion of SAS database findings 
This section presents a discussion of the results of this study in relation to prior research.  
 
- Types of medications and polypharmacy 
There was variation in the types of medications prescribed for service users, with high 
levels of prescribing of antidepressants. The high prevalence of antidepressants likely 
reflects the high levels of mood and/or anxiety disorders among those attending the SAS 
since they are used in the treatment of these disorders in the UK (National Institute for 
Health and Clinical Excellence, 2006; 2009; 2011b). In particular, antidepressants are 
initially recommended only for the treatment of severe forms of depressive and anxiety 
disorders. Other classes of medications such as benzodiazepine anxiolytics may be used for 
short-term treatment of anxiety disorders or where anxiety disorders are disabling and 
severe (Baldwin et al., 2013).  
 
As earlier described in section 1.5.2.1, mood and anxiety disorders commonly co-exist 
with SUDs, with a high prevalence occurring in treatment populations (Delgadillo et al., 
2012; Weaver et al., 2003; Arora and Kaur, 2012; Cole and Sacks, 2008). Weaver et al. 
(2003) found that 68% and 81% of drug service and alcohol service patients, respectively, 
in a substance misuse setting had a comorbid mood and/or anxiety disorder. The 
prevalence of severe depression was found to be 27% and 34% among drug and alcohol 
service patients respectively. Severe anxiety was reported in 19% and 32% of drug and 
alcohol service patients respectively. In total, 50.3% of patients (both drug and alcohol 
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service patients) had either severe depressive or anxiety disorders. Delgadillo et al. (2012) 
reported similar prevalence of current depressive and/or anxiety disorders among people 
with SUDs in a UK community drug treatment service with 58% of patients having severe 
symptoms.  
 
Furthermore, this study found that about 15% of service users were prescribed 
antipsychotics. This is within the reported prevalence of psychotic disorders (7.4% to 
56.6%) (Weaver et al., 2003; Walsh and Copello, 2014) among people with SUDs in the 
UK. As discussed in section 1.5.2.2, differences in the prevalence rate reported in the 
literature may be due to how psychotic disorders were defined and identified in these 
studies. Weaver et al. 2003 reported on the prevalence of non-substance-induced psychotic 
disorders whereas it is unclear if Walsh and Copello (2014) reported only on non-
substance induced psychotic disorders. Walsh and Copello (2014) who reported the highest 
prevalence (56.6%) considered psychotic disorders to include schizophrenia, psychosis, 
schizoaffective and delusional disorders while Weaver et al. (2003) who reported the 
lowest prevalence (7.4%) included only schizophrenia and non-specific psychosis. 
Furthermore, in the study by Walsh and Copello (2014), psychotic disorders were recorded 
if there was evidence that a psychiatrist had previously diagnosed a patient. For one-third 
of patients who did not have a psychiatrist’s diagnosis, psychotic disorders were identified 
by the patient’s keyworker who were neither doctors nor psychiatrists. This may have led 
to overestimation of the prevalence of psychotic disorders in the above study.   
 
It has been argued that the adverse consequences of SUDs are likely to make people 
unhappy and anxious and may mistakenly be diagnosed as a mental disorder (Horwitz and 
Wakefield, 2007). Psychological distress associated with dependence is often difficult to 
separate from an independent mood or anxiety disorder. Intoxication and withdrawal 
symptoms of alcohol and other substances often resemble those of anxiety and depressive 
disorders and they can sometimes be severe, though resolving within two to four weeks of 
abstinence (Grant et al., 2004; Raimo and Schuckit, 1998). Consequently, such disorders 
may be unnecessarily treated with medications. There is therefore the possibility that 
prescribers have inappropriately prescribed psychiatric medications such as antidepressants 
and anxiolytics for service users. The extent to which this was the case could not be 
determined in the current study as information on the original prescriber’s clinical 
decision-making processes was not available. It is also possible that these medications 
were prescribed for other indications. For instance, some antidepressants are also used in 
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the management of pain and eating disorders (Royal College of Psychiatrists, 2012; 
National Collaborating Centre for Mental Health, 2004). The lack of consistent 
documentation of indication for medication use on the electronic database made it 
impossible to know the actual reasons for which these medications were prescribed. The 
extent of prescribing argues for more research on this issue and further consideration of 
prescribing practice in this group of people.  
 
Almost 30% of service users were prescribed analgesics. These comprised substitute 
opioids, non-substitute opioids and non-opioid analgesics. Substitute opioids such as 
methadone, buprenorphine and suboxone made up half of prescribed ‘analgesics’. Non-
substitute opioids and non-opioid analgesics were prescribed for 15% of service users, with 
non-substitute opioids in particular being prescribed for 10% of service users. Non-
substitute opioids and non-opioid analgesics were probably prescribed for pain, since they 
are usually used in pain management (Fishbain et al., 2008; Juska and Balon, 2013).  
 
Pain, including chronic pain, is a common comorbid condition in people with SUDs (Peles 
et al., 2005; Rosenblum et al., 2003; Jamison et al., 2000; Larson et al., 2007; Caldeiro et 
al., 2008). More than half of people in a residential detoxification programme for alcohol 
and drug use disorders (cocaine and heroin) have been reported to have moderate to very 
severe pain with 16% reporting persistent pain of two years duration (Larson et al., 2007). 
Caldeiro et al. (2008) found the prevalence of moderate to very severe pain to be almost 
60% among veterans attending outpatient addiction centres who were dependent on other 
substances beside opioids. Over one-third of patients had chronic pain of over one year 
duration.  
 
When compared to the high prevalence of pain reported among people with SUDs in other 
studies, the fact that only 10% of service users reported taking prescribed non-substitute 
opioids is surprising and may be due to a number of reasons. Firstly, it may represent a 
tendency to under-report prescribed opioid use. Under-reporting of opioid use may be due 
to fear of losing access to this medication among people who are dependent on them 
(Action on Addiction, 2013). Secondly, it may have resulted because of the study focus on 
prescribed opioids and not on opioids obtained from other sources such as over-the-counter 
or illicit sources. Evidence from the US and Australia shows that non-medical users of 
opioids frequently obtain them from friends, relatives and drug dealers (Jones, Paulozzi 
and Mack 2014; Nielsen et al., 2013). Thirdly, it may represent a tendency to use other 
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medications in pain management in this group of people. Lastly, it may be due to a 
tendency to undertreat pain in this population. Under-treatment of pain has been 
highlighted as a problem among people with SUDs, such as those maintained on 
methadone for OUDs (Dunn, Brooner and Clark, 2014). 
 
The prescribing of opioids is particularly challenging in people with SUDs as prescribers 
must ensure that opioids are appropriately prescribed for them, that is, not withheld 
unjustly or overprescribed. This is due to the need to prevent opioid misuse, dependence 
(Fishbain et al., 2008; Portenoy, 1996; Turk, Swanson and Gatchel, 2008; Morasco et al., 
2013), diversion and drug interactions (Baldacchino et al., 2010) while ensuring that pain 
is adequately managed.    
 
- Prevalence of polypharmacy and psychiatric polypharmacy 
The prevalence of polypharmacy and of psychiatric polypharmacy were 27% and 1.7% 
respectively. No previous study was found that examined polypharmacy or psychiatric 
polypharmacy among people with SUDs. Consequently, the prevalence reported in this 
study could not be compared with a SUD population. In addition, studies have tended to 
adopt different definitions of polypharmacy making direct comparison difficult. 
Polypharmacy has been defined using various cut-offs such as the use of two or more 
drugs for 240 days or more (Veehof et al., 2000), use of four or more medications 
(Bikowski, Ripsin and Lorraine, 2001) and use of five or more different prescription 
medications (Linjakumpu et al., 2002; Jorgensen et al., 2001). The PRACTICE study 
involving 15 general practice settings in England reported that 17% of patients were 
receiving between five and nine medications and 9.7% ten or more (Avery et al., 2012). 
Findings from the Health Survey for England 1998, showed that in people over 75 years 
approximately 36% were taking four or more prescribed drugs (Department of Health, 
1998).  
 
The prevalence of psychiatric polypharmacy is lower than that reported among psychiatric 
outpatients (Goldberg et al., 2009; Mojtabai and Olfson, 2010). Mojtabai and Olfson 
(2010) examined prescribing patterns of psychiatric medications comprising 
antidepressants, antipsychotics, mood stabilisers and sedative-hypnotic among psychiatric 
outpatients in USA and found that 33.2% of patients had three or more of these 
medications prescribed for them between 2005 and 2006. Goldberg et al. (2009) also 
examined the prescribing patterns of psychiatric medications comprising lithium, 
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anticonvulsants, antidepressants and antipsychotics among patients with bipolar disorder in 
USA and found that 18% of patients were taking four or more of these medications 
(Goldberg et al., 2009). Again, these studies are not directly comparable to the database 
study because they do not focus on people with SUDs.   
 
The prevalence of polypharmacy found in this database study may reflect the complex 
health problems and comorbidities of service users (Dickey et al., 2002). Dickey et al. 
(2002) reported a high prevalence of medical disorders among people with comorbid SUDs 
and severe mental illness. Where there are multiple conditions, polypharmacy may be 
needed and beneficial. However, it may also be harmful as it increases the risk of drug 
interactions and adverse events (Duerden, Avery and Payne, 2013; Guthrie et al., 2011; 
Bourgeois et al., 2010). Medications such as opioids and benzodiazepines that are used in 
the treatment of conditions that commonly co-occur with SUDs have been implicated in 
the occurrence of drug overdose and mortality in patients with SUDs (Darke, Duflou and 
Torok, 2011; Darke and Hall, 2003; Darke and Ross, 2000; Zamparutti et al., 2011). The 
number of unnecessary or inappropriately prescribed medications increases with 
polypharmacy (Rambhade et al., 2012; Goh, 2002). It is therefore important to consider 
whether each medication is being prescribed appropriately, both individually and in the 
context of the service user's total medication exposure, risk of drug interactions and 
comorbidities (Hilmer, 2008; Duerden, Avery and Payne, 2013). This is particularly 
apposite among people with SUDs due to their comorbid conditions, need for management 
by different specialists and increased tendency for risky interactions between medications 
and substances. In this study, it was not possible to evaluate whether polypharmacy was 
necessary because the indication of medications were often absent from the electronic 
database. 
 
- Variables associated with polypharmacy 
The variables that were significantly associated with polypharmacy were age, level of 
dependence, quality of life, referral source, referral substance and employment status. The 
odds of polypharmacy increased as age increased. This finding is in line with previous 
studies (Veehof et al., 2000; Moen et al., 2009; Al Ameri et al., 2014) that have found 
similar associations between age and number of prescribed medications. Polypharmacy 
tends to increase with age due to increased comorbidities (Duerden, Avery and Payne, 
2013; Olsson, Runnamo and Engfeldt, 2011). Level of dependence measured using the 
LDQ showed an inverse relationship with polypharmacy. In particular, as the level of 
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dependence on opioids increased, polypharmacy decreased (p = 0.01) (data not shown). 
This association was not observed with alcohol and ‘other’ substances. This could have 
resulted because prescribers were wary of prescribing medications to people with more 
severe opioid dependence probably due to apprehension about drug interactions. The type 
of referral substance was also significantly associated with polypharmacy. Compared to 
those whose referral substance was alcohol, those who had opioids as their referral 
substance were less likely to be on polypharmacy. This may reflect the extensive damage 
that alcohol causes to the organ systems compared to opioids. Alcohol has been linked to 
over 60 diseases (Gutjahr et al., 2001). Given that a number of service users in this study 
used other substances in addition to their primary referral substance, it is not possible to 
disentangle the extent to which the different substances contributed to polypharmacy. For 
instance, some service users whose referral substance was opioids were also drinkers
18
.  
 
Polypharmacy was associated with lower quality of life. The use of multiple medications 
may adversely affect service users’ quality of life through the possibility of side effects 
from the different medications. For instance, antipsychotics have been associated with 
weight gain, and this has been linked to lower quality of life among schizophrenic patients 
(Allison, Mackell and McDonnell, 2003). Similarly, the sexual side effects from 
antidepressants can result in lower quality of life among those taking them (Higgins, Nash 
and Lynch, 2010). While medications may contribute to improvement in quality of life 
through their beneficial effects, they may also contribute to decreasing it (Olsson et al., 
2011). An alternative explanation is that those on polypharmacy were less healthy and 
therefore they reported lower quality of life.  
 
When compared to service users referred from general hospital, those referred from drug 
services and self-referrals were significantly less likely to be on polypharmacy. This may 
be due to the fact that service users from these settings were less ill compared to those 
referred from hospital. Service users treated in hospitals are usually complex with co-
occurring medical and mental health disorders (O'Toole et al., 2006).   
 
Employment status was also significantly associated with polypharmacy although only the 
‘inactive’ category was statistically significant (p = 0.001). The odds of polypharmacy 
among service users in the ‘inactive’ category were two times that among employed 
people. The inactive group comprised those who are neither in the employed nor 
                                                 
1838% of service users whose referral substance was opioids were also drinkers. 
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unemployed category such as those who are long-term sick, retired, students and home 
makers. The higher likelihood for polypharmacy among the ‘inactive’ category may be due 
to the nature of this group. Retired people are more likely to be older with more comorbid 
conditions (Boutayeb, Boutayeb and Boutayeb, 2013) while sick people would suffer from 
one or more health conditions. Consequently, they are more likely to be on polypharmacy.  
 
There have been two major hypotheses concerning the relationship between employment 
and health: the social causation hypothesis proposes that employment improves health 
whereas the social selection hypothesis suggests that health shapes people’s employment 
status (Adda, Chandola and Marmot, 2003; Blane, Smith and Bartley, 1993; Ross and 
Mirowsky, 1995). It is believed that these mechanisms may also reinforce each other 
(Blane, Smith and Bartley, 1993; Ross and Mirowsky, 1995), as poor health may lead to 
unemployment which may lead to further deterioration in health (Bartley, 1994). The fact 
that more people in the ‘inactive’ category had polypharmacy may therefore reflect the fact 
that they comprised people with more health problems.  
 
Unemployed people were unlikely to be on polypharmacy when compared to those in 
employment. The evidence concerning the relationship between unemployment and poor 
health is contradictory, and physical health does not necessarily decline during 
unemployment (Bartley, 1988). One study even found that health may improve during 
unemployment (Ramsden and Smee, 1981). Psychological health may however be 
diminished during unemployment as some studies have reported higher levels of 
depression and anxiety in this population when compared to those in employment (Khlat, 
Sermet and Le Pape, 2004; Kasl and Jones, 2000). Unemployment may also lead to 
deterioration in health behaviours such as alcohol use leading to morbidity. However, 
studies have not consistently reported this finding (Cook et al., 1982; Lee et al., 1990). 
Cook et al. (1982) did not find any significant difference in heavy drinking between 
employed and unemployed British men while in another UK study by Lee et al. (1990), 
more unemployed people reported being non-drinkers compared with those in 
employment.  
 
4.5. Strengths and limitations 
The limitations of this study include the fact that it was a retrospective study of routinely 
collected data and therefore there were quality issues relating to missing or inaccurate data 
and self-report. Data entered into the self-completion booklets by service users were self-
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written. This data was not collected as part of an interactive interview with a healthcare 
professional which may have assisted in gathering more comprehensive information 
regarding service users’ medication history. It is possible that service users may not report 
some of their medications due to a perceived need to avoid disclosure or even due to 
cognitive impairment secondary to substance use (Simpson et al., 2004). It is therefore 
possible that this study underestimated the number of prescribed medications and 
consequently polypharmacy.  
 
Furthermore, entry of information about service users into the database was reliant upon 
human input and therefore prone to errors. Data entered into the SAS electronic database 
were extracted from self-completion booklets by secretaries of the different clinical teams 
and then included on the database. Although secretaries who entered this information have 
been trained in the use of the database, they have limited knowledge on different types of 
medications and health conditions. It is therefore possible that they may have missed 
recording some medications on the database. Names of medications were also sometimes 
incorrectly spelt. For example, citalopram (an antidepressant) was sometimes spelt as 
citaolpram or citaloopram. Where the spellings of medications could not be reconciled 
with a known medication, they were not included in the analysis. Again, this study may 
consequently have underestimated the number of prescribed medications and 
polypharmacy. Poor quality data are often a problem in studies that utilise routine clinical 
data (Iezzoni, 1997) rather than data specifically collected for research.  
 
It is possible that some medications that were grouped under a particular BNF class were 
used for other indications. For example, amitriptyline could be used as an antidepressant 
and also for neuropathic pain. However, it was classified only as an antidepressant in this 
study in order to avoid multiple counting. Furthermore, the reason for medication use was 
not consistently documented on the electronic database from which the data analysed in 
this study were obtained. It was therefore not possible to know the actual indications for 
medications. Other details such as dose and duration of prescribed medications were often 
not included on the database. This may have resulted because service users did not report 
these details or secretaries did not include them on the database. Despite these limitations, 
the use of routine clinical data represented a relatively fast and inexpensive method of 
research. Descriptive studies employing routinely available data are cheaper to execute and 
are less time consuming compared to studies that involve prospective collection of primary 
data. 
138 
 
The use of routine clinical data also hindered data collection on some important factors 
such as number and types of comorbidities. The lack of such information including 
indication, dose and duration precluded the assessment of prescribing appropriateness. If 
these data were available, they would have been useful in judging prescribing 
appropriateness. This study was however necessary due to a lack of previous research and 
it represents a first step in exploring this area.  
 
A strong point of this study is the fact that it included all relevant service users during the 
period assessed. Consequently, it was comprehensive in describing service users’ 
prescribed medications. One of the research questions (distinguishing profiles of those on 
psychiatric polypharmacy) could not be addressed because of the large numbers of 
independent variables in the logistic regression analysis. The minimum number of 
independent variables recommended for the outcome variable when using logistic 
regression is 10 (that is, 10 service users with psychiatric polypharmacy and 10 service 
users without psychiatric polypharmacy (Hosmer and Lemeshow, 2000). The number of 
service users with psychiatric polypharmacy was however small compared to the required 
minimum of 10 variables per independent variable. This prevented the calculation of the 
odds ratio and 95% CI for some of the variables in the logistic regression analysis. Lastly, 
this study was carried out in a single SAS and its findings are not generalizable to other 
SAS services in the NHS.  
4.6. Summary of key findings 
This study found that almost half of service users were on antidepressants at their first 
assessment at the SAS. Other classes of medications whose prevalence exceeded 10% were 
analgesics, vitamins/minerals, anxiolytics/hypnotics, antihypertensives, antipsychotics and 
proton pump inhibitors. All other classes of medications were below 10%. The prevalence 
of polypharmacy and psychiatric polypharmacy were 27% and 1.7% respectively. The 
independent variables that were significantly associated with polypharmacy were age, level 
of dependence measured using the LDQ, quality of life measured using the EQ5D, referral 
source, referral substance and employment status. A journal article reporting on aspects of 
this study, in particular, the psychiatric medications taken by service users with a range of 
SUDs has been published in Advances in Dual Diagnosis (Oluyase et al., 2013). The 
published study is shown in appendix 4.7.  
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Chapter 5: Medication Appropriateness 
Study (MAS) 
5.1. Study rationale 
This chapter reports on the second quantitative study in this thesis. Evidence from the 
scoping review showed that only limited dimensions of prescribing appropriateness have 
been assessed in previous studies. In addition, no study has assessed prescribing 
appropriateness among service users being treated in a SAS. The medication 
appropriateness study (hereafter MAS) therefore involved the use of the A-MAI by SAS 
prescribers (medical doctors and nurse prescribers) in assessing the appropriateness of 
current prescribed medications (in particular, opioids and psychiatric medications) for 
service users attending the SAS between August 2012 and April 2013. In the MAS, the 
MOQ was also used in assessing failure to prescribe needed psychiatric medications and 
opioids for SAS service users. 
 
Service users recruited and assessed at their first SAS visit were followed up at their three-
month review appointment. For instance, service users recruited and assessed at their first 
SAS visit in August 2012 were followed up at their three-month review appointment in 
November 2012. The last set of service users were recruited in December 2012 and were 
followed up at their three-month appointment in March 2013. Where service users did not 
attend their three-month review appointment but attended a subsequent one, they were 
followed up at this appointment until the end of data collection in April 2013.    
 
One of the questionnaires used in assessing appropriateness, the medication omissions 
questionnaire (MOQ), and the adherence questionnaire (AQ) were both designed for this 
study and were used only at service users’ first SAS visit. The MOQ was only used by 
SAS prescribers at service users’ first SAS visit in order to ascertain if there was an 
omission of both psychiatric medications and opioids or either of them when service users 
were coming into treatment while the AQ was administered to service users to assess their 
level of adherence to their medications when coming into treatment. The A-MAI was 
however used by SAS prescribers in assessing medication appropriateness at service users’ 
first SAS visit and at three-month follow-up review appointment. Both time periods 
usually involve extensive assessments of service users’ medical and medication history. 
Assessment at service users’ three-month review appointment assisted in determining if 
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there have been any changes in medications found to be inappropriate at first SAS visit. 
The research questions addressed are highlighted below: 
   
1. What is the level and nature of inappropriate prescribing? 
2. How do service users with inappropriate prescribed medications differ from those 
who do not have such medications? 
3. Does the appropriateness of prescribed medications change over the course of 
service users’ treatment? 
4. What are the potential cost savings that could result from stopping or reducing the 
use of inappropriate medications?     
5.2. Questionnaire survey as a research method in the MAS 
A survey generally refers to the selection of a sample of people from a population, asking 
them a set of questions and using their answers to make some inference about the wider 
population (Fowler, 2014). Questionnaire surveys involve the use of questionnaires to 
collect data (Kelley et al., 2003). There is usually no attempt to control conditions in 
survey research. Surveys do not involve the allocation of respondents into groups and the 
treatments they receive are not varied (Kelley et al., 2003). They are therefore appropriate 
for descriptive studies. Surveys are also well suited for analytical studies whose intention is 
to assess the effect of a set of variables on another variable. These may involve the use of 
longitudinal study designs where data are collected at more than one point in time (Kelley 
et al., 2003). Data may be collected from the same sample on each occasion (cohort or 
panel studies). In this study, while the MOQ and AQ were used to collect data on 
medication omissions and adherence respectively at one point in time (service users’ first 
SAS assessment), the A-MAI was used to collect data on medication appropriateness at 
two time-points (service users’ first SAS assessment and three-month review 
appointment). 
5.3. Sampling strategy and sample size 
Service users 
A purposive sampling strategy was utilised in order to recruit service users who were able 
to provide evidence relevant to addressing the research questions (MacNealy, 1999). This 
involved recruiting only those assigned to be assessed by prescribers (nurse prescribers or 
medical prescribers) during their new treatment episode in the study period, so that 
appropriateness could be rated in such service users by their SAS prescribers.  
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The sample size for this study was estimated from the current case load of SAS prescribers. 
It was estimated that the maximum number of service users that could be assessed by the 
seven prescribers who worked as permanent staff
19
 at the SAS between August 2012 and 
December 2012 was 112 because each prescriber sees an average of one newly referred 
service user per week. Weaver et al. (2003) reported that 79% of drug and alcohol service 
clients took part in their study assessing comorbidity of SUDs and mental illness in 
community mental health and substance misuse services. Assuming that a similar 
percentage of service users would consent to take part in this study, the number of service 
users that could be recruited was 88. The total number of service users actually seen by 
prescribers was 76, and 60 of them were recruited into this study.      
 
Prescribers 
All prescribers (nurse prescribers and medical doctors) at the SAS were recruited into this 
study. Nurse prescribers were included despite their limited remit of prescribing because 
this study sought to understand prescribing practice in general. 
5.4. Inclusion/exclusion criteria 
Inclusion criteria 
 Service users who were attending the SAS for the first session of a new treatment 
episode during the study period; 
 Service users assessed by prescribers (nurse prescribers or medical doctors) only. 
 
Exclusion criteria 
 Service users who were unable to be interviewed using spoken English; 
 Service users who were intoxicated; 
 Service users who were assessed by non-prescribers. 
5.5. Recruitment 
Service users 
Service users attending the SAS could self-refer or they could be referred from sources 
such as general practitioners (GPs), psychiatrists, hospital, social services, drug services as 
well as the criminal justice system. Information obtained about newly referred service 
users by SAS staff included their demographic information, health history and 
medications. This information was included on their referral form. All new referrals were 
                                                 
19There were only seven prescribers at the SAS at the onset of this study. Seven other prescribers joined the SAS at 
various points during this study.  
142 
 
required to book an appointment for their first assessment at the SAS. They were also sent 
a self-completion booklet (hereafter SCB) to fill out before their first assessment and were 
asked to arrive at the SAS reception 30 mins before their appointment so that they could 
have a health check. Those who did not come along with their completed SCB were given 
another one to fill out by the receptionist.  
 
The first point of contact for new referrals on arrival at the reception was the SAS 
receptionist who had a register containing all service users attending for the day. Evidence 
from a senior SAS staff suggested all new referrals to the SAS were screened by a nurse on 
the basis of their referral information before their first SAS assessment in order to 
determine if the referral should be accepted or declined and whether the person should be 
seen by a doctor as well as the team the person should be allocated to. Allocation to a 
doctor in any of these teams was said to be based on complexity and in particular any 
prescribing issues while allocation to nurse prescribers and other therapists was decided by 
the team whose clinic day it was
20
. However, evidence obtained by the researcher 
suggested receptionists tended to allocate service users to doctors, nurse prescribers and 
other therapists in the team whose clinic day it was. Allocation occurred when service 
users arrived at the SAS. Evidence from this study (see section 5.9.6) and that obtained by 
the researcher therefore suggested inadequate implementation of the allocation system 
described by the SAS staff in practice.  
 
The receptionists, having been briefed by the researcher, introduced the study to service 
users who were to be assessed by either nurse prescribers or doctors only since these 
prescribers would assess the appropriateness of prescribed medications in this study. The 
study was not introduced to 13 service users who were to be assessed by prescribers due to 
intoxication (n = 1), communication problems about service users’ arrival time (n = 2), 
prescribers were new to the SAS and they informed the researcher they wanted to get 
accustomed to SAS routine at their first assessment of service users (n = 10). Service users 
who were to be assessed by non-prescribers were excluded.  
 
Service users who were interested in the study were referred to the researcher for further 
information (all service users informed about the study agreed to speak with the 
researcher). The researcher went through the participant information sheet (hereafter PIS) 
(see appendix 5.1) with all interested service users in the waiting area (it was not possible 
                                                 
20As described in section 3.2, the three teams are the dual diagnosis team, hospital team, and the pregnancy and parenting 
team. Each team has its own clinic day in which newly referred service users are assessed. 
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to use a private room because they were either being used by SAS staff or for other SAS 
activities) before their routine health check. Those who were happy to participate in the 
study were asked to sign a consent form (appendix 5.2) and a photocopy of this form was 
given to the service user as their own copy. The researcher then administered the 
medical/medication history form (appendix 5.3) and AQ (appendix 5.4) to service users to 
complete. The medical/medication history form includes information on the current 
prescribed medications being taken by service users, their doses, dosage interval, length 
and reason for use, who made diagnosis and when diagnosis was made. Where service 
users requested the researcher’s assistance in completing the forms, she obliged them. This 
was followed by a routine health check, which was usually conducted by trained SAS staff 
after which the results of the health check and the SCB were given to the prescriber who 
would conduct the assessment. 
 
Following the health check, the service user sat in the waiting area to be ushered into the 
consulting room by the prescriber. The prescriber (who the researcher would have given 
the study questionnaires: A-MAI and MOQ prior to the consultation) then came to the 
waiting area to take the service user to the consultation room for a 45- to 60- minute 
assessment. Prescribers were given flexibility concerning when to complete the study 
questionnaires. Generally, they either completed them at the end of each consultation or at 
the close of the clinic for the day. The researcher then collected the completed 
questionnaires back from prescribers. Recruited service users were followed up at their 
three-month review appointment by the same prescriber with the exception of three service 
users who were followed up by different prescribers because one prescriber (two service 
users were assessed by this prescriber) left the SAS while the other prescriber’s clinical 
team was changed. Again, prescribers assessed the appropriateness of service users’ 
medications using the A-MAI during their consultations with service users at their three-
month follow-up review appointment. Figure 5.1 delineates the recruitment process.  
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         Figure 5.1: The study recruitment process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Service user is assigned to 
doctors, nurse prescribers or 
other therapists by receptionist.  
Service user meets receptionist. SCB is 
collected by receptionist. Those 
without their SCB are given a new one 
to complete.  
Service user arrives at the SAS 
 
Receptionist introduces research 
to service users assigned to 
prescribers only and refers those 
interested to the researcher. 
Health check by SAS staff 
Prescriber takes service user for 
consultation and completes the A-MAI 
and MOQ afterwards  
Result of health check and SCB given to 
prescriber 
The researcher goes through the PIS and 
recruits interested service users. The 
medical history form and AQ are 
administered to service users. 
Prescriber follows up service user at 
their 3-month review appointment and 
also completes the A-MAI 
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Prescribers 
The researcher distributed information sheets about this study to all the SAS prescribers. 
She then arranged a brief meeting with each prescriber where she discussed the study in 
detail, including the principles of informed consent. The prescribers were each given one 
week to consider participating in this study after which she obtained written informed 
consent and collected their demographic information (see appendix 5.5, 5.6 and 5.7 for the 
information sheet, consent form and demographics questionnaire respectively). All the 
SAS prescribers agreed to take part in this study.  
5.6. Data collection tools 
The data collection tools in this study included questionnaires for assessing 
appropriateness (A-MAI and MOQ) and adherence, and forms for documenting 
medical/medication history. The choice and adaptation of the MAI as well as the 
development of the MOQ, AQ and forms for documenting medical/medication history are 
described below.  
5.6.1. Choice and adaptation of the MAI 
The MAI has been described in chapter 1 (section 1.4.7.2). It is a validated questionnaire 
that was developed to assess 10 dimensions of appropriateness, namely: indication, 
effectiveness, dosage, correct directions, drug-drug interactions, drug-disease interactions, 
practical directions, expense, duplication and duration (Hanlon et al., 1992). These 
dimensions are rated as A (appropriate), B (marginally appropriate), C (inappropriate) or Z 
(don’t know) for each medication that is being used by the patient. To provide clarity for 
raters while also improving reliability, the MAI has general instructions for use, specific 
definitions of each criterion, instructions on how to answer each of the 10 questions and 
specific examples of ‘A’, ‘B’ and ‘C’ (Hanlon and Schmader, 2013). 
 
Raters may tick Z (don’t know) if they need additional information from patients’ notes to 
rate the dimension. In this study, raters were asked to rate Z (don’t know) if they cannot 
make a judgment on the appropriateness of the medication. The MAI has a section for 
comments after each question. Prescribers were asked to elaborate on the reasons why they 
gave a rating other than ‘A’ (appropriate) in the comments section. These comments aided 
an understanding of why a medication was marginally appropriate or inappropriate. The 
MAI was therefore used to collect both quantitative and qualitative data.  
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Weights ranging from 0 to 3 are assigned to each dimension of the MAI and these can be 
summated to give a total score ranging from 0 to 18 (Samsa et al., 1994). A score of 0 
indicates the absence of inappropriate dimensions while a score of 18 indicates that all 
dimensions for the medication are inappropriate. If the patient is taking multiple 
medications, the score for each medication could be summed up to obtain a score for the 
patient. Either the patient or the medication could be used as the unit of analysis. Although 
Z (don’t know) ratings are included on the MAI, there is no guidance in the MAI 
instructions on the score to be given for Z (don’t know) ratings. Consequently, in this 
study, weightings were not used as prescribers may rate Z (don’t know) for dimensions 
they are unsure of. Z (don’t know) ratings were particularly useful in this study because of 
variability of knowledge among doctors and nurse prescribers regarding some of the 
assessed medications.  
 
The MAI was chosen for this study because it allows for the use of clinical judgment when 
assessing the appropriateness of prescribing for each patient. Unlike the explicit or 
criterion-based measures described in section 1.4.7.1, the MAI allows the patient to be the 
centre of focus rather than diseases (Spinewine et al., 2007). Furthermore, the fact that 
SAS prescribers had contact with service users before using the adapted-MAI provided an 
avenue for them to elicit service users’ preferences before assessing prescribing 
appropriateness. Decision-making concerning prescribing appropriateness could therefore 
incorporate service users’ preferences. In addition, the MAI measures multiple dimensions 
of appropriateness and can be used to assess different types of medications. Its dimensions 
have been considered by healthcare professionals to be important in the assessment of 
prescribing appropriateness (Samsa et al., 1994).  
 
The researcher sent the developer of the MAI, Prof Joseph Hanlon, an email to request a 
copy of the MAI and the instructions for rating it. Prof Hanlon subsequently sent a copy of 
the MAI (appendix 5.8) to her. She examined the MAI and its corresponding instructions 
and found the instructions to be based on American formularies and medication texts such 
as the American Hospital Formulary Service (AHFS) drug information. Consequently, she 
requested a version of the MAI that has been adapted for use in the UK (UK-MAI) in the 
Randomised Evaluation of Shared Prescribing for Elderly People in the Community over 
Time (RESPECT) trial (Richmond et al., 2010). Appendix 5.9 shows the UK-MAI.  
 
147 
 
Another problem with the US version of the MAI was that its instructions were not specific 
on how to rate the other items on it if question 1 ‘is there an indication for the drug?’ is 
rated as inappropriate. However, the UK-MAI provides clearer rating instructions. For 
example, it specifies that raters should answer other questions (questions 2, 3, 4, 5 and 9) 
by assuming that the service user has the diagnosis or indication for which they were 
prescribed the medication. This is because it is possible that a medication is not indicated 
and the dosage, direction and duration of use are also inappropriate. 
 
The researcher subsequently adapted the instructions on the UK-MAI for use with the US 
version of the MAI in this study. The instructions on the UK-MAI were adapted for two 
reasons:  
 
 Firstly, the adapted instructions provided specific examples of when medications 
assessed in this study (prescribed opioids and psychiatric medications) would be 
considered as appropriate, marginally appropriate and inappropriate;  
 Secondly, the adaptation was necessary so that service users’ preferences could be 
incorporated into decision-making when assessing appropriateness.  
 
In previous studies (Hanlon et al., 1992; Hanlon et al., 2004; Schmader et al., 1994; West, 
Cordina and Cunningham, 2012), the MAI had been rated using only the medical history 
problem list and the medication list of the patient without face-to-face contact with them. 
However, in this study, SAS prescribers had face-to-face contact with service users before 
using the MAI. They could therefore elicit service users’ preferences and take them into 
consideration when making decisions about prescribing appropriateness. 
  
After adapting the instructions, the researcher discussed them with one of the consultant 
psychiatrists at the SAS and he suggested minor amendments. The adapted-MAI (A-MAI) 
is shown in appendix 5.10. Despite the general utility of the MAI, it does not assess 
medication adherence and omissions (Spinewine et al., 2007). Medication adherence and 
omissions were assessed using questionnaires designed for these purposes. 
5.6.2. Pilot and training on the A-MAI 
The researcher had two different training sessions for SAS prescribers on the A-MAI. The 
first training session included seven prescribers (3 doctors and 4 nurse prescribers) and 
involved discussion of the A-MAI and its operational definitions. The researcher had 
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initially proposed that nurse prescribers use a different questionnaire to document any 
concerns they have about service users’ medications because some nurse prescribers had 
earlier expressed reservations about assessing appropriateness due to their more limited 
area of expertise. Nurse prescribers’ areas of expertise cover medications used in the 
management of SUDs such as benzodiazepines for alcohol withdrawal, vitamin 
supplementation in AUDs, disulfiram and acamprosate for alcohol relapse prevention, 
methadone and buprenorphine for opioid maintenance or detoxification. Occasionally, 
other opioids such as dihydrocodeine may be prescribed for opioid maintenance.  
 
However, this study also involved assessment of the appropriateness of other psychiatric 
medications and opioids which are not within the scope of practice of SAS nurse 
prescribers. The researcher decided to include nurse prescribers despite this limitation 
because the focus of this thesis was on understanding prescribing practice in general. Nurse 
prescribers are increasingly playing key roles in addiction medicine as medical expertise is 
being decimated. Furthermore, the non-medical prescribing course is generic (Public 
Health England, 2014c) and nurse prescribers would therefore have some level of 
knowledge about psychiatric medications and opioids. It could also be argued that 
experienced nurse prescribers working with complex service users with comorbidities will 
sometimes identify medications that they have concerns about. For instance, there might be 
concerns about interactions between the medications within their expertise and other 
prescribed medications. This study provided an opportunity for nurse prescribers to 
highlight such concerns and the particular areas of prescribing they are concerned about. 
Where they could not reach a decision or make a judgment, they could rate Z (don’t know). 
After discussing the A-MAI and its instructions at this meeting, the nurse prescribers 
decided that they would use it in their assessment of prescribing appropriateness.  
 
The second meeting with prescribers involved discussion of a case study (appendix 5.11) 
comprising a service user’s medical and substance history as well as prescribed psychiatric 
medications with all prescribers. The researcher discussed each of the operational 
definitions of the A-MAI using the case study and the prescribers shared their views and 
asked questions. For staff (seven prescribers) who joined the SAS after the start of the 
study and therefore missed this initial training, the researcher arranged a face-to-face 
meeting to discuss the A-MAI and its operational definitions so that they could also 
participate in the study. This however did not include discussion of the case study due to 
their busy schedules. 
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The developer of the MAI recommends that two individuals should rate the MAI in order 
to compare the reliability of ratings. However, it was not possible for two prescribers to 
have face-to-face contact with the same service user in order to assess their medications 
using the A-MAI. The busy workload of prescribers made this impossible. An alternative 
approach could have been that one prescriber has face-to-face contact with the service user 
and assesses their prescribed opioids and/or psychiatric medications using the A-MAI 
while the researcher would abstract relevant patient information such as their substance use 
history, medical and medication history for a second prescriber to utilise in assessing the 
appropriateness of these medications. However, this would have made inclusion of service 
users’ preferences impossible by the second prescriber since he/she will not have interacted 
with the service user in a face-to-face discussion before assessing medication 
appropriateness. Consequently, service users’ preferences will not be taken into 
consideration in the assessment of appropriateness. In this study, only one rater filled out 
the A-MAI. A previous study by Tobia et al. (2008) also had only one rater.  
 
5.6.3. Medication omission questionnaire (MOQ) design 
Medication omissions defined as failure to prescribe needed medications (Spinewine et al., 
2007) was assessed using the MOQ. Initially, an adapted version of the Assessment of 
Underutilisation of Medication Index (AOU) was considered but this was dropped at the 
pilot stage with prescribers in order to reduce the number of questionnaires to be filled out. 
The AOU is used in assessing underprescribing (that is, the omission of a needed 
medication) (Jeffery et al., 1999). Medication omission was assessed using a single 
question: are any of the medications of interest not being prescribed for an active condition 
without reason? This question had two response choices (yes or no) with a section to 
describe the omitted medications and actions to be taken concerning them. The MOQ is 
shown in appendix 5.12.  
5.6.3.1. Feasibility testing and face validity 
The ease of completion and face validity of the MOQ was tested with seven SAS 
prescribers (3 doctors and 4 nurse prescribers) prior to its use in the medication 
appropriateness study. They found it easy to understand and complete. They did not 
suggest any change to it.   
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5.6.4. Adherence questionnaire design 
While designing this study, I considered different measures that could be used in assessing 
service users’ adherence to their prescribed medications such as medical records, pill count 
and self-report. There is no ‘gold standard’ measure of adherence as all measures have 
their pros and cons (Haddad, Brain and Scott, 2014). Medical records were considered to 
be unsuitable because they would not be available for majority of service users attending 
for their first assessment. Similarly, service users are unlikely to visit the SAS with their 
pills. Hence, pill count was also considered to be unsuitable. Moreover, the use of medical 
records and pill count does not indicate actual usage of medicines (Garfield et al., 2011). 
Consequently, the only feasible means of assessing adherence in this study was via self-
report questionnaires by service users.  
 
Self- report is limited because it is subject to the ability of the service user to recall and 
patients have been reported to overestimate their levels of adherence (Horne et al., 2005). 
Despite these limitations, NICE guidelines have identified self-report of adherence as 
appropriate for use in clinical settings (Nunes et al., 2009) since it is cheap (Gagne and 
Godin, 2005; Hawkshead and Krousel-Wood, 2007), quick and easy to use (Miller and 
Hays, 2000; Paterson, Potoski and Capitano, 2002). Self-report questionnaires should be 
brief, generic rather than disease-specific and should be suitable for patients taking single 
or multiple medications for different conditions (Garfield et al., 2011). It should also 
reflect the varied ways in which people take medications.  
 
The researcher considered existing adherence questionnaires such as the Medication 
Adherence Questionnaire (hereafter MAQ) (Morisky, Green and Levine, 1986) and 
Medication Adherence Rating Scale (hereafter MARS) (Thompson, Kulkarni and 
Sergejew, 2000) and the Brief Medication Questionnaire (hereafter BMQ) (Svarstad et al., 
1999) based on these criteria but none was suitable. The MARS focuses on people with 
psychosis only and therefore was not suitable. The BMQ consists of three sections with 
multiple sub-sections. The BMQ has to be completed for each prescribed medication and 
therefore was considered unsuitable due to its potential to become lengthy for service users 
on multiple medications. The MAQ was dropped because of its limited response choices 
(dichotomous response categories of ‘yes’ and ‘no’) as it does not reflect the varied ways 
in which people take medications and also because its items are designed to focus on one 
specific disease state at a time (Tan, Patel and Chang, 2014). Consequently, the researcher 
designed a short questionnaire (AQ) (appendix 5.4) for assessing service users’ adherence 
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to their prescribed medications. The aim was to create a questionnaire which took less than 
five minutes to complete.  
5.6.4.1. Response mode 
One response mode was used in the questionnaire design: Likert scale. This questionnaire 
asked service users ‘how often do you take this medication as recommended?’ and 
provided five potential responses in a Likert scale format: very often, often, sometimes, 
rarely and never. Five point Likert scale was used because it is quick to complete and 
allows responses to be scaled depending on service users’ level of adherence. It was 
administered during service users’ first assessment at the SAS.  
5.6.4.2. Feasibility testing and face validity 
The ease of completion and face validity of the adherence questionnaire items were tested 
with two ex-service users who serve as mentors for other service users at the SAS prior to 
its use in the medication appropriateness study. They found it easy to understand and fill 
out. The questionnaire took less than five minutes to complete. They did not suggest any 
change to it.  
 
5.6.5. Forms for documenting medical/medication history  
The form for documenting medical/medication history was piloted with seven SAS 
prescribers (3 doctors and 4 nurse prescribers). The prescribers suggested the inclusion on 
the form of the person who diagnosed a service user with a health condition and when the 
diagnosis was made. This form comprised name of medication, dose, frequency, length and 
reason for use, who made diagnosis and when diagnosis was made (see appendix 5.3). 
 
5.7. Data analysis and management 
This section presents how data obtained from the medication appropriateness study were 
analysed and managed.  
5.7.1. Data analysis 
Data analysis was performed using SPSS (v 18) at the Department of Health Sciences, 
University of York. Descriptive statistics for continuous variables were expressed as means 
(SD) and those for categorical variables as frequencies and proportions. Median and 
interquartile range (Q1, Q3) were presented for variables that are not normally distributed. 
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The independent samples t-test was used in the analysis of data comprising two 
independent groups that are normally distributed. The independent samples t-test is used to 
compare the means between two independent or unrelated groups on the same continuous, 
dependent variable (Peacock, 2010). Data that are not normally distributed were 
transformed to the logarithmic form for improvement in their distribution. However, if the 
logarithmic transformation did not improve the distribution, then analysis of two 
independent groups was carried out using a non-parametric test (Wilcoxon Rank Sum test). 
Wilcoxon Rank Sum test is a non-parametric test that is used to compare two independent 
groups when the assumption of normality is not met (Bland, 2000). Chi-squared test was 
used in the analysis of two or more categorical variables. Where the assumptions for it 
were not met, Fisher’s exact test was used. For chi-squared to be used in testing for 
association between variables, 80% of the expected frequencies must be greater than five 
and all expected frequencies must be greater than one (Bland, 2000).  
 
In this thesis, A-MAI dimensions rated as A (appropriate) or B (marginally appropriate)
21
 
were considered to be appropriate while dimensions rated as C (inappropriate) were 
considered inappropriate. Dimensions rated as Z (don’t know) were reported but not taken 
into consideration when analysing data
22
. Where a medication had no A-MAI dimension 
rated as C (inappropriate), it was considered to be appropriate while a medication that had 
one or more C (inappropriate) ratings was considered inappropriate. Analysis of 
appropriateness therefore involved dichotomising ratings of A-MAI dimensions into two 
groups: appropriate or inappropriate. While dichotomising the appropriateness ratings may 
lead to the loss of useful information and may be associated with greater error, it was 
decided to carry out the analysis as described above because it simplifies the analysis, 
leads to easy interpretation and presentation of results (Altman, 2006). This approach to 
analysis was also used by the originators of the MAI (Hanlon et al., 1992).  
 
The number of service users with one or more inappropriate medications was reported. 
Among the different classes of prescribed medications, the number of medications with 
one or more inappropriate dimensions was also reported. For example, the number of 
antidepressants that had one or more inappropriate dimensions was reported. 
 
                                                 
21Refer to appendix 5.13 for reasons cited by prescribers for marginally appropriate ratings on the A-MAI. 
22None of the medications (prescribed opioids and psychiatric medications) assessed in this study had all MAI 
dimensions rated as Z (don’t know). 
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Binary logistic regression was used to assess for the presence of significant differences 
between service users with inappropriate medications (one or more C ratings in their 
prescribed medications) and those without them, using number of prescribed medications 
as a predictor variable. Number of prescribed medications was used as a predictor variable 
because it has been found to be associated with the medication appropriateness in previous 
studies that used the MAI (Duerden, Avery and Payne, 2013; Schmader et al., 1994; 
Spinewine et al., 2007). Statistical information relevant to modelling such as the value of 
R-squared and goodness of fit test are not presented in the results section because the 
purpose of this analysis is not model building. Statistical significance was at the 5% level 
and all reported p-values were two-sided. Where multiple testing occurred, Bonferroni 
adjustment (Bland and Altman, 1995) was carried out. 
5.7.2. Data management 
After consent, participants (service users and prescribers) were given a unique anonymous 
identification (ID) code. This code was used in all data collection forms and 
questionnaires. The consent forms were the only document containing identifiable 
information among service users’ data collection forms while the demographics 
questionnaire and consent forms for prescribers contained identifiable information. These 
were kept in a locked cabinet at the SAS, separate from other data generated in this study. 
They would be stored for five years. Participants were only identifiable by their study ID 
code. Any information which could be used to identify participants was not included on the 
questionnaires and other data collection forms. Electronic data were stored on a double 
password protected computer at the SAS and were only accessible to the researcher. 
Electronic data were transferred via an encrypted memory stick from the SAS to a 
password protected computer at the University of York for analysis. Again, electronic data 
will be retained for five years at the University of York (except audio recording which will 
be retained at the SAS) to allow for completion of the PhD programme and dissemination 
of results.  
5.8. Ethical considerations 
Ethical application for the MAS and the interviews with service users and prescribers were 
made in the same application. This section therefore reports on the ethical issues that are 
relevant to the MAS as well as issues relevant to both the MAS and interviews. Issues 
relevant to the interviews only are described in section 6.3. The ethical application was 
first submitted to the HSRGC. Some ethical issues relevant to both studies were considered 
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such as how incriminating disclosure other than those required by law would be addressed. 
The researcher addressed this by stating that all information provided in the course of this 
study would be kept confidential except there is a disclosure of risk of harm to self or 
others. Such disclosures will be discussed with the appropriate staff at the SAS for further 
action. Service users were informed about this in the participant information sheets and 
also before their interviews. A situation warranting disclosure did not however arise in the 
course of the interviews. Other suggestions by the HSRGC include the use of less technical 
terms on the information sheet and possibility of including non-English service users. The 
latter was not possible as there were no resources for this. Subsequently, all the documents 
were posted to the NRES Committee Yorkshire &The Humber for consideration on the 8
th
 
of June 2012. One of the researcher’s supervisors and the researcher attended an interview 
by the NRES committee on the 27
th
 of June 2012.  
 
The main ethical issue relating to the MAS discussed at this meeting was the short time 
interval (20 mins) in which service users needed to make a decision about taking part in the 
study. However, the researcher stated that she would go through the information sheet with 
interested service users to ensure that they understand what the study is about and what it 
will involve. She argued that her face-to-face discussion with service users will allow a full 
explanation of the study and the principles of informed consent before service users sign 
the consent form. This is particularly apposite for service users, many of whom have low 
literacy levels. Furthermore, she gave service users her contact details (this was also stated 
on the information sheet) in case they have any further queries concerning this study. 
Service users were informed that consent is voluntary and they can withdraw at any time.  
 
During the design of this study, the researcher considered the option of sending the 
information sheet to service users along with the SAS self-completion booklets before their 
first assessment so as to ensure they had adequate time to consider taking part in the study. 
However, this would have been a waste of resources because only service users who were 
assessed by prescribers were the focus of this study and not all service users attending the 
SAS. It would have been difficult to know which service users were to be allocated to 
prescribers or other therapists a priori because they were allocated to keyworkers at their 
baseline assessment.   
 
Another ethical issue relating to both studies was the need for absolute confidentiality 
regarding all the information provided by the participants (service users and prescribers). 
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This is because the service users may be concerned that the information they provided 
might affect their care. For example, they may be concerned that their participation in this 
study may lead to the withdrawal of medications they value. Therefore, the researcher 
assured all service users that the information they provide will not be shared with their 
prescribers. Prescribers were also assured of the confidentiality of all information they 
provided in this study. Furthermore, all participants were assured that the information they 
provide would be anonymised in all publications stemming from this study. All the consent 
forms for service users and prescribers were stored in a locked cabinet at the SAS. The 
questionnaires used in this study did not contain the name or clinic identification numbers 
of service users rather the study identification numbers were used.  
 
The REC gave a favourable ethical opinion of the research (appendix 5.14) based on 
meeting a number of conditions. The conditions that need to be met relate to the interviews 
and are described in section 6.3 which highlights the ethical considerations for the 
interviews. The conditions were met and a confirmation letter for the study was obtained 
from the committee. After approval by the NRES Committee Yorkshire & the Humber, 
some minor changes were made to the study. The A-MAI and the form for documenting 
service users’ medical/medication history were combined into a single data collection form 
for ease of completion. The researcher was sent a minor amendment acknowledgement 
letter (appendix 5.15) on the 30
th
 of August 2012. 
 
5.9. Results 
5.9.1. Recruitment and response rates of participants 
A total of 76 service users were assessed by prescribers (nurse prescribers and doctors) at 
their first SAS visit between August 2012 and December 2012. Of these, 63 were 
approached
23
 and 60 (95%) consented to participate in the MAS. These 60 service users 
include those who were either on target medications (psychiatric medications and/or 
opioids) as well as those were not on them. Information on service users’ prescribed 
medications was obtained using the medical/medication history form. Medication 
appropriateness was assessed by SAS prescribers using the A-MAI and MOQ. While all 60 
service users were assessed for omission of any of the target medications using the MOQ, 
                                                 
23The reasons the 13 service users were not approached for consent includes: intoxication (n = 1), miscommunication 
about service users’ arrival time (n = 2) and prescribers were new to the SAS and informed the researcher that they 
wanted to get accustomed to SAS routine at their first assessment of service users (n = 10). 
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only 37 service users (61.7%) who came into treatment with these target medications had 
them assessed for appropriateness using the A-MAI. Consequently, the denominator in the 
MOQ and A-MAI population were different. As described in section 5.1, the MOQ was 
only used at service users’ first SAS visit while the A-MAI was used both at first SAS visit 
and three-month follow-up appointment.  
 
Almost two-thirds (23) of the 37 (62%) service users were available for follow-up data 
collection three months later. They had their medications (prescribed opioids and/or 
psychiatric medications) assessed again at their three-month follow-up appointment by the 
same prescriber (except three service users) using the A-MAI. Three service users were 
assessed by different prescribers at first SAS visit and three-month follow-up appointment 
because one prescriber (two service users were assessed by this prescriber) left the SAS 
while the other prescriber’s clinical team was changed. Of those not followed up (n = 14), 
10 were discharged before their three-month visit, 3 did not attend their appointment and 
one attended but was not seen by the researcher. Figure 5.2 delineates the recruitment 
process. 
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      Figure 5.2: Service users’ recruitment and response rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.9.2. Omission of opioids and psychiatric medications  
All 60 service users who consented to this study were assessed for omissions of opioids 
and psychiatric medications. There were however no medication omissions. The reasons 
for this finding were further explored in the interviews with prescribers in chapter 7 
(section 7.3.6). 
Service users approached for 
consent (n = 63)  
 
All 60 service users were assessed for 
failure to prescribe psychiatric 
medications or opioids without reason 
using the MOQ at their first SAS visit 
Exclude: did not consent (n = 3)  
Service users assessed using the A-
MAI at three-month follow-up 
appointment (n = 23) 
Exclude: service users who are not 
on prescribed psychiatric 
medications and/or opioids (n = 23) 
Service users on prescribed opioids 
and/or psychiatric medications and 
assessed using the A-MAI at first 
SAS visit (n= 37) 
Exclude: discharge before three 
months (n = 10), did not attend 
three-month appointment (n = 3), 
attended but not seen by researcher 
(n = 1). 
All 60 service users were 
administered the medication history 
form for information about any 
prescribed medication they are on 
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5.9.3. Sociodemographic characteristics of service users assessed using 
the A-MAI at first SAS visit 
Thirty-seven service users were on both psychiatric medications and opioids or either of 
them at their first SAS visit and therefore had their medications assessed by SAS 
prescribers using the A-MAI. Their mean age was 44.4 (SD: 11.4) and there were more 
males (59.5%) than females. The majority (81.1%) were referred for their alcohol 
problems. Over 90% were of white ethnicity and half (51.4%) of service users lived in 
rented accommodation. Self-referral accounted for over half (54.1%) of referrals and only 
14% were employed. 
 
The characteristics of the 37 service users were compared to those of service users from 
the SAS database analysis and they were similar in their gender distribution. There were 
however differences in the following characteristics: the A-MAI population were slightly 
older, had more whites, more alcohol and opioid referrals, more home owners and those 
with ‘other’ housing status. They also had more self- and GP-referrals and those in ‘other’ 
employment status. Statistical analysis was not carried out due to the large difference in 
sample size between the database population (n = 1783) and A-MAI population (n = 37). 
The table below compares the characteristics of these two populations. 
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Table 5.1: Comparison of the sociodemographic characteristics of service users assessed 
using the A-MAI with the SAS database population (n and % presented for all 
characteristics except age) 
 
Sociodemographic 
characteristics  
A-MAI population (n = 
37 except stated 
otherwise) 
SAS database 
population (n = 1783 
except stated otherwise) 
Age (Mean, SD) 44.4 + 11.4 40.5 + 11.2 
Gender    
Males 22 (59.5%) 1040 (58.3%) 
Females 15 (40.5%) 743 (41.7%) 
Ethnicity    
White 33 (94.3%) 1536 (86.1%) 
Non-white 2 (5.7%) 92 (5.2%) 
Not stated 0 155 (8.7%) 
Housing status
a 
   
Rented 19 (51.4%) 1011 (59.8%) 
Home owner 9 (24.3%) 349 (20.7%) 
Other 9 (24.3%) 330 (19.5%) 
Referral substance
b 
   
Alcohol 30 (81.1%) 1395 (78.2%) 
Opioids 6 (16.2%) 263 (14.8%) 
Other 1 (2.7%) 125 (7%) 
Referral source
c
   
Self 20 (54.1%) 561 (31.5%) 
GP 10 (27%) 385 (21.6%) 
Other 7(18.9%) 837 (47%) 
Employment status
d 
   
Employed 5 (13.9%) 333 (19.8%) 
Unemployed 11 (30.6%) 894 (53.1%) 
Others 20 (55.6%) 457 (27.1%) 
aOther housing status comprises homeless (30%), temporary (55.6%) and hostel (11.1%) accommodation, bother referral 
substance for A-MAI population includes only cocaine while that for the database population includes sedatives, 
cannabis, stimulants and others, cother referral source comprises hospital, psychiatrist, criminal justice, drug services, 
community mental health team, social services and other referral sources, dother employment status includes long-term 
sick or disabled, student, retirees and others. 
 
5.9.4. Other characteristics of service users assessed using the A-MAI at 
first SAS visit  
The median level of dependence and interquartile range (hereafter IQR) measured using 
the LDQ was 19 (7.8, 26.8). When compared to the normative ranges for LDQ scores 
(Heather et al., 2001), service users referred for their alcohol problems were moderately 
dependent on alcohol whereas those referred for opioids were mildly dependent (data not 
shown). Level of psychological distress measured using the CORE-10 resulted in a mean 
score of 24.1 (SD = 10.7). The mean CORE-10 score of service users indicates the 
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presence of moderate-to-severe levels of psychological distress (Connell and Barkham, 
2007). Mean quality of life score measured using the EQ 5D was 0.6 (SD = 0.3), and is 
slightly higher than that reported by Foster, Peters and Kind (2002) in a UK outpatient 
alcohol dependent population. Mean level of social satisfaction score measured using the 
SSQ was 12.2 (SD = 6.8), and is similar to that reported in a recent study among the SAS 
population (Raistrick et al., 2014). The median number and IQR of prescribed medications 
and previous SAS episodes were 2 (2, 5) and 1 (0, 2) respectively. Some of the above 
reported values were similar to that of the database population with the exception of LDQ, 
CORE-10 and SSQ scores. LDQ and CORE-10 scores were slightly higher among the A-
MAI population while SSQ score was higher in the SAS database population. Table 5.2 
shows the table comparing these characteristics in the A-MAI and database population. 
 
Table 5.2: Comparison of other characteristics of service users assessed using the A-MAI 
with SAS database population 
 
Characteristics of service 
users 
A-MAI population SAS database population  
LDQ
a
  19 (7.8, 26.8) 17 (9, 24) 
CORE-10
b
  24.1 + 10.7 21.8 + 9.1 
SSQ
b
  12.2 + 6.8 13.9 + 5.6 
EQ 5D
a
  0.7 (0.4, 0.9) 0.6 (0.2, 0.8) 
No of previous SAS 
episodes
a
  
1 (0, 2) 1 (1, 2) 
No of prescribed medicines
a
  2 (2, 5) 2 (1, 4) 
aMedian and interquartile range are presented because data are not normally distributed, bmean and standard deviation are 
presented because data are normally distributed. 
5.9.5. Level and nature of inappropriate prescribing at first SAS visit 
This section presents the following results: 
 Number of inappropriate medications 
 Inappropriate A-MAI dimensions and reasons for inappropriateness 
 Factors associated with prescribing appropriateness at first SAS visit 
5.9.5.1. Number of inappropriate medications  
This study found that almost half (n = 16) of the 37 service users on prescribed opioids 
and/or psychiatric medications
24
 had one or more inappropriate ratings on the A-MAI. The 
total number of prescribed medications (opioids and/or psychiatric medications) for the 37 
service users was 59. The total number of prescribed medications exceeds 37 because some 
                                                 
24 25 service users were on at least one prescribed psychiatric medication, 5 service users were on prescribed opioids 
while 7 service users were on both prescribed opioids and psychiatric medications.  
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service users were prescribed two or more classes of medications concurrently. Of the 59 
prescribed medications, over one-quarter (n = 17) were inappropriate on one or more MAI 
dimensions
25
. The next paragraph will describe the types of medications with inappropriate 
A-MAI dimensions. 
 
One of five prescribed antipsychotics had at least one inappropriate A-MAI dimension, 
whereas all the four prescribed non-benzodiazepine hypnotics (all z-drugs) were deemed to 
be inappropriate on one or more A-MAI dimensions. Similarly, the two prescribed 
benzodiazepines had at least one inappropriate A-MAI dimension. Two of the twelve 
prescribed opioids had one or more inappropriate dimension on the A-MAI. Of the 28 
prescribed antidepressants, over one-quarter (n = 8) were deemed to have at least one 
inappropriate A-MAI dimension. Other types of prescribed medications such as beta 
blockers prescribed for anxiety disorders, antimanic agents, anticonvulsants and drugs used 
in treating substance dependence were without inappropriate dimensions. The distribution 
of appropriate and inappropriate ratings across different medications is shown in figure 5.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
25Indications for prescribed medications are presented in appendix 5.16 
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Figure 5.3: Distribution of appropriate and inappropriate ratings across different 
medications 
 
 
Note: The total number of prescribed opioids and/or psychiatric medications = 59. There were 28 antidepressants, 5 
antipsychotics, 4 non-benzodiazepine hypnotics, 12 opioids, 2 benzodiazepines, 2 drugs for substance dependence, 4 
beta-blockers for anxiety problems, 1 anticonvulsant and 1 antimanic agent. All beta-blockers were propranolol 
prescribed for anxiety problems while all non-benzodiazepine hypnotics were z-drugs prescribed for sleep problems. The 
anticonvulsant was pregabalin prescribed for sciatica.  
 
5.9.5.2. Inappropriate A-MAI dimensions and reasons for inappropriateness 
This section describes the A-MAI dimensions that were rated to be inappropriate. A-MAI 
dimensions rated to be marginally appropriate are presented in appendix 5.13. The A-MAI 
dimensions comprise indication, effectiveness, dosage, correct directions, drug-drug 
interactions, drug-disease interactions, practical directions, expense, duplication and 
duration. There were a range of inappropriate A-MAI dimensions cited for the different 
classes of medications except antipsychotics. The eight antidepressants that were rated 
inappropriate had 12 inappropriate A-MAI dimensions. The dimension with the highest 
percentage of inappropriateness was ‘indication’. Some of the reasons cited for 
inappropriateness include prescribing of antidepressants for low mood
26
 and prescribing 
                                                 
26
 NICE (2009) does not recommend the use of antidepressants for the initial treatment of mild depression 
such as low mood because the risk-benefit ratio is poor. 
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for alcohol-related depression. Other reasons cited for inappropriateness are shown in table 
5.3. Only one antipsychotic was rated inappropriate in its dosage due to prescribing above 
the BNF recommended limit. The two benzodiazepines had four inappropriate A-MAI 
dimensions with duration of therapy having the highest percentage of inappropriateness. 
Duration of therapy also had the highest percentage of inappropriateness for non-
benzodiazepine hypnotics. Duration of benzodiazepines and non-benzodiazepine hypnotics 
were inappropriate due to prescribing beyond the BNF recommended period. Overall, the 
four non-benzodiazepine hypnotics had six inappropriate A-MAI dimensions. The two 
opioids that were rated inappropriate had three inappropriate A-MAI dimensions. In 
particular, drug-disease interactions had the highest percentage of inappropriateness due to 
potential interactions that could occur between opioids such as dihydrocodeine and 
alcohol
27
. Table 5.3 shows the range of reasons for inappropriate medication ratings while 
table 5.4 provides a description of the total number of inappropriate A-MAI dimensions for 
each class of medications at service users’ first SAS visit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
27Dependence on substances, including alcohol, was considered to be the disease among service users.  
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Table 5.3: Reasons for inappropriate medication ratings at first SAS visit 
 
Medications Inappropriate A-
MAI dimensions 
Reasons cited for inappropriateness 
Antidepressants Indication Antidepressants (in particular, citalopram and 
sertraline) prescribed for low mood. 
Antidepressant (sertraline) prescribed for alcohol-
related depression. 
Antidepressant (amitriptyline) prescribed for an 
unlicensed indication (sleep problems). 
Effectiveness Service users reported lack of effectiveness from 
antidepressants (in particular, amitriptyline, 
mirtazapine and sertraline) 
Drug-drug 
interactions 
Potential for interaction between dosulepin and 
tramadol 
Drug-disease 
interactions 
Potential for interaction between dosulepin and 
alcohol 
Potential for interaction between mirtazapine and 
alcohol 
Duplication with 
other drugs 
Continued co-prescribing of citalopram and 
venlafaxine despite improvement in depression 
Antipsychotics Dose Antipsychotic (olanzapine 25mg daily) was 
prescribed at a dose above the BNF limit 
Benzodiazepines Indication Chlordiazepoxide prescription was continued after 
alcohol detoxification  
Directions Lack of clarity about temazepam use 
Duration of 
therapy 
Benzodiazepines (in particular, chlordiazepoxide 
and temazepam) were prescribed beyond BNF 
recommended duration without review 
Non-
benzodiazepine 
hypnotics (Z-
drugs) 
Duration of 
therapy 
Z-drug (zopiclone) duration beyond BNF 
recommendation 
Cost Z-drugs more expensive than alternative 
(benzodiazepines) 
Opioids Drug-drug 
interaction 
Potential for interaction between tramadol and 
dosulepin 
Drug-disease 
interaction 
Potential for interaction between opioids 
(dihydrocodeine and tramadol) and alcohol 
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Table 5.4: Inappropriate A-MAI dimensions at service users’ first SAS visit 
 
  
                              Number of inappropriate ratings in different A-MAI dimensions 
Indication Effectiveness Dose Direction 
Drug- 
Drug 
interact* 
Drug-
disease 
interact* 
Duplication Duration Cost  
Antidepressants 4 3     1 3 1     
Antipsychotics     1             
Benzodiazepines 1     1       2   
Non-
benzodiazepine 
hypnotics 
              4 2 
Opioids         1 2       
Where interact* = interaction 
 
5.9.5.3. Factors associated with prescribing appropriateness at first SAS visit 
Only one factor (number of prescribed medications) predicting prescribing appropriateness 
(proportion of service users with and without at least one inappropriate A-MAI dimension) 
was assessed using logistic regression due to small numbers. Sixteen service users had one 
or more inappropriate medications while 21 service users were without inappropriate 
medications at first SAS visit. The number of prescribed medications in particular was 
assessed because it has been found to be associated with prescribing appropriateness 
(Duerden, Avery and Payne, 2013; Spinewine et al., 2007). The result of the logistic 
regression analysis however showed that the number of prescribed medications was not a 
significant predictor of prescribing appropriateness (p = 0.59) in this study. The odds ratio 
obtained was 0.93 (95% CI: 0.72 to 1.21). The 95% CI shows that the odds of having at 
least one inappropriate A-MAI dimensions could be as low as 0.72 or as high as 1.21 with 
every unit increase in the number of prescribed medications. 
5.9.6. Comparison of the characteristics of service users assessed by nurse 
prescribers and doctors  
Given that evidence obtained from a senior SAS staff (see section 3.2) suggests that 
service users assessed by doctors may be more likely to be complex with more prescribing 
issues, service users assessed by doctors and nurse prescribers were compared. This study 
found that service users assessed by nurse prescribers and doctors were not significantly 
different in any of the characteristics examined. In fact, it was found that nurse prescribers 
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tended to assess service users with more medications when compared with doctors. This 
difference was however not statistically significant. Table 5.5 compares the characteristics 
of service users assessed by nurse prescribers and doctors. 
 
Table 5.5: Comparison of the characteristics of service users assessed by nurse prescribers 
and doctors 
Characteristics of 
service users 
Nurse prescriber 
assessment (n = 13) 
Doctor assessment (n = 
24) 
P-value 
Age 45.3 + 9.8 43.9 + 12.4 0.72
a
 
Gender (n, %)    
Male 8 (61.5%) 14 (58.3%)  
Female 5 (38.5%) 10 (41.7%) 0.85
b
 
Ethnicity
 
(n, %)    
White 12 (100%) 21 (91.3%)  
Non-white 0 2 (8.7%) 0.54
c
 
Housing status (n, %)    
Rented 8 (61.5%) 11 (45.8%)  
Home owner 2 (15.4%) 7 (29.2%)  
Other 3 (23.1%) 6 (25%) 0.74
c
 
Referral substance (n, %)    
Alcohol 13 (100%) 17 (70.8%)  
Opioids 0 6 (25%)  
Cocaine 0 1 (4.2%) 0.1
c
 
Referral source (n, %)    
Self 9 (69.2%) 11 (45.8%)  
GP 1 (7.7%) 9 (37.5%)  
Other 3 (23.1%) 4 (16.7%) 0.19
c
 
LDQ
 
(median, IQR) 23.5 (13.3, 27.8) 16.5 (7, 26) 0.28
d
 
CORE-10 (mean, SD) 26.2 + 10.1 22.9+ 11.1 0.38
a
 
EQ 5D
 
(median, IQR) 0.7 (0.4, 0.8) 0.7 (0.4, 0.9) 0.52
d
 
SSQ
 
(mean, SD) 10 + 6.9 13.3 + 6.7 0.2
a
 
Number of previous SAS 
episodes (median, IQR) 
1 (0, 2) 0.5 (0, 1) 0.49
d
 
Number of substances 
used in past 12 months 
(median, IQR) 
2 (1, 2) 2 (2, 4.8) 0.05
d
 
Number of prescribed 
medicines (median, IQR) 
3 (3, 5.5) 2 (1.3, 3.8) 0.08
d
 
Note: The significance level was 0.4% due to Bonferroni adjustment for multiple testing. 
aAnalysed using independent samples t-test, banalysed using chi squared test, canalysed using Fisher’s exact test, 
danalysed using Wilcoxon rank sum test.  
 
5.9.7. Analysis of “don’t know” ratings 
Due to the fact that the prescribers in this study were reviewing medication appropriateness 
but were not involved in the original prescribing of these medications, and to take into 
account variability of knowledge among doctors and nurse prescribers regarding some 
aspects of medications, the “don’t know” options in the A-MAI ratings were analysed. The 
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“don’t know” option is part of the original MAI. Raters using the original MAI may tick Z 
(don’t know) if they need additional information from patients’ notes to rate a dimension. 
In this study, raters were asked to rate Z (don’t know) if they cannot make a judgment on 
the appropriateness of an A-MAI dimension. There was no service user who had all 
medications rated as “don’t know” by prescribers. The “cost” dimension had the highest 
proportion of “don’t know” ratings. Table 5.6 shows the distribution of “don’t know” 
ratings among different medications.  
 
Table 5.6: Distribution of “don’t know” ratings among different medications 
  
                             Number of ‘don’t know’ ratings in different A-MAI dimensions 
Indication Effectiveness Dose Direction 
Drug-
drug 
interact* 
Drug-
disease 
interact* 
Duplication Duration Cost  
Antidepressants 1 3 5 1 1     2 15 
Antipsychotics                 3 
Benzodiazepines                 2 
Non-
benzodiazepine 
hypnotics 
                2 
Opioids 2 2 2 2 1 1 1 1 7 
Beta-blocker                 4 
Antimanic 
agents 
                1 
Where interact* = interaction 
Note: Anticonvulsants and drugs used in treating substance dependence did not have any A-MAI dimension rated as 
‘don’t know’ and therefore are not displayed in the table above. 
 
Nurse prescribers rated one or more “don’t know” for 9 (69.2%) of the 13 service users 
they assessed whereas doctors rated at least one “don’t know” for 16 (66.7%) of the 24 
service users they assessed. There were no statistically significant differences between 
nurse prescribers and doctors in their ratings of “don’t know” (p = 1.00).  
 
5.9.8. Follow-up at three months 
At three-month follow-up appointment, a total of 23 service users
28
 with 33 prescriptions 
of opioids and/or psychiatric medications were assessed a second time using the A-MAI. 
                                                 
28
 14 service users were on at least one prescribed psychiatric medication, 5 service users were on prescribed opioids 
while 4 service users were on both prescribed opioids and psychiatric medications. 
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The medications include 17 antidepressants, three antipsychotics, three non-
benzodiazepine hypnotics (all z-drugs), seven opioids, two beta-blockers for anxiety 
problems and one prescription for alcohol relapse prevention. Service users’ mean age was 
46.7 (SD: 10.3) and almost 70% were males. Majority (82.6%) were referred for their 
alcohol problem. Over 95% were of white ethnicity and slightly over half (52.2%) of 
service users lived in rented accommodation. Self-referral accounted for 52.2% of referrals 
and only 14% were employed. The characteristics of these 23 service users were compared 
to those of the remaining 14 who were only assessed at their first visit and they were no 
statistically significant differences. Table 5.7 shows the comparison of these 
characteristics. The findings presented in sections 5.9.8.1 to 5.9.8.3 relate to the 23 service 
users. 
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Table 5.7: Comparison of service users assessed using the A-MAI at both first visit and 
three-month appointment with those assessed only at first SAS visit 
Characteristics of service 
users 
Service users assessed 
only at first SAS visit 
(n= 14 except 
otherwise specified) 
Service users assessed 
at both first and three-
month visit (n= 23 
except otherwise 
specified) 
P-values 
Age (mean, SD) 40.6+ 12.6 46.7 + 10.3 0.12
a
 
Gender (n, %)    
Males 6 (42.9%) 16 (69.6%)  
Females 8 (57.1%) 7 (30.4%) 0.11
b
 
Ethnicity (n, %)    
White 12 (92.3%) 21 (95.5%)  
Non-white 1 (7.7%) 1 (4.5%) 1.00
c
 
Housing status (n, %)    
Rented 7 (50.0%) 12 (52.2%)  
Home owner 5 (35.7%) 4 (17.4%)  
Other 2 (14.3%) 7 (30.4%) 0.37
c
 
Referral substance (n, %)    
Alcohol 11 (78.6%) 19 (82.6%)  
Opioids 3 (21.4%) 3 (13%)  
Cocaine 0 1 (4.3%) 0.79
c
 
Referral Source (n, %)    
Self 8 (57.1%) 12 (52.2%)  
GP 3 (21.4%) 7 (30.4%)  
Other 3 (21.4%) 4 (17.4%) 0.82
c
 
Employment status (n, %)    
Employed 2 (14.3%) 3 (13.6%)  
Unemployed 4 (28.6%) 7 (30.4%)  
Other 8 (57.1%) 12 (52.2%) 1.00
C
 
LDQ (median, IQR) 17.5 (6.5, 28.2) 20 (9.3, 26.3) 0.91
d
 
CORE-10 (mean, SD) 20.8+ 11.9 26.1 + 9.7 0.15
a
 
SSQ (mean, SD) 13.9+ 7.8 11.2 + 6.3 0.28
a
 
EQ 5D (median, IQR) 0.7 (0.4, 0.8) 0.7 (0.4, 0.9) 0.93
d
 
No of previous SAS 
episodes (median, IQR) 
0 (0, 1.75) 1 (0, 2) 0.41
d
 
No of substances used in 
the past 12 months 
(median, IQR) 
2 (2, 4.3) 2 (1, 3) 0.41
d
 
No of prescribed 
medicines (median, IQR) 
3 (2, 3.5) 3 (1, 5) 0.86
d
 
Note: The significance level was 0.4% due to Bonferroni adjustment for multiple testing. aAssessed using the 
independent samples t-test, bassessed using chi-squared test, Cassessed using Fisher’s exact test, dassessed using the 
Wilcoxon rank sum test. 
 
5.9.8.1. Inappropriate prescribing at three-month follow-up appointment 
This section reports on inappropriate prescribing among the 23 followed-up service users. 
A total of 33 opioids and psychiatric medications were prescribed for these service users.  
Over one-third (8) of the 23 service users had one or more inappropriate medications. Of 
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the 33 medications taken at this follow-up appointment, one quarter (n = 8) had at least one 
inappropriate A-MAI dimension. The most common medication taken by these service 
users were antidepressants. The next paragraph will describe the types of medications with 
inappropriate A-MAI dimensions. 
 
Of the 17 prescribed antidepressants, two had inappropriate dimensions in terms of cost. 
By comparison, all the three non-benzodiazepine hypnotics were inappropriate in their 
duration because they had been prescribed for a longer period than recommended by the 
BNF
29
. An antipsychotic had an inappropriate rating in its dosage because it exceeded the 
BNF limit
30
. Two opioid medications had inappropriate ratings due to duration and drug-
disease interaction
31
. Table 5.8 provides more information on the reasons for inappropriate 
A-MAI ratings at three-month follow-up appointment while figure 5.4 shows the 
medications with and without inappropriate A-MAI dimensions at three-month follow-up 
appointment. 
 
Table 5.8: Reasons for inappropriate A-MAI ratings at three-month appointment 
 
Medications Inappropriate 
A-MAI 
dimensions 
Reasons for inappropriateness at 3-month 
follow-up appointment 
Antidepressants (n = 
17) 
Cost Venlafaxine was rated to be more expensive than 
alternative medications for anxiety problems. 
Trazodone was rated to be more expensive than 
alternative medications for sleep problems. 
Antipsychotics (n = 
3) 
Dose Olanzapine 25mg daily, prescribed for 
schizophrenia, exceeded the BNF recommended 
dose 
Non-benzodiazepine 
hypnotic (n = 3) 
Duration of 
therapy 
Duration exceeded BNF recommendation 
Opioids (n = 7) Drug-disease 
interactions 
Potential for interaction between dihydrocodeine 
and alcohol 
Duration of 
therapy 
Co-codamol was rated to be inappropriate due to its 
long duration of use 
Note: Beta-blockers for anxiety problems and drugs used in treating substance dependence were without inappropriate A-
MAI dimension at three-month follow-up appointment. Service users on benzodiazepines, anticonvulsants and antimanic 
agents at their first SAS visit were not assessed at their three-month follow-up appointment due to a number of reasons: 
discharge from SAS due to completion of treatment, service user did not turn up and service user was not seen at three-
month follow-up. 
 
 
 
                                                 
29 These three non-benzodiazepine hypnotics were also inappropriate in their duration at first SAS visit. 
30 The antipsychotic (olanzapine) was also inappropriate in its dose at first SAS visit.  
31 One opioid (dihydrocodeine) was also inappropriate due to potential interaction between it and alcohol at first SAS 
visit. 
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Figure 5.4: Medications with and without inappropriate A-MAI dimensions at three-month 
follow-up appointment 
Note: Benzodiazepines, anticonvulsants and antimanic agents were not assessed at both first SAS and three-month 
follow-up appointment due to the following reasons: discharge from SAS due to completion of treatment, service user did 
not turn up and service user was not seen at three-month follow-up visit. 
 
5.9.8.2. Changes in appropriateness of prescribed medications between first SAS visit 
and three-month follow-up appointment 
This section further describes the changes in the appropriateness of service users’ 
prescribed medications between first SAS visit and three-month follow-up appointment. It 
is of interest that none of the medications identified to be inappropriate at baseline were 
changed by prescribers at three-month follow-up appointment. In a further four cases, the 
appropriateness of individual medications changed, such that two medications formerly 
rated as appropriate were later rated inappropriate. This includes the venlafaxine and co-
codamol described in table 5.8. An antidepressant, paroxetine prescribed for anxiety 
problems, was changed to venlafaxine between first SAS visit and three-month follow-up 
visit. Venlafaxine was rated to be more expensive at three-month follow-up visit. Co-
codamol initially rated appropriate was considered to be inappropriate at three-month 
follow-up appointment due to its long duration of use.  
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Another two medications rated inappropriate at baseline were later rated appropriate.  
Citalopram was rated inappropriate at first SAS visit because it was considered to have 
been prescribed for low mood. However, at three-month follow-up visit it was rated 
appropriate because the prescriber stated that it is now being prescribed for severe 
depression. Furthermore, the service user prescribed citalopram had reduced his alcohol 
use. Other reasons for a switch from inappropriate to appropriate ratings are changes in 
ratings given for drug-drug and drug-disease interaction for an antidepressant, dosulepin. 
Reasons for these changes are further described in table 5.9. 
 
Table 5.9: Reasons for change in medication appropriateness between first and three-
month visit 
Medications A-MAI 
dimensions 
where 
changes 
occurred 
Reasons for change in medication appropriateness 
Antidepressants Indication Citalopram was rated inappropriate at first SAS visit in an 
alcohol dependent service user due to prescribing for low 
mood. However, at three-month follow-up visit it was rated 
appropriate because the prescriber stated that it is now being 
prescribed for severe depression that is unlikely to be 
related to alcohol dependence. 
Drug-drug 
interaction 
Dosulepin initially rated inappropriate due to potential drug 
interaction with tramadol at first SAS visit was rated to be 
appropriate at three-month follow-up visit because service 
user had stopped tramadol. 
Drug-
disease 
interaction 
Dosulepin initially rated inappropriate due to potential 
interaction with alcohol at first SAS visit was rated to be 
appropriate at three-month follow-up visit because service 
user had become abstinent from alcohol. 
Cost Venlafaxine was rated to be more expensive for a service 
user with anxiety problems whose paroxetine was changed 
to venlafaxine between first SAS visit and three-month 
follow-up visit.  
Opioids Duration Co-codamol initially rated appropriate at first SAS visit was 
rated to be inappropriate at three-month follow-up visit due 
to its long duration of use 
 
5.9.8.3. Changes made to the medications of followed-up service users  
Eight of the 23 followed-up service users had changes made to their prescribed 
medications. The total number of medications that were changed among these eight service 
users was 10. These medications did not have inappropriate A-MAI ratings at first SAS 
visit. They were however changed due to the reasons described below:  
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 Discontinuation of acamprosate due to its use for almost a year in an alcohol 
abstinent service user; 
 Reduction of methadone32 dose at service user’s directive;  
 Reduction of propranolol dose due to ECG abnormality (slow and irregular heart 
rhythm);  
 Discontinuation of prochlorperazine (prescribed for anxiety disorder) due to 
excessive sedation; 
 Reduction of dihydrocodeine dose due to its dependence potential; 
 Reduction of zopiclone dose due to its dependence potential; 
 Co-codamol was stopped on completion of therapy;  
 Tramadol was also stopped on completion of therapy. 
 
The reasons for dose reduction for two medications (fluoxetine and co-codamol) could not 
be ascertained from service users. SAS prescribers described either carrying out or 
influencing the first three changes described above. Changes carried out by service users’ 
GPs during the study duration include: discontinuation of prochlorperazine, reduction of 
dihydrocodeine and zopiclone doses. Information about GP-initiated reduction or 
discontinuation of medications was obtained from service users during their three-month 
follow-up visit.  
 
5.9.9. Adherence to prescribed medications 
At first SAS visit, service users were given questionnaires for self-reporting of their 
adherence to their medications. While the majority of service users reported taking their 
medications very often or often, there was variation in reported adherence. Table 5.10 
provides a summary of service users’ levels of adherence to opioids and psychiatric 
medications.  
 
 
 
 
 
 
 
 
 
                                                 
32
As described in section 3.3.3, consultant psychiatrists suggested that the appropriateness of opioids 
prescribed as substitution therapy should be assessed in addition to other opioids. 
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Table 5.10: Service users’ reported level of adherence at first SAS visit 
Types of 
medicines 
Number of 
prescribed 
medicines 
Medicines 
taken very 
often or 
often (n, %) 
Medicines 
taken 
sometimes 
(n, %) 
Medicines 
taken rarely 
or never (n, 
%) 
Medicines 
taken prn (n, 
%) 
Antidepressants 28 24 (85.7%) 3 (10.7%)  1 (3.6%) 
Antipsychotics 5 4 (80%)   1 (20%) 
Benzodiazepines 2 1 (50%) 1 (50%)   
Non-
benzodiazepine 
hypnotic 
4 1 (25%) 1 (25%) 1 (25%) 1 (25%) 
Anticonvulsant 1 1 (100%)    
Antimanic agent 1 1 (100%)    
Beta-blockers
a
 4 3 (75%)   1 (25%) 
Drugs for 
substance 
dependence 
(disulfiram and 
acamprosate) 
2 2 (100%)    
Opioids
b
 12 7 (77.8%) 1 (11.1%) 1 (11.1%)  
prn = as needed 
aAll beta-blockers presented are propranolol prescribed for anxiety disorders.  
bOpioids also include combination of opioids and paracetamol (for example, co-codamol and co-dydramol). Of the 12 
opioid medications, adherence was reported for only nine (9) of them. Thus, nine (9) was used as the denominator when 
calculating adherence percentage. 
5.9.10. Discussion  
This section presents a discussion of the findings of this study.  
 
- Level and nature of inappropriate prescribing 
This study found that nearly half of service users had at least one inappropriate medication 
at their first visit to the SAS while over one-quarter of prescribed opioids and psychiatric 
medications have inappropriate A-MAI dimensions. The A-MAI dimensions that were 
assessed to be inappropriate varied across the different medications. These findings could 
not be directly compared with any previous studies on prescribing appropriateness among 
the population studied due to limited number of previous studies, use of multiple 
appropriateness dimensions, the assessment of a variety of medications and its setting.  
 
Thirion et al. (2002) assessed the appropriateness of benzodiazepines among a treatment 
population comprising buprenorphine-maintained opioid-dependent patients and reported 
that prescribed doses of benzodiazepines were often above the limits specified in its SPC. 
The percentage of benzodiazepines in which this occurred was however not stated. One 
study by Baca-Garcia et al. (2009) compared the appropriateness of antidepressant 
medications of 39 depressed bipolar patients with a history of AUDs with those of 58 
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depressed bipolar patients without AUD history using the ATHF. The ATHF rates 
antidepressant treatment based on indication, dose, duration of treatment and adherence 
(Oquendo et al., 2003). It found that bipolar patients with AUDs had a higher proportion of 
inadequate antidepressant treatment than those without AUDs (74.3% vs 67.3%, p = 
0.025). 
 
This study showed that a significant proportion of service users’ medications were 
inappropriate. It was however not possible to determine whether this level of 
inappropriateness is higher or lower when compared to those without SUDs prescribed 
similar medications. The prevalence of inappropriateness might have been influenced by 
several factors. For instance, it is possible that the prevalence in this study was 
underestimated because some prescribers (especially nurse prescribers) have limited 
expertise in prescribing most of the classes of medications assessed. Similarly, doctors may 
be unable to adequately assess the appropriateness of classes of medications they prescribe 
less often among the medications considered.  
 
On the other hand, inappropriateness might have been overestimated in some instances due 
to lack of adequate understanding of the circumstances surrounding prescribing. Barber et 
al. (2005) reported that their judgment of prescribing appropriateness among primary care 
patients in England sometimes changed depending on the amount of circumstantial 
evidence they had. In this study, the duration of therapy for all benzodiazepines and non-
benzodiazepine hypnotics were rated inappropriate because they had been prescribed for 
longer than recommended by the BNF (Joint Formulary Committee, 2010) and UK 
guidelines (Baldwin et al., 2013). An antipsychotic dose was also rated inappropriate 
because it exceeded BNF recommendation. However, service users with very severe 
mental health symptoms and complex situations may need higher doses or longer duration 
of treatment than recommended in guidelines for optimal functioning. Without adequate 
understanding of the circumstances surrounding prescribing, such prescribing may be 
judged to be inappropriate.  
 
This study attempted to incorporate service users’ perspectives in the assessment of 
appropriateness. For example, SAS prescribers assessed some antidepressants service users 
reported as lacking effect to be ineffective in the ‘effectiveness’ dimension of the A-MAI. 
Several reasons have been advanced on the need for inclusion of patients’ perspectives in 
decision-making concerning prescribing (Barber, 1995). It is the patient who bears the 
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immediate burden of illness and their views should therefore be incorporated when making 
decisions (Cribb and Barber, 1997). As discussed in section 1.4.3, prescribing is not devoid 
of risk. It is therefore important that decisions about prescribing incorporate patients’ 
views and the concessions they are willing to make concerning the risk of various health 
outcomes (Tinetti, Bogardus and Agostini, 2004). 
 
Prescribing outside the confines of best practice recommendations carries its own risks. 
For instance, the need for higher-than-usual doses of psychiatric medications and opioids 
may predispose the patient to high levels of side effects, toxicity and the risk of 
dependence on those with dependence potential. Prolonged use of opioids, 
benzodiazepines and non-benzodiazepine hypnotics such as the z-drugs may lead to 
dependence on them (Action on Addiction, 2013; Baldwin et al., 2013; Hajak et al., 2003) 
or exacerbation of an existing SUDs (Brunette et al., 2003). Use of benzodiazepines and 
non-benzodiazepine hypnotics beyond the BNF duration in this study may be an indicator 
of dependence on them. SUDs have been recognised as a risk factor in the development of 
dependence when taking these medications (Hajak et al., 2003). Long-term use of these 
medications may result in suboptimal benefit (Vinkers and Olivier, 2012; Willems et al., 
2013) and adverse drug events.  
 
People with SUDs may exceed the recommended doses of these medications with the 
potential for overdosing (Action on Addiction, 2013). Their use of substances such as 
alcohol and illicit drugs with their medications greatly increases this risk (Darke, Duflou 
and Torok, 2011; Zamparutti et al., 2011). A UK study (Zamparutti et al., 2011) assessing 
fatal cases involving dihydrocodeine among opiate misusers found that 96% of accidental 
deaths included the presence of other substances such as alcohol, hypnotics/sedatives and 
other opioids (heroin, morphine and methadone). Almost half (45%) of victims who 
accidentally overdosed on dihydrocodeine had it prescribed for them. Similarly, a previous 
study of oxycodone toxicity in New South Wales, Australia, reported that 70% of such 
oxycodone were prescribed and psychoactive substances (benzodiazepines, alcohol, other 
opioids, tricyclic antidepressants, antipsychotics) other than oxycodone were detected in all 
cases of toxicity (Darke, Duflou and Torok, 2011). While service user involvement is 
important, it needs to be carefully considered in this group of people for prescribing to be 
safe and optimal.   
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Depression was the most common indication in this study and antidepressants were the 
class of medications most commonly prescribed. This is in line with the findings of the 
database study which also showed high levels of prescribing of antidepressants among 
service users (Oluyase et al., 2013). Over one-quarter of prescribed antidepressants were 
rated as having at least one inappropriate A-MAI dimension: the highest dimension of 
inappropriateness was the ‘indication’ at service users’ first SAS visit. This reflects the fact 
that prescribers questioned the decision to prescribe antidepressants for people who were 
actively using substances. There is evidence that substance use, for example, heavy 
drinking may lead to depressed affect (Graham et al., 2007) and such high levels of alcohol 
consumption may counteract the benefits accruing from antidepressants (Ramsey, Engler 
and Stein, 2005).  
 
- Characteristics of service users assessed by nurse prescribers and doctors 
This study found that service users assessed by nurse prescribers did not differ from those 
assessed by doctors in any of the characteristics examined in this study including their 
“don’t know” ratings. This is despite the fact that the referral system described by the SAS 
staff was supposed to allow assessment of more complex service users by doctors rather 
than nurse prescribers. While it is possible that service users assessed by these two groups 
of prescribers may differ in characteristics not measured in this study, it appears that nurse 
prescribers and doctors were assessing service users with similar characteristics. However, 
nurse prescribers and doctors could not be compared in their decision-making processes 
concerning appropriateness because they assessed different service users. It is therefore not 
possible to make any assumption about similarity of decision-making concerning 
prescribing appropriateness. 
  
- Adherence to prescribed medications 
Adherence to prescribed medications varied in this study although most service users 
reported taking their medications very often or often. The regular use of medications 
reported by most service users is surprising given that current SUDs have been associated 
with non-adherence (Manwani et al., 2007; Sajatovic et al., 2006). While it is possible that 
service users tended to adhere to their medications, previous studies (Owen et al., 1996; 
Sajatovic et al., 2006; Weiss, 2004) that have assessed adherence among people with and 
without co-occurring mental disorders and SUDs have found higher levels of non-
adherence among those with SUDs. Owen et al. (1996) assessed medication adherence 
between schizophrenic patients with and without SUDs and found that those with SUDs 
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were significantly more likely to report non-adherence to their neuroleptic medications 
(Owen et al., 1996). Similarly, bipolar patients with current SUDs have been found to be 
more likely to report non-adherence (Sajatovic et al., 2006). SUDs represent a risk factor 
for non-adherence among people with mental disorders (Jonsdottir et al., 2013; Montes et 
al., 2013). It is therefore possible that service users may have overestimated their 
adherence or that response was subject to recall bias (Schechter and Walker, 2002). 
Service users’ memory may have been negatively affected by substances thus affecting 
their ability to recall information (Bates, Bowden and Barry, 2002; Sullivan and 
Pfefferbaum, 2005). They may also be insincere about their level of adherence (Chesney, 
2000), and may report a high level of adherence in order to avoid embarrassment 
(Schechter and Walker, 2002; Tiv et al., 2012). However, the possibility of this was 
mitigated in this study as service users were informed that any disclosure about their 
medication adherence will not be shared with healthcare professionals at the SAS. 
Adherence was also assessed on a separate questionnaire that was not attached to the A-
MAI that was rated by prescribers.  
 
- A-MAI dimensions with “don’t know” ratings 
The cost dimension on the A-MAI had the highest number of “don’t know”. This may 
reflect the fact that prescribers consider knowledge of cost a low priority. In addition, a 
systematic review on cost awareness among physicians that included many UK studies 
found that doctors were ignorant of cost (Allan, Lexchin and Wiebe, 2007). There may 
well be a need to support prescribers in making cost-effective prescribing decisions.  
 
- Change in prescribing appropriateness 
It is interesting to note that while almost half of service users had at least one inappropriate 
medication at baseline assessment, none of the medications identified to be inappropriate 
were changed by three-month follow-up appointment. The reason for this finding was 
explored during the interviews with prescribers. This finding precluded the calculation of 
potential cost savings accruing from stopping or reducing inappropriate medications which 
was initially one of the research questions.  
 
An antidepressant that was rated to be inappropriate at first SAS visit was rated as 
appropriate at three-month follow-up appointment because the prescriber described the 
service user as having reduced his substance use, and his antidepressant as being 
prescribed for severe depression rather than low mood resulting from symptoms of 
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intoxication. Addressing SUDs may be helpful in clarifying the relationship between SUDs 
and depression (Miele, Trautman and Hasin, 1996). However, completely removing or 
reducing the contribution of substances to a mental disorder is often not achieved 
(Lingford-Hughes et al., 2012). In particular, this finding supports the evidence that people 
with substance-induced mental disorders may be later re-classified as having independent 
mental disorders (Magidson et al., 2013; Nunes et al., 2006; Ramsey et al., 2004). Where 
this occurs, withholding psychiatric medications from those with substance-induced 
disorders may indicate poor quality of care with the potential to predispose such service 
users to worse outcomes including increased severity of illness (Torrens, Martin-Santos 
and Samet, 2006) and suicide (Aharonovich et al., 2002; Appleby, 2000) compared to 
those with single disorders. 
 
- Variability in prescribers’ ratings of ‘marginally appropriate’ and ‘inappropriate’ 
A-MAI dimensions 
The findings of this study suggest there was a degree of variability in how prescribers rated 
some A-MAI dimensions
33
 (in particular, indication, drug-drug and drug-disease 
interactions). For instance, this study found that while some prescribers rated 
antidepressants to be marginally appropriate because they were prescribed for alcohol-
related depression, other prescribers cited a similar reason for rating some antidepressants 
as inappropriate. Similarly, there was also evidence of differences in how drug-drug 
interactions and drug-disease interactions were rated by prescribers.  
 
These differences may have resulted because different clinicians assessed appropriateness. 
The clinician evaluators were from different backgrounds and also had varying lengths of 
practice experience (see section 7.3.1). These differences have been suggested as possible 
reasons for clinical disagreements among raters (Bregnhoj et al., 2005; Stuijt et al., 2009). 
Stuijt et al. (2009) assessed the reliability of the MAI in a Dutch residential home using 
abstracted patient information and reported lower inter-rater reliability for some MAI 
dimensions including indication and drug interactions. Similar findings were reported in an 
earlier study in Denmark by Bregnhoj et al. (2005). It is a possibility that more 
homogeneity among the clinician evaluators could have resulted in more consistent ratings. 
 
Furthermore, variability in the quality of information available during service users’ 
assessments may have resulted in different appropriateness ratings. For instance, it would 
                                                 
33
 Refer to appendix 5.13 for reasons cited by prescribers for marginally appropriate ratings on the A-MAI 
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be easier to make judgments on the appropriateness of prescribed medications where 
service users provide a comprehensive and clear history and vice versa. Decision-making 
may be more variable due to lack of contextual information surrounding prescribing. In 
this study, assessment of drug-drug and drug-disease interactions may also be affected by 
clinicians’ judgments on the risk posed by these interactions. This judgment may differ 
between clinicians. The observed variability in rating may be further due to insufficient 
training on the use of the A-MAI. Although group training sessions involving practising 
the use of the A-MAI with a case study of one patient were organised with SAS 
prescribers, this may not have been adequate. The MAI developers recommend practising 
on 10 to 20 patients (Hanlon and Schmader, 2013). In addition, seven prescribers had not 
joined the SAS when the group training sessions took place. These prescribers joined the 
SAS at different periods during the course of this research. The researcher therefore had to 
train each of the seven prescribers individually when they joined the SAS. The training 
sessions involved discussion of the A-MAI and its operational instructions with each of 
them. Again, it is possible that the training sessions organised for these prescribers were 
insufficient and sometimes led to variable A-MAI ratings.  
 
It is pertinent to say that variability of rating is expected in such a study as this because 
prescribers rated different service users whose clinical presentations may differ. This may 
also have contributed to different ratings of MAI dimensions.    
5.9.11. Strengths and limitations  
One limitation of this study is the fact that diagnoses and associated pharmacotherapeutic 
management were based on self-report. These information were also self-written by service 
users, with the possibility that they were sometimes inaccurate. There was no independent 
assessment of service users’ diagnoses due to the length of time needed for completion of 
diagnostic instruments (Anderson, Michalak and Lam, 2002; McGrady et al., 2010) in this 
time-pressured setting. The SAS setting has been previously described in section 3.2. 
Furthermore, most service users were referred from sources other than GPs and GP/referral 
notes were not available. Consequently, self-report represented the only feasible means for 
assessment of diagnosis and prescribed medications.  
 
Self-reported diagnosis and associated pharmacotherapy may be limited because patients 
may not know their diagnosis and the names of their medications (Marks et al., 2010). 
Further, cognitive impairment from substances such as alcohol may also hinder the ability 
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to recall information (White, 2004) or there may be deliberate avoidance of disclosure. 
There is evidence that some illnesses such as depression may negatively affect self-report 
due to their symptomatology (Corser et al., 2008). It is therefore possible that this study 
underestimated the prevalence of inappropriate prescribing due to the above limitations.  
This study focused on exploring the appropriateness of prescribing of psychiatric 
medications and opioids for people with SUDs. However, it is pertinent to state that the use 
of prescribed medications sits alongside other non-prescribed medications such as over-
the-counter (hereafter OTC) medicines, herbal medicines as well as the use of substances. 
Prescribers assessed for the presence of interactions between substances and prescribed 
opioids and psychiatric medications using the A-MAI. However, the use of OTCs and 
herbal medicines were not considered when assessing for interactions and prescribing 
appropriateness in general, though their use may impact on judgments made about 
appropriateness. The focus of this study on prescribed medications represents a limitation 
of this thesis as safe practice in prescribing would entail considering both prescribed and 
non-prescribed medications.  
 
Although this study found no significant difference in the characteristics of service users 
assessed by nurse prescribers and doctors, it is not possible to make any inference about 
similarity of decision-making concerning appropriateness among both groups of 
prescribers because they each assessed different service users. Furthermore, it is possible 
that service users may differ in characteristics that were not assessed in this study. It is also 
possible that there were instances where prescribers did not accurately assess 
appropriateness since they were not present when service users’ original diagnoses were 
made. Some medications they assessed as lacking indication or being inappropriate due to 
dose or duration may actually be appropriate depending on the context and service user’s 
circumstances which prescribers may not be adequately knowledgeable about. For 
instance, some antidepressants were assessed as lacking indication due to the absence of 
depressive symptoms. An alternative explanation may be that the antidepressant has led to 
improvement in depressive symptoms.  
 
Furthermore, most of the psychiatric medications and opioids assessed in this study are 
outside the remit of prescribing of nurse prescribers. This may have made assessment of 
their appropriateness challenging for nurse prescribers. While nurse prescribers could rate 
“don’t know” where they had difficulties making a decision, there was no statistically 
significant difference between nurse prescribers and doctors in the number of such ratings. 
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However, as stated above, they assessed different service users and so no firm conclusion 
can be drawn from this finding. The identification of omissions of psychiatric medications 
and opioids would also be challenging for nurse prescribers because they are outside their 
scope of practice. Nurse prescribers were included despite this obvious limitation because 
of the need to understand prescribing practice in general as nurse prescribing proliferates 
and medical expertise declines in addiction medicine specialty. It could be argued that 
nurse prescribers working with complex service users with comorbidities will sometimes 
identify medications that they have concerns about or be concerned about omission of 
needed medications. This study provided an opportunity for nurse prescribers to highlight 
such issues and the particular areas of prescribing they are concerned about. In addition, 
where there are concerns about interactions between the medications within their scope of 
practice and other prescribed medications that were the focus of this thesis, this study was 
able to capture them. It is however acknowledged that the presence of concerns does not 
necessarily imply inappropriateness.  
 
A summated score for each medication assessed using the A-MAI could not be calculated 
as done in some previous studies (Hanlon et al., 2004; Samsa et al., 1994; Schmader et al., 
1994) because prescribers rated “don’t know” for A-MAI dimensions they could not 
confidently assess. Although the “don’t know” option is part of the original MAI (it was 
not added by the author of this thesis), it has been rarely used in previous studies. It was 
necessary for prescribers to utilise the ‘don’t know’ option when necessary because they 
are not the original prescribers of the medications they assessed and also because they may 
not have adequate knowledge about the circumstances of prescribing. In addition, as stated 
above, some groups of prescribers such as nurse prescribers have a more limited remit of 
prescribing compared to doctors and were allowed to rate ‘don’t know’ if they could not 
make a judgment on the appropriateness of prescribing decisions. A previous study 
(Steinman et al., 2006) that used the MAI also did not use summated scores. Steinman et 
al. (2006) assessed inappropriate prescribing using subscales of the MAI (indication, 
effectiveness and duplication) and the Beers criteria
34
 (Beers et al., 1991).  
 
Some research questions such as whether the appropriateness of prescribed medications 
changed between baseline assessment and three-month follow-up appointment could not be 
adequately addressed due to lack of a summated score for each medication. If this had been 
possible, this study could have assessed whether prescribing appropriateness improved or 
                                                 
34 Section 1.4.7.1 provides a very brief overview of Beers criteria. 
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declined using the summated score. It will also have been possible to find out factors 
associated with this change in appropriateness. Factors predicting prescribing 
appropriateness could not be adequately explored in the logistic regression analysis due to 
small numbers. Lack of medication omissions also meant that this area could not be 
explored. Despite these limitations, the use of the adapted-MAI in this study was 
advantageous as it allowed for clinical judgment when assessing prescribing 
appropriateness. Further, the sample size for this study was small and was estimated based 
on the maximum number of service users that could be assessed by seven prescribers who 
were permanent staff
35
 at the SAS during the study period. This study estimated that the 
number of service users that could be recruited was 88. During the study duration, seven 
other prescribers joined the SAS at various points while some others left. The total number 
of service users seen by the 14 prescribers who took part in this study was actually 76 and 
60 of them provided consent for this study. Actual recruitment was therefore less than 
anticipated. This resulted mainly due to non-attendance of appointments by service users.  
 
It is possible that some instances where there were no statistically significant differences 
between those with and without inappropriate medications were due to the small sample 
size of this study. This study might have been underpowered to detect variation due to its 
sample size. Although this small scale exploratory study was necessary as it represents the 
first attempt at exploring opioid and psychiatric medication prescribing on as many 
appropriateness dimensions, a future study that includes a larger number of service users is 
needed to support or refute its findings. Sample size estimation should be carried out in 
order to ensure that the future study is adequately powered in order to achieve worthwhile 
results (McCrum-Gardner, 2010).   
 
In addition, limited validity tests were carried out with the A-MAI and other questionnaires 
developed for assessing medication omissions and adherence. More studies are needed to 
carry out further psychometric tests. Some previous studies (Samsa et al., 1994; Schmader 
et al., 1994) that utilised the MAI involved the use of two raters to assess abstracted 
patients’ data. Inter-rater and intra-rater reliability tests were carried out in these studies. 
Inter-rater reliability assesses the agreement between ratings made by two or more 
clinicians when assessing the same patient whereas intra-rater reliability measures 
agreement between ratings made by the same clinician on at least two occasions when 
assessing the same patient (Sim and Wright, 2005). While training sessions were organised 
                                                 
35There were only seven prescribers at the SAS at the onset of this study. Seven other prescribers joined the SAS at 
various points during this study.  
184 
 
in this study for prescribers on how to use the A-MAI, with discussion of a case study of 
one patient to ensure comparable ratings, inter-rater and intra-rater reliability tests were not 
carried out. The limited number of training sessions may be insufficient and may have led 
to variability in how prescribers rated appropriateness. The originators of the MAI 
recommend training raters using 10 to 20 patients to ensure reliability of rating (Hanlon 
and Schmader, 2013).   
 
Although testing inter-rater and intra-rater reliability before the commencement of this 
study would have been important to assess consistency of ratings, the applicability of these 
tests would have been somewhat limited in practice for the following reasons:  
 
 Firstly, inter-rater reliability tests would have had limited applicability because 
prescribers assessed different service users. Assessment of different service users 
would most likely introduce variability; 
 Secondly, intra-rater reliability tests would also be limited because improvement or 
deterioration in service users’ health status over time has the potential to introduce 
variability when assessing the appropriateness of prescribed medications. For 
example, some medications assessed to be appropriate at first SAS visit were rated 
inappropriate by three-month follow-up visit and vice versa due to changes in the 
health of service users or medications. There were different ratings given to the 
same service users in these situations. 
  
Variability of rating is expected in this type of study. Unlike previous studies that assessed 
appropriateness by applying the MAI to abstracted patient data, prescribers had actual 
contact with service users before assessing appropriateness. Each prescriber assessed 
different service users whose clinical presentation will most likely differ. Furthermore, 
prescribers’ judgments on appropriateness incorporated service users’ perspectives or 
subjective views. Consequently, two service users with the same conditions may express 
different views about their medications. Again, this may lead to different judgments on 
prescribing appropriateness.  
 
In this study, face-to-face contact with service users was advantageous as service users’ 
perspectives and the actual benefit they report from their medications could be taken into 
consideration when rating their appropriateness. This is the first study where the A-MAI 
was used in a clinical setting as described above, making the assessment of appropriateness 
service-user focused. Unlike some previous studies (see section 2.7, page 94) that focused 
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only on particular dimensions of prescribing appropriateness such as dose due to non-
availability of information on other aspects, this study was able to assess many dimensions 
of prescribing appropriateness.  
 
This study was carried out in a single SAS and its findings may not be generalizable to 
present-day addiction services in the UK. SAS are now rare in the UK, with a move from 
mainly NHS service provision to include a more mixed economy of service providers in 
the alcohol and drug treatment sector (Public Health England, 2014c). Furthermore, it was 
not possible to determine how representative service users assessed by prescribers were of 
those attending the SAS during the study duration because information on service users 
assessed by non-prescribers was not collected.  
5.9.12. Summary of key findings 
Almost half (43.2%) of service users were found to have one or more inappropriate 
medications at their first SAS visit. The A-MAI dimensions that were assessed to be 
inappropriate varied across the different medications. Depression was the most common 
indication and antidepressants were the most commonly prescribed medications. Over a 
quarter of antidepressants prescribed were rated as having at least one inappropriate A-
MAI dimension with the highest dimension of inappropriateness at first SAS visit being 
indication. This study also found that all benzodiazepines and non-benzodiazepine 
hypnotics had one or more inappropriate A-MAI dimensions, with the duration of therapy 
being inappropriate for all of them. They had all been prescribed for longer than 
recommended in the BNF. Further, while almost half of service users had at least one 
inappropriate medication at baseline assessment, none of the medications identified to be 
inappropriate were changed by their three-month follow-up appointment. Adherence to 
prescribed medications varied though most service users reported taking their medications 
very often or often. The cost dimension on the A-MAI had the highest number of ‘don’t 
know’ ratings.  
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Chapter 6: Qualitative interview studies 
with service users: methodology, results 
and discussion 
6.1. Introduction to the chapter 
This chapter presents the qualitative research methodology adopted for the interviews with 
service users as well as the results and discussion of its findings. Qualitative research is a 
form of inquiry in which the researcher collects and analyses textual rather than numerical 
data with the aim of understanding human actions and experiences (Schwandt, 2007). 
Qualitative research is founded on the premise that researchers can garner a deeper 
understanding of phenomena than is possible with quantitative research (Silverman, 2013). 
Qualitative research is therefore useful for exploring complex and under-researched areas 
such as the topic considered in this thesis. It can also be used to answer questions around 
the meaning of illness and medications to patients as well as adherence to such medications 
(Stevenson et al., 2000). 
   
As described in section 3.4.1.2, the phenomenological methodology adopted in this thesis 
aims to discover people’s interpretations of their experience of the world (Green and 
Thorogood, 2004). A phenomenological perspective argued for the use of interviews as a 
research method because of the need to understand the perceptions of service users 
concerning the appropriateness of prescribing decisions. In particular, semi-structured 
interviews were utilised for an in-depth understanding of the perspectives of service users 
on the appropriateness of their prescribed medications. The study rationale, design, 
research questions addressed, sampling strategy, recruitment method and topic guide 
development are presented in section 6.2. The ethical process is presented in section 6.3 
while the interview process, data analysis and storage plans are delineated in section 6.4. 
 
6.2. Study rationale, design, research questions, sampling 
strategy, recruitment and topic guide development 
6.2.1. Study rationale 
In chapter 2 (section 2.7), the scoping review highlighted a lack of research into the views 
of service users with SUDs concerning prescribing decisions. This is despite increasing 
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calls for the involvement of patients in treatment decisions (Farrelly et al., 2015; Institute 
of Medicine, 2001). Patients are the single person present throughout their care and are 
often knowledgeable about their illness and treatment (Institute of Medicine, 2001). Their 
views therefore represent a valuable source of information concerning their management. 
In relation to this thesis, it is possible to learn about the quality of prescribing decisions by 
exploring the views of service users concerning the appropriateness of their medications.  
6.2.2. Study design 
This study involved semi-structured interviews with 14 service users who were attending 
the SAS. All interviews were carried out at service users’ three-month follow-up 
appointment or at their next appointment if this was more convenient. Interviews were 
carried out with a single service user at a time due to the sensitivity of the topic and to 
maintain confidentiality (McIntyre, 2012).      
6.2.3. Research questions 
The following research questions were addressed in this study: 
1. How do service users perceive the appropriateness of their prescribed medications, 
changes to them and its impact on their quality of life? 
2. What factors do service users consider to be important in assessing if their 
medications are appropriate for them? 
3. To what extent do service users adhere to their medications and is this influenced 
by their perceptions on appropriateness? 
 
Appropriateness in the service user interviews was explored by asking service users about 
their need for medications, medication effectiveness, medication changes, assessment and 
review. Exploring appropriateness in this way was necessary because it is a complex 
concept that requires holistic exploration. Furthermore, ex-service users who serve as 
mentors for other service users did not suggest any other areas for inclusion when their 
views were sought concerning these different aspects of appropriateness included on the 
interview topic guide. The first research question was addressed by exploring service 
users’ views about their need for medications, effectiveness, assessment and review, 
medication changes and impact of change on quality of life. The second question explored 
service users’ views on factors important in assessing whether their medications are right 
for them. The last question dealt with service users’ views on their medications and the 
influence of this on adherence. Semi-structured interviews were employed for an in-depth 
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understanding of the perspectives of service users on the appropriateness of their 
medications. Complex areas like appropriateness may be open to interpretation and 
interviews are a good way to explore their meaning.  
6.2.4. Sampling strategy 
Interviews were carried out with a convenience sample of service users on current 
prescriptions of opioids and/or psychiatric medications. All interviewed service users were 
a convenience sample of those who took part in the medication appropriateness study 
during their first SAS visit. Convenience sampling involves recruiting people who are 
available to take part in research (Marshall, 1996), and may not be representative of the 
study population (Robinson, 2014). However, the representativeness of a sample is not the 
goal of qualitative research (Thompson, 1999). Qualitative research and in particular 
phenomenology is concerned with sampling participants who have had the relevant 
experience (Englander, 2012), so that they can provide insight concerning the 
phenomenon. The impact of this sampling strategy on the transferability of study findings 
is further considered in chapter 7 (section 7.3.8.2). 
6.2.5. Recruitment 
Service users recruited into the medication appropriateness study who were still attending 
the SAS prior to their three-month follow-up appointment and who were on prescribed 
opioids and/or psychiatric medications at their first assessment were contacted by 
telephone to determine if they would be happy to be interviewed during their follow-up 
appointment. Service users who attended for their follow-up appointment and who had 
initially indicated interest in being interviewed were reminded of the study aims and 
encouraged to ask for clarification where needed. They were then given a consent form to 
sign. A copy of the signed consent form was given to service users before the interviews 
commenced.  
 
All interviews with service users took place in a private room at the SAS. Where service 
users could not be interviewed during their three-month visit, another interview was 
scheduled for their next visit. For qualitative studies, Kvale (2007) recommends recruiting 
between 5 and 25 participants depending on the nature of the study, in order to reach a 
compromise between collecting excessive data that may be unmanageable during analysis 
and collecting enough data so that sufficient level of depth can be gained with meaningful 
conclusions. In particular, a sample size of six was recommended by Janice Morse (Morse, 
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1994) for phenomenological studies. A total of 14 service users were interviewed in the 
current study.  
6.2.6. Developing the topic guide for interviews with service users 
The topic guide for service users (appendix 6.1) was developed from the research questions 
as well as discussion with my academic supervisors. It covered six major areas: service 
users’ medical/substance use history, need for medications, effectiveness of medications, 
assessment and review, medication change and quality of life, and adherence. The views of 
ex-service users who serve as mentors for other service users at the SAS were sought about 
the topic guide during one of their meetings to determine if there were other areas that 
needed to be covered. The ex-service users did not suggest any changes to the topic guide 
as they considered it to be comprehensive. Before the commencement of interviews with 
service users, the topic guide was developed into questions to be asked. The questions were 
piloted with the researcher’s supervisors who suggested rewording a few of the questions. 
The questions were then piloted with two ex-service users who did not suggest any 
changes.  
6.3. Ethical considerations  
As described in section 5.8, ethical application for the medication appropriateness study 
and interviews with service users and prescribers were made in the same application. 
Section 5.8 has covered aspects of the ethical process that were common to both studies 
such as submission of the application to the HSRGC, issues raised at the meeting with 
HSRGC as well as the need for absolute confidentiality concerning information provided 
by study participants during the meeting with the NRES Committee Yorkshire & the 
Humber. This section will address the ethical issues that were specific to the interviews in 
general (both service user and prescriber interviews) because they were similar.    
 
A problem that could have arisen from taking part in interviews is that lack of anonymity 
could lead to some participants withholding information. Service users can be concerned 
that the information they provide may affect their care. For example, they may be 
concerned that their participation in this study may lead to the withdrawal of medications 
they value. The researcher assured all service users that the information they provide will 
not be shared with their prescribers. Prescribers were also assured of the confidentiality of 
all information they provided in this study. Furthermore, all participants were assured that 
the information they provide will be anonymised in all publications stemming from this 
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study. The purpose of the research was explained to all participants. These steps were 
taken to ensure that they feel at ease during the interviews. A pertinent ethical 
consideration for the interview process is the potential vulnerability of service users. For 
instance, it is possible that some service users could feel anxious or distressed talking 
about their medications and medical/SUD history. This was minimised by making it clear 
to service users that they could stop at any point and did not have to continue with the 
interview. This scenario did not however occur. Service users were also informed that 
arrangements could be made for them to speak to one of the therapists at the SAS if they 
were overwhelmed during the interview. The REC gave a favourable ethical opinion of the 
research based on meeting the following conditions: 
 
1. The inclusion of a clause allowing participants to consent to their interview being 
audio-recorded on the consent form for service users and prescribers. 
2. Statement 7 (I agree to be contacted in the future concerning this study ) on the 
consent form for service users should be more specific about when and why service 
users may be contacted in the future. 
3. The service user information sheet should explain that not all participants will be 
invited to take part in the interview stage of the study. 
 
The changes specified by the REC were made and a confirmation letter for the study was 
subsequently obtained.  
 
6.4. Interview process, data analysis and storage 
This section presents the process for conducting the interviews, analysing and storing 
them. Section 6.4.1 covers the interview process while section 6.4.2 presents the data 
analysis and storage plans. These processes were broadly similar for both service user and 
prescriber interviews. They are therefore presented together.  
6.4.1. Interview process 
Interviewed service users had been in treatment for at least three months, were familiar 
with the SAS setting and had developed a level of relationship with the researcher
36
. 
Similarly, prescribers who were interviewed had all participated in the medication 
appropriateness study and had built a level of rapport with the researcher.  
                                                 
36
 The researcher had recruited all service users who agreed to take part in this study and also communicated 
with them via the telephone before the interviews. 
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The setting of data collection is important in qualitative research, as interviewees are more 
likely to be relaxed in a comfortable and familiar environment (Stevenson et al., 2000). 
Service users were interviewed in a private room at the SAS which enabled them to 
comfortably discuss their illness and medications used in managing them. Prescribers’ 
interviews also took place in a private room at the SAS.  
 
The identity of the interviewer may impact on the interview (Stevenson et al., 2000). For 
prescribing research, if the interviewer is a healthcare professional, the interviewee (for 
example, service users) may not want to disclose actual information concerning their 
prescribed medications (for example, information concerning their adherence). They may 
provide answers that they feel the researcher wants to hear. Consequently, in this study the 
researcher did not introduce herself as a pharmacist to service users but rather as a research 
student at the University of York. She only went further to disclose her professional 
identity if asked. However, no service user asked about her professional background. She 
conducted all interviews in a systematic manner.  
 
Before each interview, the purpose of the research was explained to participants in order to 
put them at ease about the process. Participants were informed that the interview would be 
audio-recorded and direct quotations from them may be used in write-ups from this thesis. 
Such quotations would be anonymous and any information disclosed would be kept 
confidential. In particular, service users were informed that exceptional disclosures which 
suggest that the service user or some other person is at risk of harm may be disclosed for 
further action to be taken. Participants were then invited to ask any questions before the 
interview started and then sign the consent form. A copy of the signed consent form was 
given to them. 
 
The topic guides provided a rough framework for the interviews. A flexible approach to 
questions was taken during the interviews in order to allow the interviewer probe 
participants in more detail where necessary. The use of a topic guide however ensured that 
similar questions were asked and therefore permitted comparison of themes across each 
subject. Examples of questions asked during the service user interviews include “what 
prescribed medications are you taking?” as well as questions concerning when the 
medication was prescribed and by whom. More sensitive questions, for example, regarding 
need for medications, their effectiveness and adherence in service user interviews were 
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asked further into the interviews once participants felt comfortable with the process. 
Examples of questions asked prescribers during their interviews include “how would you 
define inappropriate prescribing?” and “how do you assess the appropriateness of service 
users’ medications?”. Where necessary, responses were reiterated to participants to check 
comprehension. At the end of the interview, participants were asked whether they had 
anything else to say. The duration of interviews with service users ranged between 10 and 
104 minutes (45.7 + 30.5). There were three short interviews between 10 and 17 minutes. 
In one of these interviews, the service user’s partner was present and this might have 
prevented her from engaging with the interview. She gave very short responses to the 
questions. Another service user requested that the interview be stopped because it was 
boring him. The third interview was brief because the interview room needed to be used by 
SAS staff. Other interviews were between 27 and 104 minutes. Interview duration with 
prescribers lasted between 36 and 74 minutes (48.1 + 12.5). The difference in interview 
time was primarily because some participants spoke at length while others did not.  
 
All interviews were audio-recorded except one in which a service user did not want to be 
recorded. After each interview, the researcher made brief notes on the interview experience 
and a critical reflection on the interview process was begun. On listening back to the audio-
recording of her first service user interview, the researcher realised she did not really probe 
some of his responses sufficiently. She consequently made it a priority to follow-up the 
responses of other service users more fully when interviewing them. Questions exploring 
why medication omissions were absent in the medication appropriateness study were 
added to the topic guide for prescriber interviews. 
6.4.2. Data analysis and storage 
Analysis of semi-structured interviews 
This section describes how interviews were transcribed and analysed and is similar for 
both the service user and prescriber interviews. 
 
Transcription 
The researcher transcribed four of the interviews (all service user interviews) alongside 
data collection. As data collection progressed, a professional transcriber was engaged (with 
the assistance of my supervisors) in order to keep pace with the data collection process. 
Transcribing some of the interviews provided the opportunity for the researcher to 
familiarise herself with the data and emerging themes while also planning for other 
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interviews. All transcribed interviews were saved on her secured double passworded 
computer at the Department of Health Sciences, University of York, for analysis.  
 
Analysis 
Initially, the researcher had proposed to use a qualitative data analysis software (Atlas. ti 
version 6.0) to support her analysis of the interviews. However, she decided to use Atlas ti 
for data coding only (appendix 6.2a provides a screenshot of codes generated using Atlas 
ti) while she undertook further data analysis in Microsoft word due to the relatively small 
number of interviews she carried out. Qualitative data analysis software such as Atlas ti is 
particularly useful for large amounts of qualitative data (St John and Johnson, 2000). 
Furthermore, Coffey and Atkinson (1996) have stated that none of the qualitative data 
analysis softwares will perform automatic data analysis, rather they depend on the 
researcher defining what analytical issues are to be explored, what ideas are important and 
their mode of representation. All codes generated in Atlas ti were exported to Microsoft 
word for further analysis.  
 
Although there are different ways to analyse qualitative data, the thematic framework 
proposed by Miles and Huberman (1994) was used as a guide in this study. Miles and 
Huberman outline 13 points that make up their thematic framework analysis. They consist 
of:  
 
1. Noting patterns, themes 
2. Seeing plausibility 
3. Clustering 
4. Making metaphors 
5. Counting 
6. Making contrasts/comparisons 
7. Partitioning variables 
8. Subsuming particles into the general 
9. Factoring 
10. Noting relations between variables 
11. Finding intervening variables 
12. Building a logical chain of evidence 
13. Making conceptual/theoretical coherence 
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Steps 1, 2 and 3 assist the researcher in seeing ‘what goes with what’. Step 4 helps in 
achieving more integration of the data. Step 5 shows what’s there. Step 6 sharpens 
understanding of data while step 7 assists in differentiating the variables. Step 7 is 
especially useful when coding schemes are being developed and elaborated as it assists in 
highlighting differences that might otherwise be blurred. Steps 8, 9, 10 and 11 help in 
seeing things and their relationship more abstractly. Finally, steps 12 and 13 bring about a 
coherent understanding of data with step 13 in particular leading to building of a more 
conceptual overview of the subject area (Miles and Huberman, 1994). The steps the 
researcher took in data analysis are described below with reference to aspects of the 
thematic framework used.  
 
Firstly, the researcher read the interview transcripts several times in order to ensure that 
she became familiar with them. Familiarisation involves immersion in the data and is 
essential to gain in-depth knowledge of the nature and diversity of the data (Bradley, Curry 
and Devers, 2007). This ensured that she gained a holistic understanding of her interview 
data while constantly addressing her research questions. She became aware of key ideas 
and concepts and coded these themes on her interview transcripts (this refers to the first 
and third steps of the thematic framework analysis: noting patterns and themes and 
clustering). Themes are recurrent unifying ideas or statements about the subject of inquiry 
(Bradley, Curry and Devers, 2007). She also re-read the reflexive journals she had made 
during the interviews to identify if any of the themes located in the data related to her 
reflexive thoughts. Some of these themes were expected as the topic guide was constructed 
in order to explore them.  
 
As she became immersed in her interview data, she ensured that any new themes she 
identified were added to her coding framework and also that they were rooted in the data 
(this refers to the second step of the thematic framework analysis: plausibility). As new 
themes emerged, she went over each transcript to code the data where relevant for the new 
themes. Consequently, her data analysis was open and inductive as the key issues and 
themes that were expressed by interviewees formed the basis of the coding framework. 
Where similar issues or views were expressed by interviewees they were clustered under 
the same theme. The inductive method utilised in this analysis ensured that she was 
immersed in the data and also had a comprehensive knowledge of it. Some of the themes at 
this stage were descriptive such as reasons for prescribing while others were more 
analytical such as antidepressants as a ‘crutch’.  
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This stage was followed by the stage of managing the data by combining or eliminating 
coded themes (this refers to the following steps of the thematic framework analysis: 
making metaphors, making contrasts or comparisons, partitioning variables, subsuming 
particles into the general and factoring, noting relations between variables and finding 
intervening variables). All codes were exported to Microsoft word where data were 
managed.  
 
A metaphor is defined by the Oxford Dictionary as a figure of speech in which a word or 
phrase is applied to an object or action to which it is not literally applicable (Oxford 
Dictionaries, 2016b). It is also defined as a thing regarded as representative or symbolic of 
something else. It is used to achieve more integration of data (Miles and Huberman, 1994). 
A metaphor ‘medical crutch’ was used by a service user when describing his view of his 
antidepressant.  
 
Making contrasts or comparisons and partitioning variables (differentiation) between the 
themes derived from the different cases assisted in seeing how they differ as well as their 
similarities. Furthermore, differentiation sometimes involved breaking up a theme into 
more than one theme if needed. For example, closer examination of the theme ‘benefit 
from medications’ from service users’ interviews showed that it also included ideas about 
trade-off of risks and benefits, a decision was therefore made to make trade-off of risks and 
benefits a theme.  
 
Subsuming particles into the general and factoring are more than the first-level process of 
clustering similar themes. They involve trying to locate themes in a more abstractly 
defined class thereby further reducing the bulk of data and finding patterns in them. Each 
theme was further examined and similar ones were grouped together to form meta-themes. 
For example, benefit from medications, trade-off of risks and benefits, antidepressants as a 
‘medical crutch’ and interference of alcohol with antidepressants were all grouped under 
the meta-theme ‘functional outcomes’ in service users’ interviews since they were all 
related to service users’ functioning. Noting relation between variables shows how 
variables relate to each other while finding intervening variables examines whether there 
are other variables that are involved in a relationship observed between two variables.  
 
Building a logical chain of evidence and making conceptual/theoretical coherence involves 
putting all the information gathered from previous steps together in order to provide a 
holistic understanding. The process of managing the coded themes was discussed with the 
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researcher’s academic supervisors. The feedback she obtained from her supervisors was 
helpful in combining or sometimes separating out themes and clarifying the reasons why 
different themes were placed under the overarching themes.  
 
While some of the themes such as ‘functional outcomes’ related to a large proportion of 
participants, a few did not. For example, the theme ‘entitlement to prescribed medications’ 
was described by only four service users. This was reflected when presenting the results by 
counting the number of participants reporting particular themes (this refers to the fifth step 
of the thematic framework analysis: counting). Even though counting was used to reflect 
intensity of themes, the meaning participants have constructed concerning prescribing 
appropriateness was given priority in accordance with the principles of qualitative research 
(Merriam, 2009). Overall, the thematic framework by Miles and Huberman (1994) was 
useful as a guide in analysing data. However, it was not possible to follow its steps rigidly 
in sequence, because analysis is an ongoing iterative process in qualitative research 
(Bradley, Curry and Devers, 2007). Appendices 6.2b and 6.2c show samples of the coding 
framework for service user and prescriber interviews respectively. 
 
6.5. Results and discussion 
6.5.1. Participants’ characteristics 
Only service users taking prescribed opioids and/or psychiatric medications at both first 
SAS visit and before their three-month follow-up appointment were approached for 
interview in order to obtain their views on their current medications. Twenty three (23) 
service users were taking such prescribed medications at first visit and were still attending 
the SAS prior to their three-month review appointment. Twenty of them were contacted by 
telephone prior to their follow-up appointment to determine if they would consent to 
participate in an interview during their follow-up assessment. The remaining three service 
users could not be contacted before their follow-up assessment. 
 
Four service users were not interviewed because they did not attend for their scheduled 
interviews whilst two service users attended but refused to be interviewed. Therefore, a 
total of 14 service users (of 20: 70%) were interviewed. The 14 service users did not differ 
from the six people who were not interviewed in their sociodemographic characteristics or 
level of dependence, quality of life, level of psychological distress and social satisfaction 
(see appendix 6.3 for table showing comparison). The mean age of those interviewed was 
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48.9 years (range: 26 to 66 years) and the mean number of medications they were being 
prescribed at their first SAS visit and three-month assessment were 3 (range: 1 to 8) and 
3.4 (range: 1 to 8) respectively. The mean number of target medications (prescribed 
opioids and/or psychiatric medications) at first SAS visit was 1.7 (range: 1 to 3). The 14 
service users comprised three females and 11 males. Alcohol was the referral substance for 
all but two service users who were referred for problems with heroin. 
6.5.2. Themes highlighted by service users 
Eight themes were highlighted by service users in relation to the topics addressed in the 
interviews: functional outcomes, entitlement to medications, prescribing in response to 
stressful situations, assessment and review, discussion with clinicians, improved quality of 
life, adverse effect of medications and adherence. Some themes such as functional 
outcomes, entitlement to medications, prescribing in response to stressful situations, 
discussion with clinicians and adverse effect of medications were inductive themes that 
came out of the thematic analysis (Spencer, Ritchie and O'Connor, 2003b) while others 
(assessment and review, quality of life and adherence) were deductive, arising from the 
topic guide.  
6.5.2.1. Functional outcomes 
The phrase ‘functional outcomes’ proved a very useful and unifying theme under which to 
consider the views of a number of service users concerning the need for their medications 
and their effectiveness. This phrase has been used in the literature to describe physical, 
social and psychological functioning of patients (Collett, 2001). Functional outcomes came 
out strongly when service users discussed their need for medications and their 
effectiveness. All service users described their medications in relation to the effect they 
had on their health conditions and wider life. Some service users went on to describe the 
influence of substances, mainly alcohol, on the effectiveness of their medications. Four 
sub-themes are considered under this theme: benefit from medications, trade-off of risks 
and benefits, interference of alcohol with antidepressants and antidepressants as ‘a medical 
crutch’. 
 
Benefit from medications  
Thirteen service users thought that their medications had led to some degree of 
improvement in their health conditions and functioning. Two service users described the 
positive impact of their antidepressants on their functioning: 
 
198 
 
My Fluoxetine, yeah, I know if…  I don’t take it for a couple of days I… very quickly start 
to feel meself, you know, going … downhill again, and start feeling low and tearful [ID 35, 
female, alcohol dependency]. 
 
…because a few months ago, I didn’t take them [Citalopram] for a while and I just hit rock 
bottom again and then when I started back on them again, within a couple of weeks I was 
back to normal [ID 5, male, heroin dependency]. 
 
Service users reporting positive effects from particular medications also sometimes 
described doubtful benefits from others. One service user who has a three-year history of 
co-codamol and citalopram use for pain and post-traumatic stress disorder (hereafter 
PTSD) respectively, as well as a three-month history of disulfiram use for alcohol relapse 
prevention, described benefits from his co-codamol and disulfiram but was uncertain about 
the benefit of his citalopram: 
 
[Co-codamol] don’t take the pain fully away but it gets you to where you can get about and 
move around, but it does …work… [Later, talking about disulfiram]: I’ve not had a drink 
for three... months, last time I’d gone three months without a drink I… was in me teens, I’d 
be… a teenager. So it, yeah, it has worked… [Later, talking about citalopram]: I don’t 
know if it’s working or not. I don’t know. I can’t feel any difference taking it [ID 16, male, 
alcohol dependency]. 
 
Among service users who described positive effects from their medications were those 
who reported benefits despite being prescribed outside BNF recommendations. One elderly 
service user referred for his alcohol problems, with a 12-year history of olanzapine use at a 
dose above the BNF recommendation for long-standing paranoid schizophrenia, described 
the benefit he derived from his medication: 
 
As soon as I was put on 25mg of Olanzapine a day, at night, all slight psychotic symptoms 
disappeared. And I’ve been on those tablets for a number of years now and I find that they 
do very well for me psychiatrically… I haven’t been mentally ill for something like oh 
about ten/twelve years now… thanks to the medications… I’ve been on the maximum dose 
of Olanzapine for a number of years now… but fortunately, with Olanzapine…, no side 
effects whatsoever; in my case that is, no side effects at all, they work very well [ID18, 
male, alcohol dependency]. 
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Another service user with a year history of zopiclone use for sleep problems described 
benefit from his zopiclone (the duration of zopiclone use had exceeded BNF 
recommendations): 
 
The zopiclone works because within ten, twenty minutes I’m asleep. So that does work… 
[ID 15, male, alcohol dependency]. 
 
On the other hand, a service user who continued alcohol misuse despite receiving treatment 
at the SAS described lack of benefit from his zopiclone. Again, zopiclone duration had 
exceeded BNF recommendation as he has been prescribed it for six months for sleep 
problems:  
 
… I’ve got to… take it [zopiclone] to try and get that sleep and hope I do go to sleep and 
… not wake up till morning, but it don’t happen, it just doesn’t happen… I’ve never had a 
full night’s sleep, even with the medication I don’t have a full night’s sleep. Like if I take 
my medication tonight at about eleven/half past eleven, an hour later I’ll start to go to 
sleep and I’ll be awake for two/three o’clock (ID 27, male, alcohol dependency). 
 
Overall, most service users described benefits from their medications, including service 
users who had been prescribed medications outside guideline recommendations. It was 
unclear whether all those prescribed outside guideline recommendations were aware of it 
because the interviews did not explore this issue due to its sensitive nature. Prescribing 
outside guideline recommendations is common in psychiatry (Ali and Ajmal, 2012). 
Baldwin and Kosky (2007) reported that one of the most common types of off-label 
(unapproved or unlabelled) prescribing in psychiatry is prescribing higher-than-approved 
dosages of antipsychotics and antidepressants for patients who do not respond to the 
maximum approved dosages. Furthermore, while non-benzodiazepine hypnotics such as 
zopiclone and benzodiazepines are recommended for short-term use in insomnia (four 
weeks) (Joint Formulary Committee, 2010), they are commonly prescribed long-term 
(Baldwin and Kosky, 2007; Haw and Stubbs, 2007). 
 
Best practice recommendations including dosing and duration recommendations are 
usually established in clinical trials especially RCTs and where available, they serve as the 
foundation for clinical guidelines (Tucker and Roth, 2006) including the BNF. Where there 
is no evidence from clinical trials, recommendations are based to a large extent on the 
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opinions of experts who make up the guideline committee (Geleris and Boudoulas, 2011). 
It may not be possible to directly extrapolate recommendations from guidelines on 
prescribing of opioids and psychiatric medications to people with SUDs because most of 
the evidence from RCTs exclude people with SUDs (Furlan et al., 2006; Ostacher, 2011; 
Samet and Walley, 2008). Where they are included, the sample does not reflect the 
heterogeneous group of people with SUDs who usually have multiple health problems and 
complex situations (Humphreys et al., 2005).  
 
In clinical guidelines, the maximum approved dose is that which gives the best balance 
between the desired clinical effect and unwanted side effects (Baldwin and Kosky, 2007). 
This dose may not be optimal for people with SUDs and may need to be increased or 
decreased depending on the severity of service users’ conditions and comorbidities. For 
example, people with co-existing SUDs and mental disorders may need higher doses or 
longer duration of treatment compared to those with single conditions because they may 
have more severe and persistent symptoms or they may be more disturbed and resistant to 
treatment (Green, 2005; Soyka, 2000; Soyka et al., 2001; Volkow, 2010). Conversely, the 
presence of hepatic impairment may lead to prescribing of lower doses of medications 
(Kane et al., 1998). Changes in the neurochemistry of the reward pathways of the brain 
secondary to chronic use of medications may also affect prescribing decisions (Gershwin 
and Hamilton, 1998) including dosing. Opioid doses in people with SUDs may need to be 
higher than in those without SUDs due to tolerance (Gershwin and Hamilton, 1998).  
 
Generally, the effectiveness of off-label practices is often not supported by strong evidence 
(Baldwin and Kosky, 2007; Kane and Leucht, 2008). Naylor (1995) suggested that the 
patient’s perspective is particularly important and should be considered where there is lack 
of adequate evidence or doubt about the best course of action. Continued benefit reported 
by patients and a lack of desire to stop treatment may be factors that fuel prescribing 
outside guideline recommendations (Wright, Caplan and Payne, 1994).  
 
Furthermore, consideration of the repercussions of relapse to substance use on the 
individual and society may well justify the need to sometimes prescribe outside guideline 
recommendations in order to maintain the well-being and equilibrium of people with 
SUDs. Evidence from this study suggests that the appropriateness of prescribing is open to 
interpretation as some service users tended to view medications that improved their 
functioning as appropriate for them even when they were inappropriate by guideline 
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standards. There was therefore sometimes conflict between these two different 
perspectives. This study suggests that pharmacologically inappropriate prescriptions may 
well be appropriate in another sense if they are perceived to provide benefit by service 
users.  
  
While off-label prescribing may be clinically beneficial (Ali and Ajmal, 2012) for patients 
with severe and complex problems such as those with SUDs, it also carries clinical risks 
such as adverse effects. For instance, prescribing supra-BNF doses of antipsychotics 
carries a greater risk of unwanted side effects such as extrapyramidal side effects 
(parkinsonism, akathisia, acute dystonias, tardive dyskinesia), sedation, tachycardia, 
weight gain, postural hypotension, seizures and hyperprolactinaemia (Royal College of 
Psychiatrists, 2014b).  
 
The management of insomnia in people with SUDs requires careful consideration in order 
to ensure that it is not being caused by the SUDs (Royal College of Psychiatrists, 1997). 
Where insomnia is secondary to SUDs, there is need for management of the SUD (Baldwin 
et al., 2013). Long-term prescribing of non-benzodiazepine hypnotics such as zopiclone 
may lead to dependence especially among people with a history of SUDs (Cimolai, 2007; 
Hajak et al., 2003). There is therefore a need for extreme caution when prescribing off-
label as well as consideration of acute and long-term benefit to patients (Ali and Ajmal, 
2012). There should also be regular monitoring and follow-up throughout treatment 
(Baldwin et al., 2013).  
 
Mental disorders such as PTSD reported by the service user with ID 16 may exacerbate 
chronic pain (Otis, Keane and Kerns, 2003; The British Pain Society, 2007), as it is 
associated with increased rates of psychological and physical symptoms (Otis et al., 2003; 
Sullivan et al., 2006). Sullivan et al. (2006) have suggested that it is possible that opioids 
are being used to treat an undifferentiated state of mental and physical pain. Diagnosis and 
treatment of mental disorders are therefore important when considering prescribing 
opioids. Adequate care for mental disorders may improve chronic pain (Lin et al., 2003; 
Sullivan et al., 2006) and also reduce the need for chronic opioid use (Sullivan et al., 
2006).  
 
Where opioids are helpful in the management of chronic pain, they should be used. 
However, where they do not work in adequate doses, they may need to be stopped 
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(Stannard, 2013). Opioids are usually prescribed for longer periods than their known 
efficacy in the management of chronic pain (Noble et al., 2010). Most studies have a 
follow-up period of less than six months (Samet and Walley, 2008), and there is limited 
evidence for the effectiveness of opioids over the long duration of treatment typical of 
chronic pain (Noble et al., 2010). Again, the patient’s perspective would need to be 
considered for optimal decision-making. Complete symptomatic relief of chronic pain may 
often not be possible and an acceptable balance between improved functioning and side-
effects should be seen as the goal of therapy (Department of Health (England) and the 
devolved administrations, 2007). Non-pharmacological treatment options such as 
psychological therapies (for example, cognitive behavioural therapy) may be useful 
alternatives or a combination of these and pharmacotherapy may need to be considered for 
optimal management of chronic pain (Holliday, Hayes and Dunlop, 2013) and insomnia 
(Baldwin et al., 2013).      
 
Trade-off of risks and benefits 
Four service users described having side effects which they tolerated due to the benefits 
they felt they obtained. One service user with a five-year history of citalopram use for 
long-standing depression described sexual dysfunction resulting from citalopram but 
reported that it was nevertheless effective for his depression: 
 
Citalopram’s been great. Easy to work with, you know,... easy to take, it doesn’t make me 
drowsy… I can live a normal life on it, and I’m happy now... the only contraindication or 
side-effect I have from citalopram is that sometimes it prevents ejaculation. I can get to the 
point of climax but, ... I don’t ejaculate [ID 23, male, alcohol dependency]. 
 
Another service user with a six-month history of venlafaxine use for anxiety disorder of 
six-year duration described benefit from it but also acknowledged that he does not strictly 
follow the instructions for taking it due to the sleepiness it causes: 
 
… it’s [Venlafaxine] made me very balanced, calm, relaxed… it has been mentioned to me 
that I should take two the same time, perhaps in the afternoon when I take my Disulfiram, 
but I don’t because I don’t want to be… too, too sleepy… [ID 7, male, alcohol 
dependency]. 
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One service user who described benefits from his co-codamol and disulfiram also 
described side effects from taking this combination of medications: 
 
Co-codamol and Disulfiram have been helpful… A combination of that [Disulfiram] and 
the Co-codamol was a concoction for me, …it’s like a sleeping tablet, cos I… tend to sleep, 
or drowsiness, not sleep, the drowsiness [ID 16, male, alcohol dependency]. 
 
Service users therefore described having to make compromises due to the benefits and 
adverse effects they experience from their medications. Prescribing appropriateness as 
suggested here involves weighing the risks and benefits of medications. The fact that 
service users decided to continue with their prescriptions suggests that the perceived 
benefits outweighed the disadvantages. This finding is similar to those found in a range of 
different contexts (Moncrieff, Cohen and Mason, 2009; Schofield et al., 2011), and do not 
appear to be particularly linked to their substance use status. Moncrieff et al. (2009) in a 
study that assessed patients’ subjective experience with antipsychotic medications found 
that some patients described a similar trade-off between the risk and the benefit of their 
medications. Comparable findings were also described by Schofield et al. (2011) in a 
qualitative study exploring patients’ views on antidepressant use, as patients described 
continued antidepressant intake despite the side effects they experienced.  
 
There was also evidence from this study that there were situations where service users did 
not follow the instructions for medication use in order to minimise adverse effects. They 
appear to have chosen to take medications or modify them according to their own beliefs 
of what works best for them. Section 6.5.2.7 further considers issues around medication 
adherence. Medications often have side effects due to the fact that most of them exert their 
pharmacological effects on different parts of the body simultaneously (Barsky et al., 2002). 
The concurrent use of multiple medications further increases the risk of side effects 
(Rambhade et al., 2012) especially among medications that have the potential to cause 
such effects on their own. Co-codamol and disulfiram both have the potential to cause 
drowsiness (Centre for Substance Abuse Treatment, 2009) and this may be worsened when 
they are taken concurrently. Given the literature and the findings of this study, judgment on 
the appropriateness of prescribing among service users involves balancing the risks and 
benefits of medications.      
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Interference of alcohol with antidepressants 
Three service users who all described some levels of benefit from their antidepressants 
highlighted the negative impact of alcohol on its effectiveness. One service user with a six-
year history of fluoxetine use for depression described alcohol as hindering the effect of his 
fluoxetine: 
 
It does work,… but the… drink is hindering it I think, cos obviously I’m not getting the full 
effect of the antidepressant because I’m getting me brain drunk, so it’s interfering with that 
[ID 27, male, alcohol dependency]. 
  
Another service user who was using two antidepressants for his long-standing depression 
described the negative effect of alcohol on his antidepressants whilst also stating that the 
impact of alcohol has been explained to him by his doctors: 
 
Well as long as I… don’t drink, the Fluoxetine and the Mirtazapine work marvellously 
well… I’ve had periods of depression recently but I put that down to drinking because, 
from what I’ve had explained to me by doctors, alcohol destroys the effects of the 
medication. In other words, you can take as much fluoxetine and mirtazapine as you like, 
but if you’re drinking three or four pints of beer a day that kills the effect of it, and that’s 
why you end up depressed [ID18, male, alcohol dependency]. 
 
The evidence that symptoms of depression could result from AUDs (Boden and Fergusson, 
2011; Schuckit et al., 1997) raises the concern that alcohol misuse by depressed persons 
may counteract the benefits of antidepressants (Ramsey, Engler and Stein, 2005). This is in 
line with the findings reported by service users as they described suboptimal benefit from 
their antidepressants (all selective serotonin reuptake inhibitors) in the presence of alcohol. 
Furthermore, a recent meta-analysis found that although antidepressants such as those with 
noradrenergic activities are effective in treating depression in people with comorbid 
depression and AUDs, the selective serotonin reuptake inhibitors such as fluoxetine are not 
very effective (Iovieno et al., 2011). Torrens et al. (2005) in a previous meta-analysis 
comprising people with depression and more diverse SUDs including AUDs also reported 
similar findings. Overall, it appears alcohol hinders the effectiveness of antidepressants 
among people with SUDs and co-existing depression.   
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Antidepressants as a medical ‘crutch’ 
As well as the health impact of their medications, four service users described their 
medications (in particular, antidepressants) as providing valuable support in their lives. 
One service user who had a five-year history of citalopram use for long-standing 
depression described the impact of his citalopram during stressful periods as follows: 
 
…and during a very stressful period which, my mood didn’t really change that much, I 
used it as like a comfort blanket or a crutch to sort of like, I’m taking 40mg [Citalopram] 
now, so I’m bound to be all right [ID 23, male, alcohol dependency]. 
 
Similarly, another service user with a six-month history of venlafaxine use for anxiety 
disorder of six-year duration described his venlafaxine as helping his decision-making in 
addition to its effect on his anxiety: 
 
…and should there be any periods of anxiety I feel very… comfortable, relaxed and… any 
decision making I feel, you know, I feel as though venlafaxine is helping me at that [ID 7, 
male, alcohol dependency]. 
 
Other research on people’s experiences with antidepressants has found that people describe 
them as providing valuable support in their daily lives, using terms such as ‘crutch’ or 
‘cushion’ or ‘burden reliever’ (Knudsen, Hansen and Eskildsen, 2003; Knudsen, Hansen 
and Traulsen, 2002). While people involved in these studies sometimes described 
antidepressants as helping their emotional problems disappear, others described them as 
something that assisted them in managing their problems. This is similar to what service 
users in this study reported.  
 
Furthermore, a meta-ethnography of patients’ experience of antidepressants also reported 
that they described antidepressants as helping them return to normal functioning through 
fulfilling their social roles as well as carrying out their daily activities and regaining 
control (Malpass et al., 2009). The need to use prescribed medications such as 
antidepressants as a ‘medical crutch’ may well be greater among people with SUDs due to 
their myriad of health issues (Hoertel et al., 2014; McLellan, 2009) and life problems 
(Lloyd, 1998). Consequently, antidepressants may be needed to help maintain equilibrium, 
and thus prevent disintegration of their lives. 
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6.5.2.2. Entitlement to medications 
Four service users described a sense of entitlement to being prescribed medications. One 
service user who had bought street zopiclone for some years before being prescribed it for 
sleep problems by his GP, described his awareness of the potential for addiction to 
zopiclone: 
  
I feel a lot better now, mm, and… I do appreciate that … they [Zopiclone] are addictive… 
but so’s smoking, so’s driving really fast, so’s doing a lot of other things. It’s my health 
and I’ve chosen to look after it how I want and this is how I want (ID 57, male, alcohol 
dependency). 
 
Another service user went on to describe his preference for asking for what he needs from 
his doctor: 
 
Well… my personal opinion is that I think with… doctors these days, I think you have to 
tell them what’s wrong with you or basically tell ‘em what you need, rather than the sort of 
old school where you went to… the doctor and you spent a long time… explaining your 
symptoms (ID 7, male, alcohol dependency). 
 
This theme was also evident when one service user described how he requested an 
alternative to his dihydrocodeine after his GP expressed concerns about his misuse of it. 
He further described being addicted to his medication:  
 
I had said to me doctor, well when he were showing concerns about how many I was 
taking [Dihydrocodeine], and I says “well just stop ‘em and give me summat else.” And he 
says “No, you can’t because your body is…”. Basically I’m addicted to ‘em even though 
I… don’t feel addicted to ‘em, but apparently me body will crave ‘em if I just stop taking 
‘em, so [ID 29, male, alcohol dependency]. 
Another service user who had deliberately taken an overdose of his prescribed 
antidepressant (fluoxetine) and sleeping tablet (zopiclone) in order to self-harm and had 
been admitted to hospital was afraid his zopiclone could be stopped by his GP but 
demonstrated a recognition of his right to be prescribed it: 
And the sleeper [Zopiclone], they (hospital doctors) won’t prescribe it to me, so now I have 
to go back to my GP and hope that he’ll prescribe me it again, because obvious he’s gonna 
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know on… computer that I took an overdose, so he might refuse me…  treatment… so I’ve 
put meself in a predicament there to try and get me medication back… but I know he can’t 
refuse it because he’s putting me physically in danger then (ID 27, male, alcohol 
dependency).  
  
Patient involvement in their own care now represents a core value in the medical 
profession and NHS (Department of Health, 2013b; General Medical Council., 2009). The 
NHS constitution states that NHS services must reflect the needs and preferences of 
patients (Department of Health, 2013c). Ethical and practical reasons have been advanced 
on the need for patient choice in prescribing as it is the patient who takes the medication 
(Barber, 1995). Cribb and Barber (1997) have further suggested that one aspect of good 
prescribing is that it does what patients want done. However, there is sometimes conflict 
between physician-assessed need and what patients want, and how far prescribing should 
be determined by either of this remains an unresolved question (Barber, 1995; Cribb and 
Barber, 1997).  
 
The issue of patient choice is even more challenging in addiction medicine because 
patients may be less than open about the reasons for which they want medications. They 
may want medications in order to suspend reality or for their pleasurable effects. Craving 
and an impaired control over their lives (Action on Addiction, 2013) including medication 
use may also be factors underlying service users’ request or need for certain types of 
medications. Furthermore, this need may be driven by the service user’s desire to avoid 
withdrawal symptoms. It is therefore possible that the responses of some service users 
above (ID 57, 29 and 27) may be a consequence of these factors.  
 
The management of risk is a particularly important issue in addiction medicine because 
service users may be at great risk from medications (Action on Addiction, 2013). It is 
therefore paramount to ensure that prescribing decisions are justified, and also prescribe 
with due precautions that may involve limit setting, monitoring and behavioural rules in 
this population (Action on Addiction, 2013). Nevertheless, prescribers may be under 
considerably greater pressure to respond to the self-perceived needs of substance users 
compared with other patient groups. People with SUDs appear to have a particularly strong 
sense of their own needs and seek to make their own choices about their prescriptions. This 
sense of empowerment may well influence prescribing decisions. 
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6.5.2.3. Prescribing in response to stressful situations 
One service user described being prescribed medication (in particular, increase in dose) in 
response to his situation rather than a medical issue. The service user had earlier described 
the valuable support he got from using his citalopram during a very stressful period in 
section 6.5.2.1 under the theme ‘antidepressants as a medical crutch’: 
  
Two days before New Year’s Eve, … I went to see me GP, got a special appointment, 
and… we discussed what was happening in my life [marital problems]… and he said 
“Look, if you’ve made that decision that you want to leave your home you’ve gotta 
leave”… So he upped the dosage [of Citalopram for depression] to 40mgs and he said 
“You come back in a week’s time and tell me how you feel... If you’ve made the decision 
you’ve made it, go do it. If you can’t do it then talk with your wife, cos from a… medical 
point of view, it’s really not a medical issue (ID 23, male, alcohol dependency). 
 
Prescribing in response to life stresses rather than a clear medical indication has raised 
concerns about unnecessary ‘medicalisation’ of life’s challenges (Baldwin et al., 2014; 
Horwitz and Wakefield, 2007). There is a growing trend to use mood-altering drugs 
including antidepressants to treat instances of human distress or emotional unhappiness 
(Heath, 1999; Manninen, 2006). It is possible that prescribing in response to life’s 
challenges and problems may be more common among people with SUDs because of their 
high levels of vulnerability. Their situations are often complex with family disruptions, 
social and economic deprivation being prominent features (Gossop et al., 1998; Lloyd, 
1998). The lifestyle of service users usually contributes to these problems and may result 
in demoralisation, a sense of distress and hopelessness (Action on Addiction, 2013) which 
prescribers may be tempted to ‘fix’ with a pill. Although this pattern of prescribing may be 
considered to be inappropriate in the sense that such medications are being prescribed or 
their doses increased in order to manage conditions for which they have no known 
efficacy, it may be appropriate in another sense if it provides support that assists the 
service user during such stressful periods.  
6.5.2.4. Assessment and review 
This theme came out when service users were asked about the assessment and review of 
their medications. The following sub-themes were described by service users: medication 
review, addiction to medications and fear of losing medications. 
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Medication review 
Eleven service users described regular review of their medications. One service user with a 
six-month history of sertraline use for postnatal depression described the fact that her 
medication is regularly reviewed:  
 
Yeah, … , I have reviews every, I think it’s every couple of months or every few months, to 
see if …, I’m still ok on the medication, so the GP knows that, … it’s working basically. I 
get reviews …, ever so often. So they can know that it’s doing what it’s supposed to be 
doing [ID 61, female, alcohol dependency]. 
 
Similarly, another service user who described a possible lack of indication for his 
paroxetine described regular review of his medication:  
 
It has been reviewed several times and, he said “I don’t want you to come off it just yet.” 
… and it’s due to be reviewed …, so he’s [GP] going to see me and review it [ID 15, male, 
alcohol dependency].  
 
One service user prescribed propranolol for anxiety disorder and dosulepin for anxiety and 
depression went on to describe the fact that he sometimes misses his review appointments: 
 
…sometimes I don’t honour … the appointments, I sometimes forget … they’re [GP] doing 
everything right on their side, obviously, but I’m just a bit lax with that … I’ve missed a 
couple of appointments now, you know [ID 21, male, alcohol dependency] . 
 
By contrast, three service users described lack of optimal practices regarding review of 
their medications. One service user with a five-year history of citalopram use for long-
standing depression described the fact that his citalopram is not reviewed regularly, and 
that he could easily obtain a repeat prescription without adequate monitoring: 
 
But what happens with GPs and practices,… you just become a repeat prescription, and I 
can go for a year without a review when they’re supposed to be every two months or every 
three, you know, …you can be left to sort of float around. And I can ring the chemist up 
and say “I need another script”. And he’ll go “right, OK” and it’s there two days later. 
You don’t have to go see a GP. But that’s always been the case, which is not really about 
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monitoring the effect of the drug, it’s more a case of, well you’re on it now, so just… keep 
taking it [ID 23, male, alcohol dependency]. 
 
Similarly, another service user who has a three-year history of co-codamol use for pain 
described the fact that his present GP has never enquired about his medications from him 
and just keeps prescribing them: 
 
… you know, my doctor, now though, I’ve been transferred now, for about eighteen months 
maybe, she’s just continued prescribing co-codamol, and I don’t think she’s ever asked me 
once why I’m on it ... Honestly, I don’t think she has [ID 16, male, alcohol dependency]. 
 
Another service user with a ten-year history of dihydrocodeine use for pain secondary to an 
operation on his spine described how his dihydrocodeine is rarely reviewed during his 
appointment for medication review with his GP: 
 
… you used to get review dates but very rarely they actually went through them, maybe 
once a year [ID 29, male, alcohol dependency]. 
 
The standards being followed in repeat prescribing as well as its safety have been issues of 
concern in primary care (Garfield et al., 2009; Taylor, 1996). Repeat prescribing has the 
advantages of saving time, convenience and reduction in the workload of prescribers (De 
Smet and Dautzenberg, 2004). However, the views expressed by some service users in this 
study clearly suggest that their repeat prescriptions were not being regularly reviewed.  
 
In addition, repeat dispensing (NHS Confederation Publication, 2013) where repeat 
prescriptions are managed by the patient’s pharmacy of choice was also a problem due to 
lack of review by a pharmacist. Without regular review of repeat prescriptions, patients 
may end up being stuck on unnecessary medications and may become dependent on 
medications that have such tendencies. Lack of medication review could make prescribed 
medications become inappropriate over time. A few service users described becoming 
dependent on their prescribed medications. Furthermore, it is also impossible to evaluate 
whether patients are still taking their medications with repeat prescribing. Consequently, 
lack of regular review of repeat prescriptions can lead to failure to detect and resolve drug-
therapy problems as well as drug wastage (Avery et al., 2000; De Smet and Dautzenberg, 
2004; Saastamoinen, Enlund and Klaukka, 2008).  
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Swinglehurst et al. (2011) in a recent ethnographic study that was carried out in primary 
care settings in the UK involving observation of interactions between doctors, receptionists 
and administrative staff concerning repeat prescribing routines, found that when patients 
taking repeat prescriptions attended the clinic for medication reviews prompted by their 
electronic records, clinicians sometimes described the reviews as unnecessary. They tended 
to enter the codes for medication reviews even when there was no formal review of 
patients’ medications during the appointment (Swinglehurst et al., 2011). As with the 
wider issue of communication discussed in section 6.5.2.5, this sort of behaviour by 
doctors may be more common towards people with SUDs and may contribute to 
inappropriate prescribing. 
 
Addiction to prescribed medications 
Two service users described being addicted to their prescribed medications as has been 
touched on above and another service user expressed concerns about the possibility of 
addiction to his medication. Two of the quotations used here have been previously used in 
section 6.5.2.2. They are used here because they describe this theme aptly. One of the 
service users who expressed concerns about the review of his medication (dihydrocodeine 
at a dose of 30mg, 1 to 2 tabs qds) also described having developed addiction to it as he 
takes more than his prescribed dose: 
 
I had said to me doctor, well when he were showing concerns about how many I was 
taking [Dihydrocodeine], and I says “well just stop ‘em and give me summat else.” And he 
says “No, you can’t because your body is…”. Basically I’m addicted to ‘em even though 
I… don’t feel addicted to ‘em, but apparently me body will crave ‘em if I just stop taking 
‘em [ID 29, male, alcohol dependency]. 
 
Another service user who had bought street zopiclone for some years before being 
prescribed it for sleep problems by his GP also demonstrated awareness of his addiction to 
zopiclone (3.75mg every other day): 
 
... I do appreciate that they [Zopiclone] are addictive, … but so’s smoking, so’s driving 
really fast, so’s doing a lot of other things [ID 57, male, alcohol dependency] 
 
There was also a service user with a six-month history of venlafaxine use for anxiety 
problems who expressed fear of becoming dependent on his antidepressant: 
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I know, I do realise at some point that in my recovery these tablets will… eventually have 
to be phased out, I don’t want to... become dependent on them [ID 7, male, alcohol 
dependency]. 
 
This finding is supported in the literature as service users in alcohol and drug services have 
reported problematic use of prescription-only medicines (POM) such as opioids, 
benzodiazepines and non-benzodiazepine hypnotics (National Treatment Agency for 
Substance Misuse, 2011). The issue of addiction to prescribed medications such as opioid 
analgesics is a recognised public health problem in countries such as the USA (Sehgal et 
al., 2012). Data from the UK suggests that there is an increase in the number of people 
seeking help for opioid dependency (Stannard, 2013).   
 
A contributing factor in the rise in opioid prescription misuse is the increase in opioid 
prescribing (Wisniewski, Purdy and Blondell, 2008). Risk factors for opioid dependence 
among those with chronic pain include a current or past history of dependence, type of 
opioid (short or long acting), dose and duration of opioids (Gourlay and Heit, 2008; Sehgal 
et al., 2012; Solanki et al., 2011; Sullivan et al., 2010). People with a history of SUDs have 
a higher risk of misusing prescription drugs (Simoni-Wastila and Strickler, 2004; Solanki 
et al., 2011). While people who are dependent on alcohol, who made up over 78% of 
service users in this SAS are unlikely to have the same drive or craving for opioids as those 
who are dependent on illicit opioids or those on opioid substitution therapy, there is still 
the possibility of misuse and dependence on prescribed opioids when used in chronic pain 
management (Substance Abuse and Mental Health Services Administration, 2011). High 
doses of opioids (greater than 120mg morphine equivalent per day) and short-acting 
opioids such as dihydrocodeine also increase risk of opioid misuse (Sullivan et al., 2010). 
Similar risk factors for dependence have been reported for non-benzodiazepine hypnotics 
such as zopiclone and zolpidem (Hajak et al., 2003).  
 
The dihydrocodeine and zopiclone dependence reported in this study may reflect a 
combination of factors such as co-existing SUDs, high dose and long duration of use of 
these medications. There is need to adequately monitor the medications of people with 
SUDs, especially those with dependence potential as it is possible for medications that 
were appropriately prescribed to become inappropriate over time. In addition, for chronic 
pain to be managed optimally, staff in pain clinics would need a basic competence in 
identifying and diagnosing dependence and also access to addictions consultation while 
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those working in addiction clinics need a basic knowledge of chronic pain management 
and access to pain clinic consultations (Action on Addiction, 2013).   
 
Fear of dependence on antidepressants has been reported among people using 
antidepressants with some patients believing that they could become dependent and thus 
altering their doses or even stopping them without involving their prescribers (Schofield et 
al., 2011). This implies that there is the need to address the misconceptions of service users 
about their medications so as to forestall unwanted outcomes such as non-adherence 
(Malpass et al., 2009). 
 
Fear of losing medications 
Two service users expressed their fears about losing their prescribed medications. One 
service user had expressed concerns about the review of his dihydrocodeine, demonstrated 
a sense of entitlement to it and also described being addicted to it. He however did not 
want his medication stopped although this was the intention of his GP: 
Well only thing it [Dihydrocodeine] does is kill the pain so at least I can get on with me life 
like without any pain. So yeah, if I don’t… take it I’d just be in constant pain…. and that’s 
the one thing they want to take off me (ID 29, male, alcohol dependency). 
Another service user previously described in section 6.5.2.2, who had a strong sense of 
entitlement to zopiclone and had been treated in hospital because he deliberately overdosed 
on his zopiclone and antidepressant (fluoxetine), expressed fears that his GP may not 
continue prescribing zopiclone for him due to his overdose: 
… cos I’ve always just gone and explained and had me medication [Zopiclone] given… to 
me. I just don’t know if I’m gonna get it… this time (ID 27, male, alcohol dependency). 
These quotations and their contexts highlight how difficult decision-making around service 
users’ medications could be for prescribers. Service users wanted continued prescribing of 
their medications because they met their self-perceived needs while their prescribers 
wanted to stop these medications for other reasons. Consequently, service users and 
prescribers had contrasting views about the appropriateness of prescribing decisions.  
 
Fear of the unpleasant and painful opioid withdrawal symptoms may make it difficult for 
people who are opioid dependent to reduce their dose or stop using them. While there may 
sometimes be a clear distinction between prescribing for pain and prescribing for 
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dependence, the difference is not always clear-cut (Action on Addiction, 2013; Rosenblum 
et al., 2008). For instance, it may be difficult to determine if opioids are being prescribed 
for pain relief, to prevent withdrawal symptoms or to satisfy craving (Action on Addiction, 
2013). Furthermore, treatment with opioids may worsen pain due to rebound pain 
occurring during withdrawal and opioid-induced hyperalgesia may also be a contributing 
factor (Action on Addiction, 2013). Generalised pain is a symptom of opioid withdrawal 
and during such withdrawal, pain sensitivity is higher (Action on Addiction, 2013). In 
addition, opioid-induced hyperalgesia has been observed in patients chronically treated 
with high dose of opioids for chronic pain (Angst and Clark, 2006). Ironically, 
hyperalgesia is only reversible through opioid dose reduction or cessation of therapy (Lee 
et al., 2011). Again, as has been touched on under the theme ‘addiction to prescribed 
medications’, these pieces of evidence highlight the need for clinicians in pain 
management to have basic competence in addiction medicine as well as access to addiction 
medicine consultations for optimal management and vice versa (Action on Addiction, 
2013). 
 
The challenge in managing complex patients such as those with SUDs is therefore to  
effectively engage the service user (Action on Addiction, 2013). Furthermore, there may 
be need to set boundaries when needed to prevent harm (Action on Addiction, 2013). 
Although appropriate prescribing entails respecting service user choice in decision-making, 
this has to be balanced against safety concerns in order to prevent medication-related harm.  
6.5.2.5. Discussion with clinicians and adverse effect of medications 
These themes came out when service users were asked about factors they consider 
important in assessing if their medications are ‘right’ for them. They are considered below. 
 
Discussion with clinicians 
Six service users described discussion with clinicians as a factor they consider important in 
assessing if their medications are ‘right’ for them. Below are two examples of quotations 
from service users who described talking and listening as factors they considered 
important: 
 
Talking to me, listening to me, asking me, you know, why I was feeling the way I was, was 
there anything that had triggered things off, that sort of thing [ID 35, female, alcohol 
dependency]. 
215 
 
Well like having a sit-down and talk with me doctor [ID 26, male, heroin dependency]. 
 
Another service user with a particularly strong sense of entitlement to his medication 
(zopiclone) described how this process provided an opportunity for him to express his 
views on what he wants: 
 
Oh sitting down, talking to him about sleeping tablets and what I want…, it’s up to me 
really [ID 57, male, alcohol dependency]. 
 
On the other hand, one service user described not being listened to:  
 
… I could do with something better for my anxiety but I don’t know what other medication 
I can get. I’m just taking what the doctor prescribed me. I feel like I could, it would be nice 
if they could give me something to help me relax more [mentions Temazepam later], you 
know what I mean, to calm me down but the doctor won’t prescribe anything for me like 
that [ID 5, male, heroin dependency]. 
 
Another service user described not being listened to and the short interval in which he was 
prescribed a medication:  
 
… So I was just telling the doctor basically what my problems were and was prescribed 
Paroxetine, yeah, Paroxetine,… I don’t think my GP probably listened and, yeah, listened 
and prescribed me a drug. I just went for a… five minute chat with my doctor … it was just 
I went … for a quick … meeting with my GP and told him my problems and sent away with 
a prescription [Paroxetine]… it was just, go to the doctor and off you go,… there’s your 
prescription off you go [ID 7, male, alcohol dependency]. 
 
The importance of communication in dealing with patients has been emphasized in 
previous studies (Hahn, 2009; Stevenson et al., 2004). Patients value being listened to, as 
part of a two-way communication. This helps to increase patients’ understanding of their 
medications and allows them to seek clarification where needed (Bultman and Svarstad, 
2000). It also promotes satisfaction with treatment options and improves adherence 
(Bultman and Svarstad, 2000; Siminoff et al., 2000). The responses of service users in this 
study highlighted the fact that many of them valued this two-way communication. 
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There were however other service users who described ineffective communication or 
dissatisfaction with their medications. This may be associated with challenging behaviour, 
suspicions concerning requests for prescribed drugs and/or wider stigmatisation of people 
with SUDs. People with SUDs have often been described as difficult, aggressive, 
manipulative and rude (Conway, 2000; McGillion et al., 2000; McKeown, Matheson and 
Bond, 2003) and consequently challenging to treat.  
 
Negative attitudes towards people with SUDs may result in them receiving poor quality 
care. For instance, service users may be denied needed medications due to their substance 
using status (Ahern, Stuber and Galea, 2007; Link et al., 1997). A qualitative study of 
problem drug users admitted to a hospital in the USA found that patients expressed 
concern about receiving poor medical care and described being intentionally mistreated 
due to their addiction (Merrill et al., 2002). Henderson et al. (2008) in a similar study of 
healthcare delivery to substance users in a hospital emergency department in USA 
concluded that care had a different tone or quality when patients had alcohol or drug 
problems.  
 
Evidence from this study shows that some service users were dissatisfied with prescribing 
decisions as their doctors did not listen to them. It has been suggested that prescribing may 
be used as a means of terminating difficult consultations (Britten, 1995). This may be more 
common in those with SUDs, especially in time-pressured settings such as general practice. 
In the UK, general practice consultations often last no more than10 mins (Bashir, King and 
Ashworth, 1994). People with SUDs are known to attend GP practices more frequently 
than other patients and GPs have often described these patients as time-consuming to 
manage due to their complex problems (Deehan, Taylor and Strang, 1997; McKeown, 
Matheson and Bond, 2003). Time pressure is a problem in most primary care settings 
(McKenna, Ashton and Keeney, 2004).  
 
A study by Tamblyn et al. (1997) showed that GPs are more likely to prescribe 
inappropriate medications during shorter consultations. In shorter consultations, GPs are 
less likely to ask questions concerning symptoms of the presenting illness, carry out less 
in-depth clinical examinations and are less likely to provide lifestyle advice compared to 
guideline recommendations (Tsiga et al., 2013). Conversely, longer consultations are 
associated with less prescribing and increased lifestyle advice (Wilson and Childs, 2002; 
Wilson et al., 1992). This suggests that where service users with SUDs do have their health 
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conditions reviewed, GPs may prescribe without careful assessment and prescriptions may 
therefore be inappropriate. 
 
Adverse effect of medications 
One service user who was on two prescribed medications (six-month history of venlafaxine 
and five-month history of disulfiram use) described the fact that he does not want to 
experience adverse effects from the use of his medications: 
  
...Just, yeah, make sure I don’t have any adverse effects… Just make sure I wouldn’t have 
any reaction. As with any other drugs that I’m taking, like make sure, my doc, it’s OK 
taking different drugs at,… the same time [ID 7, male, alcohol dependency]. 
 
Adverse effects resulting from medications are a problem among patients in general. They 
have been implicated in 6.5% of admissions in England (Pirmohamed et al., 2004). One of 
the risk factors for adverse drug events is polypharmacy as it increases the potential for 
drug-drug interactions (Gandhi et al., 2003). Adverse effects emanating from combining 
medications with substances could have dire consequences for people with SUDs. Since 
polypharmacy may be the norm rather than the exception among service users compared to 
patients in the general population due to multiple comorbidities (Dickey et al., 2002), there 
is the need to ensure that unnecessary medications are not prescribed to foreclose the 
possibility of dangerous drug interactions. 
6.5.2.6. Quality of life   
This theme arose when service users were asked about their views concerning changes 
made to their medications and the influence of this on their quality of life. Service users 
described one element: improved quality of life. 
 
Improved quality of life 
All the eight service users who had medication changes described these changes as a 
positive event that improved their functioning. Some service users had their medications 
changed due to their adverse effects while others were changed due to lack of effect. One 
service user with a six-month history of sertraline use for postnatal depression who has had 
two previous antidepressants described the change to sertraline as being beneficial. Her 
past antidepressants were not effective for her depression: 
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… I feel glad that they realised that they weren’t working for me, because I didn’t... feel 
myself when I was on, like, the Fluoxetine, and …, I was getting wound-up with myself 
because I wanted to feel better but I didn’t know how, which is what prompted me to go to 
the GP and ask if there’s any other medication I can take, because I... do want to feel, I 
don’t know if the right word is normal, but. I just wanted to feel like everybody else, and I 
knew that the fluoxetine, it didn’t seem to be making my moods any better, and I’d see 
people that were out and about and happy, and…, I’d just want to be like them, which the 
sertraline is… doing for me, cos I do go out a lot more now than what I used to, so it seems 
to be working [ID 61, female, alcohol dependency]. 
 
Another service user prescribed a supra-BNF dose of olanzapine for long-standing 
paranoid schizophrenia described the negative effects of his previous medication 
(fluphenazine decanoate) and benefits from the change of his antipsychotic from 
fluphenazine decanoate injection to olanzapine: 
 
They’ve been for the better. Olanzapine has been easier to cope with than carrying… 
hypodermic syringes of modecate [Fluphenazine decanoate injection] around …anything 
was… better than the painful injections which eventually, you know, 75mgs of 
Fluphenazine decanoate wasn’t working, the psychotic symptoms were coming through, 
even on 75mgs a week. But as soon as I was put on 25mgs of Olanzapine a day, at night, 
all slight psychotic symptoms disappeared [ID 18, male, alcohol dependency]. 
 
Similarly, one service user described changes to her medications as a result of their 
untoward effects: 
 
I’ve had Citalopram, oh I can’t remember the name (pause)... it was something that began 
with... V, but… that made me lose so much weight that they had to take me off it because it 
affected me in a way that I just didn’t want to eat, I didn’t want to do anything. They’ve 
tried several different antidepressant medications and this is the one [Fluoxetine] that I’d, 
seems to suit me best at the moment [ID 35, female, alcohol dependency]. 
 
Another service user who had earlier described the benefits from his citalopram as 
outweighing the sexual dysfunction it causes also described the presence of side effects as 
the reason why his previous antidepressants were changed:  
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I’d take it [Dosulepin] on an evening and it just wiped me out, and I was almost like a 
zombie, you know, … I had to take it on a night to sleep, not to sleep, but I took it on a 
night because it made me go to sleep and, and I couldn’t possibly function outside that 
during the day. So eventually came off that and then they put me onto things like Prozac 
[Fluoxetine], which was not a good drug for me. It… just, libido went up through the roof, 
self-control went out of the window, and that was a poor drug to be on... Citalopram’s 
been great. Easy to work, you know, …easy to take, it doesn’t make me drowsy [ID 23, 
male, alcohol dependency]. 
 
Medication changes were viewed positively by service users. Patients taking psychiatric 
medications often have their medications changed over the course of their illness due to 
factors such as side effects and lack of effectiveness (Buckley and Correll, 2008; Mitchell 
and Selmes, 2007a). Such changes often lead to improved functioning in patients’ lives 
(Kartalova-O'Doherty and Doherty, 2011). The findings of this study suggest that service 
users’ views on the appropriateness of their present medications are influenced by their 
previous experiences with other medications. They may be more willing to tolerate side 
effects from their present medications if they feel that it improves their functioning 
compared with previous medications. Furthermore, they may view present prescribing 
decisions to be appropriate if it provides benefit irrespective of whether such prescribing is 
outside guideline recommendations.     
6.5.2.7. Adherence 
Service users described different levels of adherence when discussing how their 
perceptions of their medications influenced their adherence. 
 
High level of adherence 
Eight service users who all described their medications to be effective also reported a high 
level of adherence to them. One service user with a 12-year history of olanzapine use for 
long-standing paranoid schizophrenia described adhering to his olanzapine in order to 
prevent a recurrence of his psychotic symptoms: 
 
So in other words, I don’t want to go back to those days again... hallucinating and… 
having psychotic thoughts, that’s why I religiously take all me medication every day [ID 
18, male, alcohol dependency]. 
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Similarly, another service user with a six-month history of sertraline use for postnatal 
depression described adhering to her sertraline: 
 
I take them [Sertraline] every night. I take ‘em all at the same time, every night. It’s usually 
at about, between nine and ten o’clock, on a night time, so I’ve got into the routine of 
taking them all at the same time so I don’t forget any [ID 61, female, alcohol dependency]. 
 
Three service users described their medications to be suboptimally effective but still 
reported a high level of adherence to them. Below are examples of quotations from these 
service users: 
 
...and that’s one of the reasons why I was put on paroxetine, to see if it could lift that 
general mood. But it hasn’t and I’m just going round in a circle, every month go for me 
prescription, take the tablets on a daily basis [ID 15, male, alcohol dependency]. 
 
I’ve got to… take it [Zopiclone] to try and get that sleep and hope I do go to sleep and …, 
not wake up till morning, but it don’t happen, it just doesn’t happen [ID 27, male, alcohol 
dependency]. 
 
Variable level of adherence 
Four service users reported variable adherence to their medications. Two of them reported 
their medications to be effective but reported variable adherence to them. One of such 
service users prescribed co-codamol for pain secondary to an operation on his spine and 
who also described being addicted to his medication, reported going above the prescribed 
dose depending on the level of his pain: 
 
I’d say the minimum [Dihydrocodeine] would be two to three and the maximum has gone 
eight to ten, depending on how much pain I were in… but I might not take ‘em separately, I 
might take two, two at a time instead of just the one, to take the pain away faster [ID 29, 
male, alcohol dependency]. 
 
Another service user with a three-year history of co-codamol and citalopram use for 
chronic pain and PTSD respectively as well as a three-month history of disulfiram use for 
alcohol relapse prevention also reported variable adherence to his different medications: 
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high levels of adherence to the co-codamol and disulfiram because he finds them effective 
and variable level of adherence to citalopram because he is uncertain about its benefits: 
 
The Co-codamol I take regular, the Lansoprazole regular, the Ci-[citalopram], hit or miss 
with that, because I don’t know if it’s doing me any good, to be quite honest with you. I 
know the effects of the Co-codamol and the Lanso-[Lansoprazole],… I need it, so I do take 
it regular, very rarely miss…Is it [Citalopram], is it doing any good? I probably, 
personally think it isn’t, I’ve no need to be on it,… and that’s why, subconsciously, I’m not 
taking it regularly, if you understand what I mean, I don’t think it’s important [ID 16, 
male, alcohol dependency]. 
 
One service user described above (ID 27, male, alcohol dependency) reported that he 
sometimes forgets to take his antidepressant (fluoxetine) due to his use of multiple 
medications and alcohol use: 
 
Yeah, yeah… some days … I have forgot to take it because I’m on… that many different 
ones and different things, it’s like, phew, and some days you… do get a bit cheesed off with 
‘em, cos I struggle to take ‘em anyway. But some days if I’ve gone out, gone out and got 
drunk I’ve forgot [ID 27, male, alcohol dependency]. 
 
For patients to benefit optimally from their medications, they need to take them as intended 
(Cramer, 2004). Patients’ perceptions of medications have been found to influence their 
level of adherence (Byrne, Regan and Livingston, 2006; Chao et al., 2005; Mann et al., 
2009). In the interviews carried out with service users, all those who perceived their 
medications to be effective described a high level of adherence to them. There was also 
evidence of misuse of a prescribed opioid medication as a service user who had earlier 
described being addicted to the medication reported going above the recommended limit.  
 
Lack of benefit from medications may lead to non-adherence and ultimately 
discontinuation of treatment (Holt, 2007). However, patients who believe their medications 
might still help may continue treatment (Malpass et al., 2009). This was reflected in this 
study as a few service users continued treatment despite their suboptimal benefits. Most 
service users appeared to have consciously made decisions about whether to take their 
medications, modify their adherence or even stop taking their medications according to 
their beliefs about their efficacy. Although mental health conditions such as psychotic 
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disorders could negatively affect service users’ adherence due to lack of insight and stigma 
(Chan et al., 2014; Higashi et al., 2013; Mitchell and Selmes, 2007a), it is possible that 
service users who find their medications beneficial may continue to take them to maintain 
their mental stability. Adherence may be negatively affected by substance use (Sajatovic et 
al., 2006) and polypharmacy (Murray and Kroenke, 2001). Sajatovic et al. (2006) reported 
that bipolar patients with a current SUD were more likely to be non-adherent compared to 
those without SUDs. This may be due to factors such as intoxication and poor judgment 
resulting from active SUDs (Sajatovic et al., 2006). 
6.5.2.8. Summary on service users’ interviews 
Service users generally described improved functioning as a result of their medications 
though there was also an awareness of the adverse effects they experienced from them.  
Consequently, they sometimes described making compromises between the risks and 
benefits of their medications, with self-perceived benefits outweighing adverse effects. 
Lack of benefit or suboptimal benefit was sometimes described when using alcohol with 
antidepressants.  
 
There was evidence that the appropriateness of prescribing is an area of conflict and 
depends on whose views are being represented. Service users’ views often differed from 
the medical view represented in guidelines and those of prescribers, with improved 
functioning being paramount to them. The findings of this study suggest that prescribing 
decisions are sometimes made in response to stressful life events rather than a clear 
medical indication. It also appears that people with SUDs have a particularly strong sense 
of their own needs and seek to influence prescribing decisions. While this sense of 
empowerment may negatively influence decision-making leading to inappropriate 
prescribing, such prescribing decisions may well be appropriate in another sense if they 
prevent disintegration and disruption of the lives of this vulnerable group of people.     
 
Service users described differing practices regarding the assessment and review of their 
medications. While some service users described regular reviews, others identified 
suboptimal or inadequate practices. Repeat prescribing or dispensing without adequate 
monitoring or review may result in poor quality care as such service users may become 
stuck on unnecessary medications or become dependent on those with such tendencies. 
Lack of regular review therefore represents a missed opportunity for identifying 
medication-related problems (NHS Confederation Publication, 2013). 
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Service users further highlighted the importance of talking and listening to them (under the 
theme “discussion with clinicians”) during their consultations. Some service users 
described not being listened to and resulting dissatisfaction with prescribing decisions. 
This may be associated with service users’ challenging behaviour, suspicions by 
prescribers or a wider stigmatisation of service users. One factor that may contribute to 
lack of careful assessment/review and ineffective communication in general practice is 
time constraint. The findings of this study revealed that a service user considered the time 
period in which he was prescribed an antidepressant medication in a GP consultation as 
“too short”. The busy workload of GPs coupled with the complexity of people with SUDs 
may result in situations where GPs prescribe without careful assessment, resulting in 
inappropriate prescribing. Time constraints may also preclude the use of non-
pharmacological interventions (for example, the provision of lifestyle advice, such as 
alcohol abstinence and advice on sleep hygiene) in busy general practice settings though 
they may assist in improving symptoms of mental disorders. 
 
Service users viewed changes to their medications positively if they led to better 
functioning. Most service users who derived benefit from their medications reported a high 
level of adherence to them compared to those who did not. While there was evidence of 
misuse of some prescribed medications, service users appeared to have chosen to adhere to 
their medications or modify their use according to their own beliefs of what works best or 
is appropriate for them. Chapter 7, section 7.3.8 presents the researchers’ reflections on the 
quality (in particular, validity and transferability) of these interviews. 
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Chapter 7: Qualitative interview studies 
with SAS prescribers: methodology, 
results and discussion 
7.1. Introduction to the chapter 
This chapter presents the qualitative research methodology adopted for interviews with 
SAS prescribers, the result and the discussion of its findings. The purpose of qualitative 
research has already been described in section 6.1. Qualitative interviews have a place in 
prescribing research as they can be used to illuminate the factors that influence prescribing 
decisions (Stevenson et al., 2000). The phenomenological perspective (Green and 
Thorogood, 2004) adopted in this thesis argued for the use of interviews as a research 
method because of the need to explore how prescribers understood and responded to 
inappropriate prescribing. In particular, semi-structured interviews were employed in this 
study.  
 
The study rationale, design, research questions addressed, sampling strategies, recruitment 
methods and topic guide development are presented in section 7.2. The ethical process, 
interview process, data analysis and storage plans were similar for both the prescriber and 
service user interviews and would not be described again in order to avoid unnecessary 
repetition. The ethical process has been described in section 6.3 while details of the 
interview process, data analysis and storage plans are provided in section 6.4. 
7.2. Interviews with prescribers: rationale, study design, 
research questions, sampling, recruitment and topic guide 
development 
7.2.1. Study rationale  
As shown in the scoping review in chapter 2, there has been a paucity of research into 
prescribers’ views on the appropriateness of prescribing of psychiatric medications and 
opioids for people with SUDs. Furthermore, how prescribers in a SAS respond to 
inappropriate prescribing among the service users they treat is unknown. The evidence 
suggests that service users in these settings usually have comorbid conditions (Delgadillo 
et al., 2012; Marsden et al., 2000; Weaver et al., 2003) and are on multiple prescribed 
medications (Oluyase et al., 2013), with the potential for unnecessary prescribing and 
dangerous drug interactions. Medications such as benzodiazepines, opioids and 
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antidepressants have been implicated in overdose incidents and mortality in people with 
SUDs (Darke, Duflou and Torok, 2011; Darke and Hall, 2003; Darke and Ross, 2000). The 
prescribers in this setting represent a particularly apposite group for exploring questions 
around prescribing appropriateness due to the large number of medications their patients 
take.  
7.2.2. Study design 
This study involved semi-structured interviews with 12 prescribers who were working at 
the SAS. Four of the interviewed prescribers were nurses while the remaining were doctors 
of varying seniority (see section 7.3.1). One-on-one interviews were used because it would 
be very difficult to get time-pressed clinicians together for a focus group discussion. Group 
interviews were also considered to be unnecessary since interactions within the group may 
be prohibitive (Crawford, 1997) to some prescribers. 
7.2.3. Research questions 
Prescribers’ interviews explored how they responded to inappropriate prescribing. The 
following research questions were addressed: 
 
1. How do prescribers at the SAS assess the appropriateness of prescribed 
medications, and how are changes made? 
2. What factors are considered before initiating changes to service users’ medications? 
3. How has the MAI impacted prescribers’ practices? 
7.2.4. Sampling strategy 
In line with qualitative research inquiry, the aim of the sampling strategy adopted in this 
study was to recruit respondents who can provide valuable insight into the topic and also to 
provide a broad overview of the perspectives of different prescribers (nurse prescribers and 
doctors). All but two prescribers working at the SAS during the study duration took part in 
the interviews. One prescriber was not interviewed due to time limitations while another 
prescriber was not invited to take part in the interviews because he left the SAS before the 
interview phase began. The similarities and differences between nurse prescribers and 
doctors in the topics explored are considered in the presentation of results and discussion.  
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7.2.5. Recruitment 
The researcher distributed participant information sheets (appendix 7.1) to all prescribers 
working at the SAS. It contained information about the medication appropriateness study 
and the interviews. All prescribers who consented and participated in the medication 
appropriateness study were informed that they would be subsequently interviewed. 
Interviews were organised with prescribers before they left the SAS if they were on short 
rotation or at the completion of the medication appropriateness study if they were 
permanent staff. All interviews were arranged to take place at a convenient time for 
prescribers at the SAS.  
7.2.6. Developing the topic guide for interviews with prescribers 
The topic guide for prescribers (appendix 7.2) was designed to cover the following areas: 
assessment of prescribing appropriateness: types of inappropriate prescribing encountered, 
factors considered when assessing prescribing appropriateness, challenges encountered and 
interventions made concerning inappropriate medications; negotiation of medication 
changes with service users as well as impact of A-MAI on prescribing. The opinion of the 
researcher’s academic supervisors and one of the consultant psychiatrists at the SAS were 
sought about the topic guide. Minor changes were suggested such as clarifying the reason 
for the interview. All areas covered were developed into questions. The questions were 
piloted with the researcher’s academic supervisors who suggested a few changes such as 
re-wording and re-ordering some of the questions. The changes suggested were carried out 
before the researcher began interviewing prescribers. 
 
7.3. Results and discussion 
7.3.1. Prescriber characteristics 
There were fourteen prescribers who worked at the SAS during the duration of this study 
consisting of four nurse prescribers and ten doctors. The doctors had different grades: one 
senior house officer (hereafter SHO), one locum doctor, five specialist registrars (hereafter 
SPR) training to be consultant psychiatrists and three consultant psychiatrists. Thirteen of 
the 14 prescribers were invited to take part in the interviews and all but one of those 
invited were interviewed. One SPR was not interviewed due to time limitations and 
another SPR was not invited to take part because he left the SAS before the interview 
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phase began. Consequently, the sample of prescribers interviewed consisted of four nurse 
prescribers, one SHO, one locum doctor, three SPRs and three consultant psychiatrists. 
 
The interviews took place at the SAS and lasted between 36 and 74 minutes (48.1 + 12.5). 
The difference in interview time was as a result of the varying length of time that 
prescribers spoke. The interview length was not found to be related to the number of years 
of experience in addiction. The topic guide was covered during all the interviews. The 
prescribers represented a broad range of qualifications and experience in the addiction 
field. Three of them had no prior experience of practicing in addiction specialty but the 
remaining nine prescribers had prior experience of addiction specialty ranging from 6 
months to 35 years. Other characteristics of prescribers are described below: 
 
Nurse prescribers 
One male and three female nurse prescribers took part in the interviews. They had 
practiced as nurse prescribers in addiction specialty for between one and five years and as 
nurses in addictions for between five and twenty-two years. Their ages ranged from 34 to 
55 years. 
 
Doctors 
Six male and two female doctors took part in the interviews. Three of the male doctors 
were consultant psychiatrists. While two doctors had no prior experience of working in an 
addiction specialty before coming to the SAS, others had between six months and thirty-
five years of experience. Consultant psychiatrists in particular, had between three and 35 
years of experience in addiction specialty. Doctors’ clinical practice ranged from between 
six and 41 years. Their ages ranged from 31 to 65 years.  
7.3.2. Assessment of the appropriateness of service users’ medications 
As discussed in section 3.2, service users are referred to the SAS from different sources: 
namely GPs, psychiatrists, hospital, social services, drug services, community mental 
health teams as well as the criminal justice system. Some service users also self-refer.  
Information such as the service users’ demographics, health conditions and medications are 
obtained from all referred service users by SAS staff and are included on the referral form. 
All referred service users are sent a self-completion booklet where they document their 
demographics, health conditions and prescribed medications amongst other information 
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before coming to the SAS. Those who come to the clinic without the booklet are given a 
new copy to complete before they are assessed by keyworkers (including prescribers).  
 
Evidence obtained from a senior SAS staff suggested that new referrals to the SAS are all 
screened by a nurse on the basis of their referral information, in order to assign service 
users to one of the three teams (hospital team, dual diagnosis team, pregnancy and 
parenting team) and also determine whether the person should be seen by a doctor. 
Allocation to a doctor was said to be based on complexity and, in particular, any 
prescribing issues. Where a service user is not required to be seen by a doctor, allocation to 
nurse prescribers and other therapists was decided by the SAS team organising the clinic. 
The findings of the medication appropriateness study (see section 5.9.6) and evidence 
obtained by the researcher suggests the allocation system described above was not always 
implemented. The researcher observed that receptionists tended to allocate service users to 
doctors, nurse prescribers and other keyworkers in all the three SAS teams on their clinic 
days.  
 
Each team has its own clinic day where new referrals are assessed. The keyworker (nurse 
prescriber, doctor or other therapists) carries out the baseline assessment which involves a 
45 to 60 minute comprehensive assessment of the service user. All keyworkers including 
prescribers are expected to complete booklets relating to their assessment of the service 
user (including filling in a care plan) after the consultation. Keyworkers also provide a 
summary of their assessment to the secretary of their team who has the responsibility of 
typing and documenting it in the service user’s folder. Keyworkers will also need to attend 
to existing service users who they have scheduled appointments with. The clinic is 
therefore usually busy for keyworkers and participation in this research made extra 
demands on their already tight schedule. Service users are usually followed up by the same 
prescriber throughout the duration of their treatment. 
 
Depending on the referral source, prescribers have varying levels of information when 
assessing service users. With the exception of service users referred from GPs, the 
information available is usually only that documented in the self-completion booklet and 
the referral information. Prescribers may also seek clarification directly from the service 
user or contact service users’ GPs if considered necessary. Service users referred by their 
GPs usually have a GP summary in addition to their completed booklet. The summary 
usually includes a brief outline of the medical and medication history of the service user. 
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Interviews with prescribers provided an exploration of the process of clinical decision-
making that prescribers go through in order to assess the appropriateness of medications 
prescribed by others, since the medications that service users arrive with would have been 
prescribed by a range of practitioners in different settings. The focus of this thesis is on 
judgments made about service users’ current medications by prescribers in the SAS, rather 
than the original decisions made by prescribers elsewhere. It would have been very 
difficult to trace the original prescribers and this was beyond the resources of this thesis. 
Prescribers were therefore asked how they assess the appropriateness of prescribing at the 
SAS and the following themes emerged: review of medications, assessing risk, guideline 
adherence versus successful prescribing, history-taking, communication, lifestyle change, 
adherence, addiction and understanding the relationship between SUDs and mental health 
disorders. 
7.3.2.1. Review of medications 
The classes of medications reviewed varied among prescribers with only three of them 
stating that they reviewed all of service users’ medications for their appropriateness. These 
three prescribers were doctors (two consultants with 12 and 41 years prescribing 
experience and a locum doctor with 16 years of prescribing experience): 
 
So I’d… look at the list of drugs prescribed and see how they matched up to what I thought 
the person was…  showing in terms of… addiction illness,… physical illness and mental 
illness, and then I’d look at those that… I would look to prescribe and look at the ones that 
other people might prescribe, […] and link up with the other prescribers if I didn’t think 
what was going on was appropriate, but link up with the other prescribers anyway to let 
them know what I’ve done [P3, consultant]. 
 
Classes such as antidepressants, antipsychotics or that sort of thing. I mean, I would think 
anything, any medications could be covered, so. Nothing is excluded, I would say all the 
medications… just because they come here for addiction doesn’t mean we don’t look at 
them as a whole. So I would say any medication. I mean you’ll look at them the same way 
you would look at them, see, if you were the GP, you just look at… the whole presentation 
[P5, locum doctor]. 
 
In addition to psychiatric medications, the third consultant psychiatrist reported reviewing 
a relatively narrower group of medications when compared to the other consultants: 
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It would be mainly antidepressants, antipsychotics, anxiolytics, mood stabilisers. We would 
also be reviewing certain physical health aspects such as proton pump inhibitors, some 
basic review of antihypertensives, because alcohol, particularly alcohol withdrawal has an 
effect on your blood pressure, and alcohol consumption as well, and sometimes blood 
pressure completely resolves once the individual refrains from drinking… We also, of 
course, review the prescription of analgesia, the appropriateness of that, particularly 
opiate-based analgesia, and substitute prescribing [P7, consultant]. 
 
The remaining eight prescribers reported that they reviewed only medications within their 
areas of expertise: 
 
…we tend to, well I mean at least me, tend to concentrate more on psychotropic 
medications, unless otherwise we are aware that their other medications for physical 
health problems are interfering with psychotropic medications [P8, SPR]. 
 
I think for… each patient that I see, usually, whether it’s a new patient or… review patients 
then… I assess the medication and, well not medication that they are getting for their 
physical health but… for mental health and for substance misuse I’ll do [P13, SPR]. 
 
Nurse prescribers (NPs) also described a limited remit of prescribing and consequently 
focused on medications within their scope of practice during reviews: 
 
For… me it would just be the, the small range of, you know, detoxification and relapse 
prevention in relation to alcohol. Anything else it’s what’s prescribed by the GP, … I don’t 
review that or question that. If the GP’s seen fit to initiate it then I don’t see that it’s my 
place to… say otherwise [P6, NP]. 
 
So I… don’t really see, with psychiatric medication, that that would be within my… remit 
really. If somebody came and they were prescribed 100mgs of Methadone and they 
couldn’t even open their eyes then, yeah, I could, you know, I would be assessing the… 
appropriateness of the dosage and making necessary adjustments to things like that [P10, 
NP]. 
 
Nurse prescribers further described involving doctors at the SAS or service users’ GP if 
they had particular concerns about clinical management: 
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As I say, if I was particularly concerned about someone’s mood… or… I have particular 
concerns about the medication I would… defer to a medic. You know, it’s… not an area I 
feel strongly confident on [P6, NP]. 
 
Again, I think if I thought there was something that wasn’t right I would be asking a medic 
to have a look at that patient, I wouldn’t be making any changes myself [P10, NP]. 
 
I’d probably look at it [medications] at the…initial assessment and if there’s anything that 
comes up or that was sort of glaringly obvious …, I’d refer to the GP and … ask the GP to 
review, if they’re prescribing, because obviously they’re putting their signature to the 
prescription and I think it’s up to them to… review that [P11, NP]. 
 
The practice of medication review therefore varied considerably among prescribers. When 
compared to less experienced prescribers, the most experienced doctors (consultants and 
the locum doctor) in this study tended to review all service users’ medications presumably 
due to their more extensive clinical knowledge. Other doctors and nurse prescribers tended 
to focus on medications within their remit, with the former considering their expertise to be 
largely around psychiatric medications, addiction medications and sometimes opioids, and 
the latter describing their expertise as being limited to addiction medications. The focus of 
prescribers on only medications within their remit may result in fragmentation of service 
delivery (Detsky, Gauthier and Fuchs, 2012).  
 
Although nurse prescribers described referring service users who they had concerns about 
to SAS doctors or GPs, their limited area of competence implies that inappropriate or 
problematic prescribing of psychiatric medications and opioids may sometimes not be 
picked up by them. This finding is particularly important because evidence from the 
medication appropriateness study (see section 5.9.6) suggests that service users assessed by 
nurse prescribers and doctors were not significantly different in the number of prescribed 
medications they were taking. Consequently, it appears nurse prescribers were assessing 
service users with complex medication regimen. 
 
7.3.2.2. Assessing risk 
The evaluation of risk is a theme that was highlighted by all prescribers as a means through 
which they assess the appropriateness of service users’ medications. All the twelve 
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prescribers said they considered the risk posed by a medication, including drug-drug 
interactions and drug-disease interactions, when assessing its appropriateness. Prescribers 
tended to consider the issue of risk particularly carefully because the service user group 
they treat are people with SUDs. Some of the quotations relating to risk assessment 
captured this: 
  
Well if it’s going to do ..., first of all, less harm than the actual substance, not more harm, 
that’s a possibility in pregnant people, people with liver disease, advanced kidney disease 
or heart problems,… any multi, lots of organ problem, or near organ failure then, so the 
actual prescription  can… be worse than… doing nothing ... but mostly… you’re doing less 
harm [P5, locum doctor]. 
 
One prescriber described a service user who she felt had an inappropriate and high risk 
prescription of olanzapine (an antipsychotic). The service user was an elderly man who 
was being prescribed olanzapine (25mg) at a dose higher than that stated in the BNF 
without monitoring by a psychiatrist: 
 
[…] I have a… patient on my caseload who has a very old diagnosis of paranoid 
schizophrenia dating from his late teens, and he’s now in his sixties, and for this he’s 
prescribed a very high dose of medication called olanzapine, which is an antipsychotic, 
which has quite a few well known side-effects, and he’s prescribed over the limit in the 
British National Formulary… and he’s not under the supervision of a specialist, which he 
should be. So I would label that as an inappropriate prescription because (a) he’s elderly, 
which means that he’s more prone to… cardiac disease, and the drug, because it has high 
metabolic complications, can cause diabetes which can lead to heart disease. It can cause 
arrhythmias, he’s not being monitored regularly with regards to that, and he’s not being 
monitored with regards to his clinical symptoms, which, you know, are actually, from a 
psychosis point of view, negligible [P12, SHO]. 
 
The SHO described contacting the service user’s GP concerning the antipsychotic 
medication. His GP refused to alter it due to the service user’s stability on the dose for a 
prolonged period and lack of psychotic symptoms. There was therefore no change made to 
the antipsychotic.  
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Risks posed by interactions between prescribed drugs and substances were also highlighted 
by prescribers as well as the need to address such risks: 
 
For example, if somebody came into treatment and they were on, I’ll use methadone and 
alcohol cos it’s an easy example. So if they were prescribed methadone for opiate 
dependence, and there was no evidence that they were using opiates on top of that 
prescription but they were drinking twenty units of alcohol a day, the first thing I would 
want to do is, is reduce the risk to that person’s health, and the… first line that I would 
take is, right, that person needs to stop drinking. So you would have the appropriate 
intervention for them to stop drinking: could be detoxification …  if X amount of time… 
down the line this person’s drinking heavily, on top of a methadone prescription, and 
shows no motivation to change their alcohol use, then I would have to consider whether 
methadone needed to be reduced and stopped because of the risk to that person’s health 
[P10, NP]. 
 
It depends on the risk involved. If we’re… prescribing, if I use methadone, let’s say, for an 
example, and somebody’s using heroin on top of the prescription and maybe drinking 
dependently and there’s lots of other risky things going on and that behaviour doesn’t 
change, then to continue prescribing would be dangerous and we’d have to look at 
reducing that down and stopping that prescription… obviously the risks outweigh not 
doing anything [P11, NP]. 
 
Similarly, risks posed by drug-drug interactions were highlighted by prescribers: 
 
… for example, you know, if somebody’s taking citalopram and they are on aspirin that is 
… also a concern for me and I will be looking at that and be exploring with the patient 
because of the … risk associated  [with] bleeding. So, you know, obviously there are 
certain medications very explicitly we know are not the best combinations so we will be 
obviously assessing their suitabilities [P8, SPR]. 
 
The fact that risk assessment was mentioned by all prescribers is not surprising as medical 
practice emphasizes the need to evaluate the risk and benefit of therapeutic decisions 
(Pantilat, 2008). In medical ethics, the Principle of Beneficence and Nonmaleficence aims 
to produce net benefit over harm (Beauchamp and Childress, 1989; Gillon, 1994). The use 
of medications among service users with SUDs sometimes raises complex clinical and 
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ethical issues. For instance, the principles of beneficence require that all persons have 
equal access to effective medications (Cohen et al., 2002). This can however come into 
tension with the nonmaleficence principle when the presence of SUDs raises concerns 
about potential harmful interactions that could occur between medications and substances.  
 
Furthermore, as seen in the case of the service user with schizophrenia described above, 
there is sometimes conflict between balancing effectiveness and risk (Barber, 1995). While 
higher-than-recommended doses of antipsychotics may be needed to effectively manage 
psychotic symptoms, it carries significant risks of antipsychotic-related adverse effects 
(Royal College of Psychiatrists, 2014b). Furthermore, this evidence also highlights how the 
views of different prescribers could differ concerning prescribing appropriateness. While 
the SAS prescriber with a more limited overview of the circumstances of antipsychotic 
prescribing was focused on the potential risks of high dose prescribing, the GP presumably 
with a deeper understanding of the circumstances of prescribing was of the opinion that the 
benefit of the high dose of antipsychotic exceeded the risk and therefore made no change 
to its dose.       
  
Risks posed by medication-substance interactions such as interactions between 
medications and alcohol and illicit drugs have been implicated in many adverse events 
among substance users. For example, benzodiazepines and alcohol are usually involved in 
opioid-related overdose and fatalities (Darke, Duflou and Torok, 2011; Darke and Hall, 
2003). Antidepressants in combination with CNS depressants such as alcohol, 
benzodiazepines and opioids have also been associated with mortality in the UK (Cheeta et 
al., 2004). Furthermore, substances such as alcohol could result in hepatic impairment 
(Osna, 2009), thereby inhibiting the ability of the liver to metabolise medications. Harm 
resulting from medication use may be more common in people with such impairment 
(Amarapurkar, 2011). Consequently, safety measures such as regular monitoring and 
assessment of the appropriateness of prescribed medications should be in place in order to 
avoid doing harm to service users.  
 
7.3.2.3. Guideline adherence versus successful prescription 
Eight prescribers mentioned guidelines when assessing the appropriateness of prescribing: 
 
And during the comprehensive assessment you try to get more information about why they 
were prescribed certain medication, why they think they were prescribed, what the class of 
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that medication is, for how long they’ve been having it, the dose of the medication and 
what… the effects are now, and then all that information is collated and then taken back 
and… then measured against the guideline… to see whether we think… there’s some 
inappropriateness or not, yeah [P7, consultant]. 
 
…or sort of somebody that’s got maybe a very mild sort of low mood but not what you 
would say depression, and being prescribed high dose of … antidepressants over long 
periods of time. Inappropriate lengths of time, longer than, for example the, the guidelines 
would suggest is necessary, or it’s not being reviewed and you just go on and on [P5, 
locum]. 
 
Five of the eight prescribers acknowledged that prescribing may not be in conformity with 
guidelines for a variety of reasons. One doctor described a situation where a service user is 
struggling: 
 
… we shouldn’t be blindly following a set protocol and not swaying… from it, when you 
very clearly see the individual is… struggling [P7, Consultant]. 
 
Other prescribers described the importance of the circumstances of prescribing: 
  
And I think any comment about any prescribing should only be made when you know about 
the circumstances in which the decision was made because I think it’s… very easy to 
criticise another person’s prescribing unless you’ve looked at the circumstances when they 
started the prescribing and whether it’s been reviewed and so forth, and whether they think 
you should continue. For example, we prescribe very high doses of some drugs, now some 
people say that… you shouldn’t prescribe at those levels, but they are appropriate if you 
know about the circumstances, you know [P1, NP]. 
 
… prescribing is something of an art as well as a science, so… prescribers will sometimes 
prescribe things that they know are not really indicated but with the aim of achieving a 
particular goal. For example, somebody may believe that they can’t possibly stop using 
alcohol or other drugs without a detox, so the prescriber might prescribe a short, …brief 
low dose detox even though they thought a medicated detox wasn’t indicated because the 
person didn’t experience significant withdrawal symptoms. And so, in a sense, that would 
be an inappropriate prescription in that it, it isn’t for a standard indication, but it might be 
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a successful prescription because it achieves the goal of somebody becoming abstinent 
from alcohol or other drugs [P3, Consultant]. 
 
While guidelines provide best practice recommendations for disease management, they are 
not applicable to all groups of patients (Tinetti, Bogardus and Agostini, 2004). It is not 
possible for guidelines to encompass all possible comorbidities and circumstances (Geleris 
and Boudoulas, 2011). Clinical trials that usually serve as the foundation of guidelines are 
carried out in homogeneous groups of patients (Geleris and Boudoulas, 2011). However, in 
real life settings patients rarely have only the characteristics of those enrolled in trials, with 
those seen in everyday practice representing a wide spectrum of cases ranging from the 
very mild to the very complex (DeMaria, 2008). Recommendations from such guidelines 
cannot therefore be directly extrapolated to the heterogeneous population of people with 
SUDs who are likely to have multiple health problems and complex situations (Hughes, 
2011; Humphreys et al., 2005). Evidence from this study suggests that the appropriateness 
of prescribing cannot be viewed solely from the perspective of guidelines as there is need 
for an appreciation of the context of prescribing. Furthermore, a successful prescription 
among people with SUDs may well be a prescription that is pharmacologically 
inappropriate. The range of problems people with SUDs experience and the need to 
prevent relapse to substance use may make pharmacological appropriateness of lesser 
importance if prescribing assists in maintaining the service user’s stability.  
7.3.2.4. History-taking 
All the eight doctors and one of the four nurse prescribers identified history-taking as a 
part of their assessment of the appropriateness of service users’ medications. The 
prescribers described considering the information obtained during history-taking when 
assessing prescribing appropriateness: 
 
Looking at the history of … their substance use, … history of any physical health problems, 
mental health history, and current mental state as well … so I’d get the full history and I 
think then you can kind of gauge whether something might be inappropriately prescribed 
[P11, NP]. 
 
In the… new assessment clinic, you know, having taken… a comprehensive medical and 
mental health history, I talk through… with the patient about why they’ve been prescribed 
something, why they think they’ve been prescribed something, and their perceived benefit, 
their knowledge… of risks, and then I have a look,… using the history that I’ve taken and 
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the physical health check that the nursing assistants kindly do for us, I formulate an 
opinion based on those as to whether a medication is… appropriate or not [P12, SHO]. 
 
Two nurse prescribers reported that they asked service users about their medications, 
however they did not go beyond this to exploring the appropriateness of prescribing: 
 
…I would, in as much as part of the assessment, I would ask the service user what 
medication, are they on any medications. If they are, what it is, what dose, what’s it 
prescribed for and are they taking it. That would be the total sum of my assessment. I 
wouldn’t move to beyond exploring that condition or whether that was appropriate, I don’t 
think that’s my place [P6, NP]. 
 
Another nurse prescriber described the fact that he does not spend a lot of time on 
assessing the appropriateness of prescribing: 
 
I don’t spend a lot of time assessing the appropriateness of medication, that isn’t the 
reason for me being there… [P1, NP]. 
  
Prescribers described some challenges with self-report when obtaining service users’ 
histories. These include problems with the reliability of information provided by service 
users as some of them may withhold information: 
 
It could be that patients may not tell you what medications they’re on, which means then 
the focus would be completely defeated, because if it’s not mentioned, we all tend to rely 
on the patient [to say] what medication they are on, if they chose not to say that they’re on 
a benzodiazepine then the purpose of screening will be defeated. So better be aware of 
that, where we are getting the information and, you know, are we actually collating the 
information from the GP, and then … putting that information in the text, or is it that we 
are just depending on the service user to tell us what medication they are taking… [P8, 
SPR]. 
 
…but I think sometimes patients are not candid with the prescriber…, I can think of one 
woman in particular, who, when I questioned her, she hadn’t revealed to the GP that she 
was drinking very heavily. She said she was very anxious and the GP accepted this and 
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prescribed her the Propranolol. It was pretty clear to me though that this was alcohol 
withdrawal that she was suffering from, and she hadn’t been candid with the GP [P1, NP]. 
 
Prescribers also described service users who do not know details of their medications such 
as the name and reason for medication use. Some may be cognitively impaired by 
substances. Consequently, prescribers may have to contact GPs concerning needed 
information: 
 
I think in the first assessment, … you don’t always have a long history from a GP, 
sometimes, you know, in our clinic patients have self-referred and you literally have the 
booklet in front of you that they have completed and the initial referral sheet, and that’s it 
… So in that first assessment, it’s the strength of your history [that] is going to determine 
what you do, so, and sometimes… you get patients… who come in here and sometimes 
they’re slightly intoxicated, they’re … cognitively impaired and you have to try and 
decipher the history through these difficulties… Patients don’t necessarily remember drugs 
as well … you know, patients remember, well I take the blue one and then the red one... I 
like to take… a full history, make them a follow-up appointment, use that time in between 
to contact GP and…, collect some collateral history and find out what medication they’re 
on…, before I … prescribe anything, because I think that’s safer [P12, SHO]. 
 
Prescribers therefore discussed challenges they encountered during history-taking. Such 
challenges raise questions about the quality of information available to prescribers for 
decision-making, especially, during service users’ first assessment at the SAS. During 
periods when service users are actively misusing substances, prescribers lose access to the 
most fundamental tool in medicine, the patient’s self-report (Action on Addiction, 2013). 
People with SUDs may be less than open and sometimes manipulative (Action on 
Addiction, 2013; McKeown, Matheson and Bond, 2003). It is therefore good practice to 
use other evidence to corroborate self-report.  
 
The findings of this study showed that although some prescribers stated that they contacted 
service users’ GPs for further information concerning medications, this was not routine 
practice. The practice of depending on information obtained from service users in 
assessing appropriateness implies that some medications which are potentially 
inappropriate may not be identified, as service users may not disclose information 
concerning them. Lack of disclosure may result from the need to obtain such medications 
for non-legitimate reasons (Hall et al., 2008; Martyres, Clode and Burns, 2004). Stigma 
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may also play a role in non-disclosure (Pound et al., 2005). For instance, people with 
mental health problems have reported feeling stigmatised and labelled by their medications 
(Smith, Francis and Rowley, 2000). People on prescribed benzodiazepines have also 
reported feeling ashamed of taking them (North, Davis and Powell, 1995).  
 
There is the potential for unnecessary prescribing as prescribers may go ahead to prescribe 
undisclosed medications. People with SUDs have been reported to present fraudulently to 
multiple prescribers requesting for medications such as opioid analgesics and 
benzodiazepines (Bendtsen et al., 1999; White and Taverner, 1997). Consequently, in 
addiction medicine, the patient’s self-report needs to be viewed circumspectly (Action on 
Addiction, 2013), and where possible collateral information should be obtained.   
 
Cognitive impairment was identified as another challenge in relation to history-taking. 
Impairment in memory and attention is a recognised problem in people who use substances 
such as alcohol. Over half of people with AUDs are impaired due to alcohol-related brain 
damage (Bates et al., 2002; Sullivan and Pfefferbaum, 2005). Majority of cases go 
undiagnosed (Royal College of Psychiatrists, 2014a). Similarly, illicit drugs such as 
cannabis and ecstasy have been associated with cognitive impairment (Fletcher et al., 
1996; Schilt et al., 2008). Impairment may vary from mild to severe memory deficits such 
as in Wernicke-Korsakoff Syndrome (Parsons, 1998). Consequently, memory deficits may 
lead to the inability of service users to remember information accurately or forgetfulness. 
This will negatively impact on the ability of prescribers to judge the appropriateness of 
prescribing, especially, where they rely on the information provided by service users. 
 
Only one nurse prescriber described considering the information obtained during history-
taking when assessing prescribing appropriateness. This finding may have resulted due to 
the more limited scope of practice of nurse prescribers when compared doctors. Nurse 
prescribers have a discrete area of practice and as already highlighted in section 7.3.2.1, 
they describe a strong focus on medications within their remit when assessing 
appropriateness. Previous studies have also shown that nurse prescribers only tend to take 
professional responsibility for their areas of competence (Bradley and Nolan, 2007; 
Scrafton, McKinnon and Kane, 2012). The limited scope of nurse prescribers’ practice 
implies that they may be unable to capture some medications that have been 
inappropriately prescribed for service users. 
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7.3.2.5. Communication 
This theme was described by all prescribers. They described communicating with other 
SAS prescribers or prescribers outside the SAS when dealing with issues around 
prescribing appropriateness:  
 
The first thing I’m gonna do with a couple of those cases, simply discuss it with one of my 
medical colleagues here actually, that’s my first step, because it’s… the degree or level of 
reaction to the inappropriateness that, I think, needs checking out with the medical 
colleague. And then it… generally results in alerting the patient and alerting the GP, and 
saying to the patient, you need to go and see the GP to get reviewed, and then the GP, 
who’s usually the prescriber, will review them hopefully [P1, NP]. 
 
… I might question the appropriateness of, say, an antidepressant medication or I might 
suggest that the patient’s mental health is reviewed, if I saw somebody that was on an 
antipsychotic and I thought that it either wasn’t treating the psychosis or there was no 
evidence of psychosis and they seemed heavily sedated, then I might question whether that 
medication was the… right medication, but I would then ask a medic to assess the 
appropriateness of it and consider further prescribing [P10, NP]. 
 
Doctors at the SAS also described communicating with GPs: 
 
Well… mainly I would be contacting other people to take over the prescriptions 
[psychiatric medications], in which case they’re usually delighted cos they… usually 
realise themselves that this isn’t really a very good prescription but they’re struggling in 
trying to get a more sensible sort of prescription, so they’re usually delighted that we 
should take it over. Sometimes there are prescriptions that I’d be a bit doubtful about but 
wouldn’t really be in my sort of remit to prescribe and so I’d… essentially…  write to the 
prescribers and express my doubts and possibly ask them to review, which they do [P3, 
Consultant]. 
 
Because… if I find… something that’s maybe been overlooked or prescribed wrongly, then 
I will let the GP know about it, and it could be anything. Doesn’t have to be addiction 
medication or psychiatric medication, it could be anything [P5, locum doctor]. 
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Furthermore, communication with other prescribers sometimes depended on whether SAS 
prescribers felt immediate action should be taken concerning inappropriate prescribing:  
 
For the example I started with [patient with schizophrenia on supra-BNF dose of 
Olanzapine], I wrote to the… GP saying, you know, Mr So-and-So is stable and is 
relatively symptom free on this but I’m worried about this monitoring [Olanzapine 
monitoring], would you be able to instigate some monitoring and consider re-referral back 
to the community mental health team, and I copied it into his former psychiatrist, even 
though they’d discharged him. Nothing as yet has come of that and the patient’s very 
reluctant… to reduce this medication but, so that’s a wait and see scenario. But generally 
if I think something’s really inappropriate and I’m in a position to contact the original 
prescriber I’ll try to do that, but I’d always discuss a case with my consultant and make a 
decision about whether or not I need to do something imminently [P12, SHO]. 
  
… if I felt that, you know, it [inappropriate prescribing]… definitely needed to be 
addressed, I would take it to our prescribing, either prescribing governance meetings or 
speak to one of the consultants here and seeing if there’s a way round of dealing with that 
[P11, NP]. 
 
Evidence from these interviews show that good communication is essential for safe and 
effective care of service users (Action on Addiction, 2013). Nurse prescribers often 
communicated with doctors at the SAS when addressing issues around inappropriate 
prescribing. These doctors seemed to have been a valuable source of support to nurse 
prescribers when making decisions about prescribing. Similarly, the more junior doctors 
(non-consultants) also relied on the support of their senior colleagues in dealing with issues 
around prescribing. There was also evidence that SAS prescribers provided support to GPs 
around prescribing and also played a “safety net” function. Addiction specialist doctors 
such as consultant psychiatrists are skilled in working with people with the most severe 
and complex needs and provide expert advice to other doctors and non-medical prescribers 
on clinical management including prescribing (Public Health England, 2014d).  
 
Furthermore, inappropriate prescribing appears to be on a continuum ranging from mild 
inappropriateness which prescribers may not necessarily seek advice from senior 
colleagues about, to severe inappropriateness which may require expert opinion.  
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7.3.2.6. Lifestyle change 
Six prescribers (two nurse prescribers and four doctors) described the way that lifestyle 
changes may sometimes preclude the need for medications for comorbid mental health 
problems and sleep problems: 
 
And again, sort of the antidepressants and looking at other people’s lifestyles and… trying 
to improve that so they don’t… necessarily need their medication [P11, NP]. 
 
The second example which can be thought of is prescribing antidepressants, particularly 
…SSRIs [selective serotonin reuptake inhibitors] which have been commenced with… 
people who have… a mental health problem, but also a comorbid substance misuse or 
comorbid addiction like regular alcohol use, and there’s lots of mounting evidence that 
alcohol has an impact on mental health, particularly on mood…so these… medications 
have been started without really suggesting any lifestyle intervention like, you know, 
changing the alcohol habit, which in itself could have helped the person recover from their 
mood symptoms [P7, Consultant]. 
 
I mean… mainly the ones who are successful in coming off drugs or substances and 
alcohol, then sometimes they would… themselves see that the problems that they used to 
have, like sort of sleep reversal, sleep without structure, or anxiety, low mood or… 
emotionality, these things can subside after they… come off the substance use and they are 
stabilised [P13, SPR]. 
 
Although change of lifestyle can have a positive impact on mental disorders and sleep, 
lifestyle recommendations are often underutilised in mental health (Walsh, 2011). SAS 
prescribers appear to suggest that lifestyle interventions should be initially utilised before 
prescribing of psychiatric medications. The provision of lifestyle advice such as the need 
for alcohol abstinence could be helpful in ameliorating mental health symptoms of patients 
(Davidson, 1995; Frances, 1997; Schuckit, 2006) and also lead to improvement in sleep 
(Arnedt, Conroy and Brower, 2007; Stein and Friedmann, 2005). 
7.3.2.7. Adherence to prescribed medications 
Adherence to prescribed medications was mentioned as a theme by four prescribers (one 
consultant, two NPs and the SHO). These prescribers described service users’ non-
adherence to their medications: 
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…equally you find that they’re not taking several of the medications they’re prescribed, or 
at least they’re not taking them in the way that’s prescribed, they take them when they feel 
like it, or if they feel unwell then they take one tablet, which is… depending on the tablets 
of course, but commonly that isn’t going to make any difference to anything, it’s… the 
wrong way to take them [P3, consultant]. 
 
And …often people…, don’t comply fully with their medication anyway [P11, NP]. 
 
Furthermore, a nurse prescriber described how service users may sometimes be on multiple 
medications that are not reviewed with resultant non-adherence: 
 
So, you know, and most have been on them, I think there’s a lot of medications as well that 
are long-term prescriptions and they’re not reviewed, you know, they’re set up by GPs and 
put on repeats with often people not really knowing why they’re taking them, and often 
aren’t taking them [P6, NP]. 
 
The responses of prescribers indicate that many service users do not take their medications 
as prescribed. This is similar to findings in the literature which indicate that non-adherence 
is a problem especially among people with SUDs (Azar et al., 2010; Cohn et al., 2011; 
Weiss, 2004). Sajatovic et al. (2006) found that active SUDs are associated with non-
adherence. This is because active SUDs could lead to intoxication, with poor judgments 
including non-adherence resulting from the cognitive and psychoneurological effects of 
substances (Bates et al., 2002; Sajatovic et al., 2006). Cognitive and other 
psychoneurological conditions are a frequent occurrence in people with SUDs (Royal 
College of Psychiatrists, 2014a; Schilt et al., 2008). In addition to lack of optimal benefit 
from prescribed medications, non-adherence is a predictor of adverse outcomes such as 
treatment drop-outs and relapse among people with SUDs (Mitchell and Selmes, 2007a; 
Sannibale et al., 2003). 
 
Factors contributing to non-adherence are numerous and include patient and prescriber 
factors. Patient factors include level of health literacy, degree of involvement in clinical 
decision-making as well as substance use (Brown and Bussell, 2011; Margolese et al., 
2004). Prescriber factors that serve as contributors to non-adherence include complexity of 
the prescription regimen including polypharmacy (Duerden, Avery and Payne, 2013), 
communication barriers and number of prescribers (Brown and Bussell, 2011). Non-
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adherence to prescribed medications lead to failure to translate potentially effective 
treatments into health gains for service users (National Institute for Health and Clinical 
Excellence, 2009). It may ultimately lead to worsening of service users’ conditions and 
represents a waste of healthcare resources (Chapman and Horne, 2013; Horne et al., 2005).  
7.3.2.8. Addiction to prescribed medications 
Addiction to prescribed medications was identified as a theme by four prescribers (two 
consultants, one SPR and one NP). The prescribers described situations in which service 
users were prescribed medications (especially opiates) with dependence potential for 
prolonged periods without review and the subsequent development of dependence on 
them: 
 
But we also see … people who are dependent on prescribed medication, so they’re finding 
it difficult to wean themselves off a medication that they were prescribed for a condition. 
Again, a common problem out of that is people who have some sort of pain, pain 
management, again, commonly lower back pain, and being prescribed opiate-based 
analgesia or codeine, dihydrocodeine type of medication, which then is not reviewed and is 
prescribed for a prolonged period of time and the patient continues to use it not 
understanding that they’ve become dependent and then when they try to come off it they 
start experiencing withdrawal and hence they think they’re not ready, but actually it’s the 
medication causing all these symptoms and the withdrawal from these medications [P7, 
consultant]. 
 
Similarly, another doctor described service users who were initially prescribed high doses 
of opiates in pain clinics but later became dependent to them: 
 
Again, a lot of people would come to us, particularly from the general hospital where 
they’ve had some clear pathology, pancreatitis for example, and the question would be 
what’s the appropriate level of… analgesia, and that’s often quite a difficult problem, … 
the sort of protocol used by the pain clinics tends to be an escalating dose of opiates and 
so we often end up seeing people who are on a high dose of opiate, and then addicted to 
the high dose of opiate, and we then have to think well we can’t withdraw them totally from 
the opiates because they’ve got genuine pathology, but this dose is too high. So… it’s kind 
of finding a … sensible sort of balance then [P3, consultant]. 
 
One doctor also described service users who are likely dependent on benzodiazepines: 
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It’s not uncommon to see patients on hypnotics, such as benzodiazepines. Binge on… a 
benzodiazepine for a number of years for, the initial intention was for insomnia, but it’s… 
highly likely that they have become dependent on that, so we’d definitely consider that as 
inappropriate [P8, SPR]. 
 
As described in section 6.5.2.4, addiction to prescribed medications is a widespread 
problem (Centers for Disease Control and Prevention, 2011; Home Affairs Committee, 
2013). In the UK, 1.5 million people are believed to be addicted to prescription drugs, 
surpassing the number of people in treatment for illicit drug addiction (Home Affairs 
Committee, 2013). The problem of addiction to prescribed medications, especially, opioids 
for pain treatment, was also highlighted by prescribers. The treatment of pain with opioids 
is challenging because of their dependence potential (Ballantyne and Mao, 2003). 
Consequently, prescribers are usually faced with the challenge of ensuring effective pain 
control while trying to reduce the possibility of dependence (Wiedemer et al., 2007). 
Ensuring effective pain control requires regular monitoring and review.  
 
Lack of medication review may result from inadequate care co-ordination and 
fragmentation of care when service users are transferred between health-care sectors and 
providers (Department of Health, 2005b; 2006d; Hofmarcher, Oxley and Rusticelli, 2007). 
In pain clinics, the prevalent view that “pain is what the patient says it is” (McCaffery, 
1968) often leads to the use of escalating doses of opioids (Stannard, 2013), on which 
patients may eventually become dependent. On the other hand, in addiction medicine, 
clinicians are well aware of the risk of misuse of prescribed medications and the fact that 
the psychopathology of addiction often means that patients may sometimes demand more 
medications than they need (Action on Addiction, 2013). Consequently, addiction 
medicine is more structured, including limit setting, monitoring, behavioural rules and 
seeking external corroboration of patients’ self-report (Action on Addiction, 2013). This 
structure is designed to reduce risk to both the patient and the public. People with SUDs 
and comorbid pain may well benefit from a team approach incorporating the differing 
views of pain medicine and addiction medicine clinicians (Action on Addiction, 2013).    
7.3.2.9. Understanding relationship between SUDs and mental disorders 
The need to understand the relationship between SUDs and mental disorders when 
assessing prescribing appropriateness was described by five prescribers who were all 
doctors (three consultants, one specialist registrar and the SHO). One of the doctors 
described the following strategies that could assist in understanding this relationship (this 
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substantial quotation from the doctor was included because it highlights pointers to 
reaching a mental health diagnosis in the presence of SUDs): 
 
Well it may be difficult to reach a diagnosis while somebody is currently using. The kind of 
pointers that you … could use would be what … sort of person were they before they 
started using substances,… is there a strong family history of disorders that are known …, 
to have a… genetic element to them, and those would be really the most important things 
to look for. Of course the problem there is that, certainly with drugs such as heroin and 
those kinds of drugs, people often start using at a very young age so you don’t really have 
much of a picture of what they were like before they started using anything. So in the 
absence of that you can look at their mental state while they are using, and that’s really 
quite difficult I think. …if somebody had a really severe depressive disorder… you would 
pick up the hopelessness in their life…, the total lack of … any positive kind of feelings or 
enjoyment… but there’d be a lot of grey in the middle where you’re not sure about it. And 
when you’re not sure, the only way that you can then determine what’s going on… is to go 
for a period of total abstinence, or if not total abstinence, at… the very least, stable 
moderation of drug use and… see what happens to the person’s mental state ... [P3, 
consultant]. 
 
This quotation describes how challenging it can be to establish the relationship between 
SUDs and mental disorders. As discussed in section 1.5.2.1, intoxication and withdrawal 
symptoms of substances are similar to those of mental disorders (Boden and Fergusson, 
2011; Fergusson, Boden and Horwood, 2009; Nunes and Levin, 2004). This may lead to 
uncertainty when diagnosing mental disorders. Substance-induced symptoms have been 
found to resolve within weeks of abstinence or moderation in substance use unlike 
symptoms associated with independent mental disorders (Brown and Schuckit, 1988; 
Davidson, 1995).  
     
In addition to understanding the relationship between SUDs and mental health disorders, 
one doctor highlighted the challenge of establishing diagnosis of a mental disorder during 
service users’ first assessment and its impact on judging medication appropriateness: 
 
And also just meeting a patient once you can’t build a big enough picture to establish a 
diagnosis of depression or schizophrenia, so you don’t know whether or not the medication 
is appropriate for that cos you haven’t had a big enough assessment [P9, consultant]. 
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The relationship between SUDs and mental disorders is complex and there is sometimes 
uncertainty around diagnosis when these conditions co-exist. Despite this challenge, 
doctors described using a variety of strategies in teasing out this complex relationship. 
Nurse prescribers however did not describe exploring this relationship. The widespread 
prescribing of psychiatric medications in people with co-occurring mental disorders and 
SUDs may reflect the inability of clinicians such as GPs to address this connection in their 
busy work environment. As a result, some of the medications for these conditions may be 
inappropriately prescribed. There have however been arguments for the treatment of both 
SUDs and mental disorders when they co-exist due to the poor prognosis of such service 
users as well as the risk of suicide (Burns, Teesson and O'Neill, 2005; Davis et al., 2008;  
Lingford-Hughes et al., 2012; Martín-Santos et al., 2006). 
7.3.3. Factors considered before initiating medication changes 
One of the areas this study explored was the factors considered by prescribers before 
initiating changes to service users’ medications. The A-MAI study showed that almost half 
of service users have at least one inappropriate medication at first SAS visit. However, 
none of the medications identified to be inappropriate were changed by prescribers. The 
factors considered before initiating medication changes were explored with SAS 
prescribers. The following factors were described by prescribers: communication, nature of 
addiction, benefit and risk of medications and prescribing expertise. 
7.3.3.1. Communication  
Communication was described by all prescribers. It involved discussing with service users 
in order to understand their views and also involving the prescriber of the medication: 
 
Well, firstly I discuss with the … patient to see what … the patient’s view is, and explain … 
what I think, … which are the reasons for this inappropriateness, and also I… sort of 
communicate with the prescriber …, I give them my thoughts, and then they would be able 
to review… things again. So basically communicating with the… service user as well as 
the prescriber [P13, SPR]. 
 
Similarly, another doctor described communicating with service users when making 
decisions about medications but also highlighted the fact that there are usually negotiations 
around management plans: 
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So I ask the patient what they think about their prescription, if they have any … concerns, 
any worries about where things are at the moment, side effects, future, long-term risks and 
benefits, and the perceived benefit they’re getting from it, and what they’re expecting with 
regards to me making changes, and are they expecting me to make a change, do they think 
I’m going to keep it the same, do they think I’m going to add something, take something 
away. And then I put forward my proposed management plan and then it becomes a bit of 
to and fro sometimes [P12, SHO]. 
 
However, prescribers also highlighted the fact that there is sometimes ineffective 
communication which ultimately affects decisions around prescribing. Service users’ lack 
of communication and engagement with the service was described by prescribers: 
 
… if somebody is not engaging, if they’re not attending appointments, if they’re not 
providing urine samples for toxicology and… you’re struggling to make contact with them, 
you know, … the only choice I guess you’ve got then is to say, you know, … these are all 
the avenues I’ve tried to get in touch with you, you know, you’re not attending 
appointments, therefore you leave me no choice but to alter your medication. But again, 
you know, you… can hold somebody’s prescription before it comes to that. You know, it 
would be very… rare that I think that… had to happen without somebody knowing first 
[P10, NP]. 
 
Then again there may be somebody who really is … not … engaging with us and is 
perhaps really using us as a free drug supply. That’s unusual I think, but if it does happen, 
… under those circumstances…, it’s a case of, I think, very often stating, this is what is 
going to happen [reducing or stopping script]… but … that’s pretty rare… it’s unusual that 
I get involved in that kind of reducing against a person’s will, and that’s partly because I 
don’t prescribe for that many heroin users, you see, so I’ve got quite a small number [P1, 
NP]. 
 
Other prescribers highlighted obstacles such as service user resistance to medication 
changes:  
 
If they… don’t agree with it then they don’t want to use it, and this is a common problem in 
addiction. Most people don’t wanna come off Methadone to go onto Buprenorphine, … 
they don’t want to do it. They’ve been on it before, or they’ve heard stories about it and 
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they don’t want to do it, in which case you don’t get as far as actually making the change. 
So in a way it doesn’t happen then because the patient just refuses. Or lowering the doses, 
all these sort of things [P5, locum]. 
 
I mean sometimes you have to be very, you know, tentative and sensitive because 
obviously, like I said before, people can be quite precious about their prescriptions, even 
though you can see that it’s not, you know, appropriate or not necessary at that time… 
[P11, NP]. 
 
The relationship between healthcare professionals and their patients has changed over the 
years from a predominantly paternalistic model to one in which patients have increasingly 
become active partners whose views are important, and should be incorporated into the 
care process (Bezreh et al., 2012; Elwyn, Edwards and Kinnersley, 1999). Therefore, it is 
not surprising that all prescribers described the importance of communication with service 
users before initiating medication changes. Effective communication assists in building a 
therapeutic relationship with patients. Such a positive relationship assists the prescriber in 
eliciting information and is useful in decision-making concerning treatment (Barnett, 
2001). There is evidence that building and maintaining such therapeutic relationships can 
lead to positive client and treatment outcomes (Leach, 2005).   
 
There were also downsides to communication as service users may not engage with the 
service or they may be resistant to medication changes. While resistance to change may 
lead to continued prescribing of medications considered to be inappropriate by prescribers, 
they sometimes described setting boundaries including stopping medications if service 
users are not engaging with treatment. Boundary setting in addiction medicine may result 
from the need to protect the service user from harm and minimise the risk of diversion of 
medications (Action on Addiction, 2013).  
7.3.3.2. Nature of addiction 
Nine prescribers (three nurse prescribers and six doctors) highlighted the nature of 
addiction such as loss of control and the experience of withdrawal symptoms as possible 
hinderances to initiating medication changes. One doctor described service users’ 
difficulties in coming off diazepam that has been prescribed over a long period of time:  
 
Sometimes patients… can be very difficult and can be challenging… for example, let’s say 
if somebody’s on Diazepam 30mgs for a number of years and when you try and reason 
250 
 
with them and trying to cut them down they can be very challenging because of their… 
perceived difficulties in coming off them [P8, SPR]. 
 
Pressure resulting from a sense of entitlement by service users was also described by 
prescribers:  
 
…because some people are very challenging, demanding… they have a lot of previous 
history of treatment so they sort of know what they want, how they want it, and it might not 
be what you want to, necessarily to give them. So yeah, it could be… challenging straight 
away... So there could be lots of demands, challenges, difficulties, when patients present 
[P5, locum]. 
 
And then our… patient population is also quite complex in terms of their needs. So there 
will be a group of people who would be using or wanting or demanding medication to 
suffice their substance misuse habit. So it would be them trying to forcefully get a 
prescription [P7, Consultant]. 
 
… some of the service users are keen to secure medication [P6, NP]. 
 
Addiction is characterised by loss of control over drug use (Action on Addiction, 2013). 
Loss of control refers to loss of the ability to regulate and control behaviour (Griffiths, 
2013). Loss of control may underline service users’ perceived need for medications, as 
they may want medications for other effects (such as their pleasurable or euphoric effects) 
rather than their therapeutic benefits. Similarly, the experience of withdrawal symptoms 
may lead to service users resisting medication changes even when these medications are 
perceived to be inappropriate by prescribers.  
 
As discussed in section 6.5.2.4 under ‘fear of losing medications’, service users and 
prescribers may hold different views concerning the need for medications. This variation in 
views may occur to a higher degree among people with SUDs compared to other patient 
groups due to the nature of addiction. Some previous studies have shown that patients’ 
demand for medications can sometimes lead to uncomfortable prescribing decisions 
(Bendtsen et al., 1999; Britten and Ukoumunne, 1997; Macfarlane et al., 1997). Moreover, 
prescribing could be used as a means of terminating challenging consultations (Britten, 
1995). This is particularly likely to be the case among service users as they may pressure 
clinicians into prescribing medications.   
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7.3.3.3. Benefit and risk  
Prescribing practice is centred around the benefits that patients can gain from medications 
(General Medical Council, 2013), with the lowest possible harm. Although prescribers 
have described assessing risk (section 7.3.2.2) when considering the appropriateness of 
prescribing decisions, it re-surfaced when prescribers discussed factors considered before 
initiating medication changes. All prescribers described evaluating the benefit and risk of 
medication changes. This may include stopping a medication before contacting the original 
prescriber if it poses immediate risk: 
 
There have been occasions … when I felt that prescribing, you know, … the combination of 
medications that the patient’s on..., the risks are significantly high enough that I need to do 
something about it and then I’ve acted and let the… original doctor know and invited them 
to contact me if they’ve got any concerns or questions [P12, SHO]. 
 
Obviously if it’s a… serious one which needs to be changed now, then obviously we’ll 
make those changes now and let the GP know over the phone. So it depends on how acute 
the change should be made [P8, SPR]. 
 
Prescribers also described situations where medications may remain unchanged if they are 
perceived to be low risk: 
 
I generally don’t take any actions at all, unless I felt that this was actively harmful to 
somebody [P1, NP]. 
 
Unless there was, I thought there was a … particular risk, … it wouldn’t be as urgent [P9, 
Consultant]. 
 
If something was just inappropriate, like Methadone, there was a situation where, you 
know, one person might say well why not and another might say better if it was reduced, 
then that’s… as I say, that… would then be a… task to… motivate the person to think about 
changing it [P3, Consultant]. 
 
The interest of the service user should also be considered when making medication 
changes: 
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The other side of it as well is, you know, you’ve got patients that have been in mental 
health services for many… years as well and, you know, you could really destabilise them 
if… their medications are altered or changed. So you have to kind of be very flexible, I 
think [P10, NP]. 
 
Yeah, I mean people can… string you along, and… get more out of you than they actually 
should be, but that’s normally for a short while, because it’s sometimes good to calm the 
situation down, even if you give them a milligram or two too much of something, because 
always you get them back again a month later when things have calmed down. And then, 
yeah, so one might… feel they’ve given somebody a…bit, bit too lenient sometimes with 
medication, but it’s just the... patient group, they could be in… real dire straits in their life 
and it might make them safer by giving them a little bit more of something that you 
wouldn’t normally do in … a normal population, for example the benzodiazepines, 
hypnotics, things like that, so [P5, locum doctor]. 
 
The initiation of medication changes revolved around the benefit and risk posed by 
medications. Prescribers described taking action on those with immediate risk. This 
implies that where medications are inappropriate but not posing immediate risk, prescribers 
may take less action. Prescribers described concerns about destabilizing service users’ 
health when considering medication changes. Similar concerns have also been expressed 
by providers including general practitioners about stopping medications such as 
benzodiazepines prescribed for elderly patients (Iliffe et al., 2004). Patients prescribed 
benzodiazepines have often described their reliance on it (Cook et al., 2007; Iliffe et al., 
2004) and attribute characteristics beyond an ordinary medication such as affording control 
over daily stress and prolonging life to their use (Cook et al., 2007). Consequently, 
benzodiazepines were considered necessary in maintaining a normal life. Most of these 
patients also expressed resistance to reducing or discontinuing them and fear of being left 
suffering without these medications (Cook et al., 2007) .  
 
Medications such as benzodiazepines have sometimes been prescribed for reasons that 
extend beyond their recognised indications. For instance, they have been found to be 
prescribed out of sympathy for those with complex circumstances such as dysfunctional 
relationships and domestic violence (Rogers et al., 2007). Evidence from this study 
suggests that before SAS prescribers initiate medication changes they consider the impact 
such changes will have on the service user’s life as a whole. If therefore stopping an 
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inappropriate medication will lead to disintegration of the service user’s life, a decision 
may be made to continue such medications for the service user’s benefit. 
7.3.3.4. Prescribing expertise 
Prescribing expertise was another factor highlighted by prescribers as a consideration 
before initiating medication changes. All prescribers expressed reluctance at altering 
medications that are outside their remit of practice: 
 
If the patient has been discharged from the mental health services but is on an 
antidepressant and I see, or… has got a diagnosis of mental disorder, and I see them in 
SAS clinic and I think their… dose of the medication needs to be tweaked, rather than 
referring them to another specialist community mental health unit, I could do that. But with 
regards to their physical health medication, I wouldn’t necessarily change anything, I 
think that could be dealt with by their GP. I would normally ask the GP to look into it. 
Obviously they are more expert in that … field [P14, SPR]. 
 
… because the… nurse prescribers at LAU, our… remit of …medications that we can 
prescribe is very, very small. So myself, I would only prescribe addiction medication, I 
wouldn’t prescribe an antidepressant or an antipsychotic or, or change the doses even, of 
those medications, that isn’t within my sort of specialist knowledge [P10, NP]. 
 
In addition to expressing reluctance to changing medications outside his area of expertise, 
one doctor also highlighted that even where the prescribed medications are within his area 
of expertise, he would contact the original prescriber to alter medications if he has any 
concerns: 
 
[…] if it’s … been prescribed by others, … how can I make change? You know, I 
sometimes say that if… its medications, which are in my area of … expertise, like 
psychotropic medication, I would say that it’s better that this person is not on this 
medication, or reduced. And usually, … when it’s psychotropic medication like 
antidepressants or, or antipsychotics then GPs would… actually sort of act on what is 
recommended [P13, SPR]. 
 
The reluctance of doctors to make changes to service users’ medications might have 
resulted because they have limited knowledge of the reasons why the medications were 
prescribed and the circumstances surrounding prescribing in the first place. Moreover, 
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prescribers may also want to avoid taking responsibility for medications they did not 
initiate. It has also been recognised elsewhere that physicians may not stop inappropriate 
medications due to a sense of discomfort in stopping medications initiated by other 
physicians (Kroenke and Pinholt, 1990; Tamblyn et al., 2003). 
 
Specialists may tend to focus on their areas of expertise and may not take a holistic 
approach to treatment, resulting in suboptimal patient care or even adverse outcomes 
(Lipscombe, Hux and Booth, 2005). Specialisation in medical practice has been criticised 
as it often leads to fragmentation of patient care (Detsky et al., 2012). As has been 
discussed, nurse prescribers may not have adequate knowledge and experience in areas 
outside their scope of practice. The nursing and midwifery council has further 
recommended that nurse prescribers should only practice within their area of competence 
(Nursing and Midwifery Council., 2006).  
7.3.4. Negotiation of medication changes with service users 
One of the questions explored in the interview with prescribers is how potential changes to 
service users’ medications are negotiated with them. Shared decision-making was 
identified as the means through which such changes are negotiated. 
7.3.4.1. Shared decision-making 
All prescribers described negotiating medication changes with service users through shared 
decision-making. Shared decision-making involves both service user participation in 
decision-making as well as a further step of agreement being reached between the service 
user and the healthcare professional concerning treatment (Charles, Gafni and Whelan, 
1997). With the exception of circumstances where prescribers had to withdraw medications 
due to lack of engagement (section 7.3.3.1), all prescribers described working in 
collaboration with service users to achieve goals jointly set with them: 
 
I… think it’s collaborative. I think that the best way to achieve change is to do it in 
collaboration with the service user. I’ve got a lady, for example, who was on multiple 
prescriptions, and drinking, and is hugely… at risk of overdose. Very … unwilling to 
change. She’s been on these medications for twenty years, and one of the ways we’ve 
negotiated change is… to line the prescriptions out and ask her to identify which the least 
important one is in her life, and that’s the one that we’re reducing… hopefully she sees the 
positives of doing that, she feels better for doing it, she feels more in control of her life, 
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less medicated, and hopefully that might open the door for further reductions elsewhere 
[P10, NP]. 
 
I think the easier way to… sort of stop this inappropriate prescribing is when you’ve got 
the patient on board with you. So if… the patient has been explained fully, in… a sort of 
collaborative way, then if they agree with what you’re saying or what you are trying to do 
then it would be much easier to… implement those sort of changes that you want to do 
[P13, SPR]. 
 
… either by talking to the patient and explaining, you know, I usually tell the patient … 
what I’m going to be doing, cos I …like to work …collaboratively with my patients [P12, 
SHO]. 
 
Similarly, another nurse prescriber described working collaboratively with service users to 
facilitate the realisation of set goals: 
 
And I think, for the most part, for me, very much it would be about (sighs) I see my role is 
about facilitating change but it’s ultimately about what the service user wants to achieve 
their goal and I think it’s about giving them as much choice about what and how they do. 
So for me it’s not about imposing a change on, it’s about working with them to support 
them setting realistic goals [P6, NP]. 
 
Shared decision-making gives patients a voice in their own management (Hamann, Leucht 
and Kissling, 2003). It is a two-way communication in which the patient and the prescriber 
share information, deliberate about treatment options, weigh risks and benefits together 
and then agree on treatment decisions to be implemented (Charles et al., 1997). This assists 
in ensuring that patient-specific goals are not just elicited but that patients take 
responsibility by being actively involved in the line of action that is agreed with the 
prescriber for their management. Some patients may however be resistant to change. 
Patient resistance has been discussed in section 7.3.3.1. Patients’ resistance has been 
identified as a reason needed changes are sometimes not made to medications (Kroenke 
and Pinholt, 1990; Tamblyn et al., 2003). The negotiation of medication change may thus 
be a continuous process where healthcare professionals elicit patients’ beliefs and attitudes 
and try to address them appropriately (Bezreh et al., 2012; Marinker and Shaw, 2003). It is 
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important to involve service users in treatment decisions in order to obtain optimal 
outcomes (Barry et al., 2000).    
 
7.3.5. Impact of the A-MAI on prescribers’ practices 
The A-MAI was used by SAS prescribers to assess the appropriateness of service users’ 
medications during their first visit and three-month follow-up appointment. Prescribers 
were asked for their views on how the use of the A-MAI impacted on their clinical 
practice. Nine prescribers (two nurses and seven doctors) stated that the A-MAI prompted 
them to reflect on prescribing decisions. One nurse prescriber described the fact that it 
made her consider prescribing in more depth including reviewing service users’ 
medications: 
 
[…] I think since you’ve been doing this and we’ve had a look at this, it’s… definitely 
made me think a bit more about people’s prescriptions and sort of, not just at the initial 
assessment but asking them afterwards as well. Yeah, so it’s… kind of made me think a bit 
more about reviewing people, yeah [P11, NP]. 
 
Similarly, one doctor described the A-MAI as having increased her awareness of different 
aspects of prescribing while also providing a structure for assessing prescribing 
appropriateness: 
 
I think just being… more aware of the different aspects of prescribing, like thinking about 
indication, contraindication, interactions, and that kind of thing, adverse reactions, you 
know, perhaps I… think about things a… bit more, in a bit more of a structured way, … as 
a result of reading and filling out MAIs [P12, SHO]. 
 
In addition, another doctor described the A-MAI as highlighting the important domains in 
assessing prescribing appropriateness: 
 
We have been using the scale that you introduced as part of your study, which has been 
quite helpful as well, which makes you think about particular things when thinking of 
inappropriateness… I think it’s a good scale, it makes you think of the domains, which are 
pretty much essential in establishing why something should be considered inappropriate 
[P7, consultant]. 
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There were however three prescribers (two nurses and a doctor) who felt the A-MAI did 
not have any significant impact on their prescribing practice: 
 
Well as far as the study goes it’s fine, yeah, otherwise it wouldn’t have changed my 
prescribing habits, because I think this is the way doctors look at things in any case… it 
wouldn’t have made me more aware of, or less aware of anything like that, no [P5, locum 
doctor]. 
 
Prescribers were also asked how long it took them to complete the A-MAI for each 
medication and their responses varied from two minutes to about ten minutes. Generally, 
prescribers felt the completion time depended on how much relevant information they had 
for assessing appropriateness and also the complexity of the regimen: 
 
…roughly I would say approximately five minutes, three to five minutes, it depends on how 
complex their medication is. If it’s a simple medication they’re much more easier, [if] it’s a 
complex kind of medication then probably spend more time. And all depends on how much 
information I’ve got in front of me, otherwise it’ll take more time for me to ask patients… 
[P8, SPR]. 
 
Yeah,… it really varied. If you had all this information at hand, the diagnosis, duration, 
frequency, it was done, I would say, on an average of five minutes. For each medication I 
would say well two to three minutes, but if you were unsure about the drug, drug 
interaction then that took some more time, and if you weren’t sure about the doses and… 
duration then that took some more time, so it was very variable. So I would say on an 
average between two to six minutes [P7, consultant]. 
 
I don’t think it took me very long, but… I guess if somebody came in on multiple 
prescriptions I would be wanting to check the drug interactions. So that would take, 
obviously, longer to do. But generally it didn’t take long… two to five minutes [P10, NP]. 
 
The majority of prescribers described the A-MAI as having a positive impact on their 
prescribing practice. However, there were a few who felt it had no impact. Nurse 
prescribers’ views on the impact of the A-MAI were quite varied with two of them 
reporting no impact. Despite the positive views expressed by most prescribers, the time 
taken to complete the A-MAI for each medication implies that where service users are on 
258 
 
complex medication regimen, there is the potential to increase clinicians’ workload. This 
may prohibit the use of the A-MAI in clinical practice.   
7.3.6. Medication omissions 
The result of the medication appropriateness study described in section 5.9.2 showed that 
there were no omissions of opioids or psychiatric medications among service users’ 
medications. This finding was further explored in the interviews with prescribers. The 
following quotation expresses a consultant’s views on medication omissions: 
 
Very unusual [medication omissions], I would think. Almost by definition, people who are 
coming to an addiction clinic are taking a number of drugs, or certainly one drug that 
they’re addicted to, and they’re usually adept at collecting other prescriptions along the 
way. So I… think omissions are probably quite unusual (P3, consultant). 
 
Similarly, one nurse prescriber expressed her views on medication omissions thus: 
 
… I can’t think of anything really that springs to mind where I’ve felt that this person 
needs that. I would say … I’ve seen more the other way, when people are on lots of 
medications and not, you know, not aware of what it’s for and not taking it as prescribed. 
So I don’t think, … I can’t recall an omission, but that might also be about my limited 
knowledge and skills around assessing for them (P6, NP). 
 
Another consultant stated that thiamine and other B vitamins may sometimes be omitted: 
 
Maybe B vitamins and thiamine in people that are chronic heavy drinkers. They’re often 
malnourished with risk of thiamine deficiency and deficiency of other B vitamins. So if 
someone was heavily drinking and not prescribed those that might be regarded as a 
medication omission. Fortunately, most GPs are quite good at prescribing thiamine and B 
vitamins (P9, consultant). 
 
Medication omissions were considered by prescribers, both nurses and doctors, to be very 
uncommon among service users attending the SAS. However, omission of thiamine and 
other B vitamins may sometimes occur.  
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7.3.7. Summary of prescribers’ interviews 
The evidence from this study shows that the assessment of the appropriateness of 
prescribed medications is a complex judgment. In particular, prescribers described 
assessing appropriateness by either checking or carrying out the following: reviewing of 
medications, assessing risk, guideline adherence versus successful prescription, history-
taking, communication, lifestyle change, addiction to prescribed medications, medication 
adherence and understanding the relationship between SUDs and mental disorders.  
 
Besides a few more experienced doctors, all other prescribers (doctors and nurse 
prescribers) tended to review medications within their competency. These prescribers 
described a strong focus on medications within their areas of expertise when assessing 
appropriateness. While doctors focused on reviewing psychiatric and addiction 
medications and sometimes opioids, nurse prescribers described a more limited area of 
expertise comprising only addiction medications. Nurse prescribers further described 
referring service users who they had concerns about their medications to SAS doctors or 
service users’ GPs. SAS doctors particularly represented a valuable source of support to 
nurse prescribers when dealing with issues around prescribing. The more junior doctors 
(non-consultants) also relied on their senior colleagues, especially consultants, for expert 
advice on medications. There was further evidence that SAS prescribers provided support 
to GPs in the management of service users.  
 
Prescribers identified problems with the quality of information provided by service users 
when taking their history. Although all prescribers reported taking service users’ histories, 
doctors and nurse prescribers largely differed in how they utilised the history taken when 
assessing the appropriateness of medications. Doctors described considering the 
information obtained during history-taking when assessing appropriateness while only one 
nurse prescriber described utilising the history taken in the assessment of medication 
appropriateness. The poor quality of information by service users and the divergent 
approaches of nurse prescribers and doctors to history-taking and medication review may 
lead to prescribers missing out inappropriately prescribed medications. This may be more 
of a problem among nurse prescribers due to their focus on a limited area of practice.  
 
Judgment on the appropriateness of prescribing among service users also involves 
assessing risk. This risk may result from potential adverse effects secondary to drug 
interactions or interactions between substances and medications. Where there is a high 
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level of potential risk, prescribers often intervened by using appropriate interventions such 
as detoxification or in some cases discontinuing prescribed medications. Risk appeared to 
be on a continuum with prescribers addressing medications that posed immediate risk.  
The limited applicability of guidelines to service users was also recognised by prescribers. 
There was an acknowledgment that successful prescribing may not always be the 
pharmacologically appropriate prescribing represented by guidelines. Successful 
prescribing is prescribing that produces good physical, psychological and social outcomes 
and this may well be outside guideline recommendations. Moreover, the need to maintain 
service users’ equilibrium with minimal risk of harm in spite of their complex problems 
should be paramount when evaluating the appropriateness of prescribing decisions. 
Judgments on the appropriateness of prescribing will need to involve consideration of the 
whole individual’s context. Doctors further highlighted the challenge of diagnosing mental 
disorders among people with SUDs. This theme was not mentioned by nurse prescribers 
probably due to their more limited scope of practice.  
 
The factors considered by prescribers before initiating medication changes include 
communication, nature of addiction, benefit and risk of medication and their prescribing 
expertise. Communication involves discussing with service users as well as understanding 
their views. Consequently, the involvement of service users in decision-making was 
critical in communication. While such a positive relationship is essential before initiating 
medication changes, it also has its drawbacks as resistance and pressure from service users 
as well as the psychopathology of addiction may influence decision-making. 
 
Prescribers highlighted the trade-offs they sometimes have to make through consideration 
of the risks and benefits of prescribing decisions. While medications may need to be 
initiated for reasons beyond mere pharmacological appropriateness, concerns about 
destabilising a service user may prohibit medication changes. Prescribers described 
negotiating potential changes to service users’ medications through shared decision-
making. Most prescribers described the positive impact of the A-MAI on their clinical 
practice, although there were a few others who reported a lack of benefit.  
 
Owing to the fact that the interviews were conducted with prescribers after they had taken 
part in the medication appropriateness study where they utilised the A-MAI, it is possible 
that participation in this study may have influenced some of their responses to the different 
areas explored in the interviews. Consequently, prescribers’ responses might be different if 
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they were interviewed before taking part in the medication appropriateness study. Section 
7.3.8 presents the researcher’s reflections on other factors that may have influenced study 
findings.  
7.3.8. Reflections on service user and prescriber interviews 
The interviews in this study contributed towards a greater understanding of the perceptions 
of service users concerning the appropriateness of prescribing decisions made by their 
prescribers while interviews with prescribers were used to understand their responses to 
inappropriate prescribing. These studies were limited because participants were only 
recruited from a single site. The findings may therefore lack generalizability to service 
users and prescribers in other addiction services, especially given the changes that have 
occurred in drug and alcohol treatment services in the UK. There has been an increase in 
the number of third sector organisations providing drug and alcohol services. Medical 
expertise has also diminished in these services.  
 
Furthermore, data collection was by a single researcher. There is the possibility that the 
researcher’s own perspectives may have affected interpretations that were made. However, 
the conduct, analysis and interpretation of data were overseen by a thesis advisory panel 
which strengthens the validity of findings as they are not limited to the perspective of the 
researcher. This is in line with recommendations for ensuring rigour in qualitative research 
(Barbour, 2001; Mays and Pope, 1995). The validity and transferability of study findings 
are considered below. 
7.3.8.1. Validity 
Validity can be considered to be the quality, rigor or trustworthiness of qualitative research 
(Davies and Dodd, 2002; Lincoln and Guba, 1985; Stenbacka, 2001). There are various 
techniques for ensuring that research findings are credible in qualitative research 
(Whittemore, Chase and Mandle, 2001). Patton (1999) has suggested that sufficient details 
should be provided concerning data collection and analysis so that others can assess study 
quality. Details of the interview and data analysis process for the interviews were therefore 
presented in sections 6.4.1 and 6.4.2 respectively. Previous researchers have further 
advocated the use of quotations because it assists in linking the data, interpreting them and 
drawing conclusions (Beck, 1993; Spencer et al., 2003a). The use of quotations is therefore 
a means of demonstrating the validity of research findings in this thesis. However, it is by 
no means the only indicator of quality in qualitative research. There have been suggestions 
that the quality of qualitative inquiry could be enhanced by reporting competing themes 
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and explanations (Mays and Pope, 2000; Patton, 1990). Consequently, competing themes 
were presented in order to provide alternative explanations for study findings.  
 
Respondents’ validation has also been recommended as a validity check in qualitative 
research (Lincoln and Guba, 1985). However, there are limitations to its use as a validity 
test. For instance, the findings reported by a researcher are usually for a wider audience, 
provide an overview of the research outcomes and are different from the perspectives of 
respondents who have their own individual concerns (Mays and Pope, 1996; 2000). 
Consequently, respondent validation was not carried out as a validity test for the 
interviews. Other issues that may impact on study quality including the researcher’s 
influence on the research process have been presented in section 3.5 under reflexivity.  
7.3.8.2. Transferability 
Qualitative research usually seeks depth and attempts to understand phenomena in context-
specific settings (Ambert et al., 1995; Patton, 1999). This is achieved by studying a small 
number of participants in-depth without the aim of generating statistically representative 
findings (Malterud, 2001). The qualitative studies therefore involved a small number of 
participants (12 prescribers and 14 service users). In qualitative inquiry, the aim with 
respect to external validity is to ascertain the extent to which study results can be applied 
(transferred) to other settings, and this is usually achieved through a description of context 
such as demographics of participants and study setting (Malterud, 2001; Onwuegbuzie and 
Leech, 2007; Patton, 1999).  
 
In this study, participants and clinic setting have been described previously (sections 3.2 
for SAS setting, 6.5.1 for service user characteristics and 7.3.1 for prescriber 
characteristics), thus enabling the reader to judge the transferability of findings to their 
own setting. As described in section 6.5.1, twenty of the 23 eligible service users were 
invited for interview because the remaining could not be contacted before their three-
month follow-up visit. With the exception of two service users who declined interview, all 
14 service users who turned up for their follow-up appointment were interviewed. 
Interviews were therefore carried out with a convenience sample of service users on 
prescribed opioids and/or psychiatric medications.  
 
Convenience sampling  involves selection of the most accessible participants for research 
(Marshall, 1996). It has however been criticised because it may result in poor quality data 
(Marshall, 1996). It is possible that this study may well have benefited from a purposive 
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sampling design where service users are actively selected based on a framework of 
variables that might influence their perspectives on prescribing appropriateness such as 
gender, age, referral substance and type of illness. There is however very limited 
knowledge in this area and it is possible that these variables do not have any influence on 
the views of service users.    
 
Convenience sampling was necessary because people with SUDs are particularly difficult 
to recruit for research (Blanco et al., 2008). For instance, some of the service users who 
were invited for interviews did not attend their follow-up appointment. Furthermore, the 
effective implementation of a sampling framework would have been difficult because 
variables highlighted above were not evenly distributed among service users. For example, 
none of the service users invited for interviews was less than 25 years. There were also 
small numbers of female subjects and those on other substances besides alcohol. There 
were only three females among interviewed service users. None of the service users were 
on other referral substances besides alcohol and heroin. Consequently, the views of these 
groups of service users (females and those with referral substances other than alcohol and 
heroin) were under-represented in the interviews and are therefore areas to explore in 
future studies.  
 
During the interview phase of this study, two service users refused to be interviewed while 
four others who initially agreed did not attend the interviews. When the characteristics of 
these service users were examined, they did not differ from those of the service users who 
were interviewed (see appendix 6.3). However, without exploring the perspectives of these 
service users concerning their prescribed medications, it is not possible to determine if they 
may differ in their perspectives. For example, it is possible that those service users who 
declined interview may have less concern about the appropriateness of their prescribed 
medications.       
 
Twelve of the 14 SAS prescribers who took part in the medication appropriateness study 
were interviewed because one prescriber (an SPR) left the SAS before the interviews 
began while the other prescriber (an SPR) was not interviewed due to the time limitations 
of this thesis. The prescribers interviewed differed in their professions (nurses and 
doctors), grades, years of experience, age and gender. There were more female nurse 
prescribers but more male doctors among interviewed prescribers. Although data obtained 
from under-represented prescriber groups (male nurse prescribers and female doctors) 
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support the findings of this research, there may be some benefit in exploring their 
perspectives in future studies for any sources of variation. Recent research has suggested 
that gender may indirectly influence doctors’ prescribing habits (The Medical Bag, 2014). 
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Chapter 8: Discussion and conclusion 
This chapter will provide an integrated discussion of the results obtained from the 
secondary data analysis, medication appropriateness study, interviews with service users 
and SAS prescribers as well as its implications for research and practice. The aims of this 
thesis and research questions have been previously described in section 3.1, while a 
description of the methodology is given in section 3.4. Briefly, the aims of this thesis were 
to assess the level and nature of appropriateness of current prescribed medications for 
service users while also exploring SAS prescribers’ responses to inappropriate prescribing. 
These aims were achieved using a mixed methods design.  
 
The mixed methods design adopted in this thesis facilitated the use of quantitative and 
qualitative methods in addressing the research questions. It allowed the strength of each 
method to be harnessed (Creswell et al., 2011). For instance, quantitative approaches alone 
were inadequate for the exploration of the complex and multi-dimensional concept of 
appropriateness. While quantitative methods provided a description of the pattern of 
prescribing for service users and estimates of the levels of inappropriate prescribing, 
interviews with prescribers provided a means for an understanding of their responses to 
inappropriate prescribing and the process of clinical decision-making when assessing 
prescribing appropriateness. Interviews with service users further aided an understanding 
of their perspectives on the appropriateness of their medications.  
 
Integration of the results of the four research studies is first presented. This is followed by 
an evaluation of the methodology of this thesis. Thereafter the overall strengths and 
weaknesses of the studies are considered, and implications for practice and 
recommendations for future research are given.  
 
8.1. Integration of findings from studies 
Integration of the results were carried out under five themes namely: prescribing pattern, 
functional outcomes, medicines optimisation, history-taking and effect of A-MAI. These 
themes serve as a means of summarising and integrating the different studies. Some themes 
resonate more strongly across different studies as shown in table 8.1.  
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Table 8.1: Themes from research studies 
 
Themes Secondary data 
analysis 
Medication 
appropriateness 
study 
Service user interviews Prescriber interviews 
Prescribing 
pattern  
Nearly half of 
service users 
were prescribed 
antidepressants.  
 
Over a quarter 
of service users 
were prescribed 
four or more 
medications.  
Two-thirds of 
service users were 
prescribed 
antidepressants. 
 
Almost half of 
service users had 
one or more 
inappropriate 
medications at their 
first SAS visit. 
  
Medicines 
optimisationa 
 
 Most service users 
take their 
medications 
regularly. Some of 
these medications 
were prescribed 
outside guideline 
recommendations.  
There were no 
omissions of 
psychiatric 
medications and/or 
opioids.  
There were varied 
viewpoints regarding 
review of medications 
with lack of review and 
addiction to prescribed 
medications sometimes 
described. Ineffective 
communication about 
medications sometimes 
occurred between service 
users and prescribers. 
Most people who benefit 
from their medications 
appear to be adherent to 
them.  
Medication review varied among 
prescribers with the most 
experienced doctors tending to 
review all of service users’ 
medications. Other doctors and 
nurse prescribers focused on 
medications within their 
expertise. SAS prescribers further 
described communicating with 
service users, other SAS 
prescribers37 and GPs when 
dealing with problems around 
prescribed medications. Non-
adherence to prescribed 
medications was reported to be 
common among service users 
while medication omissions are 
rare. 
Functional 
outcomes 
 
  Benefits from medications 
were reported by service 
users including those 
prescribed outside 
guideline standards. 
Conflicts sometimes 
existed between guideline 
standards and service 
users’ views and also 
between service users’ 
preferences and 
prescriber-assessed needs. 
Prescribers described evaluating 
the benefits and risks of 
medications when assessing 
prescribing appropriateness. 
There seemed to be a greater 
focus on the outcome of 
prescribing rather than its 
pharmacological appropriateness.  
History-
taking 
   Doctors and nurse prescribers 
differed in how they utilised 
information collected during 
history-taking when assessing 
appropriateness. Challenges 
encountered during history-taking 
were centred around problems 
associated with self-report among 
service users. 
A-MAI  The ‘cost’ 
dimension had the 
highest number of 
‘don’t knows’.  
 Most prescribers considered the 
A-MAI to be useful to their 
prescribing practice.  
aMedicines optimisation comprises medication monitoring and review, omissions, adherence and collaboration among 
stakeholders.  
 
                                                 
37
SAS doctors were a valuable support to nurse prescribers and GPs in addressing issues around prescribed medications. 
The more junior doctors relied on their consultant psychiatrists in dealing with prescribing problems. 
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Some themes such as medicines optimisation and effect of A-MAI cut across both 
quantitative and qualitative studies. Other themes such as prescribing pattern, functional 
outcomes and history-taking were unique to either the quantitative or qualitative studies.  
8.1.1. Prescribing pattern  
Evidence concerning the types and quantities of prescribed medications taken by service 
users were obtained from the secondary data analysis and the medication appropriateness 
study. Both studies found high levels of prescribing of antidepressants. Antidepressants 
were the most prevalent group of medications in these studies, followed by analgesics 
comprising substitute opioids, non-substitute opioids and non-opioid analgesics. Evidence 
from the medication appropriateness study showed that these antidepressants were mostly 
prescribed for depression or anxiety disorders. As already described in chapter 1 (section 
1.5.2.1), this is not surprising given that co-occurrence of SUDs with mental disorders (in 
particular, mood and anxiety disorders) is well documented in the literature.  
 
The medication appropriateness study found that almost a third of antidepressants had 
inappropriate A-MAI dimensions. The A-MAI dimension with the highest number of 
inappropriateness was ‘indication’. NICE (2009) recommends that antidepressants should 
only be prescribed for depression of a certain level of severity. However, service users 
coming into treatment with mild depression such as low mood were on antidepressants. 
This research was limited because SAS prescribers were not present when antidepressants 
were prescribed. They therefore lacked contextual information on their prescribing. While 
it is possible that the antidepressants had led to an improvement in mood over time, they 
might have been initially prescribed for mild depression. There was also evidence of 
antidepressant prescribing in response to stressful life situations such as marital distress in 
the service user interviews.  
 
While there may be greater need for prescribing of antidepressants to assist service users in 
coping with their diverse life and health problems, such prescribing has also raised 
concerns about the medicalisation of life’s challenges (Baldwin et al., 2014; Horwitz and 
Wakefield, 2007). There seems to be a growing trend in using antidepressants to treat 
instances of emotional unhappiness (Manninen, 2006). This evidence coupled with the 
possibility that SUDs may negate the pharmacological effect of antidepressants (Ramsey, 
Engler and Stein, 2005) as well as the potential for dangerous drug interactions (Gillman, 
2005; Morgan et al., 2004) and side effects (Pagura et al., 2011) brings to the fore the need 
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to consider other alternatives such as non-pharmacological therapies in the management of 
depression and anxiety disorders. Furthermore, pharmacotherapy for depression in people 
with SUDs appears to have mixed evidence with some reviews showing a beneficial effect 
(Iovieno et al., 2011; Nunes and Levin, 2004) while others question their efficacy 
(Lingford-Hughes et al., 2012; Pedrelli et al., 2011; Torrens et al., 2005). Non-
pharmacological therapies such as psychotherapies may therefore represent a viable 
alternative for this client group.  
 
Psychotherapies have been reported to be comparable with antidepressants when used in 
the treatment of depression and anxiety disorders in non-substance using populations 
(Roshanaei-Moghaddam et al., 2011; Spielmans, Berman and Usitalo, 2011). The 
psychotherapies evaluated against antidepressants by Spielmans, Berman and Usitalo, 
(2011) were cognitive and/or behavioural, psychodynamic, interpersonal or supportive in 
nature while Roshanaei-Moghaddam et al. (2011) compared cognitive behavioural therapy 
(hereafter CBT) with antidepressants or anxiolytics for the treatment of depression and 
anxiety. CBT has also been found to have modest effect in the management of life’s 
challenges including marital distress (Butler et al., 2006).  
 
Behavioural therapies such as contingency management and psychotherapies such as 
twelve-step facilitation, CBT (Kay-Lambkin, Baker and Lewin, 2004), motivational 
interviewing (hereafter MI) (Kay-Lambkin, Baker and Lewin, 2004) or a combination of 
these (Kelly, Daley and Douaihy, 2012; Riper et al., 2014) have shown promise in the 
management of comorbid SUDs and mental disorders. Psychotherapies could be useful in 
any of the following ways:  
 
 They could alleviate the symptoms of depression or anxiety; 
 They could assist service users in understanding their comorbidity thereby 
improving coping with cravings. They may thereby reduce substance use; 
 They could improve both symptoms of depression and anxiety and SUDs (Hesse, 
2009). 
 
Moreover, MI has shown additional benefit in promoting treatment engagement (Kay-
Lambkin et al., 2004; Martino et al., 2000). Twelve-step facilitation groups may be useful 
in comorbidity management for enhancing coping skills (Lopez Gaston et al., 2010; 
Humphreys, Moos and Cohen, 1997), promoting recognition of stress and problems 
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(Moos, 2008), increasing self-efficacy (Morgenstern et al., 1997) and providing social 
support (Bond, Kaskutas and Weisner, 2003). These non-pharmacological treatments may 
well have a place in the management of instances of emotional distress and less severe 
forms of depression and anxiety disorders among people with SUDs. Where the severity of 
depression and anxiety disorders leads to poor engagement with psychotherapies (Knowles 
et al., 2015), antidepressants may be prescribed before psychotherapy is initiated.  
 
Antidepressants and psychotherapy may also be combined for more effective management 
of comorbidity (Kelly, Daley and Douaihy, 2012). For example, there is evidence 
suggesting that the best outcomes in terms of reduction in drinking levels and improvement 
in mood among people with major depression and AUDs may occur when antidepressants 
are combined with psychotherapy (Kelly, Daley and Douaihy, 2012; Moak et al., 2003).   
 
When compared to the high prevalence of chronic pain reported among people with SUDs 
(Caldeiro et al., 2008; Dunn et al., 2014; Peles et al., 2005; Rosenblum et al., 2003), the 
fact that only 10% of service users were taking non-substitute opioids in the database study 
may be due to a number of reasons: under-reporting of prescribed opioid use, focus of 
thesis on prescribed opioids and not on those obtained from illicit sources or over-the-
counter, use of other medications in pain management or undertreatment of pain.  
 
Under-reporting of prescribed opioid use may result from fear of losing access to this 
medication among service users (Action on Addiction, 2013). The focus of this thesis on 
prescribed opioids rather than those obtained through other means may also have 
contributed to the low prevalence of opioids. The use of prescribed medications often 
occurs in the context of drugs accessed through other means among service users. While 
access to illicit opioids cannot be ruled out in the SAS population, it is also pertinent to 
state that the study population were predominantly those misusing alcohol. Issues around 
illicit opioid use may therefore be less salient when compared to a predominantly opioid-
using population. There was evidence in the medication appropriateness study of the 
treatment of pain with other classes of medications such as anticonvulsants. Some 
anticonvulsants such as pregabalin and gabapentin are licensed for the treatment of some 
forms of chronic pain in the UK (Moore et al., 2009). It is also possible that there may be a 
tendency to undertreat pain among service users. Service users are at increased risk of pain 
under-treatment due to the potential for dependence on opioids, the possibility of 
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dangerous drug interactions with illicit substances as well as other prescribed medications 
(Prince, 2001). 
The SAS routine clinical data showed that over one-quarter of service users were on four 
or more medications (polypharmacy). This finding appears to reflect the fact that service 
users also had other co-existing conditions. The tendency for people with SUDs to have 
comorbid conditions have been recognised elsewhere (Delgadillo et al., 2012; Dickey et 
al., 2002; Regier et al., 1990).  
 
Furthermore, the medication appropriateness study found that almost half of service users 
had at least one inappropriate medication at their baseline assessment in the SAS and over 
one-quarter of opioids and/or psychiatric medications had inappropriate A-MAI 
dimensions. Inappropriate A-MAI dimensions include indication, effectiveness, dose, 
duration, duplication, directions, drug-disease interactions, drug-drug interactions and cost. 
These inappropriate dimensions varied across the psychiatric medications and opioids 
assessed in this small-scale study. The result of this study cannot be compared to previous 
studies because it is the first of its kind. The level of inappropriate prescribing is indicative 
of suboptimal prescribing of opioids and psychiatric medications among service users 
referred to the SAS. Further studies are required to investigate prescribing appropriateness 
among service users referred to other addiction services. 
8.1.2. Functional outcomes 
This theme was expressed in the service user and prescriber interviews. As described in 
section 6.5.2.1, it refers to physical, social and psychological functioning. The service user 
interviews showed that most service users described benefit from their medications, 
including improvement in their physical, psychological and social functioning. Among 
these were those prescribed outside guideline recommendations. There was therefore 
sometimes conflict between service users’ perspectives and the recommendations in 
guidelines.  
 
As discussed in section 1.4.2, recommendations including dosing and duration are usually 
established in clinical trials which inform clinical guidelines (Tucker and Roth, 2006). 
Sometimes, due to lack of robust evidence, recommendations may be based on the 
opinions of experts (Geleris and Boudoulas, 2011). In clinical trials that inform guidelines 
for the management of people with co-occurring SUDs and psychiatric disorders or chronic 
pain, SUDs are often an exclusionary criterion (Furlan et al., 2006; Ostacher, 2011; Samet 
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and Walley, 2008). Consequently, these guidelines cannot be extrapolated to this 
population.  
While guidelines represent an important source of information, they have often been 
criticised due to their disease-specific focus and limited applicability to the varying needs 
of individual patients (Farquhar, Kofa and Slutsky, 2002). Consequently, the frame of 
reference in these guidelines for assessing appropriateness cannot be used for people with 
comorbidity since “one size does not fit all”.  
 
Evidence from this thesis suggests that the wider physical, psychological and social 
outcomes of people with SUDs may be particularly important when assessing the 
appropriateness of this client group’s medications. Although prescribing outside guideline 
recommendations carries its own risks including the potential for greater severity of 
unwanted side effects (Ali and Ajmal, 2012), there needs to be a weighing of such risks 
against more pragmatic outcomes that may be of great importance to the service user. Such 
prescribing is particularly important among service users because of their often complex 
circumstances encompassing health, social and economic problems (Humphreys et al., 
2005; Lloyd, 1998) as well as the paucity of the evidence-base for their management. 
There may well be a greater need to elicit the views of service users when assessing their 
outcomes and also to determine the level of risk they are willing to tolerate (Tinetti, 
Bogardus and Agostini, 2004). Furthermore, in the UK, the NHS constitution states that 
the service it provides must reflect the needs and preferences of patients (Department of 
Health, 2013c). There is therefore a need for appreciation of service users’ perspectives 
(Elwyn, Edwards and Britten, 2003). 
 
Medications may play a pivotal role in assisting service users maintain equilibrium in their 
wider life. Prescribers described concerns about destabilising service users’ well-being 
and, by extension, their lives when making prescribing decisions. In essence, although a 
medication may be considered inappropriate from a medical perspective, it may be 
appropriate in another sense if it prevents destabilisation of the service user’s health and 
wider life. For instance, this study found that a GP who continued prescribing a supra-BNF 
dose of an antipsychotic for a person with schizophrenia refused to reduce the dose when 
contacted by a SAS prescriber who considered the high dose inappropriate. The GP 
justified the high dose as the person was mentally stable on such a dose. The views of these 
two clinicians therefore varied on prescribing appropriateness. The findings of this thesis 
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suggest that evaluations of appropriateness may inevitably be a matter of debate among 
prescribers, and also between prescribers and service users in some circumstances.   
 
Moving beyond the medical perspective by considering context and service users’ 
preferences, introduces subjectivity into decision-making concerning appropriateness. For 
instance, two service users with the same health conditions may have different preferences 
and situations which may lead to different prescribing decisions for both of them. Barber et 
al. (2005) have argued that the introduction of subjectivity is appropriate when making a 
value judgment such as this. Considering all these perspectives further improves the 
quality of prescribing (Barber et al., 2005).   
  
In addiction medicine, incorporating service user’s preferences or choices in decision-
making is sometimes a difficult issue. People with SUDs tend to have a particularly strong 
sense of entitlement to being prescribed medications and they may seek to influence 
prescribing decisions. Both prescriber and service user interviews showed that there is 
sometimes conflict between physician-assessed needs and service users’ preferences. 
Service users’ preferences may be due to the pleasurable effects of medications or they 
may want medications for the purpose of suspending reality (Cribb and Barber, 1997) or 
for diversion to the illicit drug market. Preferences for certain medications such as opioids 
may also be driven by craving or the need to avoid withdrawal symptoms (Action on 
Addiction, 2013).  
 
Opioid prescribing in people with SUDs is particularly challenging  due to their 
dependence potential (Action on Addiction, 2013; Rosenblum et al., 2008). Evidence from 
service user and prescriber interviews showed that opioid prescribing may be problematic. 
A service user described developing addiction to his opioid medication (dihydrocodeine). 
Prescribers also described situations where service users prescribed high opioid doses for 
prolonged periods subsequently became dependent.  
 
Pain specialists and addiction specialists often have different philosophies and operate 
separately from each other (Action on Addiction, 2013). In the specialty of pain medicine, 
the prevalent view is that pain is what the patient says it is and it is therefore more oriented 
towards support (affirmation and acceptance of the patient’s experience). On the other 
hand, addiction specialists understand that addiction is characterised by loss of control and 
there is therefore an orientation towards structure (limit setting, behavioural rules, 
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monitoring and seeking collateral information in addition to patients’ self-report). There is 
a need for collaborative work between pain and addiction specialists in order to ensure safe 
and effective management of pain among people with SUDs (Action on Addiction, 2013). 
There is limited evidence of the effectiveness of opioids over the long duration of 
treatment typical of chronic pain (Noble et al., 2010). Total relief of chronic pain may not 
always be possible (Department of Health (England) and the devolved administrations, 
2007; Prince, 2001). Additional measures such as psychological and behavioural therapies 
that could assist in minimising the discomfort from chronic pain may need to be 
considered. These therapies include interventions aimed at increasing self-management, 
cognitive change and behavioural change (Roditi and Robinson, 2011). Current approaches 
to the management of chronic pain recognise the benefits of these therapies in addition to 
pharmacological treatment (Roditi and Robinson, 2011). This sort of multimodal treatment 
approach have been reported to result in improvement in pain and restoration of daily 
functioning (McCracken and Turk, 2002), and may well have a place in the management of 
comorbid chronic pain and SUDs. 
 
Taken together, prescribing appropriateness entails much more than the narrow 
pharmacological appropriateness presented in guidelines. It is sometimes an area of 
conflict with divergent views among stakeholders. Conflicts may exist between service 
users and prescribers’ views, and also among different prescribers. Assessment of the 
appropriateness of prescribing among service users needs to incorporate their physical, 
psychological and social functioning as well as their preferences and the risks posed by 
medications. The potential risk posed by medications may necessitate some sort of 
structure for prescribing to be safe. This broad view of appropriateness raises the need for a 
collaborative effort between service users and the different prescribers managing their pain 
and psychiatric comorbidities in order to improve understanding of appropriateness and for 
optimal prescribing decisions to be reached.    
8.1.3. History-taking 
For decision-making concerning prescribing to be safe and effective, there is first the need 
to gather relevant patient’s information such as medical history, medication history 
including medication adherence, and undertaking of physical investigations (Lum, Mitchell 
and Coombes, 2013). Prescribers’ interviews showed that there were differences between 
doctors and nurse prescribers in history-taking. Only one nurse prescriber described 
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considering information obtained during history-taking when assessing the appropriateness 
of medications.  
 
The difference between nurse prescribers and doctors appears to have resulted due to nurse 
prescribers’ narrower scope of practice. Unlike doctors, nurse prescribers have a discrete 
area of practice which they are expected to adhere to (Nursing and Midwifery Council., 
2006). There is however the possibility that the safety of prescribed medications may be 
affected by comorbidities and co-prescribed medications. Without giving adequate 
consideration to them when assessing appropriateness, the risk posed by prescribed 
medications may go unnoticed.  
 
A national evaluation of nurse independent prescribing in England in 2007 reported that 
there is scope for improved history-taking among this group (Latter et al., 2007). The 
findings from this study suggest that there may be training needs in this area to equip nurse 
prescribers in applying the history they have taken to the assessment of appropriateness. 
Furthermore, there may well be need for nurse prescribers to develop competence in the 
assessment of service users’ comorbid mental health conditions and pain for optimal 
decision-making about prescribing (see section 8.4.4 for more details).    
 
Prescribers’ interviews further highlighted problems with the information provided by 
service users ranging from problems resulting from cognitive impairment to deliberate 
non-disclosure of information. When service users are actively misusing substances, 
prescribers lose access to the most fundamental tool in medicine, the patient’s self-report 
(Action on Addiction, 2013). Use of other forms of evidence to corroborate service users’ 
self-report is therefore necessary. While some prescribers described contacting service 
users’ GPs for further information concerning medications, this was not done by all 
prescribers. Depending on information obtained from only service users in assessing 
appropriateness implies that medications which are potentially inappropriate may not be 
identified if service users fail to mention them. There is the possibility that prescribers may 
go ahead to prescribe such undisclosed medications. In addiction medicine, there should be 
careful consideration of self-report and collateral information should be sought where 
possible (Action on Addiction, 2013). This is however challenging in practice. There is 
therefore the need for ready availability of information about service users when they 
attend substance misuse services. Means through which this could be achieved are 
discussed in section 8.4.2.   
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8.1.4. Medicines optimisation  
Medicines optimisation ‘requires evidence-informed decision-making about medicines, 
involving effective patient engagement and professional collaboration to provide an 
individualised, person-centred approach to medicines use, within the available resources’ 
(National Institute for Health and Care Excellence, 2013). It is a patient-centred approach 
that aims to produce the best outcomes from the use of medicines (Royal Pharmaceutical 
Society, 2013). Healthcare professionals need to work together to individualise care, 
monitor outcomes more carefully, review medicines more frequently and support patients 
when needed (Royal Pharmaceutical Society, 2013). The aspects of medicines optimisation 
that will be discussed in this section include monitoring and review, adherence, medication 
omissions and collaboration among stakeholders. 
 
Monitoring and review 
Both prescriber and service user interviews explored medication assessment and review. 
Some service users described regular review of their medications while others suggested 
there were problems with medication review, including review of repeat prescriptions. 
There was support for this finding in the medication appropriateness study as some 
medications such as benzodiazepines and non-benzodiazepine hypnotics had been 
prescribed for longer than recommended by the BNF (Joint Formulary Committee, 2010) 
and UK guidelines (Baldwin et al., 2013) without review. Prescribers further described 
situations in which service users became dependent on benzodiazepines and opioids due to 
prolonged use and lack of medication review. This thesis suggests that one possible 
explanation for overly long duration of treatment besides benefits reported by service users 
is lack of medication review.  
 
Lack of medication review may be a particular problem among people with SUDs because 
they are often challenging to manage (Deehan et al., 1997; McKeown, Matheson and 
Bond, 2003) with multiple health problems, polypharmacy and high rates of non-
attendance of appointments (Milward, Lynskey and Strang, 2014; Mitchell and Selmes, 
2007b). The database study showed that over one-quarter of service users were taking four 
or more prescribed medications. GPs have often described these patients as time-
consuming (Deehan et al., 1997; McKeown, Matheson and Bond, 2003) as the presence of 
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comorbidities, polypharmacy (Duerden, Avery and Payne, 2013) and service users’ 
complex circumstances (Lloyd, 1998) increases clinical workload.  
 
There is limited time available in general practice to deal with this often complex group of 
people. General practice consultations often do not last longer than 10 minutes (Bashir, 
King and Ashworth, 1994), and it is not possible to address all of service users’ problems 
within this short time frame. Evidence from the interviews with service users further 
suggests that they were sometimes not listened to with one service user describing the very 
short time interval in which he was prescribed an antidepressant. These service users were 
consequently dissatisfied with treatment decisions. In addition to the complex situations of 
service users described above, GPs may not listen to service users due to suspicions 
concerning requests for prescribed drugs, and/or wider stigmatisation of people with SUDs 
(Matheson et al., 2003; McKeown, Matheson and Bond, 2003). Healthcare professionals 
fear being manipulated and dislike dealing with service users who they may not trust 
(Action on Addiction, 2013). Ironically, the need for regular review and effective 
communication ought to be greater in this population due to the higher potential for 
dangerous drug interactions, dependence and fatalities resulting from overdose (Prince, 
2001) and also because they may sometimes need to be prescribed outside guideline 
recommendations. Strategies that could ensure adequate monitoring and review of service 
users in practice are highlighted in section 8.4.3.   
 
Adherence 
The medication appropriateness study, service users’ interviews and prescribers’ 
interviews all addressed the issue of medication adherence. The medication 
appropriateness study found that most service users reported taking their medications 
regularly while prescriber interviews suggested that non-adherence is a significant problem 
among people with SUDs. Interviews with service users showed that those who perceived 
benefit from their medications were more likely to take them regularly. The Perceptions 
and Practicalities Approach (Horne et al., 2005) that has been used in describing factors 
contributing to non-adherence in mental health populations suggests that non-adherence 
may be due to perceptual factors such as patients’ beliefs about their illness and treatment 
as well as practical factors that include patients’ capability and resources. Two key beliefs 
have been identified within this approach: beliefs about the need for medicines and 
concerns about the adverse effects of medicines (Chapman and Horne, 2013).  
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Evidence from previous studies have shown that patients’ beliefs such as their perceived 
benefit from medications is a major reason for adherence (Byrne et al., 2006; Janz and 
Becker, 1984; Loffler et al., 2003). Loffler et al. (2003) found perceived benefit to be the 
main reason reported by patients with schizophrenia for adherence to neuroleptics. When 
compared to those without SUDs, previous studies (Owen et al., 1996; Sajatovic et al., 
2006; Weiss, 2004) among people with mental disorders have found higher levels of non-
adherence among those with SUDs. SUDs represent a significant risk factor for non-
adherence among people with mental disorders (Jonsdottir et al., 2013; Montes et al., 
2013) probably due to intoxication (Owen et al., 1996) and the negative effect of 
substances on cognitive function including memory, attention and learning (Berry et al., 
1993; Horner, 1997; Royal College of Psychiatrists, 2014a; Schilt et al., 2008; Sullivan and 
Pfefferbaum, 2005). The findings of this thesis suggest that lack of benefit from psychiatric 
medications may be an additional reason for the high levels of non-adherence reported 
among people with SUDs.  
 
The differences obtained between the results of the medication appropriateness study and 
those of the prescriber interviews may have resulted because majority of the service users 
in this study perceived their medications to be beneficial. Most service users appeared to 
have consciously made decisions about adherence according to their beliefs about the 
efficacy of their medications. Their indication of interest to participate in a research study 
may also imply that they have a high level of innate motivation when compared to other 
service users and this may have been reflected in their high levels of adherence.  
 
The high levels of adherence reported in the medication appropriateness study may also 
reflect overestimation of adherence by service users or problems with recalling information 
(Chesney, 2000; Schechter and Walker, 2002). Patients may report a high level of 
adherence to avoid embarrassment or being judged (Schechter and Walker, 2002; Tiv et 
al., 2012). However, the possibility of this was mitigated in this study as service users were 
informed that information about their adherence will not be disclosed to healthcare 
professionals. Adherence was assessed on a separate questionnaire that was not attached to 
the A-MAI that was rated by prescribers. Despite this limitation, results from this thesis 
indicate that there is a need for prescribers to enquire about the effects of medications from 
service users. Addressing instances where medications are reported to be ineffective or 
suboptimally effective may be helpful in promoting adherence, with the potential for 
realising full benefit from medications and avoiding waste (Chapman and Horne, 2013). 
278 
 
Previous research suggests that addressing such concerns may assist in supporting 
adherence (Clatworthy et al., 2009; Nunes et al., 2009).     
 
Medication omissions 
Medication omissions were explored in the medication appropriateness study and 
interviews with prescribers. Both studies showed that omissions were generally uncommon 
in service users’ medications though omission of thiamine and other B vitamins may 
sometimes occur. This finding is corroborated in the literature.  
 
Ferguson, Soryal and Pentland (2000) found that slightly over half of known alcoholics 
and only one-quarter of heavy drinkers received thiamine as in-patients. Omission of 
thiamine among people with AUDs may lead to severe consequences such as the 
development of Wernicke-Korsakoff syndrome (Cook and Thomson, 1997; Thomson, 
Guerrini and Marshall, 2009). The occasional omission of medications such as thiamine 
and other B vitamins implies that there may still be need to sensitize GPs and other 
prescribers about the importance of prescribing these medications to those with AUDs.       
 
Collaboration among stakeholders 
The findings of the prescriber interviews suggest that SAS doctors were a valuable source 
of support for nurse prescribers when dealing with prescribing issues. Consultant 
psychiatrists were likewise an important support for other doctors. SAS prescribers also 
supported GPs in prescribing-related issues.  
 
Nurse prescribers described a strong focus on medications within their scope of practice 
during assessment though they described communicating with SAS doctors when they had 
concerns about service users’ medications. Apart from consultant psychiatrists, most of the 
other doctors also tended to address medications within their remit during assessment. This 
narrow focus was further described by both nurse prescribers and doctors when 
considering medication changes, as they described reluctance in changing medications 
outside their remit of practice. There was however evidence that where medications pose 
immediate risk, necessary action would be taken including stopping such medications and 
contacting service users’ GPs. It appears SAS prescribers played a role in preventing 
medication-related harm.     
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While there are no legal restrictions on the clinical conditions that may be treated by nurse 
prescribers, clinical areas of practice are usually defined and agreed with employers 
(National Prescribing Centre, 2012; Nursing and Midwifery Council., 2006). In the case of 
those working in addiction medicine, their area of competence is around prescribing for 
drug and alcohol dependence (Public Health England, 2014c). Although it is recommended 
that nurse prescribers adhere to their areas of competence for safe practice (Public Health 
England, 2014c), it could be argued that this limited focus may well compromise service 
users’ safety where their comorbidities and co-prescribed medications that are outside this 
area put them at risk.  
 
Generally, the tendency for doctors who have a much broader training to focus on 
medications within their remit without taking a more holistic approach to management may 
result in suboptimal care. A strict focus by doctors only on their areas of practice has the 
potential to lead to fragmentation of patient care (Detsky et al., 2012). This may explain 
how some service users go on to accumulate unnecessary medications in clinical practice 
over time since no healthcare professional really takes responsibility for the review of all 
their medications. This is despite the particular challenge service users pose in terms of 
complexity and risk issues. Service users often have complex needs including severe 
comorbid mental (Delgadillo et al., 2012; Marsden et al., 2000; Strathdee et al., 2002; 
Virgo et al., 2001; Walsh and Copello, 2014; Weaver et al., 2003;) and physical health 
problems (Dickey et al., 2002). In order to meet these needs, Public Health England 
(2014c) has recommended that addiction specialist doctors such as consultant psychiatrists 
work alongside non-medical prescribers and other doctors in a multidisciplinary team.  
 
The drug and alcohol treatment system has however undergone some changes in 
commissioning in recent years. This has involved a move from mainly NHS service 
provision to a more mixed economy of service providers (Public Health England, 2014c). 
These changes have led to a decrease in the number of doctors including consultant 
addiction psychiatrists in treatment systems (Public Health England, 2014c), with nurses 
taking on more prescribing roles. Consequently, there is a reduction in the capacity of these 
new treatment systems for specialist expertise and complex case management.  
 
There is a real risk of reduction in the quality of prescribing and decision-making as a 
result of these changes as nurse prescribers and GPs may not have ready access to support 
and specialist knowledge when required. The potential for specialists to provide clinical 
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supervision that will assist nurse prescribers make clinically appropriate decisions is also 
greatly hampered. It appears future prescribing practice in alcohol and drug treatment 
systems will mostly involve nurse prescribers. There is therefore the need for the training 
of nurse prescribers so that they can be well-equipped to manage service users, including 
complex clients, adequately. Similarly, there is the need to further strengthen GPs to 
effectively manage service users.  
 
Taken together, the studies in this thesis clearly show that there is room for improvement 
in medicines optimisation. Results from these studies suggest that the practice of 
monitoring and reviewing medications examined in this thesis may be inadequate. It 
appears GPs may still need to be sensitized on the need for thiamine and other B vitamins 
among people with SUDs. The focus of prescribers on medications within their area of 
practice without a more holistic approach to treatment may result in suboptimal care. 
Furthermore, the recent reduction in medical expertise, including consultant psychiatrists, 
in alcohol and drug treatment systems poses a challenge that may negatively impact on the 
management of service users. The findings of this thesis suggest that there may be need for 
further training of nurse prescribers and GPs so that they can provide optimal care to 
service users including those with complex needs.  
8.1.5. Effect of A-MAI 
Prescribers at the SAS were asked their views on how the A-MAI impacted on their 
clinical practice in their interviews and the majority of them described it as having a 
positive impact on their practice. They described the A-MAI as prompting them to reflect 
on their prescribing, providing a structure for assessing prescribing appropriateness, 
highlighting important appropriateness domains and also prompting review of service 
users’ medications. Nurse prescribers’ views on the impact of the A-MAI were quite 
varied, with half of them reporting no impact. This may have resulted because of the way 
in which the A-MAI was used in this study. Medications assessed by nurse prescribers 
included those outside their scope of practice and they may thereby have found the A-MAI 
less useful since they have very limited expertise in prescribing medications for conditions 
outside their remit. For instance, in order to judge whether a medication is appropriate for 
an indication, there is the need to know what medications might be prescribed and what 
might be appropriate in a particular situation. There would also be need to make a decision 
concerning whether service users have those indications. For the A-MAI to be perceived as 
beneficial, there may be a need for medical and therapeutic knowledge.   
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Furthermore, the time taken to complete the A-MAI varied among different prescribers. 
The time reported differed depending on the complexity of service users’ medication 
regimen and the information available for assessing appropriateness. Where service users 
are on multiple medications, there is the potential for the use of the A-MAI to increase 
clinicians’ workload. This may prohibit its wide usage in clinical practice. Strategies that 
may encourage a wide uptake of the A-MAI in clinical practice are discussed in section 
8.4.3.  
 
The cost dimension on the A-MAI was problematic for prescribers because most of them 
do not know the cost of medications. The cost dimension on the A-MAI accordingly had 
the highest proportion of ‘don’t know’ recorded by prescribers. Inadequate knowledge of 
cost may have implications for the NHS as doctors may prescribe expensive medications 
when there are cheaper alternatives that are equally effective. There may well be need for 
prescribers to be supported in making cost-effective prescribing decisions.  
8.2. Comment on thesis methodology 
The researcher utilised both quantitative and qualitative methods in this thesis. The 
quantitative methods include a scoping review, secondary data analysis and survey that 
follow a postpositivist philosophical approach. Postpositivism has been previously 
considered in section 3.4.1.1. Briefly, it aims to address some of the weaknesses of 
positivism (Guba, 1990). Unlike positivism, it acknowledges that imperfect observations 
and errors are possible (Creswell, 2009). A postpositivist perspective resonates both in 
these quantitative methods and the interpretation of findings.   
 
A postpositivist stance was evident in the scoping review as this review allowed for the 
questioning of methods and assessment of the quality of included studies. The secondary 
data analysis and survey were also influenced by postpositivism because they involved the 
use of quantification to assess relationships (Guba and Lincoln, 1994). The secondary data 
analysis, in particular, allowed for a description of the different types of medications 
prescribed for service users attending this SAS. It specifically addressed four research 
questions. However, one of them relating to variables associated with psychiatric 
polypharmacy could not be addressed because of the large number of independent 
variables compared to the dependent variable (see section 4.3.4.6). Despite this limitation, 
this study provided valuable information on the medications prescribed for service users 
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and informed aspects of the questionnaire survey as the medications assessed in the survey 
were selected from it.  
 
The questionnaire survey addressed some of the gaps identified in the scoping review. It 
involved the use of questionnaires by SAS prescribers to assess the appropriateness of 
opioids and/or psychiatric medications prescribed for service users. The MOQ was used to 
assess for the presence of omissions of opioids and/or psychiatric medications at service 
users’ first SAS appointment while the A-MAI was used to assess multiple dimensions of 
appropriateness of prescribed opioids and/or psychiatric medications during service users’ 
first SAS visit and three-month follow-up appointment. The MOQ and A-MAI 
questionnaires were designed to collect both quantitative and qualitative data. The 
qualitative data allowed for an understanding of the reasons particular ratings were made 
on the questionnaires by prescribers. Although postpositivism is often associated with 
quantitative inquiry, it has been argued that it also sees research as broad and complex, and 
allows for the use of qualitative methods in addition to quantitative ones (Clark, 1998; 
Guba and Lincoln, 1994; Racher and Robinson, 2003).  
 
Despite the advantages of the survey design in allowing quantification of the level of 
inappropriate prescribing in this thesis, it only partially addressed the research questions. 
This is due to the reasons already described in section 5.9.11. Briefly, the reasons include 
absence of medication omissions and use of ‘don’t know’ ratings by prescribers. The 
former meant that medication omissions could not be explored further while the latter 
prevented the summation of A-MAI scores for service users. This prevented assessment of 
change in appropriateness between baseline and three-month follow-up appointment as 
well as the factors associated with this. If this had been possible, this study could have 
assessed whether prescribing appropriateness improved or declined using the summated 
score. Factors predicting prescribing appropriateness could not be adequately explored in 
the logistic regression analysis due to small numbers. 
 
Qualitative methods used include semi-structured interviews with service users and 
prescribers following the underlying principle of phenomenology. Phenomenology has 
already been described in section 3.4.1.2. It aims to explore complexity of views thereby 
highlighting similarities and differences rather than condensing them into a small number 
of categories as in quantitative inquiry (Creswell, 2009). The questionnaire survey 
informed aspects of the service user interviews as those interviewed were service users 
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found to be on prescribed opioids, psychiatric medications or both in the survey. The 
interviews with service users explored their perceptions concerning the appropriateness of 
their prescribed medications while prescriber interviews explored how they responded to 
inappropriate prescribing. The purpose was to engage indirectly through participants’ 
experiences with their views on appropriateness. For instance, while some service users 
described benefit from their medications, others did not. A phenomenological approach 
therefore enabled these different views to be represented. Limitations of the interviews 
have been described in section 7.3.8. 
 
Qualitative and quantitative methods were combined in this thesis. Although both methods 
are usually seen as opposites, some authors (Casebeer and Verhoef, 1997; Popay and 
Williams, 1998) have counselled that they are not. For instance, Popay and Williams 
(1998) suggest that the concept of measurement is not absent in qualitative inquiry as is 
often assumed. Qualitative research in fact does include measurement and quantification 
through the use of words such as ‘many’, ‘most’ and ‘all’ and themes are sometimes 
described as more or less prominent. These measurement approaches were used in the 
semi-structured interviews carried out in this thesis.  
 
Furthermore, the result of the questionnaire survey showed that there is sometimes 
variability of views among prescribers concerning the appropriateness of prescribing 
decisions. Potential reasons for variable views are discussed in section 5.9.10. One reason 
highlighted is that assessment of appropriateness may be affected by prescribers’ 
judgments on the risk posed by medications. It has been argued that risk cannot be 
measured as an absolute value (Slomka et al., 2008). It is socially constructed and subject 
to value judgments and power relationships (Slovic, 1999). These pieces of evidence 
suggest that information obtained from research is not always exclusively qualitative or 
quantitative in nature.  
 
Similarities that have been acknowledged between qualitative and quantitative research 
include the need to formulate a research aim and develop research objectives, clarity of 
questions, justifying a sampling strategy and a detailed analysis plan as well as a 
commitment of both types of studies to understanding of the world, commitment to rigour 
and critique in the research process (Casebeer and Verhoef, 1997; Reichardt and Rallis, 
1994). The use of both qualitative and quantitative methods allowed for the utilisation of 
the strength of each method (Creswell et al., 2011), leading to a greater insight than could 
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have been provided by one method. For instance, while the questionnaire survey found that 
almost half of service users were prescribed one or more inappropriate medications, the 
interviews with service users showed that most of them reported benefits from their 
medications, including those prescribed outside guideline recommendations. There were 
therefore varied views about appropriateness.  
The use of both qualitative and qualitative inquiry was facilitated by pragmatism, a 
worldview that is pluralistic in nature (Creswell, 2009; Creswell and Plano Clark, 2011) 
and employs “what works” (Creswell et al., 2011; Morgan, 2007). Pragmatism is typically 
associated with mixed methods research (Feilzer, 2010; Morgan, 2007; Tashakkori and 
Teddlie, 2003). The researcher used a mixed methods design to address different aspects 
pertaining to the appropriateness of prescribing for service users in a SAS and to gain a 
more complete understanding by combining methods as well as showing areas for future 
research.  
 
8.3. Strengths and limitations of this research   
Due to the multiple methods employed in this thesis, there was an increased awareness of 
the factors that may influence the validity of its findings. Qualitative and quantitative 
methods generate different types of knowledge (Whittemore et al., 2001). Furthermore, 
quantitative methods such as surveys may be limited by the type of questions asked or the 
perception of study participants whereas knowledge generated from qualitative methods 
such as interviews may depend on the researcher’s judgments and interpretation. A critique 
of the studies in this thesis has been carried out in sections 4.5, 5.9.11 and 7.3.8. This 
section therefore provides a brief overview of the strengths and weaknesses of these 
studies and of this thesis as a whole.      
 
The use of a combination of qualitative and quantitative methods is a key strength of this 
thesis as they provided both breadth and depth of understanding. Quantitative methods 
were employed as a starting point, firstly with analysis of SAS routine clinical data to 
provide an overview of the different classes of medications taken by service users during 
their first episode of treatment at the SAS. There were however quality issues relating to 
inaccurate data and the self-report method used by service users. It is therefore a possibility 
that this study underestimated the number of prescribed medications and consequently 
polypharmacy. Despite its limitations, this study was necessary because it represents the 
first attempt to examine all prescribed medications taken by people with SUDs. A 
particular strength of this study is that it included all relevant service users during the 
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period examined. It was therefore comprehensive in its description of service users’ 
prescribed medications. Use of routinely collected data also represented a relatively fast 
and inexpensive method of research. The strengths and weaknesses of this study have been 
considered in detail in section 4.5.  
The analysis of routine clinical data was followed by a scoping review that ascertained the 
appropriateness of opioids for relief of chronic pain and psychiatric medications prescribed 
for people with SUDs. Limitations of the studies included in this review have been 
presented in chapter 2 (section 2.7). Briefly, screening and extraction of data from included 
studies were carried out by a single researcher with the implication that some potential 
studies might have been missed. The focus on only studies published in English may also 
have resulted in potential studies being missed. Furthermore, none of the studies was 
carried out in a substance misuse setting. The studies in this review were of mixed quality 
with over half of them assessing guideline adherence. However, use of guidelines may be 
restrictive because they usually focus on particular health conditions or medications 
(Hughes, 2011) while ignoring patients’ comorbidities, co-prescribed medications, life 
circumstances and their choices (Tinetti, Bogardus and Agostini, 2004). This review 
highlighted the need for studies assessing multiple areas of appropriateness of opioids and 
psychiatric medications among people with SUDs in a substance misuse setting. This 
scoping review represented the first review in this under-researched area and highlighted 
areas for future research. 
 
Following the findings of the scoping review, a survey was carried out that involved the 
use of questionnaires by SAS prescribers to assess appropriateness: the MOQ was used to 
assess for omissions of opioids and/or psychiatric medications while the A-MAI was used 
to assess multiple dimensions of appropriateness of opioids and/or psychiatric medications 
for service users in a SAS. The study limitations have been previously described in section 
5.9.11. The limitations include the fact that diagnosis and associated medication 
management were based on service users’ self-report. In addition, the questionnaires used 
in assessing adherence and omissions have not been previously validated as they were 
developed for the purpose of this study. Although face validity was assessed during the 
pilot stage, there is a need for more extensive testing of the psychometric properties of 
these questionnaires. There is also a need for testing of the psychometric properties of the 
A-MAI as it was adapted from the original MAI for this study. Factors predicting 
prescribing appropriateness could not be adequately explored in the logistic regression 
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analysis due to small numbers. Lack of medication omissions also meant that this area 
could not be explored further using statistical analysis.  
 
Despite these limitations, the use of the adapted-MAI was a strength of this study as it 
allowed for clinical judgment when assessing prescribing appropriateness. Judgments on 
the appropriateness of service users’ medications were also service user-focused and 
incorporated their preferences or subjective views when compared to previous studies. 
Service users who could not speak English or who were too intoxicated to be assessed by 
prescribers were excluded from this study. Service users assessed by non-prescribers were 
also excluded. The findings of this study are therefore not generalizable to the groups of 
excluded service users. In defence of these limitations, this small scale study was necessary 
due to lack of prior research assessing all the dimensions covered in this study. This is also 
the first study to assess the appropriateness of medications in a substance misuse setting. 
Detailed information on the strengths and limitations of this study are presented in section 
5.9.11.   
  
The qualitative study carried out with service users assisted in exploring their perspectives 
on the appropriateness of their prescribed medications. Prescribers’ interviews explored 
how they responded to inappropriate prescribing. The limitations of these qualitative 
interview studies have been considered in detail in section 7.3.8 and include the 
recruitment of participants from a single site and data collection by a single researcher. In 
particular, service users of white background were over-represented in the interviews with 
service users. This is a reflection of the population of people attending the SAS where this 
research was carried out. Over 90% of those in the A-MAI study were of white ethnicity 
(see section 5.9.3). In addition, a number of service users did not take part in the interview 
based on the pre-specified exclusion criteria. The views and experiences of groups 
excluded are therefore under-represented in the service user interviews. Prescribers’ 
responses in the interviews might have been biased due to participation in the medication 
appropriateness study before they were interviewed. There is also the possibility that they 
provided socially desirable responses. A reflexive account that considered the possible 
influences of the researcher on the research process is presented in section 3.5.   
 
In relation to this thesis as a whole, a key limitation is that all the studies were carried out 
in a single SAS in England (as described in section 3.2). The use of a single SAS implies 
that the findings may lack generalizability to other addiction services especially with the 
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recent changes in UK drug and alcohol treatment systems. Medical expertise in UK drug 
and alcohol treatment systems is being decimated, with a proliferation of nurse prescribing. 
Furthermore, the SAS where this research was carried out no longer exists in its original 
form and specialist NHS addiction clinics are now a rarity. Further research involving the 
new drug and alcohol service providers is warranted to establish if these findings are 
applicable. The main strength associated with using a single site for the studies in this 
thesis is the opportunity to build a picture of the appropriateness of prescribing in this 
setting. The use of a single site further allowed the results of the initial studies to inform 
subsequent studies. For instance, the findings of the study analysing routine clinical data 
informed the selection of medications assessed in the medication appropriateness study.  
8.4. Implications for practice   
In the UK, the quality of healthcare has been identified as a priority by the UK 
Government (Department of Health, 2013a). The knowledge generated from this thesis 
may assist clinicians in the NHS in assessing the quality and safety of prescribing for 
people with SUDs especially those with comorbid mental disorders and chronic pain, and 
make improvements where necessary. Indeed, this thesis explored the quality of 
prescribing for people with SUDs as it sought to assess the appropriateness of their 
medications while also exploring prescribers’ responses to inappropriate prescribing 
decisions. The suggestions offered here are tentative as the findings of this thesis may not 
be applicable in other addiction services.  
 
Evidence from the studies in this thesis suggests that the appropriateness of prescribing is a 
complex concept which cannot be viewed solely from the narrow pharmacological model 
represented in guidelines. There is a need for consideration of the physical, psychological 
and social functioning of service users and their preferences when judging the 
appropriateness of prescribing decisions. This research suggests that a holistic view of 
appropriateness may result in it being a value judgment which may sometimes vary 
depending on who is assessing appropriateness. What is appropriate is sometimes a matter 
of debate among clinicians, and between clinicians and service users (MacDonald and 
Murray, 2007). A holistic assessment of appropriateness therefore entails trying to achieve 
a balance between pharmacological appropriateness, service users’ choices or preferences, 
and the risks and benefits of prescribing. The correct balance will depend on the context of 
prescribing.  
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For optimal assessment of prescribing appropriateness, there is the need for collaborative 
work between service users and healthcare professionals. This would often require 
negotiation between clinicians and service users. Consequently, clinicians need to be both 
knowledgeable and skilful when dealing with this client group. There is also the particular 
need for clinicians to be vigilant when prescribing for service users. Sections 8.4.1 
addresses knowledge and skill requirements of clinicians while section 8.4.2 deals with 
how vigilance can be effectively implemented. Sections 8.4.3 and 8.4.4 further describe the 
implications of this research for primary care and addiction services, respectively, while 
section 8.4.5 considers the utility of non-pharmacological therapies among service users.  
8.4.1. Knowledge and skills  
In dealing with service users with comorbid SUDs and mental disorders or chronic pain, all 
prescribers, irrespective of the setting in which they work, need adequate knowledge of the 
pathophysiology of these disorders as well as the pharmacology of medications for their 
management. Knowledge of pharmacology is essential in order to determine whether the 
medication is the right one to be prescribed and how it should be prescribed for optimal 
benefit. This is particularly apposite given the evidence that service users may need to be 
prescribed outside guideline recommendations.  
 
Furthermore, there is a need to build therapeutic relationships with service users as 
treatment plans are only likely to be successful if service users have a positive relationship 
with the clinician and are willing to cooperate with them (Dordevic and Jankovic, 2006). 
Effective communication skills are essential in building this relationship. There was 
evidence in the service user interviews of ineffective communication and consequent 
dissatisfaction with prescribing decisions. Skills in communication entail listening skills, 
showing empathy and concern (Action on Addiction, 2013) and discussion of treatment 
benefits and risks. Listening skills are important in ensuring that the clinician understands 
the service user (Cushing and Metcalfe, 2007). Furthermore, asking for service users’ 
views and helping them think through the problem is likely to be effective in addressing 
prescribing problems. There is also a need to discuss the benefits and risks of treatment 
with service users especially as there is often need for a trade-off between them. The 
treatment goals should be discussed and agreed at the onset of therapy. For instance, in the 
management of chronic pain among service users, it is helpful for them to understand that 
complete absence of pain may be an unrealistic goal (Prince, 2001). A decrease in pain 
with improved functioning may be more feasible. Effective communication could also 
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assist in addressing service users’ perceived barriers to medication change. There may well 
be need for follow-up appointments to come to a mutual decision and to review those that 
have been made (Cushing and Metcalfe, 2007). 
 
 
 
8.4.2. Vigilance  
This section describes how clinicians could be effective in monitoring service users’ 
prescribed medications. The implications highlighted here are relevant to primary care, 
addiction services and mental health services.  
  
As discussed in sections 1.5.1 and 1.5.2, chronic pain and mental disorders commonly co-
exist with SUDs and their presence will be the norm among this population. Additional 
measures that may be needed when prescribing medications with dependence potential 
among those used in the management of these disorders (for example, opioids and 
benzodiazepines) include limiting the quantities dispensed to service users at a time 
(Passik, 2009), pill count, urine drug testing to detect illicit substances, assessing whether 
medications are being taken (Fishbain et al., 2008) as well as the use of medication 
contracts (Chelminski et al., 2005). Medication contracts may be helpful in service users 
who are about initiating these medications to reach an agreement on the conditions under 
which they would be discontinued (Chelminski et al., 2005). These support measures may 
be useful in ensuring that prescribing of these medications is adequately structured and 
safe (Action on Addiction, 2013).  
 
Access to specialist consultations when dealing with service users, especially complex 
people, could greatly improve decision-making concerning therapy. Clinicians prescribing 
opioids for chronic pain need a basic competence in identifying and managing SUDs and 
access to addiction clinic consultation. Likewise, those prescribing psychiatric medications 
need a basic knowledge of addiction medicine and access to addiction specialists when 
needed. Addiction clinicians need to be knowledgeable about chronic pain management 
and mental health problems and also have access to pain clinic and mental health 
consultations.  
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Where different service providers are involved in the care of service users, there is a need 
for them to collaborate as they deliver services or coordinate their care with one another. It 
may be possible to have one person such as the GP as the care co-ordinator or one provider 
as the primary provider. This provider could assist in managing care among other 
providers. Good communication among these different providers would be essential to 
reducing the potential for multiple prescribing, drug interactions and conflicting treatment 
plans (Action on Addiction, 2013). The trend for service users to move around different 
prescribers expressing choice may be counterproductive in the context of addictions.  
There is a need for effective communication and linkage of electronic patients’ records 
among all providers involved in caring for service users for safety reasons, especially as 
the quality of information obtained from service users may be poor. Good communication 
is required because active dependence compromises service users’ self-report (Bailey, 
Hurley and Gold, 2010). Other sources of information such as medical records and 
interviews with family may be needed for corroboration (Action on Addiction, 2013).  
 
In addition, information should be shared among the different service providers on service 
users’ progress, barriers to progress, treatment aims and management (Marsh, Dale and 
Willis, 2007). This information should be readily available to clinicians involved in the 
care of service users so that discrepancies and inconsistencies can be easily verified. This 
could be facilitated through telephone discussions concerning the care of service users, 
joint videoconferencing involving the service user and the service providers, and use of 
electronic or paper letters. Providers of IT services to these service providers may need to 
be instructed on the agreed structure of the communication method to ensure ready access 
to information. There may well be need for the structure to be agreed upon nationally to 
facilitate interoperability and ready transfer of information (Royal Pharmaceutical Society, 
2012).   
8.4.3. Implications for primary care 
This section focuses on the implications of this research for primary care. It is divided into 
two areas: strategies for addressing inappropriate GP prescribing and strategies for 
addressing inappropriate prescribing among service users.  
8.4.3.1. Strategies for addressing inappropriate GP prescribing  
The following strategies for addressing inappropriate GP prescribing are considered in this 
section: medication review, training, audit and feedback and the use of technology. 
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Medication review  
The medication appropriateness study and service user interviews suggested that review of 
medications including repeat prescriptions of psychiatric medications and opioids is 
sometimes a problem in primary care settings. Effective monitoring of repeat prescribing 
and dispensing for people with SUDs by general practice and pharmacy staff, respectively, 
is essential because they may be at increased risk from the adverse effects of medications. 
Monitoring could be through regular audit of repeat prescribing and dispensing systems 
(Duerden et al., 2011), to flag up when reviews are needed and identify prescriptions that 
are no longer necessary. Audits of repeat prescribing systems are necessary with the 
introduction of the Electronic Prescription Service (Duerden, Avery and Payne, 2013) 
which allows for electronic transfer of prescriptions between general practices and 
community pharmacies across England. Without appropriate monitoring, this system may 
compound the problem of inappropriate prescribing and wastage in the NHS as there may 
be continued prescribing of medications that are no longer needed.  
 
Furthermore, when complex patients such as those on multiple medications visit their GPs, 
the consultation may focus on limited conditions with insufficient time for medication 
review (Blenkinsopp, Bond and Raynor, 2012). Alternative options that may assist in 
improving medication review include the involvement of other healthcare professionals in 
medication review. In the UK, healthcare professionals such as practice-based pharmacists 
and practice-based nurses may carry out medication reviews, and such reviews do not 
always have to be face-to-face with service users as it could be done through review of 
service users’ records or through the telephone (British Medical Association and the NHS 
Confederation, 2003). These healthcare professionals may be designated to take up the 
responsibility of carrying out regular reviews of service users’ medications. For instance, 
regular review of records by nurses or pharmacists could assist in flagging up medications 
such as benzodiazepines that have exceeded the time specified in guidelines. This can be 
communicated to the GP for further action.  
 
At present, the General Medical Services (GMS) contractual requirements (British Medical 
Association and the NHS Confederation, 2003) include a clinical medication review which 
should be undertaken every 15 months for all patients prescribed repeat medications. 
Clinical Medication Review (also called type 3 review) involves a face-to-face review of 
medications and condition with the patient (Clyne, Blenkinsopp and Seal, 2008). In people 
with SUDs co-existing with chronic pain or mental disorders, medication review may need 
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to be carried out during routine follow-up appointments in order to ensure medications are 
still appropriate, assess drug interactions and also prevent the development of dependence 
on medications. The other healthcare professionals suggested here could take up this role 
for optimal management of service users.  
 
Assessment tools such as the MAI may have a place in medication review. Duerden, Avery 
and Payne (2013) have suggested that tools for medication review should be developed. 
The present study explored prescribers’ perspectives on the impact of an adapted version 
of the MAI on their prescribing practice and the majority of prescribers described it as 
having a positive impact. There was however an awareness of the potential for the A-MAI 
to increase clinical workload where a service user’s medication regimen is complex. 
Where service users are on few prescribed medications, the A-MAI could be used in its 
present form for medication review. However, for the A-MAI questionnaire to be widely 
used in clinical practice, there may well be a need to reduce the number of items on it. 
Such a modified questionnaire may assist in standardising the process of medication 
review while also ensuring that important areas concerning medication appropriateness are 
covered. It may also be useful as a prompt to the need for a review of repeat prescriptions 
or as a checklist for GPs to consider before prescribing medications. 
 
Evidence from this thesis suggested that SAS prescribers reviewed the medications of 
service users when they attend the service. SAS prescribers contacted GPs if there were 
serious problems with service users’ medications. SAS prescribers were therefore a sort of 
“safety net” against potential medication-related risks. Support from specialist addiction 
services has been recognised by GPs to be crucial in providing better care for service users 
especially those who are considered to be complex (McKeown, Matheson and Bond, 
2003). With the ongoing changes in commissioning in UK drug and alcohol treatment 
services, specialist addiction services with experienced senior prescribers are increasingly 
rare. There is now a dearth of services that can provide this “safety net” function.  
 
Training needs of GPs 
There is a need for further training of GPs to adequately manage people with SUDs. GPs 
have sometimes reported lack of adequate knowledge and skill in the management of 
people with SUDs (McKeown, Matheson and Bond, 2003), who often have complex 
comorbidities such as mental disorders and chronic pain. It appears there is a need for 
continuing professional development in the management of service users’ mental health 
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problems and chronic pain. This may include improving prescribing knowledge, reflection 
on practice and identifying service users’ needs in these areas. GPs who usually have the 
primary responsibility of ensuring care continuity (Freeman and Hughes, 2010) as well as 
initiation of prescribing decisions in the community, should be competent in mental health, 
pain and addiction medicine.  
 
Barriers to safe and effective management, such as stigma, also need to be addressed 
among clinicians. This could be achieved by providing training to address negative 
assumptions and beliefs about addiction (Action on Addiction, 2013). This training could 
be provided by addiction specialist doctors such as consultant psychiatrists, GPs with 
expertise in managing SUDs or pharmacists with expertise in these areas. Additional skills 
needed by all prescribers (including GPs) working with service users have been 
highlighted in section 8.4.1.  
 
Audit and feedback  
GP prescribing of medications used in the management of comorbid mental disorders and 
chronic pain could be audited periodically with detailed feedback provided to them. 
Feedback will need to include specific recommendations for changes in prescribing 
(Lexchin, 1998). Practice-based pharmacists could carry out such audits and provide 
feedback. A study found that personalised feedback letters and targeted educational 
bulletins were effective in improving antibiotic prescribing behaviour in primary care 
(Hux, Melady and DeBoer, 1999). A review of the effectiveness of educational 
interventions in improving prescribing in primary care concluded that the more 
personalised the intervention, the more effective it is (Figueiras, Sastre and Gestal-Otero, 
2001). Consequently, personalised feedback letters may be effective in changing 
prescribing behaviour of GPs.  
 
For audit and feedback to be successful in changing prescribing behaviour, the prescriber 
should recognise that there is a need for improvement on current practice. This recognition 
could be facilitated by having periodic discussions among groups of prescribers (peer 
group) (von Ferber et al., 1992), to review the audit results and discuss means of improving 
performance. Some studies have reported improvements in physician prescribing 
behaviour due to participation in such groups (Reilly and Patten, 1978; von Ferber, 1993).  
 
Use of technology to aid decision-making 
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The safety and quality of prescribing can be improved through electronic prescribing 
(Creswell et al., 2013). Electronic prescribing is usually part of an electronic health record 
system or could be a stand-alone system (Sweidan et al., 2010). Electronic prescribing 
involves  
 
The utilisation of electronic systems to facilitate and enhance the communication of 
a prescription or medicine order, aiding the choice, administration and supply of a 
medicine through knowledge and decision support and providing a robust audit trail 
for the entire medicines use process (NHS Connecting for Health, 2007, p.18).  
 
Electronic prescribing can assist in preventing inappropriate prescribing by reducing the 
risk of prescribing contra-indicated medications, preventing duplication, reducing 
inappropriate dosing, promoting adherence to best practice recommendations and cost-
effective prescribing (Black et al., 2011; Kaushal, Shojania and Bates, 2003). Evidence 
from this thesis shows that prescribers do not have adequate knowledge of the cost of 
medications. Electronic prescribing systems provide a means to ensure that cost-effective 
medications are prescribed when considering two or more medications of equal efficacy. In 
addition, it was reported that there may sometimes be omission of thiamine and other B 
vitamins by GPs. Electronic prescribing systems may be programmed to remind clinicians 
about the need to prescribe these medications for service users with AUDs. Due to the fact 
that inappropriate prescribing is a complex, multidimensional problem (Lexchin, 1998), 
changing prescribing behaviour will likely need to involve a combination of the strategies 
highlighted above.  
 
8.4.3.2. Strategies for addressing inappropriate prescribing among service users.  
Regular medication reviews mentioned above may lead to the identification of 
inappropriate medications. This section therefore considers how to work effectively with 
service users in order to facilitate change of such medications. Furthermore, the findings of 
this research suggest that service users may be resistant to medication changes. Evidence-
based interventions that have been found to be effective in reducing or discontinuing 
chronic use of medications may be used. Such evidence-based interventions that have been 
effective in reducing chronic use of benzodiazepines among patients include brief advice 
by GPs supplemented by self-help books (Bashir, King and Ashworth, 1994), letters from 
GPs (Cormack et al., 1994; Heather et al., 2004) and clinical pharmacist’s 
recommendations (Hanlon et al., 1996).  
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Cormack et al. (1994) found that both a letter from a GP to patients advising 
benzodiazepine reduction and a letter supplemented by information sheets significantly 
reduced benzodiazepine intake compared to a control group among long-term 
benzodiazepine users in south-west England. Bashir, King and Ashworth (1994) assessed 
the effect of a short GP consultation supplemented by self-help books among long-term 
benzodiazepine users and reported similar findings. Heather et al. (2004) found that both a 
GP letter to patients advising reduction of benzodiazepine use and a short consultation with 
the patient’s GP or practice nurse or pharmacist reduced benzodiazepine consumption. All 
three studies excluded people with SUDs. They found no evidence of deterioration in 
mental or general health as a result of these interventions. Hanlon et al. (1996) further 
reported that recommendations by a clinical pharmacist to elderly patients and their doctors 
in an outpatient setting reduced inappropriate prescribing. These interventions may well be 
useful in reducing or stopping inappropriate medications among service users. 
8.4.4. Implications for addiction services 
Evidence from the interviews with prescribers suggest that besides the more experienced 
doctors such as consultant psychiatrists, the other doctors and the nurse prescribers tended 
to focus on medications within their remit when reviewing service users’ medications. 
Nurse prescribers further described the valuable support they obtained from SAS doctors 
when dealing with problems around prescribing while the more junior doctors (that is, non-
consultants) relied on the support of their consultants for prescribing issues they could not 
address. Recent changes have however led to a reduction in the medical expertise 
(including consultant psychiatrists) of drug and alcohol treatment systems (Public Health 
England, 2014c), with a potential risk of reduction in the quality of prescribing and 
decision-making. With the decline in medical expertise, it appears the onus for prescribing 
and management of service users, including complex clients, will now primarily rest with 
nurse prescribers. This raises serious concerns about the future review practices of 
psychiatric medications in addiction services if nurse prescribers are not further 
strengthened to work with service users, including complex clients.  
 
There is the need to equip nurse prescribers to work with service users, especially complex 
cases. There is a further need for training in diagnostic and therapeutic skills to enable 
nurse prescribers manage complex service users especially those with comorbid mental 
disorders and chronic pain. Practice should include regular supervision of nurse prescribers 
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by an experienced doctor or nurse prescriber to ensure that they are making optimal 
clinical decisions. The differences between nurse prescribers and doctors in this study in 
how they utilised the history they obtained when assessing prescribing appropriateness 
imply that another area for further training may be in carrying out clinical assessments 
including history-taking. Other skills required for optimal management of service users are 
described in section 8.4.1.   
8.4.5. Consideration of non-pharmacological therapies 
The choice of therapy for the management of comorbid SUDs and mental disorders or 
chronic pain may be medications or non-pharmacological therapies or a combination of 
both. Medications are often very accessible but they may not be the optimal solution. There 
is the need for consideration of the use of non-pharmacological treatment options for the 
management of mental disorders and chronic pain in people with SUDs. Psychotherapies 
such as CBT, MI and 12-step approaches may be particularly helpful in the management of 
less severe forms of depressive and anxiety disorders especially as there is limited 
evidence to support the use of medications in these situations (Fournier et al., 2010; Kirsch 
et al., 2008).  
 
Similarly, management of chronic pain and its psychological complications could benefit 
from these psychotherapies as well as behavioural therapies targeted at enhancing self-
efficacy, cognitive and behavioural change (Roditi and Robinson, 2011). These alternative 
options should be considered because evidence of the long-term effectiveness of opioids in 
chronic pain is weak (Noble et al., 2010; Passik, 2009) and there is the risk of opioid 
dependence with long-term use (Deyo and Weinstein, 2001). These psychotherapies and 
behavioural therapies may also be combined with pharmacological treatments for effective 
management of comorbid chronic pain (Passik, 2009) and mental disorders (Kelly, Daley 
and Douaihy, 2012; Moak et al., 2003). 
 
8.5. Recommendations for future research  
In this thesis, the focus has been on assessing the appropriateness of prescribing of opioids 
and psychiatric medications for people with SUDs while also exploring addiction service 
prescribers’ response to inappropriate prescribing decisions. A key focus for future studies 
is the need to assess the appropriateness of prescribing for people with SUDs from the 
original prescriber’s perspective. There is a need to focus on prescribing by general 
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practitioners since they usually initiate or continue the prescribing of most medications 
(Freeman and Hughes, 2010). Quantitative studies are needed to assess the scale of 
prescribing for service users in primary care settings as well as the appropriateness of 
prescribed medications. Such studies should shed light on the different types of 
medications service users are being prescribed and the proportion of people on them. The 
appropriateness of prescribed medications could be assessed using the medication 
appropriateness index or a variant of it.  
Qualitative interviews proved to be particularly useful in this thesis and could be carried 
out in future research to explore GPs’ views on the appropriateness of prescribing within 
their practice around SUDs and comorbidities. This study could further entail exploring 
how GPs manage service users with complex needs, including referral to other services, 
their practice around review of medications and their training/support needs. Such a 
qualitative study should also elicit the views of service users, given the contested nature of 
‘appropriateness’. Some non-participant observation of GP and service user interactions 
might also be possible.   
 
This research was carried out in a single SAS that no longer exists in its original form and 
some of the findings therefore may not be generalizable to present-day alcohol and drug 
treatment systems. Further research should involve multiple sites (including services run 
by NHS and third sector organisations), especially given the recent changes that have led 
to an increasingly mixed economy of service providers in addictions, to establish if the 
findings of this thesis are applicable. Given the reducing levels of medical expertise among 
SAS staff, an important area to explore will be the role and scope of nurse prescribers: 
including their views on the changing drug treatment landscape, management of service 
users (especially those with complex needs), the support available to nurse prescribers and 
their training needs. Service users offered NHS services may also be compared with those 
being managed by third sector organisations on the following outcomes: prescribing 
appropriateness, polypharmacy, adverse events such as overdose, patient satisfaction and 
recovery. The views of service users on the quality of care they receive should also be 
compared. Evidence obtained from these studies may well inform future practice and 
policy in this area. 
  
Studies are also needed to assess the psychometric properties of the questionnaires used in 
this thesis such as the A-MAI, adherence questionnaire and medication omissions 
questionnaire. In addition, qualitative studies are needed to assess the usefulness of the A-
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MAI to healthcare professionals as a checklist to consider before prescribing as well as an 
aid in the medication review process. Interviews could be undertaken with healthcare 
professionals working in addiction services and primary care to determine how the A-MAI 
could be further adapted for use in clinical practice in these settings. This interview may 
consider which A-MAI dimensions are more relevant for service users with SUDs. A-MAI 
dimensions that are considered to be relevant could be used to develop a more compact 
version of the A-MAI that would take less time to complete. This may be used routinely in 
clinical practice for the review of service users’ medications in primary care and addiction 
services. 
  
8.6. Conclusion 
This thesis addressed the following aims: 
 
 To investigate the level and nature of appropriateness of current medications of 
service users in a SAS; 
 To explore prescribers’ responses to inappropriate prescribing in a SAS. 
 
These aims were addressed through a mixed methods design involving a secondary 
analysis of routinely collected data, questionnaire surveys in the medication 
appropriateness study, and interviews with service users and SAS prescribers. This 
research demonstrated the presence of inappropriate prescribing of psychiatric medications 
and opioids among service users attending a SAS. Assessment of the appropriateness of 
prescribing appears to be a value judgment that may differ between prescribers, and also 
between service users and prescribers. This thesis found that the appropriateness of 
prescribing for people with SUDs is sometimes an area of conflict.  
 
Appropriateness can be understood in terms of the reductive pharmacological model. 
However, the evidence base for this model does not often include people with SUDs. An 
alternative model is the outcome-focused way of prescribing. In this model, appropriate 
prescribing is conceptualised as that which produces good outcomes for service users 
irrespective of whether it is outside guideline endorsement. People with SUDs often have a 
myriad of problems and prescribing that is inappropriate by guideline standards could be 
considered to be appropriate in another sense if it assists them in maintaining their stability 
and prevents relapse to substance use. Optimal assessment of prescribing appropriateness 
should therefore involve a balance between pharmacological appropriateness, risks and 
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benefits of prescribing including service users’ outcomes, service users’ preferences and 
context.  
 
Prescribers’ responses further showed that responding to inappropriate prescribing is a 
complex process that involved considering the benefits and risks of medications, their 
expertise, the nature of addiction as well as communication with service users and 
prescribers. Nurse prescribers described relying on the expertise of SAS doctors when 
dealing with issues around prescribing. SAS prescribers were also a sort of “safety net” 
against medication-related risks as they intervened and contacted GPs if there are serious 
problems with service users’ medications. Recent changes in the UK drug and alcohol field 
have led to diminishing medical expertise and an increasing reliance on non-medical 
prescribing. In addition, specialist NHS addiction clinics such as the Leeds Addiction Unit 
are now a rarity in the UK, with resultant lack of specialist addiction medicine support for 
GPs when needed. These changes pose a threat to the quality of decision-making around 
medications by non-medical prescribers and GPs. It appears there is a need to further 
empower non-medical prescribers and GPs to effectively manage service users with 
comorbidity. Further research is now required, especially with the changes that have taken 
place in UK drug and alcohol services, to establish if the findings of thesis are applicable.  
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Appendix 2.1: Search strategy used in Medline (1946 to February Week 4 2012)  
1 (alcoholi$ or drinker$ or drinking).tw. 
2 
exp alcohol-related disorders/ or exp amphetamine-related disorders/ or exp cocaine-related 
disorders/ or exp opioid-related disorders/ 
3 exp Substance-Related Disorders/ 
4 
((drug or alcohol$ or narcotic$ or heroin or opiate$ or opioid$ or opium or cocaine or crack 
cocaine or cannabis or marijuana or marihuana or hashish or phencyclidine or 
benzodiazepine$ or barbiturate$ or amphetamine$ or MDMA or hallucinogen$ or ketamine 
or lsd or inhalant$ or substance$) adj2 (abuse$ or misuse$ or use$ or problem$ or depend$ 
or addict$ or disorder$)).ti,ab. 
5 exp Street Drugs/ 
6 or/1-5 
7 exp Polypharmacy/ 
8 polypharmacy.tw. 
9 exp Medication Errors/ 
10 Medication Errors.tw. 
11 exp Drug Interactions/ 
12 exp Guideline Adherence/ 
13 medication appropriateness index.tw. 
14 beer$ criteria.tw. 
15 prescribing appropriateness index.tw. 
16 ACOVE indicator$.tw. 
17 Assessing Care of Vulnerable Elderly indicator$.tw. 
18 START criteria.tw. 
19 screening tool to alert to right treatment.tw. 
20 STOPP criteria.tw. 
21 screening tool of older persons prescription$.tw. 
22 (underprescrib$ or overprescrib$ or misprescrib$ or overus$ or underus$ or misus$).tw. 
23 (inappropriate prescrib$ or inappropriate prescription$).tw. 
24 exp Inappropriate Prescribing/ 
25 (dose$ or dosage$).tw. 
26 Pharmacological Appropriateness Rating of Medicines.tw. 
27 or/7-26 
28 exp Prescriptions/ 
29 (Prescription$ or prescrib$).tw. 
30 exp Drug Prescriptions/ 
31 
(drug prescription$ or drug prescrib$ or medication prescrib$ or medication 
prescription$).tw. 
32 pharmacotherap$.tw. 
33 or/28-32 
34 27 and 33 
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35 
(((selective serotonin reuptake inhibitors or serotonin) and noradrenaline reuptake 
inhibitors) or monoamine oxidase inhibitors or tricyclic drugs or agomelatine or 
amitriptyline or amoxapine or acetylcarnitine or alaproclate or amersergide or amineptine or 
amiflamine or bupropion or befloxatone or brofaromine or benactyzine or butriptyline or 
citalopram or caroxazone or cilosamine or chlorpoxiten or clorgyline or cimoxatone or 
clomipramine or clorimipramine or clovoxamine or desipramine or deanol or deprenyl or 
demexiptiline or dibenzipin or dothiepin or doxepin or diclofensine or duloxetine or 
dosulepin or escitalopram or etoperidone or fluoxetine or fluvoxamine or femoxetine or 
fluparoxan or fluotracen or flupentixol or imipramine or iproniazid or idazoxan or 
isocarboxazid or iprindole or lofepramine or mianserin or maprotiline or metapramine or 
mirtazapine or moclobemide or melitracen or minaprine or nortriptyline or nefazodone or 
nomifensine or nialamide or oxaflozan or paroxetine or phenelzine or pargyline or 
protriptylin or prosulpride or reboxetine or rolipram or setiptiline or seleginine or tianeptine 
or tetrindole or tranylcypromine or tomoxetine or trazodone or trimipramine or venlafaxine 
or viqualine).ti,ab. 
36 Exp Antidepressive Agents/ 
37 35 or 36 
38 6 and 34 and 37 
39 Animals/ 
40 Humans/ 
41 39 not (39 and 40) 
42 38 not 41 
43 
(benperidol or chlorpromazine or flupentixol or haloperidol or levomepromazine or 
pericyazine or perphenazine or pimozide or prochlorperazine or promazine or sulpiride or 
trifluoperazine or zuclopenthixol or amisulpride or aripiprazole or clozapine or olanzapine 
or paliperidone or quetiapine or risperidone or sertindole or zotepine or fluphenazine or 
pipotiazine or risperidone).ti,ab. 
44 exp Antipsychotic Agents/ 
45 43 or 44 
46 6 and 34 and 45 
47 46 not 41 
48 
(nitrazepam or loprazolam or lormetazepam or temazepam or zaleplon or zolpidem or 
zopiclone or chloral hydrate or diazepam or alprazolam or chlordiazepoxide or lorazepam or 
oxazepam or buspirone or bromazepam or meprobamate or clonazepam).ti,ab. 
49 (cyclopyrrolone$ or z?drug$ or benzodiazepine$).ti,ab. 
50 (anxiolytic$ or hypnotic$).ti,ab. 
51 or/48-50 
52 6 and 34 and 51 
53 52 not 41 
54 
(buprenorphine or codeine or diamorphine or dihydrocodeine or dipipanone or fentanyl or 
hydromorphoneormeptazinol or methadone or morphine or oxycodone or papaveretum or 
pentazocine or pethidine or tramadol).ti,ab. 
55 exp Analgesics, Opioid/ 
56 (opiate$ or opioid$).ti,ab. 
57 or/54-56 
58 6 and 34 and 57 
59 58 not 41 
60 
(carbamazepine or eslicarbazepine or ethosuximide or gabapentin or lamotrigine or 
levetiracetam or oxcarbazepine or phenobarbitone or phenobarbital or primidone or 
phenytoin or pregabalin or rufinamide or topiramate or sodium valproate or vigabatrin or 
valproate or valproic acid or zonisamide).ti,ab. 
61 exp Anticonvulsants/ 
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62 60 or 61 
63 6 and 34 and 62 
64 63 not 41 
65 exp Lithium/ 
66 6 and 34 and 65 
67 66 not 41 
 
  
305 
 
Appendix 2.2:  Search strategy used in PsycINFO (1946 to February Week 4 2012) 
1 (alcoholi$ or drinker$ or drinking$).tw. 
2 
((drug or alcohol$ or narcotic$ or heroin or opiate$ or opioid$ or opium or cocaine or crack 
cocaine or cannabis or marijuana or marihuana or hashish or phencyclidine or 
benzodiazepine$ or barbiturate$ or amphetamine$ or MDMA or hallucinogen$ or ketamine 
or lsd or inhalant$ or substance$) adj2 (abuse$ or misuse$ or use$ or problem$ or depend$ 
or addict$ or disorder$)).ti,ab. 
3 illicit drug.tw. 
4 street drug.tw. 
5 or/1-4 
6 exp Polypharmacy/ 
7 polypharmacy.tw. 
8 medication error$.tw. 
9 exp Drug Interactions/ 
10 drug interaction$.tw. 
11 exp Treatment Guidelines/ 
12 treatment guideline$.tw. 
13 guideline adherence.tw. 
14 medication appropriateness index.tw. 
15 beers criteria.tw. 
16 prescribing appropriateness index.tw. 
17 ACOVE indicator$.tw. 
18 Assessing Care of Vulnerable Elderly indicator$.tw. 
19 START criteria.tw. 
20 screening tool to alert to right treatment.tw. 
21 STOPP criteria.tw. 
22 screening tool of older persons prescription$.tw. 
23 Pharmacological Appropriateness Rating of Medicines.tw. 
24 (underprescrib$ or overprescrib$ or misprescrib$ or overus$ or underus$ or misus$).tw. 
25 (inappropriateprescrib$ or inappropriate prescription$).tw. 
26 exp Drug Dosages/ 
27 (dose$ or dosage$).tw. 
28 or/6-27 
29 exp Prescription Drugs/ 
30 exp "Prescribing (Drugs)"/ 
31 
(prescription$ or prescrib$ or prescription drug$ or drug prescription$ or drug prescrib$ or 
medication prescription$ or medication prescrib$).tw. 
32 pharmacotherap$.tw. 
33 or/29-32 
34 28 and 33 
35 
(((selective serotonin reuptake inhibitors or serotonin) and noradrenaline reuptake 
inhibitors) or monoamine oxidase inhibitors or tricyclic drugs or agomelatine or 
amitriptyline or amoxapine or acetylcarnitine or alaproclate or amersergide or amineptine or 
amiflamine or bupropion or befloxatone or brofaromine or benactyzine or butriptyline or 
citalopram or caroxazone or cilosamine or chlorpoxiten or clorgyline or cimoxatone or 
clomipramine or clorimipramine or clovoxamine or desipramine or deanol or deprenyl or 
demexiptiline or dibenzipin or dothiepin or doxepin or diclofensine or duloxetine or 
dosulepin or escitalopram or etoperidone or fluoxetine or fluvoxamine or femoxetine or 
fluparoxan or fluotracen or flupentixol or imipramine or iproniazid or idazoxan or 
isocarboxazid or iprindole or lofepramine or mianserin or maprotiline or metapramine or 
mirtazapine or moclobemide or melitracen or minaprine or nortriptyline or nefazodone or 
nomifensine or nialamide or oxaflozan or paroxetine or phenelzine or pargyline or 
protriptylin or prosulpride or reboxetine or rolipram or setiptiline or seleginine or tianeptine 
or tetrindole or tranylcypromine or tomoxetine or trazodone or trimipramine or venlafaxine 
or viqualine).ti,ab. 
36 exp Antidepressant Drugs/ 
37 35 or 36 
38 5 and 34 and 37 
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39 animal.po. 
40 human.po. 
41 39 not (39 and 40) 
42 38 not 41 
43 
(benperidol or chlorpromazine or flupentixol or haloperidol or levomepromazine or 
pericyazine or perphenazine or pimozide or prochlorperazine or promazine or sulpiride or 
trifluoperazine or zuclopenthixol or amisulpride or aripiprazole or clozapine or olanzapine 
or paliperidone or quetiapine or risperidone or sertindole or zotepine or fluphenazine or 
pipotiazine or risperidone).ti,ab. 
44 exp Neuroleptic Drugs/ 
45 antipsychotic$.ti,ab. 
46 or/43-45 
47 5 and 34 and 46 
48 47 not 41 
49 
(nitrazepam or loprazolam or lormetazepam or temazepam or zaleplon or zolpidem or 
zopiclone or chloral hydrate or diazepam or alprazolam or chlordiazepoxide or lorazepam or 
oxazepam or buspirone or bromazepam or meprobamate or clonazepam).ti,ab. 
50 (cyclopyrrolone$ or z?drug$ or benzodiazepine$).ti,ab. 
51 (anxiolytic$ or hypnotic$).ti,ab. 
52 or/49-51 
53 5 and 34 and 52 
54 53 not 41 
55 
(buprenorphine or codeine or diamorphine or dihydrocodeine or dipipanone or fentanyl or 
hydromorphone or meptazinol or methadone or morphine or oxycodone or papaveretum or 
pentazocine or pethidine or tramadol).ti,ab. 
56 exp Opiates/ 
57 (opiate$ or opioid$).ti,ab. 
58 or/55-57 
59 5 and 34 and 58 
60 59 not 41 
61 
(carbamazepine or eslicarbazepine or ethosuximide or gabapentin or lamotrigine or 
levetiracetam or oxcarbazepine or phenobarbitone or phenobarbital or primidone or 
phenytoin or pregabalin or rufinamide or topiramate or sodium valproate or vigabatrinor 
valproate or valproic acid or zonisamide).ti,ab. 
62 exp Anticonvulsive Drugs/ 
63 anticonvulsant$.tw. 
64 or/61-63 
65 5 and 34 and 64 
66 65 not 41 
67 exp Lithium/ 
68 5 and 34 and 67 
69 68 not 41 
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  Appendix 2.3: Search strategy used in Embase (1974 to 2012 March 05)  
  1 (alcoholi$ or drinker$ or drinking$).tw. 
2 addiction/ or alcoholism/ or drug dependence/ or withdrawal syndrome/ 
3 
((alcohol or drug or narcotic$ or entactogen$ or amphetamine$ or psylocibin or solvent$ or 
heroin or opiate$ or opioid$ or opium or cocaine or crack cocaine or cannabis or marijuana 
or marihuana or hashish or phencyclidine or benzodiazepine$ or barbiturate$ or MDMA or 
hallucinogen$ or ketamine or lsd or inhalant$ or substance$) adj2 (abuse$ or misuse$ or 
use$ or problem$ or depend$ or addict$ or disorder$)).ti,ab. 
4 exp street drug/ 
5 exp illicit drug/ 
6 or/1-5 
7 exppolypharmacy/ 
8 polypharmacy.tw. 
9 exp medication error/ 
10 medication error$.tw. 
11 drug interaction/ or *drug alcohol interaction/ or *drug inhibition/ or *drug potentiation/ 
12 *practice guideline/ 
13 practice guideline$.tw. 
14 treatment guideline$.tw. 
15 guideline adherence.tw. 
16 medication appropriateness index.tw. 
17 beers criteria.tw. 
18 prescribing appropriateness index.tw. 
19 ACOVE indicator$.tw. 
20 Assessing Care of Vulnerable Elderly indicator$.tw. 
21 screening tool to alert to right treatment.tw. 
22 screening tool of older persons prescription$.tw. 
23 STOPP criteria.tw. 
24 START criteria.tw. 
25 Pharmacological Appropriateness Rating of Medicines.tw. 
26 exp inappropriate prescribing/ 
27 (inappropriate prescription$ or inappropriate prescrib$).tw. 
28 
drug dose/ or *dosage schedule comparison/ or *drug dose comparison/ or *drug dose 
escalation/ or *drug dose increase/ or *drug dose reduction/ or *drug dose regimen/ or 
*drug overdose/ or *drug underdose/ or *optimal drug dose/ or *recommended drug dose/ 
29 (underprescrib$ or overprescrib$ or misprescrib$ or overus$ or underus$ or misus$).tw. 
30 or/7-29 
31 exp prescription/ 
32 (prescription$ or prescrib$).tw. 
33 
(drug prescription$ or drug prescrib$ or medication prescription$ or medication 
prescrib$).tw. 
34 pharmacotherap$.tw. 
35 or/31-34 
36 30 and 35 
37 
(((selective serotonin reuptake inhibitors or serotonin) and noradrenaline reuptake 
inhibitors) or monoamine oxidase inhibitors or tricyclic drugs or agomelatine or 
amitriptyline or amoxapine or acetylcarnitine or alaproclate or amersergide or amineptine or 
amiflamine or bupropion or befloxatone or brofaromine or benactyzine or butriptyline or 
citalopram or caroxazone or cilosamine or chlorpoxiten or clorgyline or cimoxatone or 
clomipramine or clorimipramine or clovoxamine or desipramine or deanol or deprenyl or 
demexiptiline or dibenzipin or dothiepin or doxepin or diclofensine or duloxetine or 
dosulepin or escitalopram or etoperidone or fluoxetine or fluvoxamine or femoxetine or 
fluparoxan or fluotracen or flupentixol or imipramine or iproniazid or idazoxan or 
isocarboxazid or iprindole or lofepramine or mianserin or maprotiline or metapramine or 
mirtazapine or moclobemide or melitracen or minaprine or nortriptyline or nefazodone or 
nomifensine or nialamide or oxaflozan or paroxetine or phenelzine or pargyline or 
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protriptylin or prosulpride or reboxetine or rolipram or setiptiline or seleginine or tianeptine 
or tetrindole or tranylcypromine or tomoxetine or trazodone or trimipramine or venlafaxine 
or viqualine).ti,ab. 
38 exp antidepressant agent/ 
39 antidepressive$.tw. 
40 or/37-39 
41 6 and 36 and 40 
42 human/ 
43 nonhuman/ 
44 exp animal/ 
45 43 or 44 
46 45 not (42 and 45) 
47 41 not 46 
48 
(benperidol or chlorpromazine or flupentixol or haloperidol or levomepromazine or 
pericyazine or perphenazine or pimozide or prochlorperazine or promazine or sulpiride or 
trifluoperazine or zuclopenthixol or amisulpride or aripiprazole or clozapine or olanzapine 
or paliperidone or quetiapine or risperidone or sertindole or zotepine or fluphenazine or 
pipotiazine or risperidone).ti,ab. 
49 exp neuroleptic agent/ 
50 antipsychotic$.ti,ab. 
51 or/48-50 
52 6 and 36 and 51 
53 52 not 46 
54 
(nitrazepam or loprazolam or lormetazepam or temazepam or zaleplon or zolpidem or 
zopiclone or chloral hydrate or diazepam or alprazolam or chlordiazepoxide or lorazepam or 
oxazepam or buspirone or bromazepam or meprobamate or clonazepam).ti,ab. 
55 (cyclopyrrolone$ or z?drug$ or benzodiazepine$).ti,ab. 
56 (anxiolytic$ or hypnotic$).ti,ab. 
57 or/54-56 
58 6 and 36 and 57 
59 58 not 46 
60 
(buprenorphine or codeine or diamorphine or dihydrocodeine or dipipanone or fentanyl or 
hydromorphone or meptazinol or methadone or morphine or oxycodone or papaveretum or 
pentazocine or pethidine or tramadol).ti,ab. 
61 exp opiate/ 
62 opioid$.tw. 
63 or/60-62 
64 6 and 36 and 63 
65 64 not 46 
66 
(carbamazepine or eslicarbazepine or ethosuximide or gabapentin or lamotrigine or 
levetiracetam or oxcarbazepine or phenobarbitone or phenobarbital or primidone or 
phenytoin or pregabalin or rufinamide or topiramate or sodium valproate or vigabatrin or 
valproate or valproic acid or zonisamide).ti,ab. 
67 exp anticonvulsive agent/ 
68 anticonvulsant$.ti,ab. 
69 or/66-68 
70 6 and 36 and 69 
71 70 not 46 
72 exp lithium/ 
73 6 and 36 and 72 
74 73 not 46 
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Appendix 2.4: Adapted Quality Assessment Tool for Quantitative Studies 
 Study author: 
Year: 
 A) SELECTION BIAS 
 (Q1) Are the individuals selected to participate in the study likely to be representative of the target 
population? 
1. Very likely (included all eligible patients during specified period) 
2. Somewhat likely 
3. Not likely 
4. Can't tell 
 (Q2) What percentage of selected individuals agreed to participate? 
1. 80-100% agreement 
2. 60-79% agreement 
3. Less than 60% agreement 
4. Not applicable 
5. Can't tell 
 RATE THIS SECTION: 1. Strong   2. Moderate   3. Weak 
 B) STUDY DESIGN 
 Indicate the study design 
1 Randomized controlled trial 
2 Controlled clinical trial 
3 Cohort analytic 
4 Case-control 
5 Interrupted time series 
6 Other specify ____________________________ 
7 Can’t tell 
 Was the study described as randomized? If NO, go to Component C. 
No  Yes 
 If Yes, was the method of randomization described? 
No  Yes 
 If Yes, was the method appropriate? 
No  Yes 
 RATE THIS SECTION: 1. Strong    2. Moderate    3. Weak 
 C) CONFOUNDERS 
 (Q1) Were there important differences between groups prior to the intervention? 
1 Yes 
2 No 
3 Can’t tell (the sample with SUDs were not compared to those without it). SUDs were co-morbid 
with depression 
 The following are examples of confounders: 
1 Race 
2 Sex 
3 Marital status/family 
4Age 
5 SES (income or class) 
6 Education 
7 Health status 
8 Pre-intervention score on outcome measure 
 (Q2) If yes, indicate the percentage of relevant confounders that were controlled (either in the 
design (e.g. stratification, matching) or analysis)? 
 1 80 – 100% 
2 60 – 79% 
3 Less than 60% 
4 Can’t Tell 
  RATE THIS SECTION: 1. Strong    2. Moderate    3. Weak 
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D) DATA COLLECTION METHODS 
 (Q1) Were data collection tools shown to be valid? 
1 Yes 
2 No 
3 Can’t tell 
 (Q2) Were data collection tools shown to be reliable? 
1 Yes 
2 No 
3 Can’t tell (used already existing admin data) 
 RATE THIS SECTION: 1. Strong    2. Moderate    3. Weak 
 E) WITHDRAWALS AND DROP-OUTS 
 (Q1) Were withdrawals and drop outs reported in terms of numbers and/or reasons per group? 
1 Yes 
2 No 
3 Can’t tell 
4 Not applicable 
 (Q2) Indicate the percentage of participants completing the study. (If the percentage differs by 
groups, record the lowest). 
1 80 -100% 
2 60 - 79% 
3 less than 60% 
4 Can’t tell 
 RATE THIS SECTION: 1. Strong    2. Moderate    3. Weak 
 GLOBAL RATING 
 COMPONENT RATINGS 
 Please transcribe the information from the previous sections onto this page. Rate this section 
 A SELECTION BIAS                                1. Strong    2. Moderate    3. Weak 
B STUDY DESIGN                                   1. Strong    2. Moderate    3. Weak 
C CONFOUNDERS                                   1. Strong   2. Moderate    3. Weak 
D DATA COLLECTION METHODS       1. Strong   2. Moderate    3. Weak 
E WITHDRAWALS AND DROP-OUTS 1. Strong    2. Moderate    3. Weak    4. Not applicable 
 GLOBAL RATING FOR THIS PAPER (circle one): 
1 STRONG (three or more STRONG ratings with no WEAK ratings) 
2 MODERATE (less than four STRONG ratings and one WEAK rating) 
3 WEAK (two or more WEAK ratings) 
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Appendix 3.1: Consultation process questionnaire 
 How often do you think these medications are inappropriately prescribed for patients with 
substance use disorders? Please tick the relevant box for each of the medications. 
  
          
Medications Frequently Sometimes Rarely Never  
Antidepressants         
Antipsychotics         
Anxiolytics and hypnotics         
Antihypertensives         
Positive inotropic drugs (digoxin, 
digitoxin, enoximone, milrinone) 
        
Nitrates          
Anti-arrhythmics (amiodarone, 
disopyramide, flecainide, propafenone, 
adenosine) 
        
Proton pump inhibitors (PPIs)         
Other antiulcer drugs (antacids, H2 
receptor antagonists, prostaglandin 
analogues and others) 
        
Opioids including substitute opioids         
Analgesics excluding opioids (NSAIDs, 
antimigraine drugs, paracetamol and 
nefopam) 
        
Anticonvulsants         
Drugs used in asthma and COPD 
management (adrenoceptor agonists, 
antimuscarinic bronchodilators, 
theophylline, compound preparations, 
leukotriene receptor antagonists, 
cromoglicates and others)  
        
Cholesterol-lowering agents          
Drugs used in substance dependence 
(disulfiram, acamprosate, bupropion, 
NRT, varenicline and lofexidine) 
        
Vitamins         
Minerals          
Antimanic agent (lithium)         
Corticosteroids         
Thyroid hormones         
Antihistamines         
Antidiabetic agents         
Antihyperuricaemics         
Anticoagulants         
Hormone replacement therapy         
Laxatives and purgatives         
Antimuscarinics         
Opioid antagonists         
Dopaminergic agents used in 
parkinsonism (cabergoline, pergolide, 
apomorphine, pramipexole, ropinirole, 
rotigotine, levodopa, co-beneldopa, co-
careldopa, rasagiline, selegiline, 
entacapone, tolcapone and amantadine) 
        
Antifibrinolytic agents         
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Lubricants         
Antiandrogens         
Mucolytics         
Skeletal muscle relaxants         
Anaesthetics          
Drugs affecting intestinal secretions 
(ursodeoxycholic acid, aprotinin, 
pancreatin) 
        
Aminosalicylates         
Antiobesity drugs         
hormone antagonists (anastrozole, 
exemestane, fulvestrant, letrozole, 
tamoxifen, toremifene, degarelix) 
        
CNS stimulants (atomoxetine, 
dexamphetamine, methylphenidate, 
modafinil) 
        
Systemic nasal decongestants         
Antiglaucoma agents         
Antimicrobials          
Antiplatelet agents         
Antispasmodics (alverine, mebeverine, 
peppermint oil) 
        
Drugs affecting immune system 
(azathioprine, cyclosporin, 
mercaptopurine, methotrexate) 
        
Drugs affecting bone metabolism 
(calcitonin, parathyroid hormone, 
bisphosphonates, strontium) 
        
Topical corticosteroids with 
antimicrobials 
        
Combined contraceptive pill         
Antimotility agents (co-phenotrope, 
loperamide)  
        
Antiemetics         
Supplements (ensure, fortisip, fortijuice 
and others) 
        
Topical preparations for acne         
Antihaemorrhoidals         
Drugs used for urinary incontinence         
Emollients         
Topical preparations for psoriasis         
Other drugs for rheumatic diseases 
(glucosamine, chondrontin) 
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Appendix 4.1: Favourable ethical opinion letter for secondary data analysis 
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Appendix 4.2: Prescribed medications taken by service users at their first SAS treatment 
episode 
Medications No. of service users on 
medications (1783) 
Antidepressants 868 (48.7%) 
Antipsychotics 266 (14.9%) 
Anxiolytics/hypnotics 295 (16.5%) 
Antihypertensives 282 (15.8%) 
Proton Pump Inhibitors (PPIs) 264 (14.8%) 
Antacids 24 (1.3%) 
Analgesics (including opioids, NSAIDs and others) 519 (29.1%) 
Anticonvulsants 116 (6.5%) 
Drugs used in asthma and COPD management 118 (6.6%) 
Cholesterol-lowering agents 95 (5.3%) 
Drugs used in treating substance dependence (disulfiram, 
acamprosate, bupropion, NRT, varenicline and lofexidine) 
52 (2.9%) 
Vitamins and minerals 498 (28.1%) 
Antimanic agent (lithium) 32 (1.8%) 
Antibiotics 39 (2.2%) 
Corticosteroids
a
 46 (2.6%) 
Thyroid hormones 32 (1.8%) 
Antihistamines 45 (2.5%) 
Antidiabetic agents 37 (2.1%) 
Antihyperuricaemics 21 (1.2%) 
Anticoagulants 22 (1.2%) 
Hormone replacement therapy 22 (1.2%) 
Laxatives and purgatives 22 (1.2%) 
Antimuscarinics 32 (1.8%) 
Antispasmodics
b
 22 (1.2%) 
Immunosuppressants
c
 5 (0.3%) 
Drugs affecting bone metabolism 3 (0.2%) 
Emollients and barrier preparations 6 (0.3%) 
Positive inotropic drugs 3 (0.2%) 
Antiplatelet agents
d
 3 (0.2%) 
Others
e
 10 (0.6%) 
Note: All medications were classified into only one group (for example, aspirin was grouped only under NSAIDs and not 
antiplatelet agents). a Includes corticosteroids with antimicrobials, bincludes drugs that are believed to be direct relaxants 
of intestinal smooth muscle such as alverine, mebeverine and peppermint oil, cdoes not include corticosteroids, dexcludes 
aspirin, eothers include secretin, hydrogen sulphate, tiopronin, glucosamine, chondroitin, compound haemorrhoidal 
preparations, compound preparations for psoriasis. 
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Appendix 4.3: Comparison of sociodemographic characteristics between service users with 
and without polypharmacy (n and % presented for all characteristics except age) 
Sociodemographic 
characteristics 
Service users without 
polypharmacy 
Service users with 
polypharmacy 
P-values 
Age
a
 
Total 
38.4 + 10.4 
1285 
46.2 + 11.1 
476 
P < 0.0005
#
 
Gender 
Male 
Female 
Total 
 
730 (56.8%) 
555 (43.2%) 
1285 
 
295 (62%) 
181 (38%) 
476 
 
 
 
0.05
+
 
Ethnicity
b
 
White 
Other 
Not stated 
Total 
 
1108 (86.2%) 
60 (4.7%) 
117 (9.1%) 
1285 
 
411 (86.3%) 
28 (5.9%) 
37 (7.8%) 
476 
 
 
 
 
0.42
+
 
Housing status
c
 
Rented 
Home owner 
Homeless 
Other 
Total 
 
735 (60.5%) 
232 (19.1%) 
174 (14.3%) 
74 (6.1%) 
1215 
 
260 (57.3%) 
113 (24.9%) 
51 (11.2%) 
30 (6.6%) 
454 
 
 
 
 
 
0.04
+
 
Referral source
d 
Self 
GH/A&E 
GP 
Psychiatrist 
Drug services 
Other 
Total 
 
415 (32.3%) 
124 (9.6%) 
270 (21%) 
93 (7.2%) 
196 (15.3%) 
187 (14.6%) 
1285 
 
138 (29%) 
78 (16.4%) 
110 (23.1%) 
48 (10.1%) 
44 (9.2%) 
58 (12.2%) 
476 
 
 
 
 
 
 
 
P <0.0005
+
 
Referral substance
e
 
Alcohol 
Opioids 
Other 
Total 
 
948 (73.8%) 
238 (18.5%) 
99 (7.7%) 
1285 
 
427 (89.7%) 
25 (5.3%) 
24 (5%) 
476 
 
 
 
 
P < 0.0005
+
 
Employment status
f
 
Employed 
Unemployed 
Other 
Total 
 
266 (21.9%) 
670 (55.2%) 
277 (22.8%) 
1213 
 
63 (14%) 
215 (47.8%) 
172 (38.2%) 
450 
 
 
 
 
P <0.0005
+
 
Note: The level of significance was set at 0.4% after taking the total number of variables (12) into consideration due to 
Bonferroni adjustment for multiple testing. aMean and standard deviation presented for age, bother ethnicity includes 
Asian or Asian British, Black or Black British, Mixed and other ethnic groups, cother housing status includes supported 
housing and traveller, dother referral sources includes social services, criminal justice and others, eother referral 
substances includes sedatives, cannabis, stimulants, hallucinogens, polyuse and solvents, fother employment status 
includes inactive, not stated and others, #calculated using independent sample t-test, +calculated using chi-squared test. 
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Appendix 4.4: Comparison of key measures of addiction between service users with and 
without polypharmacy 
Addiction measures Service users 
without 
polypharmacy 
Service users 
with 
polypharmacy 
P-values 
LDQ
a
 
Total 
17 (9, 24) 
1259 
18.5 (10, 25) 
464 
0.026
*
 
CORE-10 
Total 
21.4 + 9.3 
1261 
23.1 + 8.5 
467 
P < 0.0005
#
 
SSQ 
Total 
13.9 + 5.6 
1233 
13.7 + 5.5 
454 
0.45
#
 
EQ5D
a
 
Total 
0.7 (0.3, 0.9) 
1256 
0.3 (0.08, 0.7) 
470 
P < 0.0005
*
 
Number of previous SAS 
episode
a
 
Total 
1 (1, 2) 
 
1285 
1 (1, 2) 
 
476 
 
 
0.04
*
 
Note: The level of significance was set at 0.4% after taking the number of variables (12) into consideration due to 
Bonferroni adjustment for multiple testing. aMedian and interquartile range presented because data not normally 
distributed, *calculated using Wilcoxon rank sum test, # calculated using independent samples t-test. 
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Appendix 4.5: Comparison of sociodemographic characteristics between service users with 
and without psychiatric polypharmacy (n and % presented for all characteristics except age) 
Sociodemographic 
characteristics 
Service users 
without psychiatric 
polypharmacy 
Service users with 
psychiatric 
polypharmacy 
P-value 
Age
a
 
Total 
40.5 + 11.2 
1731 
42.9 + 10.2 
30 
0.23
#
 
Gender 
Male 
Female 
Total 
 
1009 (58.3%) 
722 (41.7%) 
1731 
 
16 (53.3%) 
14 (46.7%) 
30 
 
 
 
0.59
+
 
Ethnicity
b
 
White 
Other 
Not stated 
Total 
 
1491 (86.1%) 
86 (5%) 
154 (8.9%) 
1731 
 
28 (93.3%) 
2 (6.7%) 
0 
30 
 
 
 
 
0.15
*
 
Housing status
c
 
Rented 
Home owner 
Homeless 
Other 
Total 
 
976 (59.5%) 
340 (20.7%) 
222 (13.5%) 
102 (6.2%) 
1640 
 
19 (65.5%) 
5 (17.2%) 
3 (10.3%) 
2 (6.9%) 
29 
 
 
 
 
 
0.91
*
 
Referral source
d
 
Self 
GH/A&E 
GP 
Psychiatrist 
Drug services 
Other 
Total 
 
546 (31.5%) 
200 (11.6%) 
379 (21.9%) 
130 (7.5%) 
237 (13.7%) 
239 (13.8) 
1731 
 
7 (23.3%) 
2 (6.7%) 
1 (3.3%) 
11 (36.7%) 
3 (10%) 
6 (20%) 
30 
 
 
 
 
 
 
 
P < 0.0005
*
 
Referral substance
e
 
Alcohol 
Opioids 
Other 
 
1355 (78.3%) 
260 (15%) 
116 (6.7%) 
1731 
 
20 (66.7%) 
3 (10%) 
7 (23.3%) 
30 
 
 
 
 
0.008* 
Employment status
f
 
Employed 
Unemployed 
Other 
Total 
 
329 (20.1%) 
868 (53.1%) 
437 (26.7%) 
1634 
 
0 
17 (58.6%) 
12 (41.4%) 
29 
 
 
 
 
0.02
+
 
Note: The level of significance was set at 0.4% after taking the number of variables (12) into consideration due to 
Bonferroni adjustment for multiple testing. aMean and standard deviation presented for age, bother ethnicity includes 
Asian or Asian British, Black or Black British, Mixed and other ethnic groups, cother housing status includes supported 
housing and traveller, dother referral sources includes social services, probation and others, eother referral substances 
includes sedatives, cannabis, stimulants, hallucinogens, polyuse and solvents, fother employment status includes inactive, 
not stated and others, *calculated using Fisher’s exact test, +calculated using chi-squared test, #calculated using 
independent sample t-test. 
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Appendix 4.6: Comparison of key measures of addiction between service users with and 
without psychiatric polypharmacy 
Measures of 
addiction 
Service users 
without psychiatric 
polypharmacy 
Service users with 
psychiatric 
polypharmacy 
P-values 
LDQ 
 
17 (9, 24) 
1693 
16.5 (11.8, 22) 
30 
0.98
a
 
CORE-10 
 
21.8 + 9.1 
1698 
25.3 + 7.5 
30 
0.04
b
 
SSQ 
 
13.8 + 5.6 
1659 
14.9 + 5.3 
28 
0.32
b
 
EQ5D 
 
0.6 (0.2, 0.8) 
1697 
0.3 (0.2, 0.6) 
29 
0.007
 a
 
Number of previous 
SAS episodes 
1 (1, 2) 
1731 
1 (1, 2) 
30 
0.36
 a
 
aAnalysed using Wilcoxon rank sum test, banalysed using independent samples t-test 
 
  
326 
 
Appendix 4.7: A study of the psychotropic prescriptions of people attending an addiction 
service in England 
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Appendix 5.1: Information sheet for service users 
 
 
                                                                                                       Version 3.1 (08/06/2012) 
 
 
                 The Department of Health Sciences 
 
                        A study of the appropriateness of service users' prescriptions 
 
        INFORMATION SHEET FOR SERVICE USERS 
 
We would like to invite you to take part in our research study on the prescriptions you are taking. 
Before you decide we would like you to understand why the research is being done and what it 
would involve for you. One of our team will go through the information sheet with you and answer 
any questions you have. We‘d suggest this should take about 10 minutes.   
  
What is the purpose of the study? 
The purpose of this study is to assess whether your prescriptions are right for you. Prescribing for 
people who use alcohol and other drugs may sometimes not be right for them because they may 
receive too little or too much medications compared to other people. We will therefore be asking 
you what you think about your prescriptions and how you take them. We will also be asking 
prescribers what they think about your prescriptions. 
  
Why have I been invited to participate? 
You have been invited to participate in this study because you have been newly referred to the 
Leeds Addiction Unit (LAU) and are being assessed by a prescriber today. All newly referred 
service users being assessed by a prescriber will be invited to participate in this study. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to join the study. You are free to withdraw at any time, 
without giving a reason. This would not affect the standard of care you receive.  
 
What will happen to me if I take part? 
If you decide to take part in this study, you will be given a questionnaire where you will be asked 
to write down all the prescriptions you are taking. With your consent, information concerning you 
and your health conditions will be extracted from your medical records in order for us to 
understand your situation better. If you indicate on the consent form that you are interested in being 
interviewed, we may want to interview you in three months’ time for 30 to 60 mins during one of 
your LAU appointments in order to explore your feelings concerning your prescriptions and how 
this affects your sense of well-being. If this date is not suitable for you, we will try to find a more 
convenient date. In these circumstances, as it would not be your usual appointment date, we will be 
happy to reimburse your transport expenses.  
 
What are the risks of taking part? 
Participation in this study is highly unlikely to result in any physical risk to you. However, if you 
feel anxious or distressed talking about your prescriptions during the interview with the researcher, 
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the interview will be stopped and you would be asked if you would like to speak to one of the 
therapists at the LAU. 
  
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. All information which is collected about you during the course of the research will be 
kept strictly confidential. No one will be able to identify you from the study and we will not share 
the information you provide with anyone who is not a member of the research team. However, 
during the interview you may mention something which suggests you or others have been or is at 
risk of harm. If so, we would suggest sources of support, but may also have to inform the 
appropriate staff at the LAU after discussing this with you.  
 
What will happen if I don’t want to carry on with this study? 
If you withdraw from the study, we will use the data collected up to your withdrawal.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions on 01132 952775 or oak501@york.ac.uk. If you 
remain unhappy and wish to complain formally, you can do this by contacting the NHS complaints 
procedure (0345 015 4033).    
 
What will happen to the results of the research study? 
The results will be written up in a thesis and published in journals and conferences. You will be 
sent a summary of the results of this study.  
 
Who is organising and funding the research? 
This study is being funded by the Collaboration for Leadership in Applied Health Research and 
Care (CLAHRC) and supported by the University of York. It is also being undertaken as a piece of 
student research towards the award of a Doctorate at the University of York. 
 
What will happen to the information I provide if I lose authority to consent? 
If you lose authority to consent, you will be withdrawn from the study but any data you gave prior 
to then will be used in this study.  
 
Where can I get further information concerning this study? 
You can get more information about this study by contacting the study’s chief investigator 
(Obirenjeyi Kudehinbu-Oluyase). You can also contact the chief investigator if you decide to 
withdraw from the study through the following means: 
Telephone: 01132 952775 (Monday, Tuesday and Thursday between 11am and 4.00pm) 
Email: oak501@york.ac.uk. Thank you for taking the time to read this information sheet and 
considering whether to take part in this study. 
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Appendix 5.2: Consent form for service users 
                                                                                                               Version 3.1 (08/06/2012) 
 
     The Department of Health Sciences 
                 A study of the appropriateness of service users' prescriptions 
 
                            CONSENT FORM FOR SERVICE USERS 
 
Name of Researcher: Obirenjeyi Kudehinbu-Oluyase 
Please 
each  
initial 
box  
1. I confirm that I have read and understand the information sheet dated  
8
th
 June 2012 for the above study. I have had the opportunity to consider  
the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to  
withdraw at any time without giving any reason, without my medical care  
or legal rights being affected. 
 
3. I understand that relevant sections of my medical records and data collected  
during the study, may be looked at by the research team, where it is  
relevant to my taking part in this research. I give permission for these  
individuals to have access to my records.  
 
4. I agree to be contacted by telephone and email for interview in this study. 
 
5. I agree to my interview being audio-recorded.    
  
6. I agree to direct quotes from me being used in the reports of this study.   
 
7. I agree to being contacted in the future about the possibility of taking part  
in further research. 
 
8. I agree to the data I provide for this study being used even if I lose capacity  
to consent in the future. 
  
9. I agree to the Leeds Addiction Unit holding my consent form.    
 
10. I agree to take part in the above study.       
 
_______________________                     ____________               ____________        
Name of patient          Date              Signature 
 
_______________________                     ____________               ____________ 
Name of person taking consent        Date                 Signature 
 
If you have any questions, please contact the chief investigator Obirenjeyi Kudehinbu-Oluyase on 01132 952775 or oak501@york.ac.uk. 
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Appendix 5.3: Medical/medication history form 
 
1. Date  _________   2. Patient ID# ______________  3. Evaluator ID# ________________   
     
4. Prescribed drugs taken 
Medication Dose Frequency Length 
of use 
Reason for use Who made 
diagnosis? 
When? 
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Appendix 5.4: Adherence questionnaire 
 
Patient ID no:   _____________________                            Date:  ________________ 
 
Please state the details of all prescribed medications you are taking below: 
 
Medications Dose How 
many 
times were 
you asked 
to take it 
in a day?  
How often do you take this medication as 
recommended? (Please tick one box) 
 
 
 
 
Very     Often  Sometimes     Rarely   Never       
Often 
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Appendix 5.5: Information sheet for prescribers  
                                                                                                        Version 3.1 (08/06/2012) 
    
         The Department of Health Sciences 
            
      A study of the appropriateness of service users' prescriptions 
 
                                   INFORMATION SHEET FOR PRESCRIBERS 
 
We would like to invite you to take part in our research study on the appropriateness of 
prescriptions for service users. Before you decide we would like you to understand why the 
research is being done and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. We‘d suggest this should take 
about 10 minutes.   
  
What is the purpose of the study? 
The purpose of this study is to assess the use and appropriateness of prescriptions of psychotropic 
medications such as antidepressants, antipsychotics, anxiolytics/hypnotics, antimanic agents, 
anticonvulsants, opioids (including substitute opioids) and medications used in treating substance 
dependence (disulfiram, acamprosate, lofexidine, bupropion and baclofen) for service users who 
are newly referred to the Leeds Addiction Unit (LAU). Prescribing for service users with substance 
use disorders (SUD) is a relatively unexplored area and the few studies available mostly examine 
prescribing appropriateness by assessing adherence to treatment guidelines relating to the adequacy 
of the duration of medication therapy and dosage. However, other important aspects of medication 
appropriateness such as the presence of drug interactions, unnecessary prescriptions and medication 
omissions (underutilisation), which are equally important, have been rarely considered despite their 
contribution to morbidity, adverse events and increased health care costs. Furthermore, the reasons 
for prescribing decisions among service users with SUD have not been well researched.  
 
We would therefore wish to find out how you rate the appropriateness of the prescriptions of 
interest using the Medication Appropriateness Index (MAI) and the Assessment of Underutilisation 
of Medication (AOU) Index respectively. We would be interested in changes you make to service 
users prescriptions from their first assessment to their three month follow-up review and would be 
interviewing you to explore how you assess the appropriateness of service users’ prescriptions 
towards the end of this study.  
 
Why have I been invited to participate? 
You have been invited to participate in this study because you are a medical prescriber at the Leeds 
Addiction Unit (LAU). All medical prescribers at the LAU will be invited to participate in this 
study. 
 
Do I have to take part? 
No, it is up to you to decide to join the study. If you agree to take part, we will then ask you to sign 
two consent forms, out of which one will be given to you to keep. You are free to withdraw at any 
time, without giving a reason.  
 
What will happen if I decide to take part? 
If you decide to take part in this study you will be administered a demographics questionnaire 
where you will fill in your demographic information. You will be given the AOU to assess 
omission (underutilisation) of the prescriptions of interest during service users’ first assessment 
whilst you will be given the MAI to assess the appropriateness of the prescriptions of interest 
during service users’ first assessment and three month follow-up review. This study will last for six 
months. You will be interviewed for 30 to 60mins towards the end of the study (at six months) to 
explore how you assess prescribing appropriateness.  
 
Will my taking part in the study be kept confidential? 
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Yes. We will follow ethical and legal practice and all information we obtain from you will be 
handled in confidence. All information which is obtained from you during the course of the 
research will be kept strictly confidential. No one will be able to identify you from the study and 
we will not share the information you provide with anyone who is not a member of the research 
team.  
 
What will happen if I don’t want to carry on with this study? 
If you withdraw from the study, we will use the data collected up to your withdrawal.  
 
What will happen to the results of the research study? 
The results of this study will be written as a PhD thesis, published in journals and presented in 
conferences. We would also feedback the results to you. The results of this study should be 
published by 2013. 
 
Who is organising and funding the research? 
This study is being funded by the Collaboration for Leadership in Applied Health Research and 
Care (CLAHRC) and supported by the University of York. It is also being undertaken as a piece of 
student research towards the award of a Doctorate in the Department of Health Sciences at the 
University of York. 
 
What will happen to the information I provide if I lose authority to consent? 
If you lose authority to consent, you will be withdrawn from the study but any data you gave prior 
to then will be used in this study.  
 
Where can I get further information concerning this study? 
You can get more information about this study by contacting the study’s chief investigator 
(Obirenjeyi Kudehinbu-Oluyase). You can also contact the chief investigator if you decide to 
withdraw from the study through the following means: 
 
Telephone: 01132 952775 (Monday, Tuesday and Thursday between 11am and 4.00pm) 
Email: oak501@york.ac.uk 
 
Thank you for taking the time to read this information sheet and considering whether to take part in 
this study. 
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Appendix 5.6: Consent form for prescribers 
                                Version 3.1 (08/06/2012) 
 
 
    The Department of Health Sciences 
              
A study of the appropriateness of service users' prescriptions 
 
CONSENT FORM FOR PRESCRIBERS 
 
Name of Researcher: Obirenjeyi Kudehinbu-Oluyase 
Please 
initial 
each 
box  
1. I confirm that I have read and understand the information sheet dated  
8
th
 June 2012 for the above study. I have had the opportunity to consider  
the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to  
withdraw at any time without giving any reason, without my legal  
rights being affected. 
 
3. I understand that relevant sections of data collected from me during the  
study, may be looked at by individuals from the research team, where  
it is relevant to my taking part in this research. I give permission for these  
individuals to have access to these data.  
 
4. I agree to my interview being audio-recorded.     
  
5. I agree to direct quotes from me being used in the reports of this study.   
 
 
6. I agree to the data I provide for this study being used even if I lose capacity  
to consent in the future. 
 
7. I agree to the Leeds Addiction Unit holding my consent form.    
 
8. I agree to take part in the above study.       
 
 
 
_________________________                     ____________               ____________ 
Name of patient              Date              Signature 
 
_________________________                     ____________               ____________ 
Name of person taking consent            Date                 Signature 
 
 
If you have any questions, please contact the chief investigator Obirenjeyi Kudehinbu-Oluyase on 
01132 952775 or oak501@york.ac.uk. 
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Appendix 5.7: Demographic information questionnaire for prescribers 
 
1. Name: ___________________________ 
 
2. Age (years): _______________________ 
 
3. What is your sex? (Please tick one box)    Male                 Female  
 
4. How do you describe your ethnicity? (Please check the one that applies to you) 
� White British               � Other    � African 
� White Irish               � Indian   � Other Black  
� Other white               � Pakistani                � Chinese 
� White and Black Caribbean    � Bangladeshi               � Other 
� White and Black African         � Other Asian               � Prefer not to say 
� White and Asian                      � Caribbean 
 
5. What is your current position? (Please check the one that applies to you)  
� Nurse prescriber 
� Senior House Officer 
� Registrar 
� Consultant 
 
6. What year did you qualify as a prescriber?       _______________   
 
7. How many years have you practiced for?         _______________  
 
Thank you for taking the time to complete this questionnaire 
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Appendix 5.8: The Medication Appropriateness Index 
 
 
Patient ID# __________   Evaluator _______________________Date_____________________ 
 
Drug Code ____________  Drug___________________________________________________ 
 
To assess the appropriateness of the drug, please answer the following questions and circle the 
applicable rating: 
 
 1.  Is there an indication for the drug? A________ B_______ C________ Z 
 Indicated  Not Indicated DK 
     Comments:     
 2.  Is the medication effective for the  
      condition? 
A________ B_______ C________ Z 
 Effective  Ineffective DK 
Comments:     
 3.  Is the dosage correct? A________ B_______ C + or C - Z 
 Correct  Incorrect DK 
Comments:     
 4.  Are the directions correct? A_______ B_______ C________ Z 
 Correct   Incorrect DK 
Comments:     
 5.  Are the directions practical? A________ B_______ C________ Z 
 Practical  Impractical DK 
Comments:     
 6.  Are there clinically significant drug-drug 
interactions? 
A________ 
Insignificant  
B_______ C________ 
Significant  
Z 
DK 
Comments:     
 7.  Are there clinically significant drug-
disease/condition interactions? 
A________ 
Insignificant  
B_______ C________ 
Significant  
Z 
DK 
Comments:     
 8.  Is there unnecessary duplication with 
other drug(s)? 
A_______ 
Necessary 
B_______ C________ 
Unnecessary 
Z 
DK 
Comments:     
 9.  Is the duration of therapy acceptable? A________ 
Acceptable 
B_______ C________ 
Not acceptable 
Z 
DK 
Comments:     
10.  Is this drug the least expensive alternative 
compared to others of equal utility? 
A________ 
Least 
expensive  
B_______ C________ 
Most 
expensive  
Z 
DK 
Comments:     
 
 
  USE OF THE MEDICATION APPROPRIATENESS INDEX (MAI) 
For further information/articles using the MAI address inquiries to Joseph T. Hanlon, PharmD, MS, 
Department of Medicine (Geriatrics), Pharmacy and Therapeutics, and Epidemiology, University of 
Pittsburgh and Health Scientist, Center for Health Equity Research and Promotion (CHERP) and Geriatric 
Research Education and Clinical Center (GRECC) VA Pittsburgh Healthcare System, Kaufmann Medical 
Building-Suite 514, 3471 5
th
 Ave, Pittsburgh, PA 15213, Tel#- 412-692-2360, Fax#-  412-692-2370, Email: 
jth14@pitt.edu 
  
A. General Instructions  (See Hanlon JT, Schmader KE, et al.  J Clin Epidemiol 1992;45:1045, and 
Fitzgerald LS, Hanlon JT, et al.  Ann Pharmacother 1997;31:543-8). 
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This instrument is intended for the evaluation of the appropriateness of medications prescribed by a health 
care provider.  It may also be used to evaluate self-medication practices by patients.  It requires, at a 
minimum, that a medical history problem list and medication list is available for review.  Medication history 
information obtained from patients can be helpful in applying the MAI.  Before evaluation, review the case 
information available and medication profile for each patient.  It is important that clinical judgment must be 
applied in regards to patient’s preference, and life expectancy.  Complete the scale for each regularly 
scheduled active medication.  The MAI can be used to assess the use of “prn” or as needed medication used 
frequently.  Each question in the scale pertains to the individual patient and drug in question.  Read each 
question carefully and circle the score (A, B, C or Z) that represents your assessment.  If you do not 
understand the question, consult the specific instructions below for clarification.  If you do not know the 
answer to the question, consult a standard medication text or software such as the AHFS Drug Information, 
Drug Facts and Comparisons, Micromedex,  Clinical Pharmacology (an electronic drug reference and 
teaching guide), or UpToDate®, unless the specific instructions for the question indicates an alternative 
source.  At times, you may require additional information from the patient's chart to answer a question.  In 
that case, circle Z and specify the necessary information in the comments section.  Some regimens contain 
combination drugs.  If the individual components are available and used as single entities, then complete the 
scale for each individual drug.  Finally, please note your reasons for any rating of B or C in the comments 
section. 
 
 B. Scoring   A summated MAI score per drug can be calculated by the application of weights. (see 
Samsa G, Hanlon JT, Schmader KE, et al.  A summated score for the Medication Appropriateness Index:  
development and assessment of clinimetric properties including content validity.  J Clin Epidemiol 
1994;47:891-6).  For items coded as inappropriate (“C”), apply the following weights for individual criterion 
as follows:  
Criterion      Relative Weight Applied to Inappropriate Ratings 
Is there an indication for the drug?           3 
Is the medication effective for the condition?       3 
Is the dosage correct?            2 
Are the directions correct?           2 
Are there clinically significant drug-drug interactions?        2 
Are there clinically significant drug-disease interactions?        2 
Are the directions practical?           1 
Is this drug the least expensive alternative compared  
to others of equal utility?         1 
Is there unnecessary duplication with other drugs?         1 
Is the duration of therapy acceptable?          1 
 
To calculate a weighted MAI score per patient, sum MAI scores for each drug in patients’ regimens [see 
Schmader K, Hanlon JT, et al.  J Am Geriatr Soc 1994;42:1241 and Hanlon JT, Weinberger M., et al. Am J 
Med 1996;100:428-37.;  Schmader KE, Hanlon JT, Pieper CF, Sloane R, Ruby CM, Twersky J, Dove- 
Francis S, Branch LG, Lindblad CI, Artz M, Weinberger M, Feussner JR, Cohen HJ. Effectiveness of 
geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail 
elderly. Am J Med 2004]. 
 
C. Other measures that can be used to assess suboptimal prescribing  
(see Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SN  Comparison of prescribing criteria to 
evaluate the appropriateness of drug treatment in individuals aged 65 and  older: a systematic review.  J Am 
Geriatr Soc 2011;59:1521-30.) 
 
To assess unnecessary use of medications (i.e., polypharmacy), one may use combined MAI ratings from 
questions 1, 2, and 8 (see Hajjar ER, Hanlon JT, Sloane RJ, Lindblad CI, Pieper CF; Ruby CM, Branch LC, 
Schmader KE. Unnecessary drug use in the frail elderly at hospital discharge. J Am Geriatr Soc 
2005;53:S178.) 
 
To assess the underuse of medication consider the use of  implict measure (Assessment of Underutilization 
(AOU) of Medication (Wright RM, Sloane RJ, Pieper CF, Ruby-Scelsi CM, Twersky J, Schmader KE, 
Hanlon JT.  Underuse of indicated medications among physically frail older US veterans at the time of 
hospital discharge.  Am J Geriatr Pharmacother 2009;7:271-280) or alternatively the use of explict criteria 
(e.g., Barry PJ, Gallagher P, Ryan C, et al.  START (screening tool to alert doctors to the right treatment)—
an evidence-based screening tool to detect prescribing omissions in elderly patients.  Age and Ageing 
2007;36:632-638).  
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D.  Specific Instructions For Rating 
Question 1: Is there an indication for the drug? 
 
A________________________B________________________C______           Z 
indicated  marginally indicated          not indicated                     do not know 
 
Definition:  Indication is defined as the sign, symptom, disease, or condition for which the medication is 
prescribed.  The question assesses whether there is sufficient reason for the use of the drug.  Sufficient reason 
includes not only curative and palliative therapy but also preventive therapy for a disease, condition or drug 
effect.  
Instructions:  A drug is not indicated if no condition exists for its use.  Answer the question with the 
conditions found in the problem list.  If score = C, then questions 9 and 10 are scored C. 
Examples:  Hydrochlorothiazide (HCTZ) is prescribed and hypertension is recorded on the problem list = A 
(indicated).  Olanzapine is prescribed and psychosis, schizophrenia, etc. is not documented = C (not 
indicated).  KCl for prevention of hypokalemia in the setting of digoxin and diuretic use = A.  Isoniazid and 
positive PPD plus immunosuppressive condition = A.  KCl and diuretics alone, no hypokalemia = C. 
 
Question 2:   Is the medication effective for the condition? 
 
A________________________B________________________C_____                        Z 
effective   marginally effective            ineffective  do not know 
 
Definition:  Effective is defined as producing a beneficial result.  The question assesses whether the drug 
prescribed is capable of being effective for the indication in a population of patients.   
Instructions:  Indication and effectiveness are tightly but not perfectly linked items.  Physicians may 
prescribe a drug for a given condition because of theoretical and standard practice reasons (indication) but 
investigators may demonstrate in clinical trials that the drug is ineffective (hydergine and memory 
enhancement).  Conversely, an indication may not be documented for a drug yet the drug may work well for 
the intended effect (KCl and diuretics).  In those cases, the reviewer must note the assumed indication in the 
comments.  In addition, any drug considered by the FDA to be “less than effective” and appears on the DESI 
list (http://www.cms.hhs.gov/medicaid/drugs/drug11.asp) should be rated as ineffective (“C”).  Also drugs in 
which the potential risks outweigh the potential benefits, and thus are incapable of being effective in actual 
practice should be rated as ineffective (“C”).  For example, those classified by as high risk drugs by AGS 
2012 Bers Criteria should be rated as ineffective (“C”).  The exception would be the use of drugs from this 
list that are essential medications for use in palliative care (see De Lima L. International Association for 
Hospice and Palliative Care list of essential medicines for palliative care. Ann Oncol. 2007;18:395-9).  Also 
in patients with limited life expectancy and medication takes a longer period of time to reap the benefits then 
should be rated as ineffective (“C”) 
 
Examples:  HCTZ for hypertension = A.  H2 antagonist prophylaxis in a person with a history of NSAID 
induced gastric ulcer = C, Meperidine (Demerol
®
) for pain = C.  Statin newly prescribed for LDL >130mg/dl 
in patient with expected life expectancy (Life expectancy can be estimated using the National Vital Statistics 
Reports United States Life Tables 2007;56(9) (http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_09.pdf) is 
less than 1 year= C (takes 1- 2 years for statin to be effective). 
 
Question 3: Is the dosage correct? 
 
A________________________B________________________C____          Z 
correct   marginally correct           incorrect   do not know 
 
Definition:  Dosage is defined as the total amount of medication taken per 24-hour period for regularly 
scheduled medications. 
Instructions:  Amounts within the dosage range for initial and maintenance therapy noted in the specified 
texts are correct.  Other sources may specify newer, more appropriate therapeutic class specific ranges (e.g., 
ACCP consensus conference on antithrombotic therapy) or specific geriatric dosage ranges (e.g., APhA 
Geriatric Drug Dosage Handbook).  These ranges should supersede the standard texts as long as the reference 
is given.  Hence, one should take into account known age-related changes in drug pharmacokinetics and 
pharmacodynamics.  Some patients may have drug labs/levels/VS.  If dosage is too low then circling “C-” 
else if too high then circle “C+”.  In summary, a dosage is incorrect if it is outside the accepted geriatrics 
dose range; if there is no accepted geriatrics dose range, then to be incorrect it must be outside the standard 
range.  A dosage may also be incorrect if not adjusted for renal insufficiency, drug levels and laboratory or 
vital signs outcomes. For drugs being tapered to be discontinued, (e.g., anticonvulsants) low dosage and/or 
low levels will be considered correct. 
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Examples:  Glyburide in patient with estimated creatine clearncs=42ml/min - incorrect due to decreased renal 
clearance of drug in the elderly.  Captopril for CHF given in dosage range of 6.25mg bid to 37.5 mg bid = A.  
Furosemide 20-40 mg a day for hypertension = B.  Full dose Ranitidine 150mg bid for PUD greater than 8 
weeks = C+ since maintenance therapy dose is 150 qhs.  Lovastatin at highest end of usual dosage range with 
still elevated cholesterol = B since necessary and will need to add additional therapy.  Patient with chronic 
cancer pain and only on 4 gms of acetaminophen in divided doses and still rates pain as moderate to severe = 
B since necessary and will need to add additional therapy.  Warfarin 1mg/day for mechanical valve and INR 
to =1.2= C- ; Warfarin 5mg/7.5 mg alternating every other day for atrial fibrillation with INR = 2.8 = A.  
Although lab value above “normal range”, since in therapeutic range of 2.0-3.0 for this anticoagulation 
indication, dosage is correct. 
 
Question 4: Are the directions correct? 
 
A________________________B________________________C____             Z 
correct   marginally correct            incorrect    do not know 
 
Definition:  Directions are defined as the instructions in the use of a medication by a patient.  The question 
assesses the route of administration, relationship to food and liquid, the schedule and time of the day. 
Instructions:  The directions are incorrect when they specify the wrong route of administration, give wrong 
or no instructions regarding food and liquid (when specific directions regarding relationship to food or liquid 
exist), specify the wrong schedule or the wrong time of day (when specific directions regarding relationship 
to schedule and time of day exist).  See appendix IV listing of medications with food and fluid requirements, 
schedule/time of day requirements and those medications that should not be taken with grapefruit juice  
(Mertens-Talcott SU, et al.  grapefruit-drug interactions: can interactions with drugs be avoided?. J Clin 
Pharmacol 2006; 46(12):1390-416).  For new drugs consult the latest edition of the Drugs, Supplements, and 
Herbal Information at http://www.nlm.nih.gov/medlineplus/druginformation.html.  For information regarding 
meds that can't be crushed and given via enteral tube, see http://www.ismp.org/tools/donotcrush.pdf update.  
When possible, examine nurses medication administration records and/or administration time schedules to 
determine time of administration in relationship to meals.  When MAI is used to evaluate patients that are in 
institutional care settings, route, food liquid, schedule and time of day requirements do not apply.  If patient 
goes from institutional to ambulatory care settings, for consistency purposes application may be limited to 
only medications requiring a specific schedule/ time of day. 
Examples:  Captopril 25mg tid =C (incorrect) - should be taken on an empty stomach; glipizide 10mg one qd 
= C (incorrect) - should specify before breakfast; Ibuprofen 400mg one tid with meals and hs with snack = A 
(correct).  Nifedipine XL 60 mg qd is (A).  Quinine one qd is incorrect (C), should specify take at bedtime.  
Furosemide one q day = C (should specify q AM). K-Dur and no directions regarding food/liquid = C.  
Nitropaste 1" qid = C (must specify nitrate-free interval).  Patient taking Nifedipine XL 60 mg qd  with 8oz 
of grapefruit at breakfast=C 
 
Question 5: Are the directions practical? 
 
A________________________B________________________C_____                      Z 
practical   marginally practical          impractical            do not know 
 
Definition:  Practical is defined as capable of being used or being put into practice.  This question assesses 
whether the directions for use are practical for the patient to take or nurse to administer and take into 
consideration the potential for patient compliance without sacrificing efficacy.  When applicable, 
consideration of what drugs are available on formulary should be made. 
Instructions:  A drug schedule is considered impractical if the drug can be administered less frequently and 
still maintain efficacy.  Irregular day-to-day schedules that have more regular alternatives are also 
impractical.  In addition, medications specified to be given around the clock on a fixed qxhours when a more 
flexible schedule is sufficient is impractical. 
 
Examples:  Coumadin 5mg qd except Tuesday and Sunday 10mg qd - impractical (C) when 
6mg qd is easier; Glipizide 5mg bid is impractical (C) when 10mg qam is equally effective - Trazodone 
75mg qhs - practical (A) since once daily and can cue into bedtime routine.  Nifedipine 10mg tid is 
impractical (C) since equally effective alternative, Nifedipine XL 30mg qd, is simpler to administer.  
Albuterol MDI 2 puffs q6h-impractical(C) since qid is sufficient. 
 
Question 6: Are there clinically significant drug-drug interactions? 
 
A________________________B________________________C_____                 Z 
insignificant  marginally insignificant           significant         do not know 
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Definition:   A drug-drug interaction is defined as the effect that the administration of one medication has on 
another drug.  Clinical significance connotes a harmful interaction.  This question assesses whether the drug 
in question interacts with another drug in the patient's regimen by affecting its pharmacokinetics (i.e., 
absorption, distribution, metabolism and excretion) or pharmacodynamics (i.e., the effect that it has on the 
body).  
Instructions:  A drug interactions text, such as Hansten's Drug Interactions and Updates, or software program 
(e.g. Micromedex,  UpToDate® etc.) or specific articles (Malone DC, Abarca J, Hansten PD, Grizzle AJ, 
Armstrong EP, van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB.  Identification of serious drug 
drug interactions: results of the partnership to prevent drug-drug Interactions.  J Am Pharm Assoc 2004;44: 
142-151 or specific CMS guidelines for nursing homes) will serve as the reference for significant 
interactions.  If no interaction exists, then an A rating is automatic.  A “B” rating will be given when the 
reference/program indicates an interaction but no clinical evidence exists for toxicity or adverse effect.  If the 
reference/program indicates an interaction and sufficient clinical information is available and evidence of 
toxicity or adverse effect (including lack of effect) does exist, then the interaction is significant (“C”).  If the 
reference/program indicates an interaction and clinical information is not available, then the interaction may 
also be considered significant (“C”).  The drug that causes the change in pharmacokinetics or 
pharmacodynamics examples is the one that merits the C rating.  
 
Examples:  Significant pharmacokinetic interaction - Cimetidine added to warfarin in a patient with a 
prolonged PT or signs of bleeding=”C”.  Significant pharmacodynamic interaction a tricyclic antidepressant 
or an opioid added to a benzodiazepine, two CNS drugs can result in a patient having increased falls or 
confusion=C.  In the absence of sufficient clinical information, patient is taking digoxin and is now started on 
verapamil and no reduction in digoxin dose=“C for quinidine ”.  NSAID (e.g., naproxen) for osteoarthritis 
started on a patient taking warfarin chronically for atrial fibrillation=C (since increases risk of bleeding). 
 
Question 7: Are there clinically significant drug-disease/condition interactions? 
 
A________________________B________________________C_____               Z 
insignificant  marginally insignificant           significant       do not know 
 
Definition:  Drug-disease interaction is defined as the effect that the drug has on a pre-existing disease or 
condition.  Clinical significance connotes a harmful interaction.  This question assesses whether the drug in 
question may be worsening the patient's disease or condition.  A previous history of an idiosyncratic allergic 
reaction to a drug (e.g., penicillin, sulfa drugs, etc) is considered a preexisting condition.  Specific disease 
states and specific drugs or drug classes constitute drug-disease interactions determined to be clinically 
significant by consensus of a clinical panels 
Instructions:  Information about drug-disease interactions is listed in the precautions or contraindications 
sections of the above specified texts/software. If no interaction exists according to the references, then an “A” 
rating is automatic.  If the drug is contraindicated or highly risky ("extreme caution") for a patient condition, 
then the drug-disease is significant (C).  Appendix IV lists drug-disease interactions to avoid based on a 
consensus survey of a panel of health care professionals.  If a drug-disease combination is listed then the drug 
receives a C, otherwise the drug receives an A.  If the drug needs routine caution ("warning, precaution") in 
the setting of a patient condition and the patient shows clinical evidence of disease worsening following the 
prescription of the drug, then the drug-disease interaction is also significant (C).  If the references indicate an 
interaction ("warning, precaution") and the patient shows no evidence of disease worsening, then the rating is 
marginal (B). 
 
Examples:  Non-aspirin, non-COX2 NSAIDs in a patient with recent history of PUD and no PPI=(C) 
significant; High anticholinergic Tricyclic antidepressants (i.e., doxepin, amitriptyline, imipramine) started in 
patient with LUTs=C;  Dicloxacillin prescribed for someone with a previous history of rash with penicillin=C 
(clinically significant).  Codeine prescribed for someone with a previous history of gastrointestinal 
distress=B. 
 
 
Question 8: Is there unnecessary duplication with other drug(s)? 
 
A________________________B___________________C_____                 Z 
necessary  marginally necessary unnecessary  do not know 
 
Definition:  Unnecessary duplication is defined as nonbeneficial or risky copying of drug(s).  Unnecessary 
duplication exists when two drugs from the same chemical or pharmacological class are prescribed 
simultaneously. 
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Instructions:  The VA Medication Classification System will be utilized on VA PBM website.  The evaluator 
will look up the generic names of all regularly scheduled medications in the index to determine the class of 
each individual drug.  Then the evaluator will refer to Appendix V to see if modifications need to be 
considered in the evaluation.  In general, 2 drugs from the same subclass of the major therapeutic 
classifications will be considered unnecessary duplication.  In some instances, all subclasses 
(sedative/hypnotics) will be considered as one class.  In some cases, the subclasses are broken down into 
more discrete categories (i.e., antihypertensives, other).  If two (or more) drugs from the same class are 
prescribed simultaneously and the order in which prescribed cannot be determined then they are 
unnecessarily duplicated.  If the order of prescribing in known, then the last drug added receives a C and the 
other drug receives a B.  If the order of prescribing is not known, then randomly pick one drug to receive a C 
and the other to receive a B. 
 
Examples:  Same pharmacologic class - ranitidine added to a regimen with cimetidine then ranitidine 
receives a C.  Flurazepam 15mg qhs and Diazepam 5mg tid then flurazepam randomly picked and receives a 
C.  Cimetidine and sucralfate prescribed simultaneously for peptic ulcer disease, randomly assign one drug to 
receive a C and the other to receive a B. 
 
Question 9: Is the duration of therapy acceptable? 
 
A________________________B______________________C______                       Z 
acceptable  marginally acceptable     unacceptable            do not know 
 
Definition:  Duration is defined as the length of therapy.  This question assesses whether the length of time 
that the patient has received the drug is acceptable.  
Instructions:  If the duration of therapy is outside the information source specified range, then the length is 
unacceptable.  If it is within the range or no data exists to make a clear decision, then the length is marginally 
or fully acceptable.  Other sources, which may include the medical record, may specify newer, more 
acceptable durations of therapy, especially in geriatric conditions.  Those sources supersede the specified 
texts if the reference is available.  In general, for a chronic condition, a prolonged duration of therapy will be 
acceptable. 
 
Examples:  Haloperidol in a patient with dementia for 1 year and no psychotic features = C.  Digoxin in a 
patient with remote history of CHF and in NSR - marginally acceptable (B); INH prophylaxis for 12 months 
in recent skin test converter – acceptable (A).  10 to 14 day course of ampicillin for urinary tract infection - 
acceptable (A); 12 months of nitrofurantoin in patient with indwelling urinary catheter - unacceptable (C).  If 
drug is not indicated (question 1), then duration = C. 
 
Question 10:  Is this drug the least expensive alternative compared to others of equal utility? 
 
A________________________B____________________C_______                    Z 
less expensive  equally expensive more expensive       do not know 
 
Definition:  This question assesses how the cost of the drug compares to other agents of equal efficacy and 
safety.  
Instructions:  A drug is more expensive if it costs more (at least 10%) than the average cost/charge of 
alternatives of equal utility.  Alternatives should be considered as medications within the same therapeutic 
class (see question 8 for definition).  To operationalize, evaluator can use the local institutional setting prices 
(e.g., cost per month or per day supply or cost per dose) as their standard.  If site-specific cost data is not 
available for assessment, evaluators are encouraged to utilize the Redbook AWP prices or cost index in Drug 
Facts and Comparisons as their standard. 
 
Examples:  Ciprofloxacin for an E. coli UTI that was sensitive to Ampicillin - 
more expensive  = C; Lactulose for constipation before trying psyllium - more expensive =C; Morphine SR 
in hospice patient is rated A, although may be more expensive than IR form it is more convenient and 
preferred by patient and therefore demonstrates greater utility.  If drug is not indicated (question 1), then 
expense = C. 
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Appendix 5.9: UK-Medication Appropriateness Index 
 
 1.  Is the drug indicated? A 
Indicated 
B 
Possible indication 
C 
Not Indicated 
 2. Is it (the drug) effective for the 
condition? 
A 
Effective 
B 
Marginally effective 
C 
Ineffective 
 3.  Is the dosage correct? A 
Correct (dosage) 
B 
Adequate but not  
ideal 
 
C 
Incorrect (dosage) 
 4.  Are the directions correct? A 
Correct 
(direction) 
B 
Adequate but not  
ideal 
 
C 
Incorrect (direction) 
 5.  Are the directions practical, clear 
and unambiguous for this patient? 
A 
Practical 
B 
Scope for 
improvement 
C 
Impractical 
 6.  Are there clinically significant drug-
drug interactions? 
A 
No significant (drug 
to drug interaction) 
B 
Marginally 
significant 
C 
Significant (drug to 
drug interaction) 
 7.  Are there any clinically significant 
drug-disease/condition interactions? 
A 
No significant (drug 
disease interaction) 
B 
Marginally 
significant 
C 
Significant (drug 
disease interaction) 
 8.  Is there unnecessary duplication 
with other drug(s)? 
A 
No duplication 
B 
Duplication with 
possible justification 
C 
Unnecessary 
duplication 
 9.  Is the duration of therapy 
acceptable?  
A 
Acceptable duration 
B 
Questionable 
duration 
C 
Unacceptable 
duration 
10. Is the drug you are assessing less 
expensive than alternative drugs of 
equal efficacy? - using the BNF 
A 
Less 
expensive 
B 
Equally 
Expensive 
C 
More 
Expensive 
 
 
USE OF THE UK-MEDICATION APPROPRIATENESS INDEX 
This instrument is intended for the evaluation of medications prescribed normally in a primary care setting.  
It requires, at a minimum, that a medical history problem list and medication list is available for review.  
Before evaluation, review the case information available and medication profile for each patient and 
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complete the scale for each regularly scheduled active medication.  Each question relates to the individual 
patient and drug in question.  For each item please follow the specific instructions below.  Read each 
question carefully and circle the score (A, B or C) that represents your assessment. ONLY CIRCLE ONE 
SCORE.  If you do not know the answer to a question then the following are recommended texts: 
 BNF 
 Stockley’s Drug Interactions (Pharmaceutical press ISBN 0853695040 October 2002, Edition 6) 
Some regimens contain combination drugs. These are scored as single items, considering the properties of all 
constituents in turn. Finally, please note your reasons for any rating of B or C in the comment section of 
each case study.   
  
Specific Instructions For Rating: 
 
Question 1:  
 
A________________________B________________________C          
Indicated  Possible indication  Not indicated   
 
Definition:  
This is defined as there being an adequate indication for the use of this drug in one of the problems present at 
the time when it was prescribed. Indication is defined as the sign, symptom, disease, or condition for which 
the medication is prescribed.  The question assesses whether there is sufficient reason for the use of the drug.  
Sufficient reason can also include preventative therapy as well as curative or palliative.  
 
Instructions:   
Answer this question based purely upon the information presented.  If there is a clear indication presented in 
either  the problem list, clinical history or information from hospital letters then = (A).   
 
If the drug is only possibly indicated by the information presented then = (B).  Do not base your judgement 
on the list of drugs prescribed, this alone is not evidence of an indication.  Other evidence must be presented 
to support an indication either in the problem list, clinical history, information from hospital letters or test 
results. 
 
If there is no information to support an indication other than the fact that the drug has been prescribed then = 
(C). 
 
Example:  
Bendrofluazide 2.5mg is prescribed and hypertension is documented = (A). 
 
The patient is prescribed bendrofluzide 2.5mg with no history or a diagnosis of hypertension, but there is 
repeated blood pressure reading such as 170/90, 160/92 = (B).  
 
Haloperidol is prescribed but there is no evidence of psychosis, schizophrenia, movement disorder, etc., and 
no further information to suggest a relevant condition then = (C). 
 
Question 2:  
 
A________________________B________________________C                        
Effective  Marginally effective  Ineffective   
 
Definition:  
Effective refers to evidence of efficacy in this population. It is defined as producing a beneficial result.  The 
question assesses whether the drug prescribed is capable of being effective for a given indication which is 
listed in the patient’s problem list, clinical history, information from hospital letters or test results 
 
Instructions:   
Indication and effectiveness are tightly but not perfectly linked items. Assessors should evaluate each drug 
for clinical effectiveness based on the actual or assumed indication*.  Effectiveness may also be based on a 
risk to benefit assessment of each drug. 
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication from the list of drugs.  However, if you are forced to make any inferences or assumptions in order 
to answer this item then you must record these in the comments section, together with reasons to support 
these inferences / assumptions.  For example, a patient may have been prescribed insulin but no indication is 
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listed.  In this case you may be forced to assume that the patient has diabetes mellitus in order to say whether 
the drug is effective for that condition. 
 
Example: 
A drug should generally be scored as (A) ‘Effective’ when there are guidelines for its use in relation to the 
actual or assumed indication and where it is prescribed within the boundaries of these guidelines.  Evidence 
should also exist to support a beneficial treatment effect. Example: Guidelines and evidence exist to support 
the use and clinical efficacy of Diazepam for the treatment of short term anxiety, an indication which is 
documented in the patients records.  Therefore Diazepam scored (A) Effective. 
 
A drug should be scored as (B) ‘Marginally effective’ when there are guidelines for its use in relation to to 
the actual or assumed indication although evidence suggests a suboptimal treatment effect, or guidelines state 
it is not the drug of first choice. This perhaps could be drugs which are marked in the BNF as         . 
 
A drug should be scored as (C) ‘Ineffective’ if there are no guidelines for its use in relation to the actual or assumed 
indication, if it is prescribed beyond the boundaries of any guidelines which do exist or if evidence suggests 
that no benefical treatment effect is likely to be obtained. Example: Guidelines support the use of Diazepam 
for the treatment of anxiety over a short period.  However long term use is cautioned against. The patients’ 
records presented indicate a prolonged history of anxiety.  Therefore Diazepam scored as either (B) 
Marginally Effective or (C) Ineffective. Another example of this is co-danthramer in an elderly patient who 
perhaps has constipation due to a cardiovascular accident( CVA) only. Co-danthramer in this case would be 
prescribed out of the current guidelines and score (C).  
 
  
Question 3:  
 
A________________________B________________________C          
Correct (dosage)  Adequate but not ideal      Incorrect (dosage)  
 
Definition:   
Dosage is defined as the total amount of medication taken per 24-hour period (or longer, if appropriate) for 
regularly scheduled medication. 
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication from the list of drugs.  However, if you are forced to make any inferences or assumptions in order 
to answer this item then you must record these in the comments section, providing in addition the question 
number and  reasons to support these inferences / assumptions.  For example, a patient may have been 
prescribed Lustral® but no indication is listed.  In this case you may be forced to assume that the patient has 
clinical depression in order to say whether the dosage is effective for that condition.  
 
Instructions: 
BNF (current edition) dose ranges for the elderly should be used. Hence, one should take into account known 
age-related changes in drug pharmacokinetics and pharmacodynamics.  Some patients may have laboratory 
tests or investigations, these should be viewed with respect to the dose and therefore the dose may be 
incorrect and hence label (C). If you consider blood test results to be important, and they are not recorded, 
you should score (C).  
 
Also, consider other objective data such as vital signs, calculated creatinine clearance and lab values (e.g., 
blood chemistries, cholesterol, PT/INR).  In summary, a dosage is incorrect if it is outside the accepted 
geriatrics dose range; if there is no accepted geriatrics dose range, then to be incorrect it must be outside the 
standard range.  A dosage may also be incorrect if not adjusted for renal failure or drug levels if tested for, 
e.g. digoxin.  For drugs being tapered to be discontinued, (e.g., oral steroids) low dosage will be considered 
correct. 
 
Examples:  
Paracetamol 2g/dose BD incorrect, 24 hour dose correct so it should be scored (A); however, single dose 
incorrect ie direction is incorrect (see Question 4 for direction). 
 
An example of (B) “adequate but not ideal” could be diclofenac 50mg  1 daily.    
 
Flixotide® 250mcg inhaler BD. The dose is not stated as 250mcg is the strength. The dose should be “one, 
two or even three puffs BD”, so in this situation the dose is (C).  
 
Question 4:  
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A________________________B________________________C             
Correct (directions) Adequate but not ideal      Incorrect (directions)  
 
Definition:  
Directions are defined as the instructions for the use of a medication by a patient. These instructions are those 
which are given on a prescription and will therefore subsequently be dispensed to the patient by the 
pharamacist.  
 
Instructions:  
The directions are incorrect or insufficient if given with no specific instruction (with notable exceptions such 
as warfarin, insulins etc) or specify the wrong schedule or the wrong time of day (when specific directions 
regarding relationship to schedule and time of day exist).  
 
Examples: 
An example of the correct direction (A) could be digoxin 125mcg 1 OM.  
 
An example of (B) direction ‘adequate but not ideal’ could be Paracetamol 500mg 1 tablet when required.    
 
Statins in the morning, Isosorbide Mononitrate 10am and 10pm, Quinine in the morning (when indicated for 
leg cramp), QDS for inhaled corticosteroids instead of BD cf also with practical implications. Atenolol “as 
directed” are all (C). 
 
“Statutory labels” (additional directions such as “warning may cause drowsiness” or “with or after food” 
which you should be able to find in the current BNF Appendix 9) can be assumed to be included on the 
directions; these will be placed on the label by the pharmacist.  
 
Question 5:  
 
A________________________B________________________C                     
Practical     Scope for improvement       Impractical  
 
Definition:  
“Practical” is defined as capable of being used or being put into practice.  This question assesses whether the 
directions for use are practical for the patient to take, and also takes into account whether the patient may be 
able to follow the instructions. This question should assess whether the directions appear to be clear and 
unambiguous. 
 
Instructions:  
A drug schedule is considered impractical if the drug could be administered less frequently and still maintain 
efficacy.  Irregular day-to-day schedules that have more regular alternatives are also impractical.  In addition, 
medications to be given at a specific time when a more flexible schedule is sufficient is impractical.   
 
Examples:  
A practical direction (A) could be Lisinopril 10mg  1 BD. 
 
Any drug which can be given less frequently because, for instance the availability of long acting (modified 
release) preparations could be rated as (B) scope for improvement.  
 
Warfarin doses which are complicated, such as varying alternative day dosing,  which could be made easier 
by having the same dose each day - impractical (C). Adizem MR® 90mg  1 BD is impractical (C) since 
equally evidence-based alternative, Adizem XL® 180mg  1 OD, is simpler to administer.  Atenolol 25mg 1 
BD incorrect (C) when atenolol 50mg 1 OD is just as clinically justified. Fosmax® may be impractical (C) 
for a completely bed bound patient and other forms of calcium replacement may be better to prescribe.  
 
Question 6:  
 
A________________________B________________________C 
              
          
 
 
Definition:  
No significant 
(Drug-drug 
interaction) 
Marginally 
significant 
 Significant 
(Drug-drug 
interaction) 
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A drug-drug interaction is defined as the effect that the administration of one medication has on another drug.  
This question assesses whether the drug in question interacts with another drug in the patient's regimen by 
affecting its pharmacokinetics (i.e., absorption, distribution, metabolism and excretion) or 
pharmacodynamics (i.e., the effect that it has on the body). These types of interactions should be assessed on 
a risk to benefit ratio, indeed some drugs are prescribed specifically for their interaction properties e.g. to 
increase the therapeutic level by reducing metabolism. This could include potential drug-drug interactions. 
 
Instructions:  
In a drug interactions textbook, such as the BNF, clinically significant interactions are denoted by the symbol 
•. Another recommend text to use is “Stockley’s Drug Interactions”, referenced above.  
 
Examples:  
An (A) rating would be given in the situation where none of the drugs interacted.  
 
A marginally significant drug-drug interaction  (B) could be the prescribing of a low dose cardiac glycoside, 
such as digoxin 62.5mcg  and a low dose diuretic such as frusemide 20mg 1 OM. Significant 
pharmacokinetic interaction (C) - Cimetidine added to a stable Theophylline patient which could result in 
Theophylline toxicity. Significant pharmacodynamic interaction (C) - a tricyclic antidepressant or another 
benzodiazepine added to an existing benzodiazepine, which results in a patient having increased falls or 
confusion.  NSAID (e.g., naproxen) for osteoarthritis started on a patient taking warfarin long term for atrial 
fibrillation= (C) (since increases risk of bleeding).  
 
Question 7:  
 
A________________________B________________________C              
   
 
    
 
Definition:  Drug-disease interaction is defined as the effect that the drug has on a pre-existing disease or 
condition, or simple effects of ageing i.e.changes in renal and hepatic function.  This question assesses 
whether there is a significant risk that the drug in question may worsen the patient's disease or condition.  
One must also consider allergies, for example a previous history of allergic reaction to a specific drug may be 
considered a pre-existing condition.  This could also include potential drug-disease interactions.  
 
*Note: If you are forced to make any inferences or assumptions regarding the existence of any pre-existing 
disease or condition based purely upon the drug list then you must record these in the comments section, 
providing the question number and reasons to support these inferences / assumptions.   
 
Instructions:    
If no interaction exists according to the information presented, then an (A) rating should be given.    
 
If the risk is present of a drug-disease interaction, but at a very low level, then the rating is marginal (B). 
 
If the drug is contraindicated or highly risky ("extreme caution") for a patient’s condition, then the drug-
disease interaction is significant (C).  If the drug needs routine caution in the setting of a patient’s condition 
and the patient shows clinical evidence of disease worsening following the prescription of the drug, then the 
drug-disease interaction is also significant (C).   
 
Examples:  
An (A) rating would be given in the situation where no drug-disease interaction was present.     
 
A diabetic patient prescribed a thiazide diuretic, the hypoglycaemic effect is antagonsied, however, this is 
thought not to be clinically significant and could therefore be classed as (B) marginally significant. NSAID in 
a patient with recent history of peptic ulcer disease (PUD) - (C) significant; Tricyclic amitriptyline worsens 
preexisting constipation = (C). If a patient is allergic to penicillin and amoxicillin is given then the drug – 
disease interaction is significant. = (C). 
 
Non selective beta blockers in a patient with asthma/ chronic obstructive pulmonary disease (COPD)-(C) 
significant.  Oral corticosteroids for asthma/COPD in a patient with diabetes or osteoporosis (C).  
Chlorpramide is a ( C ) when prescribed in the elderly because safer short-acting alternatives exist. 
(Chlorpramide is long acting and the patients age can affect this known side effect).  Parkinson disease can 
be exacerbated or worsened by the prescribing of any piperzine or phenothiazines drug, this may be 
considered as significant (C).  
No significant 
(drug-disease 
interactions) 
Marginally 
significant 
Significant (drug-
disease 
interactions) 
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Question 8:  
 
A________________________ B_____________________C                 
 No duplication                      Duplication        Unnecessary  
         with possible justification        duplication 
                          
Definition:   
Unnecessary duplication is defined as nonbeneficial or risky co-prescribing of drug(s).  Unnecessary 
duplication can exist when two drugs from the same chemical or pharmacological class are prescribed 
simultaneously, or when a single drug could have been prescribed for more than one condition instead of 
using multiple drug therapy.  
 
Instructions: 
 Look at each drug prescribed for each condition. Could one drug be used for more than one condition? 
Caution must be exercised when two drugs in the same class may be used together synergistically. Look for 
generic and brand name duplication i.e. Tenormin® and atenolol, Zocor® and simvastatin. Look for ways in 
which rational drug prescribing could help reduce polypharmacy. 
 
Examples:  
Bendrofluzide 2.5mg 1 OD and atenolol 50mg 1 OD may be considered (A) a combination used to 
hypertension. 
 
Ramipril 1.25mg 1 OD, atenolol 25mg 1 OD and Adalat® LA 20mg 1 OD recently prescribed for 
hypertension may be considered (B) when the two previous treatments were not prescribed at therapeutic 
doses, for example the ramipril was not titrated to a therapeutic dose (2.5- 5mg) even in the elderly.   
 
Same pharmacological class - ranitidine added to a regimen with cimetidine = (C) (ranitidine).Ranitidine 
added to the prescription of Lansoprazole, unnecessary will not work, = (C) (ranitidine). SSRI plus a tricyclic 
antidepressant, while not always inappropriate, but in this age-group likely to be unnecessary, so therefore 
rate as (C).   
 
Question 9:  
 
A________________________B______________________C                      
Acceptable duration Questionable duration            Unacceptable duration  
        
 
Definition:   
Duration is defined as the length of therapy.  This question assesses whether the length of time that the 
patient has received the drug is acceptable.   
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication from the list of drugs.  However, if you are forced to make any inferences or assumptions in order 
to answer this item then you must record these in the comments section, together with reasons to support 
these inferences / assumptions.   
 
Instructions:  
 If the duration of therapy is outside what would normally be expected then it should be classed as 
unacceptable (C).  If the duration of treatment is correct using existing guidelines or knowledge than this 
should be marked as acceptable therapy (A). In general, for a chronic condition there will naturally be long 
term medication which is acceptable, although there should be evidence of review and laboratory tests. There 
are some medications which should never be prescribed long term and therefore should always be assessed as 
unacceptable. A (B) rating ‘questionable’ could be given to drugs that are prescribed for a condition but there 
is little evidence of review or monitoring if this is what is recommended.  
 
Examples:  
An example of a drug prescribed for a long period of time which is acceptable (A) may be salbutamol in an 
asthmatic patient. 
 
A “questionable duration” rating (B) could perhaps be given to amiodarone when prescribed for paroxysmal 
supraventricular without any evidence of blood tests in the last 6 months. Clinical guidelines recommend that 
when amiodarone is prescribed long term laboratory tests (T3/T4) should be preformed every 6 months.  
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Warfarin for resistant atrial fibrillation long term could be considered acceptable so long as the patient was 
having regular INR checked. However, warfarin therapy for a one off deep vein thrombosis (DVT) given 
long term may be considered unacceptable (C) especially in a geriatric age range. Benzodiapines given long 
term could be considered unacceptable (C). Long term oral corticosteroids given without a justified 
therapeutic reason may be considered inappropriate (C).  
 
Question 10:  
 
A________________________B____________________C                    
Less expensive  Equally expensive      More expensive  
 
Definition:   
This question examines the cost of the drug which has been rated in the other nine criteria.  It also assesses 
whether the prescribing of this drug is justified (cost wise) in relation to other commercially available 
alternatives of equal efficacy, therapeutic class and safety and whether there is a cheaper generic alternative. 
“Less expensive” means that the drug being assessed is less expensive i.e. the alternative(s) is/are more 
expensive (if there were any). “More expensive” means that the drug being assessed is more expensive than 
any of its alternatives, if there were any.  
 
Instructions: 
 For each branded drug is there a generic alternative available? If so then a (C) should be given. Also if there 
is an alternative medication within the same therapeutic class which is more cost effective, i.e. cheaper than 
(C). If the drug is listed as not indicated or ineffective for the condition then it is not cost-effective and 
therefore is assessed as (C).  Also drugs which are given as BD when a larger dose could safely be given OD 
are not cost-effective and therefore a (C) response should be given. A (B) rating may apply when the 
alternative drug from the one prescribed is approximately the same cost. 
  
Examples:  
Ranitidine prescribed in a patient taking warfarin is rated (A), although it may be more expensive than 
cimetidine, it is less likely to cause a clinically significant interaction.  
 
An example of a (B) rating could perhaps be ramipril and lisinopril at equivlant doses to treat post 
myocardial infaraction 
 
Lactulose for constipation before trying Fybogel® - would be classed as (C) more expenive, likewise with 
the prescribing of Zyloric® instead of allopurinol (C).  Atenolol 50mg 1 OD is more cost effective then 
25mg 1 BD, so if atenolol 25mg 1 BD was prescribed then this would be rated as (C).  
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Appendix 5.10: Adapted-Medication Appropriateness Index (A-MAI) 
 
Drug _________  Dose  __________  Frequency ____ Duration _______     Diagnosis _______ 
 
 
Medication Appropriateness Index. Please state your reasons for rating B, C or DK in the spaces 
provided 
 
1.  Is the drug indicated? A B C Z 
 Indicated Possible indication Not Indicated DK 
 
If you rated B, C or DK, please explain 
why:_______ 
 
 
____________ 
 
 
 
 
________________ 
 
 
 
 
 
__________ 
 
 
 
 
 
___ 
 
 
 
2.  Is it effective for the condition? 
 
A 
Effective 
B 
Marginally effective 
C 
Ineffective 
Z 
DK 
     
If you rated B, C or DK, please explain 
why:______ 
 
____________ 
 
________________ 
 
__________ 
 
___ 
3.  Is the dosage correct? A B C Z 
 Correct Adequate but not ideal Incorrect DK 
 
If you rated B, C or DK, please explain 
why:_____ 
 
 
____________ 
 
 
________________ 
 
 
__________ 
 
 
___ 
4.  Are the directions correct? A B C Z 
 Correct Adequate but not ideal Incorrect DK 
 
If you rated B, C or DK, please explain 
why:_____ 
 
 
____________ 
 
 
________________ 
 
 
__________ 
 
 
___ 
5.  Are the directions practical? A B C Z 
 
 
If you rated B, C or DK, please explain 
why:______ 
Practical 
 
 
____________ 
Scope for 
improvement 
 
________________ 
Impractical 
 
 
__________ 
DK 
 
 
___ 
6.  Are there clinically significant drug-drug 
interactions? 
 
If you rated B, C or DK, please explain why: 
_____ 
A 
Insignificant 
 
 
____________ 
B 
Marginally significant 
 
 
________________ 
C 
Significant 
 
 
__________ 
Z 
DK 
 
 
___ 
7.  Are there clinically significant drug-
disease/condition interactions? 
A 
Insignificant 
B 
Marginally significant 
C 
Significant 
Z 
DK 
 
 
If you rated B, C or DK, please explain 
why:______ 
 
 
 
______________ 
 
 
 
__________________ 
 
 
 
___________ 
 
 
 
___ 
8.  Is there unnecessary duplication with other 
drug(s)? 
 
 
If you rated B, C or DK, please explain 
why:____ 
A 
No duplication 
 
 
 
______________ 
B 
Duplication with 
possible justification 
 
 
__________________ 
C 
Unnecessary 
 
 
 
___________ 
Z 
DK 
 
 
 
___ 
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9. Is the duration of therapy acceptable? 
 
 
If you rated B, C or DK, please explain 
why:______ 
10. Is this drug the least expensive alternative 
compared 
to others of equal utility? 
 
If you rated B, C or DK, please explain why:___ 
 
 
A 
Acceptable 
 
 
_____________ 
A 
Least expensive 
 
 
______________ 
B 
Questionable 
 
 
__________________ 
B 
Equally expensive 
 
 
__________________ 
C 
Not 
acceptable 
 
___________ 
C 
More 
expensive 
 
___________ 
Z 
DK 
 
 
___ 
Z 
DK 
 
 
___ 
 
 
A. General Instructions 
This instrument is intended for the evaluation of the appropriateness of medications prescribed by a health 
care provider.  It requires, at a minimum, that a medical history problem list and medication list is available 
for review.  Medication history information obtained from patients can be helpful in applying the MAI.  
Before evaluation, review the case information available and medication profile for each patient.  It is 
important that clinical judgment must be applied in regards to patient’s preference.  Complete the scale for 
each regularly scheduled active medication.  The MAI can be used to assess the use of “prn” or as needed 
medication used frequently.  Each question in the scale pertains to the individual patient and drug in question.  
Read each question carefully and circle the score (A, B, C or Z) that represents your assessment.  If you do 
not understand the question, consult the specific instructions below for clarification.  If you do not know the 
answer to the question, consult a standard medication text such as the British National Formulary (BNF), the 
Maudsley Prescribing Guidelines in Psychiatry or the Summary of Product Characteristic (SPC) of the 
medication. At times, you may require additional information from the patient's chart to answer a question.  
In that case, circle Z and specify the necessary information in the comments section.  Some regimens contain 
combination drugs.  If the individual components are available and used as single entities, then complete the 
scale for each individual drug.  Finally, please note your reasons for any rating of B, C or Z in the comments 
section. 
 
 
OPERATIONAL DEFINITIONS FOR RATING THE MAI 
 
Question 1: Is there an indication for the drug? 
 
A________________________B________________________C______           Z 
indicated  possible indication         not indicated                     do not know 
 
Definition:  Indication is defined as the sign, symptom, disease, or condition for which the medication is 
prescribed.  The question assesses whether there is sufficient reason for the use of the drug.  Sufficient reason 
includes not only curative and palliative therapy but also preventive therapy for a disease, condition or drug 
effect.  
Instructions:  A drug is not indicated if no condition exists for its use.  Answer the question with the 
conditions reported by the patients. If you disagree with the indication, please state the reason in the 
comments section and rate ‘C’ (not indicated).  
 
Examples:  Risperidone is prescribed and psychosis/schizophrenia is reported = A (indicated). Olanzapine 
prescribed for treatment resistant depression = B since indicated but would have to be added to an 
antidepressant. Olanzapine is prescribed and psychosis/schizophrenia is not reported = C (not indicated).  
Continued use of sertraline and other SSRIs during manic phase of bipolar illness = C. 
 
Question 2:   Is the medication effective for the condition? 
 
A________________________B________________________C_____                        Z 
effective   marginally effective           ineffective                do not know 
 
Definition: Effective refers to evidence of efficacy in this population. It is defined as producing a beneficial 
result.  The question assesses whether the drug prescribed is capable of being effective for a given indication 
which is reported by the patient.  
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Instructions:   
Indication and effectiveness are tightly but not perfectly linked items. Assessors should evaluate each drug 
for clinical effectiveness based on the reported indication*. This should also involve consideration of 
patients’ views on effectiveness. Effectiveness may also be based on a risk to benefit assessment of each 
drug.  
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication such as that reported by the patient.  However, if you are forced to make any inferences or 
assumptions in order to answer this item then you must record these in the comments section, together with 
reasons to support these inferences / assumptions.  For example, a patient may have been prescribed 
sertraline but signs/symptoms of depression are not present.  In this case you may be forced to assume that 
the patient has depression in order to say whether the drug is effective for that condition. Furthermore, an 
indication may not be documented for a drug yet the drug may work well for the intended effect (for 
example, use of a medication for an unlicensed indication). Depending on the circumstance, this may be 
considered effective. Drugs in which the potential risks outweigh the potential benefits, and thus are 
incapable of being effective in actual practice should be rated as ineffective (“C”).  
 
Examples: 
A drug should generally be scored as (A) ‘Effective’ when there are guidelines for its use in relation to the 
reported indication and where it is prescribed within the boundaries of these guidelines.  Evidence should 
also exist to support a beneficial treatment effect. Example: Guidelines and evidence exist to support the use 
and clinical efficacy of olanzapine for the treatment of schizophrenia and patient also reports benefit.  
Therefore olanzapine scored (A) Effective. If patient reports no benefit, then a score of ‘Marginally effective’ 
(B) or ‘Ineffective’ (C) may be given depending on the circumstance.  
 
A drug should be scored as (B) ‘Marginally effective’ when there are guidelines for its use in relation to the 
reported indication although evidence suggests a suboptimal treatment effect, or guidelines state it is not the 
drug of first choice. This perhaps could be drugs which are marked in the BNF as          . 
 
A drug should be scored as (C) ‘Ineffective’ if there are no guidelines for its use in relation to the indication, 
if it is prescribed beyond the boundaries of any guidelines which do exist or if evidence suggests that no 
beneficial treatment effect is likely to be obtained. Example: Guidelines support the use of Diazepam for the 
treatment of anxiety over a short period. However, long term use is cautioned against. The patient’s records 
presented indicate a prolonged history of anxiety. Therefore Diazepam scored as either (B) Marginally 
Effective or (C) Ineffective. Continued use of sodium valproate in a pregnant woman with bipolar illness = 
C.     
 
 
 
Question 3: Is the dosage correct? 
 
A________________________B________________________C____          Z 
correct   adequate but not ideal            incorrect  do not know 
 
Definition: 
Dosage is defined as the total amount of medication taken per 24-hour period (or longer, if appropriate) for 
regularly scheduled medication. 
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication such as that reported by the patient.  However, if you are forced to make any inferences or 
assumptions in order to answer this item then you must record these in the comments section.  For example, a 
patient may have been prescribed sertraline but there are no signs/symptoms of depression.  In this case you 
may be forced to assume that the patient has clinical depression in order to say whether the dosage is 
effective for that condition.  
 
Instructions: 
BNF (current edition) dose ranges should be used. Hence, one should take into account known age-related 
changes in drug pharmacokinetics and pharmacodynamics.  Some patients may have laboratory tests or 
investigations, these should be viewed with respect to the dose and therefore the dose may be incorrect and 
hence label (C). Also, consider other objective data such as vital signs and lab values (e.g., blood chemistries, 
cholesterol, PT/INR).  In summary, a dosage is incorrect if it is outside the standard dose range.  A dosage 
may also be incorrect if not adjusted for renal failure or drug levels if tested.  For drugs being tapered to be 
discontinued, (e.g., anticonvulsants, antipsychotics) low dosage will be considered correct.  
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Examples: 50mg of sertraline prescribed for depression = A.    2.5mg of olanzapine prescribed for 
schizophrenia = C.  
 
Question 4: Are the directions correct? 
 
A________________________B________________________C____             Z 
correct   adequate but not ideal            incorrect    do not know 
 
 
Definition:  
Directions are defined as the instructions for the use of a medication by a patient.  
 
Instructions:  
The directions are incorrect or insufficient if given with no specific instruction or specify the wrong schedule 
or the wrong time of day (when specific directions regarding relationship to schedule and time of day exist).  
 
Examples: An example of the correct direction (A) could be zolpidem 10mg nocte. An example of (B) 
direction ‘adequate but not ideal’ could be diazepam 2mg prn since it does not state the maximum dose that 
should not be exceeded.    
 
Question 5: Are the directions practical? 
 
A________________________B________________________C_____                      Z 
practical   scope for improvement           impractical  do not know 
 
Definition:  Practical is defined as capable of being used or being put into practice.  This question assesses 
whether the directions for use are practical for the patient to take, and also takes into account whether the 
patient may be able to follow the instructions. This question should assess whether the directions appear to be 
clear and unambiguous. 
 
Instructions:  
A drug schedule is considered impractical if the drug could be administered less frequently and still maintain 
efficacy.  Irregular day-to-day schedules that have more regular alternatives are also impractical.  In addition, 
medications to be given at a specific time when a more flexible schedule is sufficient is impractical.   
 
Examples:   
Trazodone 75mg qhs - practical (A) since once daily and can cue into bedtime routine. Olanzapine 5mg bd – 
impractical (C) since 10mg can be prescribed once daily.  Any drug which can be given less frequently 
because of the availability of long acting (modified release) preparations could be rated as (B) scope for 
improvement.  
 
Question 6: Are there clinically significant drug-drug interactions? 
 
A________________________B________________________C_____                 Z 
insignificant  marginally significant           significant          do not know 
 
Definition:   A drug-drug interaction is defined as the effect that the administration of one medication has on 
another drug.  Clinical significance connotes a harmful interaction.  This question assesses whether the drug 
in question interacts with another drug in the patient's regimen by affecting its pharmacokinetics (i.e., 
absorption, distribution, metabolism and excretion) or pharmacodynamics (i.e., the effect that it has on the 
body).  
 
Instructions:  A drug interactions text, such as the British National Formulary (BNF), the Maudsley 
Prescribing Guidelines in Psychiatry and the Summary of Product Characteristics of the medication can be 
used in assessing drug-drug interactions. Where other sources are used, they should be stated. For instance, 
interactions where there is a black dot in the British National Formulary (BNF) under the drug interactions 
section signifies a clinically significant interaction. If no interaction exists, then an A rating is automatic.  A 
“B” rating will be given when the reference indicates an interaction but no clinical evidence exists for 
toxicity or adverse effect.  If the reference/program indicates an interaction and sufficient clinical information 
is available and evidence of toxicity or adverse effect (including lack of effect) does exist, then the 
interaction is significant (“C”).  If the reference/program indicates an interaction and clinical information is 
not available, then the interaction may also be considered significant (“C”).  The drug that causes the change 
in pharmacokinetics or pharmacodynamics is the one that merits the C rating.  
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Examples:  Methadone (especially greater than 100mg) given with antipsychotics that prolong the QT 
interval = C due to increased risk of ventricular arrhythmias. Prescription of phenelzine to a patient who is 
dependent on cocaine = C due to risk of hypertensive crisis.  
 
Question 7: Are there clinically significant drug-disease/condition interactions? 
 
A________________________B________________________C_____               Z 
insignificant  marginally significant            significant         do not know 
 
Definition:  Drug-disease interaction is defined as the effect that the drug has on a pre-existing disease or 
condition (including substance use disorders), or simple effects of ageing i.e. changes in renal and hepatic 
function.  This question assesses whether there is a significant risk that the drug in question may worsen the 
patient's disease or condition.  One must also consider allergies, for example a previous history of allergic 
reaction to a specific drug may be considered a pre-existing condition.  This could also include potential 
drug-disease interactions.  
 
*Note: If you are forced to make any inferences or assumptions regarding the existence of any pre-existing 
disease or condition then you must record these in the comments section, providing the reasons to support 
these inferences / assumptions.   
 
Instructions:    
If no interaction exists according to the information presented, then an (A) rating should be given.    
 
If the risk is present of a drug-disease interaction, but at a very low level, then the rating is marginal (B). 
 
If the drug is contraindicated or highly risky ("extreme caution") for a patient’s condition, then the drug-
disease interaction is significant (C).  If the drug needs routine caution in the setting of a patient’s condition 
and the patient shows clinical evidence of disease worsening following the prescription of the drug, then the 
drug-disease interaction is also significant (C).   
 
Examples:  High anticholinergic Tricyclic antidepressants (i.e., doxepin, amitriptyline, imipramine) started in 
patient with Lower Urinary Tract Symptoms = C.  Codeine prescribed for someone with a previous history of 
gastrointestinal distress with no evidence of worsening =B. 
 
 
Question 8: Is there unnecessary duplication with other drug(s)? 
 
A________________________B___________________C_____                 Z 
necessary  marginally necessary  unnecessary do not know 
 
Definition:  Unnecessary duplication is defined as nonbeneficial or risky co-prescribing of drug(s).  
Unnecessary duplication exists when two drugs from the same chemical or pharmacological class are 
prescribed simultaneously, or when a single drug could have been prescribed for more than one condition 
instead of using multiple drug therapy. 
 
Instructions: 
Look at each drug prescribed for each condition. Could one drug be used for more than one condition? 
Caution must be exercised when two drugs in the same class may be used together synergistically. Look for 
generic and brand name duplication i.e. lustral® and sertraline. Look for ways in which rational drug 
prescribing could help reduce polypharmacy. If two (or more) drugs from the same class are prescribed 
simultaneously and the order in which prescribed cannot be determined then they are unnecessarily 
duplicated.  If the order of prescribing is known, then the last drug added receives a C and the other drug 
receives a B.  If the order of prescribing is not known, then randomly pick one drug to receive a C and the 
other to receive a B. 
 
Examples:  Flurazepam 15mg qhs and Diazepam 5mg tid then flurazepam randomly picked and receives a C. 
 
Question 9: Is the duration of therapy acceptable? 
 
A________________________B______________________C______                       Z 
acceptable  marginally acceptable       unacceptable  do not know 
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Definition:   
Duration is defined as the length of therapy.  This question assesses whether the length of time that the 
patient has received the drug is acceptable.   
 
*Note: If there is no indication for the drug in question the assessor may be forced to infer / assume an 
indication such as that reported by the patient.  However, if you are forced to make any inferences or 
assumptions in order to answer this item then you must record these in the comments section.   
 
Instructions:  
If the duration of therapy is outside what would normally be expected then it should be classed as 
unacceptable (C).  If the duration of treatment is correct using existing guidelines or knowledge than this 
should be marked as acceptable therapy (A). In general, for a chronic condition there will naturally be long 
term medication which is acceptable, although there should be evidence of review and laboratory tests. There 
are some medications which should never be prescribed long term and therefore should always be assessed as 
unacceptable. A (B) rating ‘questionable’  could be given to drugs that are prescribed for a condition but 
there is little evidence of review or monitoring if this is what is recommended.  
 
Examples:  
An example of a drug prescribed for a long period of time which is acceptable (A) may be olanzapine in a 
patient with psychosis/schizophrenia. Diazepam or other benzodiazepines prescribed for greater than 4 weeks 
= C due to the risk of dependence.  
 
Question 10:  Is this drug the least expensive alternative compared to others of equal utility? 
 
A________________________B____________________C_______                    Z 
less expensive  equally expensive more expensive       do not know 
 
Definition:   
This question examines the cost of the drug which has been rated in the other nine criteria.  It also assesses 
whether the prescribing of this drug is justified (cost wise) in relation to other commercially available 
alternatives of equal efficacy, therapeutic class and safety and whether there is a cheaper generic alternative. 
“Less expensive” means that the drug being assessed is less expensive i.e. the alternative(s) is/are more 
expensive (if there were any). “More expensive” means that the drug being assessed is more expensive than 
any of its alternatives, if there were any.  
 
Instructions: 
A drug is more expensive if it costs more (at least 10%) than the average cost/charge of alternatives of equal 
utility.  Alternatives should be considered as medications within the same therapeutic class.  To 
operationalize, evaluator can use the BNF prices (e.g., cost per month or per day supply or cost per dose) as 
their standard.  For each branded drug is there a generic alternative available? If so then a (C) should be 
given. Also if there is an alternative medication within the same therapeutic class which is more cost 
effective, i.e. cheaper than (C). A (B) rating may apply when the alternative drug from the one prescribed is 
approximately the same cost. 
 
Examples:   
Escitalopram prescribed for depression when citalopram or other cheaper SSRIs have not been tried = C.   
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Appendix 5.11: Case study of W. T. 
W.T is a 37 year old woman who has experienced a lot of difficulties in the last few years. She has 
been through a very difficult divorce and lost custody of her two children to her ex-husband 3 years 
ago. She reports feeling depressed about her situation. She says at that time she started to drink 
alcohol on a daily basis to cope with her feelings about the loss of her children. She describes a 
current pattern of drinking of 4 cans of 5% lager per day (8.8 units). She reports that she finds it 
very difficult to control her alcohol intake and has been increasingly concerned about it, so she 
decided to self-refer to the LAU for assistance with her drinking. She has also been having sleep 
problems for the past 3 weeks.  
 
W.T has no family history of depression.  
 
Past medical history 
She was diagnosed with depression 2.5 years ago by her GP. 
She was also diagnosed with insomnia 2 weeks ago.  
 
Present medications 
Sertraline 50mg tab o.d prescribed 2 years ago by her GP. 
Zopiclone 7.5mg tab nocte prescribed 2 weeks ago by her GP. 
 
Please could you kindly use the medication appropriateness index (MAI) to rate the 
appropriateness of these medications? We would be discussing about your ratings during the 
prescribing governance meeting on friday. I have attached a copy of the medication appropriateness 
index (MAI) to this mail. 
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Appendix 5.12: Medication Omission Questionnaire 
 
1. Are any of the medications of interest not being prescribed for an active condition without 
reason?    
Yes �      No �     
 
If yes, please state the medications not being prescribed and any action you will take below: 
Medications not being prescribed Action to be taken concerning medications not being prescribed 
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Appendix 5.13: Reasons for marginally appropriate A-MAI ratings at first SAS visit 
Reasons for ratings of marginally appropriate on the A-MAI Number of service 
users with 
marginally 
appropriate 
ratings 
Indication rated as ‘marginally appropriate’  
No obvious signs of depression but could be because antidepressant is effective 1 
Possibility of alcohol-related depression 4 
Depressive symptoms are present but there is insufficient history for assessment 1 
Long-term use of antidepressant despite improvement in depressive symptoms 1 
Unlicensed prescribing of antipsychotic for paranoia 1 
Prochlorperazine is not first line in the management of anxiety disorder  1 
Possible dependence on z-drug due to chronic use 1 
Z-drug indicated only for short-term use for sleep problems 2 
Benzodiazepine indicated for short-term use for sleep problems 1 
Long term use of opioids for pain 2 
Beta-blocker is not first-line agent as an anxiolytic 1 
Effectiveness rated as ‘marginally effective’  
Lack of optimal benefit from antidepressants due to alcohol misuse 5 
Depressive symptoms still present in service user despite use of antidepressants. 
Depressive symptoms are unlikely to be secondary to alcohol misuse 
2 
Antidepressant (trazodone) not first line in the management of sleep problems 1 
Presence of anxiety and depressive symptoms in service user. Service user feels 
medication is only slightly effective 
1 
Service user still experiencing depressive symptoms 1 
Service user still experiencing paranoia  1 
Prochlorperazine is not first line in the management of anxiety disorder. Alcohol 
misuse may be worsening service user’s anxiety problems 
1 
Lack of optimal benefit from benzodiazepines 1 
Lack of optimal benefit from z-drug 3 
Z-drug only has short-term benefit and should be used for limited time 1 
Service user reports lack of optimal benefit from beta-blocker for anxiety disorder 1 
Dosage rated as ‘adequate but not ideal’  
Probable need for higher dose of antidepressant  3 
Dose of antidepressant is above BNF maximum dose in recent guidelines. Dose was 
within limit of past BNF recommendation  
1 
Tapering of benzodiazepine dose due to lack of indication 1 
Need to aim for lower doses of opioids as service user has been on present dose for a 
long time 
1 
Development of bradycardia with current dose of beta-blocker 1 
Directions rated as ‘adequate but not ideal’ for correctness  
Direction should rather be qds for benzodiazepine (chlordiazepoxide bd) prescribed 
for alcohol detoxification 
1 
Directions rated as ‘adequate but not ideal’ for practicality  
Service user unclear about the length of treatment for chlordiazepoxide prescribed for 
alcohol detoxification 
1 
Drug-drug interactions rated as ‘marginal’  
Combination of two antidepressants with serotonergic activity 1 
Possible potentiation of CNS depressant effect of morphine by alcohol and 
amitriptyline 
2 
Possible reduction of serum concentration of quetiapine by depakote (divalproex 
sodium) 
1 
Drug-disease/condition interactions rated as ‘marginal’   
Alcohol (20 – 60 units of alcohol per week) may affect the effectiveness of 
antidepressant  
1 
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Possibility of interaction between alcohol and z-drug 2 
Medication duplication with possible justification   
Co-prescribing of two antidepressants 2 
Co-prescribing of fluoxetine, prochlorperazine and propranolol for anxiety problems 1 
Marginally acceptable duration of therapy  
Use of antidepressants without regular review 4 
Commenced a reducing regimen of methadone with a view to discontinuing 1 
Use of opioid (morphine) without regular review 1 
Co-codamol prescribed for symptomatic relief. Service user also needs to abstain 
from alcohol for pain relief 
1 
Duration of co-codamol needs to be limited due to dependence risk 1 
Duration of acamprosate needs to be reviewed due to length of treatment 1 
Comparability of medication cost to those of equal utility  
Fluoxetine is comparable to other SSRIs in its cost 1 
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Appendix 5.14: Favourable ethical opinion letter for Medication Appropriateness Study 
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Appendix 5.15: Minor amendment acknowledgement letter  
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Appendix 5.16: Indications for prescribed medications at first SAS visit 
Indications reported by service users  No of service users with 
diagnoses (n = 60) 
Depression 18 (30%) 
Depression and anxiety 3 (5%) 
Anxiety 5 (8.3%) 
Sleep problem 10 (16.7%) 
Liver cirrhosis 1 (1.7%) 
Type 2 diabetes mellitus 1 (1.7%) 
Osteoporosis 1 (1.7%) 
Peptic ulcer 3 (5%) 
Abdominal abscess 1 (1.7%) 
Migraine 1 (1.7%) 
Asthma 3 (5%) 
Paranoia 1 (1.7%) 
Sinus problem 1 (1.7%) 
Arthritis 2 (3.3%) 
Oesophageal erosion 2 (3.3%) 
Heart problem 1 (1.7%) 
Pain 10 (16.7%) 
Alcohol misuse 5 (8.3%) 
Chronic Obstructive Pulmonary Disease (COPD) 2 (3.3%) 
Opiate dependence (dihydrocodeine and heroin) 3 (5%) 
Hypercholesterolaemia 3 (5%) 
Hypertension 6 (10%) 
Scalp problem 1 (1.7%) 
Schizophrenia 1 (1.7%) 
Fluid retention 2 (3.3%) 
Psychosis 1 (1.7%) 
Cyclothymia 1 (1.7%) 
Breathlessness 1 (1.7%) 
Indigestion 3 (5%) 
Tobacco dependence 1 (1.7%) 
Stomach problem 3 (5%) 
Hypothyroidism 1 (1.7%) 
Nausea 1 (1.7%) 
Hay fever 2 (3.3%) 
Eczema 1 (1.7%) 
Bipolar disorder 1 (1.7%) 
Oral contraception 1 (1.7%) 
Vitamin supplement 17 (28.3%) 
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Appendix 6.1: Topic guide for interviews with service users 
        
 
 
The Department of Health Sciences 
 
A study of the appropriateness of service users' prescriptions 
 
TOPIC GUIDE FOR INTERVIEW WITH SERVICE USERS 
 
 The purpose of this interview is to explore your views on your prescriptions. It is hard to 
predict how long the interview will take but it is likely to be between 30 to 60 mins. 
However, you can stop at any point if you do not want to continue. 
 There are no right or wrong answers as I am interested in what you think about your 
prescriptions. I am interested in your views. 
 If you are happy with this, I would like to record this interview. It will then be transcribed 
verbatim i.e. it will be typed up, recording everything that was said. 
 I may use direct quotations from your interview in writing up my thesis but these would be 
anonymous i.e. your name will not be used. 
 Everything you tell me will be kept in confidence unless you tell me something which 
suggests that you or others are at risk of harm. In this situation, I may also have to inform 
the appropriate staff at the LAU after discussing this with you. 
 Do you have any questions before we start this interview? 
 Are you happy to sign the consent form and continue? 
 
1. Introduction 
Medications 
 What prescribed medicines are you taking? Who prescribed them, when, dosage, 
frequency, length of use and medications used in the past for the same condition. 
 How and why they were prescribed these drugs. Was there a careful assessment first? Were 
they needed in the service user’s view, are they still needed now? 
 Are medications reviewed and how often? 
 
Substance use 
 Do you use alcohol at present: quantity used, type of alcohol product and strength. Amount 
used on a typical day, days used in the last 28 days. 
 Before first visit to LAU, description of pattern of alcohol use. Has service user made any 
changes to alcohol use since coming to the LAU. What changes? 
 Has your alcohol affected any of your health conditions in the past and now: how and 
which health condition? 
 Do you use illicit drugs at present: quantity used, type of drug. Amount used on atypical 
day, days used in the last 28 days. 
 Before first visit to LAU, description of pattern of drug use. Has service user made any 
changes to drug use since coming to the LAU. What changes? 
 Has your drug use affected any of your health conditions in the past and now: how and 
which health condition? 
 When did health conditions and substance use start? 
 
2. Service users’ feelings about the effectiveness of their prescribed medicines. Compare the 
effectiveness of medicines when using substances and when not (or when substances 
reduced).  
3. Adherence: Do you often take your medications as prescribed, why? How do you take your 
medications? Can you describe how you use your medications and substances on a typical 
day? Any adverse effects: what effects and what medications and substances are involved? 
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4. Medications service users are not receiving but feel they should be prescribed and why? 
Actions taken concerning such medications e.g. consultation with a health care 
professional (HCP), what did the HCP say? Have medicines been obtained from other 
sources; which sources? 
5. What service users consider important in assessing if their prescribed medicines are right 
for them and why? 
6. Were any prescribed medicines changed on coming to the LAU? If so, which and in what 
way? 
7. Involvement in the process of change of medications of interest at the LAU 
 Service users’ feelings concerning these changes. Why do you think these changes 
were made? Were there improvements? 
 Service user involvement in these decisions 
 Level of satisfaction with involvement 
 Ways in which service users can be more involved 
8. Influence of medications on patient outcomes 
 Impact of medications on service users’ quality of life 
 Degree to which medications are helping users recover from their substance use. 
 
 
Is there anything else we have missed or should have talked about? 
Thank you for your time. 
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Appendix 6.2: Coding framework for interviews 
 
Appendix 6.2a: Screenshot of codes generated using Atlas ti 
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Appendix 6.2b: A part of the coding framework for service user interviews 
Initial code list Renaming codes Amendment of codes Final codes  
 
Medication review 
Reminders about review 
appointments 
Attendance of medication 
review appointments 
 
Assessment 
 
Medication monitoring 
Medication review 
 
 
 
 
 
Assessment 
 
Medication monitoring 
Assessment and review Assessment and 
review 
Alleviation of symptoms 
Improved functioning  
Need for medicines  
 
Benefits and risks of 
medicines 
 
Effect of alcohol on 
antidepressants 
 
Antidepressants as a crutch 
Antidepressants as a 
support in decision-
making 
Benefit from 
medications 
 
 
 
Benefits and risks 
 
Impact of alcohol on 
antidepressants 
 
Antidepressants as a 
crutch  
Benefit from 
medications 
 
 
Trade-off of risks and 
benefits 
 
Interference of alcohol 
with antidepressants 
 
Antidepressants as a 
medical crutch 
Functional 
outcomes 
Control/freedom of choice 
Tell them what you want 
Craving  
Right to medication 
Right to medications Entitlement to 
medications 
Entitlement to 
medications 
 
 
Appendix 6.2c: A part the coding framework for prescriber interviews 
Initial code list Renaming codes Amendment of 
codes 
Final codes 
  
Guideline adherence 
Use of prescribing protocols 
Measuring prescribing against 
guidelines 
 
Prescribing outside guidelines 
Patient-focused prescribing 
Successful prescribing 
Prescribing as an art and science 
Guideline 
adherence 
 
 
 
Successful 
prescribing 
Guideline 
adherence versus 
successful 
prescribing 
Guideline 
adherence versus 
successful 
prescribing 
Risk of drug-drug interactions 
Risk of drug-disease interactions 
Harmful effects of medicines 
Overdosing  
Assessing risk Assessing risk Assessing risk 
Discussion with other SAS prescribers 
Discussion with service users 
Taking over prescriptions 
Communication with prescribers 
outside the SAS 
Writing to prescribers outside the SAS 
Communication Communication Communication 
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Appendix 6.3:  Comparison of interviewed service users with those who were not interviewed 
Characteristics of service 
users 
Interviewed service 
users (n = 14) 
Service users not 
interviewed (n = 6) 
P-values 
Age (mean, SD) 48.2 + 9.8 46 + 6.8 0.62
a
 
Gender (n, %)    
Males 11 (78.6%) 2 (33.3%)  
Females 3 (21.4%) 4 (66.7%) 0.12
b
 
Housing status (n, %)    
Rented 7 (50%) 3 (50%)  
Home owner 3 (21.4%) 2 (33.3%)  
Other 4 (28.6%) 1 (16.7%) 1.00
b
 
Referral substance (n, %)    
Alcohol 12 (85.7%) 5 (83.3%)  
Opioids 2 (14.3%) 0  
Cocaine 0 1 (16.7%) 0.36
b
 
Referral source (n, %)    
Self  8 (57.1%) 3 (50%)  
GP 5 (35.7%) 1 (16.7%)  
Other 1 (7.1%) 2 (33.3%) 0.36
b
 
LDQ (median, IQR) 18.5 (9.3, 23.8) 23 (10, 28) 0.55
c
 
CORE-10 25.5 + 10.4 23.6 + 10.2 0.72
a
 
SSQ 9.9 + 6.8 16.4 + 6.6 0.09
a
 
EQ 5D (median, IQR) 0.7 (0.4, 0.9) 0.8 (0.06, 0.9) 0.96
c
 
Number of previous SAS 
episodes (median, IQR) 
1 (0, 2) 0.5 (0, 1.3) 0.66
c
 
Number of substances used in 
the past 12 months (median, 
IQR) 
2 (1.8, 4.3) 2 (1, 2.3) 0.40
c
 
Number of prescribed 
medicines (median, IQR) 
2.5 (1, 5.3) 3.5 (1.8, 9) 0.48
c
 
Note: The significance level was 0.4% (that is 0.004) due to Bonferroni adjustment for multiple testing. aAssessed using 
the independent samples t-test, bassessed using Fisher’s exact test, cassessed using the Wilcoxon rank sum test. 
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Appendix 7.1: Information sheet for prescribers  
 
                                                                                                        Version 3.1 (08/06/2012) 
    
         The Department of Health Sciences 
            
     A study of the appropriateness of service users' prescriptions 
 
                                   INFORMATION SHEET FOR PRESCRIBERS 
 
We would like to invite you to take part in our research study on the appropriateness of 
prescriptions for service users. Before you decide we would like you to understand why the 
research is being done and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. We‘d suggest this should take 
about 10 minutes.   
  
What is the purpose of the study? 
The purpose of this study is to assess the use and appropriateness of prescriptions of psychotropic 
medications such as antidepressants, antipsychotics, anxiolytics/hypnotics, antimanic agents, 
anticonvulsants, opioids (including substitute opioids) and medications used in treating substance 
dependence (disulfiram, acamprosate, lofexidine, bupropion and baclofen) for service users who 
are newly referred to the Leeds Addiction Unit (LAU). Prescribing for service users with substance 
use disorders (SUD) is a relatively unexplored area and the few studies available mostly examine 
prescribing appropriateness by assessing adherence to treatment guidelines relating to the adequacy 
of the duration of medication therapy and dosage. However, other important aspects of medication 
appropriateness such as the presence of drug interactions, unnecessary prescriptions and medication 
omissions (underutilisation), which are equally important, have been rarely considered despite their 
contribution to morbidity, adverse events and increased health care costs. Furthermore, the reasons 
for prescribing decisions among service users with SUD have not been well researched.  
 
We would therefore wish to find out how you rate the appropriateness of the prescriptions of 
interest using the Medication Appropriateness Index (MAI) and the Assessment of Underutilisation 
of Medication (AOU) Index respectively. We would be interested in changes you make to service 
users prescriptions from their first assessment to their three month follow-up review and would be 
interviewing you to explore how you assess the appropriateness of service users’ prescriptions 
towards the end of this study.  
 
Why have I been invited to participate? 
You have been invited to participate in this study because you are a medical prescriber at the Leeds 
Addiction Unit (LAU). All medical prescribers at the LAU will be invited to participate in this 
study. 
 
Do I have to take part? 
No, it is up to you to decide to join the study. If you agree to take part, we will then ask you to sign 
two consent forms, out of which one will be given to you to keep. You are free to withdraw at any 
time, without giving a reason.  
 
What will happen if I decide to take part? 
If you decide to take part in this study you will be administered a demographics questionnaire 
where you will fill in your demographic information. You will be given the AOU to assess 
omission (underutilisation) of the prescriptions of interest during service users’ first assessment 
whilst you will be given the MAI to assess the appropriateness of the prescriptions of interest 
during service users’ first assessment and three month follow-up review. This study will last for six 
months. You will be interviewed for 30 to 60mins towards the end of the study (at six months) to 
explore how you assess prescribing appropriateness.  
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Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information we obtain from you will be 
handled in confidence. All information which is obtained from you during the course of the 
research will be kept strictly confidential. No one will be able to identify you from the study and 
we will not share the information you provide with anyone who is not a member of the research 
team.  
 
What will happen if I don’t want to carry on with this study? 
If you withdraw from the study, we will use the data collected up to your withdrawal.  
 
What will happen to the results of the research study? 
The results of this study will be written as a PhD thesis, published in journals and presented in 
conferences. We would also feedback the results to you. The results of this study should be 
published by 2013. 
 
Who is organising and funding the research? 
This study is being funded by the Collaboration for Leadership in Applied Health Research and 
Care (CLAHRC) and supported by the University of York. It is also being undertaken as a piece of 
student research towards the award of a Doctorate in the Department of Health Sciences at the 
University of York. 
 
What will happen to the information I provide if I lose authority to consent? 
If you lose authority to consent, you will be withdrawn from the study but any data you gave prior 
to then will be used in this study.  
 
Where can I get further information concerning this study? 
You can get more information about this study by contacting the study’s chief investigator 
(Obirenjeyi Kudehinbu-Oluyase). You can also contact the chief investigator if you decide to 
withdraw from the study through the following means: 
 
Telephone: 01132 952775 (Monday, Tuesday and Thursday between 11am and 4.00pm) 
Email: oak501@york.ac.uk 
 
Thank you for taking the time to read this information sheet and considering whether to take part in 
this study. 
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Appendix 7.2: Topic guide for interviews with prescribers 
      
  
The Department of Health Sciences 
A study of the appropriateness of service users' prescriptions 
 
TOPIC GUIDE FOR INTERVIEW WITH PRESCRIBERS 
 
 The purpose of this interview is to explore your views on the appropriateness of 
prescribing for people with addiction problems. This interview should take between 30 and 
60 mins. However, you can stop at any point if you do not want to continue. 
 With your permission, the interview will be audio recorded and transcribed verbatim.  
 Direct quotes may be used while writing up this thesis but these would be anonymous. 
 Do you have any questions before we start this interview? 
 
Topics to be explored 
1. How would you define inappropriate prescribing: probe for situations where the health 
condition is no longer present (or never present). Probe for omissions. Use of 
guidance/policies when assessing prescribing and any guidance/advice designed for LAU. 
2. What classes of medications do you assess their appropriateness; why? How do you assess 
the appropriateness of service users’ medications at the LAU, how often is prescription 
appropriateness assessed? 
3. Do you think inappropriate prescribing is a particular problem, and if so why? 
4. What types of inappropriate prescribing do you encounter? Please describe them and the 
reasons why they are inappropriate (who prescribed these medications, what is 
inappropriate about them, potential reasons for such prescribing etc). 
5. What factors do you consider before assessing medications as appropriate in the presence 
of substance use and vice versa? Give examples 
6. Challenges encountered in assessing prescribing appropriateness at service users’ first 
assessment. Compare with assessment during service users’ subsequent visits. 
7. Actions taken concerning inappropriate prescriptions/omissions and when it is taken (GP 
responses concerning them when contacted). Which prescriptions are or are not changed at 
the LAU and why, factors considered before making changes to prescriptions of interest. 
8. Negotiation of changes to prescriptions with service users: service user involvement in the 
process, service user satisfaction with changes. 
9. Impact of prescription change on service users’ well being 
10. How would you describe your experience of using the MAI in assessing prescribing 
appropriateness? Why?  
11. Has the MAI had any impact on how you assess the appropriateness of prescribing, how? 
12. How do you find the structured format of the MAI as a means of exploring prescribing 
appropriateness? Time taken to complete it. 
13. Is there anything you find helpful about the MAI, what and why? 
14. Is there anything you find unhelpful about the MAI, what and why? 
15. Suggestions on how the MAI can be improved. 
16. Do you think the MAI could be used in clinical practice for assessing appropriateness? 
17. Suggestions on improving practice with regard to inappropriate prescribing/omissions.   
 
Is there anything else we have missed or should have talked about? 
Thank you for your time. 
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List of Abbreviations 
A-MAI  Adapted Medication Appropriateness Index 
APA   American Psychiatric Association 
AQ   Adherence Questionnaire 
ATHF   Antidepressant Treatment History Form 
AUD   Alcohol Use Disorder 
BAP   British Association of Psychopharmacology 
BNF   British National Formulary 
BPS   British Pain Society 
CBT   Cognitive Behavioural Therapy 
CNCP   Chronic Non-cancer Pain 
DSM   Diagnostic and Statistical Manual of Mental Disorders 
DUD   Drug Use Disorder 
GP   General Practitioner 
HSRGC  Health Sciences Research Governance Committee 
ICD   International Classification of Diseases 
IDU   Intravenous Drug User 
MAI   Medication Appropriateness Index 
MAS   Medication Appropriateness Study 
MI   Motivational Interview 
MOQ   Medication Omissions Questionnaire 
MMR   Mixed Methods Research 
MMTP  Methadone Maintenance Treatment Programme 
NHS   National Health Service 
NICE   National Institute for Health and Clinical Excellence 
NP   Nurse Prescriber  
OUD   Opioid Use Disorder 
QATQS  Quality Assessment Tool for Quantitative Studies 
RCT   Randomised Controlled Trial 
SAS   Specialist Addiction Service 
SCB   Self-Completion Booklet 
SHO   Senior House Officer 
SPR   Specialist Registrar 
SUD   Substance Use Disorder 
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TCA   Tricyclic Antidepressant 
UK   United Kingdom 
USA   United States of America 
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